TOKEN	PREDICTED
Identification	O
of	O
targets	O
for	O
rational	O
pharmacological	O
therapy	O
in	O
childhood	O
craniopharyngioma	O
Abstract	O
Introduction	O
Pediatric	O
adamantinomatous	O
craniopharyngioma	O
(	O
ACP	O
)	O
is	O
a	O
histologically	O
benign	O
but	O
clinically	O
aggressive	O
brain	O
tumor	O
that	O
arises	O
from	O
the	O
sellar	O
/	O
suprasellar	O
region	O
.	O

Despite	O
a	O
high	O
survival	O
rate	O
with	O
current	O
surgical	O
and	O
radiation	O
therapy	O
(	O
75â	O
	O
95Â	O
%	O
at	O
10Â	O
years	O
),	O
ACP	O
is	O
associated	O
with	O
debilitating	O
visual	O
,	O
endocrine	O
,	O
neurocognitive	O
and	O
psychological	O
morbidity	O
,	O
resulting	O
in	O
excheptionally	O
poor	O
quality	O
of	O
life	O
for	O
survivors	O
.	O

Identification	O
of	O
an	O
effective	O
pharmacological	O
therapy	O
could	O
drastically	O
decrease	O
morbidity	O
and	O
improve	O
long	O
term	O
outcomes	O
for	O
children	O
with	O
ACP	O
.	O

Results	O
Using	O
mRNA	O
microarray	O
gene	O
expression	O
analysis	O
of	O
15	O
ACP	O
patient	O
samples	O
,	O
we	O
have	O
found	O
several	O
pharmaceutical	O
targets	O
that	O
are	O
significantly	O
and	O
consistently	O
overexpressed	O
in	O
our	O
panel	O
of	O
ACP	O
relative	O
to	O
other	O
pediatric	O
brain	O
tumors	O
,	O
pituitary	O
tumors	O
,	O
normal	O
pituitary	O
and	O
normal	O
brain	O
tissue	O
.	O

Among	O
the	O
most	O
highly	O
expressed	O
are	O
several	O
targets	O
of	O
the	O
kinase	O
inhibitor	O
dasatinib	O
â	O
	O
LCK	O
,	O
EPHA2	O
and	O
SRC	O
;	O
EGFR	O
pathway	O
targets	O
â	O
	O
AREG	O
,	O
EGFR	O
and	O
ERBB3	O
;	O
and	O
other	O
potentially	O
actionable	O
cancer	O
targets	O
â	O
	O
SHH	O
,	O
MMP9	O
and	O
MMP12	O
.	O

We	O
confirm	O
by	O
western	O
blot	O
that	O
a	O
subset	O
of	O
these	O
targets	O
is	O
highly	O
expressed	O
in	O
ACP	O
primary	O
tumor	O
samples	O
.	O

Conclusions	O
We	O
report	O
here	O
the	O
first	O
published	O
transcriptome	O
for	O
ACP	O
and	O
the	O
identification	O
of	O
targets	O
for	O
rational	O
therapy	O
.	O

Experimental	O
drugs	O
targeting	O
each	O
of	O
these	O
gene	O
products	O
are	O
currently	O
being	O
tested	O
clinically	O
and	O
pre	O
-	O
clinically	O
for	O
the	O
treatment	O
of	O
other	O
tumor	O
types	O
.	O

This	O
study	O
provides	O
a	O
rationale	O
for	O
further	O
pre	O
-	O
clinical	O
and	O
clinical	O
studies	O
of	O
novel	O
pharmacological	O
treatments	O
for	O
ACP	O
.	O

Development	O
of	O
mouse	O
and	O
cell	O
culture	O
models	O
for	O
ACP	O
will	O
further	O
enable	O
the	O
translation	O
of	O
these	O
targets	O
from	O
the	O
lab	O
to	O
the	O
clinic	O
,	O
potentially	O
ushering	O
in	O
a	O
new	O
era	O
in	O
the	O
treatment	O
of	O
ACP	O
.	O

Introduction	O
Adamantinomatous	O
craniopharyngioma	O
(	O
ACP	O
)	O
is	O
the	O
most	O
common	O
non	O
-	O
neural	O
brain	O
tumor	O
with	O
an	O
incidence	O
of	O
approximately	O
1	O
.	O
9	O
cases	O
/	O
million	O
patient	O
-	O
years	O
in	O
children	O
.	O

Due	O
to	O
its	O
sensitive	O
sellar	O
/	O
suprasellar	O
location	O
and	O
propensity	O
to	O
form	O
large	O
cysts	O
,	O
ACP	O
often	O
compresses	O
and	O
damages	O
vital	O
structures	O
of	O
the	O
pituitary	O
,	O
hypothalamus	O
and	O
visual	O
apparatus	O
.	O

Although	B
seemingly	O
well	O
-	O
demarcated	O
on	O
neuroimaging	O
studies	O
,	O
histology	O
reveals	O
finger	O
-	O
like	O
protrusions	O
extending	O
into	O
neighboring	O
visual	O
and	O
hypothalamic	O
structures	O
,	O
eliciting	O
tissue	O
damage	O
and	O
gliosis	O
.	O

This	O
propensity	O
to	O
invade	O
adjacent	O
structures	O
,	O
in	O
addition	O
to	O
the	O
difficult	O
surgical	O
location	O
,	O
often	O
precludes	O
total	O
resection	O
in	O
order	O
to	O
avoid	O
the	O
significantly	O
increased	O
risk	O
of	O
visual	O
and	O
hypothalamic	O
damage	O
associated	O
with	O
attempts	O
to	O
completely	O
remove	O
the	O
tumor	O
.	O

The	O
current	O
standard	O
of	O
subtotal	O
resection	O
followed	O
by	O
radiation	O
reduces	O
some	O
of	O
the	O
morbidity	O
,	O
however	B
,	O
it	O
makes	O
recurrence	O
relatively	O
common	O
,	O
even	O
after	O
apparently	O
successful	O
primary	O
therapy	O
.	O

Outcomes	O
after	O
recurrence	O
are	O
poorer	O
,	O
with	O
significantly	O
higher	O
mortality	O
and	O
morbidity	O
than	O
after	O
primary	O
treatment	O
.	O

While	B
conservative	O
surgery	O
and	O
radiation	O
confer	O
low	O
mortality	O
,	O
the	O
morbidity	O
for	O
survivors	O
is	O
still	O
unacceptably	O
high	O
.	O

Variable	O
morbidities	O
are	O
associated	O
with	O
ACP	O
but	O
include	O
endocrine	O
,	O
neurological	O
,	O
vascular	O
,	O
psychological	O
and	O
visual	O
deficits	O
.	O

As	O
a	O
result	O
,	O
ACP	O
has	O
been	O
associated	O
with	O
the	O
lowest	O
quality	O
of	O
life	O
(	O
QoL	O
)	O
scores	O
of	O
any	O
pediatric	O
brain	O
tumor	O
.	O

Lifelong	O
care	O
is	O
necessary	O
for	O
most	O
childhood	O
craniopharyngioma	O
patients	O
and	O
ACP	O
and	O
is	O
considered	O
by	O
many	O
to	O
be	O
a	O
chronic	O
disease	O
.	O

The	O
introduction	O
of	O
rational	O
therapy	O
to	O
treat	O
craniopharyngioma	O
could	O
drastically	O
reduce	O
the	O
morbidity	O
associated	O
with	O
both	O
the	O
primary	O
disease	O
and	O
current	O
treatments	O
by	O
reducing	O
the	O
extent	O
of	O
resection	O
and	O
/	O
or	O
reducing	O
or	O
eliminating	O
the	O
need	O
for	O
subsequent	O
radiation	O
.	O

Such	O
a	O
paradigm	O
change	O
in	O
ACP	O
treatment	O
is	O
critical	O
to	O
improving	O
long	O
term	O
QoL	O
for	O
patients	O
with	O
this	O
debilitating	O
disease	O
.	O

Progress	O
regarding	O
our	O
understanding	O
of	O
the	O
biological	O
drivers	O
of	O
ACP	O
growth	O
has	O
been	O
slowed	O
by	O
the	O
relative	O
rarity	O
of	O
the	O
tumor	O
and	O
the	O
recalcitrance	O
of	O
ACP	O
cells	O
to	O
laboratory	O
growth	O
.	O

Lack	O
of	O
knowledge	O
of	O
the	O
underlying	O
biology	O
,	O
combined	O
with	O
the	O
clinical	O
complexity	O
of	O
ACP	O
have	O
led	O
to	O
an	O
absence	O
of	O
standard	O
systemic	O
antitumor	O
therapies	O
.	O

Few	O
attempts	O
to	O
remedy	O
this	O
deficit	O
have	O
been	O
made	O
,	O
in	O
part	O
because	O
current	O
therapy	O
has	O
acceptable	O
survival	O
outcomes	O
.	O

Nevertheless	B
,	O
substantial	O
progress	O
has	O
been	O
made	O
recently	O
through	O
tissue	O
banking	O
collaborations	O
and	O
â	O
	O
omicsâ	O
	O
approaches	O
.	O

Virtually	O
all	O
craniopharyngiomas	O
in	O
childhood	O
are	O
of	O
the	O
adamantinomatous	O
type	O
(	O
ACP	O
),	O
contrasting	B
with	O
adults	O
in	O
whom	O
up	O
to	O
10Â	O
%	O
of	O
craniopharyngiomas	O
are	O
papillary	O
,	O
and	O
are	O
now	O
known	O
to	O
be	O
driven	O
by	O
BRAF	O
V600E	O
mutations	O
.	O

The	O
only	O
known	O
genetic	O
alterations	O
in	O
adamatinomatous	O
craniopharyngioma	O
(	O
ACP	O
)	O
are	O
point	O
mutations	O
in	O
exon	O
3	O
of	O
CTNNB1	O
that	O
lead	O
to	O
Î²	O
-	O
catenin	O
accumulation	O
and	O
upregulation	O
of	O
downstream	O
target	O
gene	O
expression	O
.	O

While	B
the	O
reported	O
frequency	O
of	O
CTNNB1	O
sequence	O
alterations	O
ranges	O
from	O
16â	O
	O
100Â	O
%,	O
Brastianos	O
and	O
colleagues	O
recently	O
used	O
whole	O
exome	O
sequencing	O
and	O
mass	O
spectrometric	O
genotyping	O
to	O
identify	O
CTNNB1	O
mutations	O
in	O
92â	O
	O
96Â	O
%	O
of	O
ACP	O
.	O

It	O
is	O
likely	O
,	O
however	B
,	O
that	O
genetic	O
,	O
epigenetic	O
or	B
other	B
biological	O
factors	O
in	O
addition	O
to	O
CTNNB1	O
mutation	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
ACP	O
.	O

For	O
instance	O
,	O
Larkin	O
and	O
colleagues	O
described	O
2	O
tumors	O
that	O
harbored	O
alterations	O
in	O
both	O
CTNNB1	O
and	O
BRAF	O
.	O

Furthermore	O
,	O
ACP	O
tumors	O
with	O
CTNNB1	O
mutation	O
contain	O
cells	O
that	O
do	O
not	O
demonstrate	O
intranuclear	O
Î²	O
-	O
catenin	O
accumulation	O
and	O
it	O
has	O
been	O
suggested	O
that	O
some	O
of	O
the	O
cells	O
that	O
comprise	O
the	O
tumor	O
may	O
not	O
actually	O
be	O
CTNNB1	O
mutant	O
â	O
	O
tumorâ	O
	O
cells	O
at	O
all	O
.	O

EGFR	O
pathway	O
activation	O
has	O
also	O
recently	O
been	O
identified	O
as	O
a	O
driver	O
of	O
migration	O
and	O
growth	O
using	O
in	O
-	O
vitro	O
and	O
xenotransplant	O
models	O
of	O
ACP	O
,	O
supporting	O
the	O
testing	O
of	O
EGFR	O
targeted	O
therapies	O
.	O

In	O
addition	O
,	O
through	O
an	O
embryonic	O
mouse	O
model	O
of	O
human	O
ACP	O
,	O
the	O
role	O
of	O
pituitary	O
stem	O
cells	O
in	O
ACP	O
tumorigenesis	O
is	O
being	O
explored	O
.	O

The	O
recent	O
identification	O
of	O
BRAF	O
mutations	O
in	O
papillary	O
craniopharyngioma	O
changes	O
the	O
paradigm	O
in	O
treating	O
this	O
(	O
primarily	O
adult	O
)	O
tumor	O
because	O
of	O
the	O
availability	O
of	O
BRAF	O
V600E	O
-	O
specific	O
inhibitors	O
.	O

By	B
contrast	I
,	O
the	O
identification	O
of	O
Î²	O
-	O
catenin	O
/	O
Wnt	O
signaling	O
as	O
a	O
driver	O
of	O
adamantinomatous	O
craniopharyngioma	O
(	O
ACP	O
)	O
is	O
of	O
little	O
use	O
in	O
guiding	O
therapy	O
because	O
inhibitors	O
of	O
Wnt	O
signaling	O
downstream	O
of	O
Î²	O
-	O
catenin	O
/	O
TCF	O
/	O
LEF	O
are	O
not	O
yet	O
clinically	O
viable	O
.	O

Global	O
gene	O
expression	O
analysis	O
is	O
therefore	O
critical	O
for	O
determining	O
the	O
epigenetic	O
effect	O
of	O
aberrant	O
Î²	O
-	O
catenin	O
driven	O
transcription	O
in	O
ACP	O
in	O
order	O
to	O
find	O
targets	O
for	O
rational	O
therapy	O
.	O

Materials	O
and	O
methods	O
Tumor	O
samples	O
Caption	O
(	O
TABLE	O
-	O
WRAP	O
):	O
TABLE	O
1	O
Î²	O
-	O
catenin	O
and	O
BRAF	O
mutational	O
status	O
of	O
tumor	O
and	O
age	O
of	O
15	O
ACP	O
patient	O
cohort	O
used	O
in	O
transcriptome	O
study	O
UPN	O
Î²	O
-	O
Catenin	O
BRAF	O
Age	O
at	O
Dx	O
411	O
S33F	O
WT	O
2	O
463	O
S37F	O
WT	O
4	O
598	O
S37C	O
WT	O
18	O
646	O
D32N	O
WT	O
7	O
673	O
S37F	O
WT	O
2	O
740	O
S33F	O
WT	O
12	O
802	O
WT	O
WT	O
7	O
883	O
WT	O
WT	O
6	O
956	O
S37C	O
WT	O
9	O
980	O
D32N	O
WT	O
13	O
1000	O
S45F	O
WT	O
0	O
9109	O
WT	O
WT	O
9	O
9201	O
T41I	O
WT	O
-	O
9202	O
T41I	O
WT	O
-	O
9302	O
WT	O
WT	O
-	O
A	O
total	O
of	O
15	O
ACP	O
tumor	O
samples	O
were	O
included	O
in	O
this	O
study	O
.	O

Eleven	O
specimens	O
were	O
from	O
patients	O
who	O
underwent	O
surgical	O
procedures	O
at	O
Childrenâ	O
	O
s	O
Hospital	O
Colorado	O
,	O
from	O
1995	O
through	O
2014	O
.	O

Tumor	O
samples	O
were	O
collected	O
at	O
the	O
time	O
of	O
surgery	O
and	O
snap	O
frozen	O
in	O
liquid	O
nitrogen	O
or	O
fixed	O
in	O
formalin	O
and	O
paraffin	O
embedded	O
.	O

Additional	O
specimens	O
were	O
contributed	O
by	O
the	O
University	O
of	O
Alabama	O
,	O
Columbia	O
University	O
and	O
Phoenix	O
Childrenâ	O
	O
s	O
Hospital	O
.	O

The	O
median	O
age	O
of	O
this	O
cohort	O
was	O
7Â	O
years	O
(	O
range	O
0	O
to	O
18Â	O
years	O
)	O
(	O
TableÂ	O
1	O
).	O

Purity	O
of	O
ACP	O
tumor	O
samples	O
was	O
determined	O
by	O
histological	O
analysis	O
using	O
hematoxylin	O
and	O
eosin	O
staining	O
in	O
addition	O
to	O
immunostaining	O
for	O
Î²	O
-	O
catenin	O
.	O

A	O
further	O
176	O
samples	O
of	O
other	O
primary	O
tumors	O
and	O
a	O
variety	O
of	O
normal	O
cerebral	O
tissues	O
were	O
used	O
for	O
comparative	O
purposes	O
.	O

This	O
cohort	O
included	O
samples	O
from	O
the	O
spectrum	O
of	O
pediatric	O
and	O
adult	O
brain	O
tumor	O
types	O
(	O
20	O
atypical	O
teratoid	O
/	O
rhabdoid	O
tumor	O
(	O
AT	O
/	O
RT	O
),	O
5	O
choroid	O
plexus	O
papilloma	O
(	O
CPP	O
),	O
46	O
ependymoma	O
(	O
EPN	O
),	O
12	O
glioblastoma	O
(	O
GBM	O
),	O
22	O
medulloblastoma	O
(	O
MED	O
),	O
9	O
meningioma	O
(	O
MEN	O
),	O
15	O
pilocytic	O
astrocytoma	O
(	O
PA	O
),	O
13	O
primitive	O
neuroepithelial	O
tumor	O
(	O
PNET	O
))	O
and	O
other	O
peripheral	O
pediatric	O
solid	O
tumors	O
(	O
6	O
malignant	O
peripheral	O
nerve	O
sheath	O
tumors	O
(	O
MPNST	O
),	O
8	O
rhabdomyosarcoma	O
(	O
RMS	O
)).	O

Specimens	O
were	O
classified	O
according	O
to	O
WHO	O
international	O
histological	O
tumor	O
classification	O
.	O

Normal	O
pediatric	O
brain	O
samples	O
from	O
a	O
variety	O
of	O
anatomic	O
sites	O
were	O
obtained	O
during	O
routine	O
epilepsy	O
surgery	O
or	O
autopsy	O
at	O
Childrenâ	O
	O
s	O
Hospital	O
Colorado	O
.	O

All	O
samples	O
were	O
obtained	O
in	O
compliance	O
with	O
internal	O
review	O
board	O
regulations	O
(	O
COMIRB	O
#	O
95	O
-	O
500	O
and	O
#	O
09	O
-	O
0906	O
).	O

Nucleic	O
acid	O
extraction	O
,	O
amplification	O
and	O
microarray	O
preparation	O
RNA	O
from	O
all	O
surgical	O
specimens	O
was	O
extracted	O
,	O
amplified	O
,	O
labeled	O
and	O
hybridized	O
to	O
Affymetrix	O
HG	O
-	O
U113	O
plus	O
2	O
microarray	O
chips	O
(	O
Affymetrix	O
,	O
Santa	O
Clara	O
,	O
CA	O
,	O
USA	O
)	O
according	O
to	O
manufacturerâ	O
	O
s	O
instructions	O
and	O
as	O
described	O
previously	O
.	O

SNaPshot	O
analysis	O
for	O
CTNNB1	O
and	O
BRAF	O
mutations	O
was	O
performed	O
at	O
the	O
University	O
of	O
Colorado	O
Pathology	O
Core	O
per	O
manufacturerâ	O
	O
s	O
instructions	O
and	O
as	O
described	O
previously	O
.	O

Patient	O
characteristics	O
,	O
including	O
presence	O
or	O
absence	O
of	O
CTNNB1	O
mutations	O
by	O
SNaPshot	O
analysis	O
,	O
are	O
shown	O
in	O
TableÂ	O
1	O
.	O

SNaPshot	O
analysis	O
was	O
also	O
used	O
to	O
examine	O
BRAF	O
mutational	O
status	O
(	O
TableÂ	O
1	O
),	O
specifically	O
BRAF	O
V600E	O
,	O
which	O
was	O
recently	O
identified	O
in	O
papillary	O
craniopharyngioma	O
.	O

This	O
mutation	O
was	O
not	O
found	O
in	O
any	O
ACP	O
sample	O
tested	O
.	O

Microarray	O
data	O
analysis	O
Data	O
analysis	O
was	O
performed	O
in	O
R	O
(	O
http	O
://	O
www	O
.	O
r	O
-	O
project	O
.	O
org	O
),	O
using	O
packages	O
publicly	O
available	O
through	O
Bioconductor	O
(	O
http	O
://	O
www	O
.	O
bioconductor	O
.	O
org	O
).	O

As	O
a	O
first	O
step	O
,	O
the	O
scanned	O
microarray	O
data	O
were	O
background	O
corrected	O
and	O
normalized	O
using	O
the	O
gcRMA	O
algorithm	O
resulting	O
in	O
log	O
2	O
gene	O
expression	O
values	O
.	O

Publically	O
available	O
microarray	O
CEL	O
file	O
data	O
were	O
obtained	O
for	O
9	O
normal	O
pituitary	O
and	O
14	O
pituitary	O
adenoma	O
samples	O
from	O
GEO	O
(	O
GSE26966	O
);	O
these	O
samples	O
were	O
chosen	O
because	O
they	O
were	O
processed	O
in	O
the	O
same	O
manner	O
as	O
ours	O
and	O
through	O
the	O
same	O
microarray	O
core	O
lab	O
.	O

These	O
were	O
combined	O
with	O
the	O
ACP	O
,	O
other	O
tumor	O
,	O
and	O
normal	O
brain	O
cohort	O
as	O
detailed	O
above	O
.	O

Multiple	O
probesets	O
for	O
a	O
gene	O
were	O
then	O
collapsed	O
to	O
1	O
entry	O
per	O
gene	O
,	O
based	O
on	O
the	O
mean	O
best	O
-	O
expressed	O
probeset	O
for	O
that	O
gene	O
.	O

Hierarchical	O
clustering	O
was	O
performed	O
using	O
the	O
normalized	O
gene	O
expression	O
data	O
.	O

Distances	O
based	O
on	O
Spearman	O
correlations	O
were	O
calculated	O
for	O
input	O
to	O
an	O
agglomerative	O
algorithm	O
with	O
use	O
of	O
complete	O
linkage	O
,	O
as	O
implemented	O
in	O
the	O
Bioconductor	O
hclust	O
function	O
.	O

These	O
microarray	O
data	O
have	O
been	O
deposited	O
in	O
the	O
National	O
Center	O
for	O
Biotechnology	O
Information	O
Gene	O
Expression	O
Omnibus	O
(	O
GEO	O
)	O
database	O
and	O
are	O
publicly	O
accessible	O
through	O
GEO	O
Series	O
accession	O
number	O
GSE68015	O
(	O
http	O
://	O
www	O
.	O
ncbi	O
.	O
nlm	O
.	O
nih	O
.	O
gov	O
/	O
geo	O
/	O
query	O
/	O
acc	O
.	O
cgi	O
?	O
acc	O
=	O
GSE68015	O
).	O

Differential	O
gene	O
expression	O
between	O
ACP	O
and	O
multiple	O
other	O
tumor	O
and	O
normal	O
tissue	O
types	O
was	O
calculated	O
using	O
the	O
Bioconductor	O
limma	O
function	O
.	O

Data	O
were	O
filtered	O
before	O
input	O
to	O
eliminate	O
genes	O
not	O
expressed	O
in	O
any	O
samples	O
or	O
that	O
showed	O
only	O
limited	O
variance	O
across	O
samples	O
.	O

The	O
limma	O
function	O
performs	O
pair	O
-	O
wise	O
comparisons	O
between	O
a	O
target	O
group	O
and	O
each	O
of	O
the	O
other	O
user	O
-	O
defined	O
groups	O
in	O
the	O
dataset	O
.	O

It	O
uses	O
an	O
Empirical	O
Bayes	O
approach	O
to	O
calculate	O
a	O
moderated	O
t	O
-	O
statistic	O
and	O
calculates	O
a	O
false	O
discovery	O
rate	O
(	O
FDR	O
)	O
that	O
accounts	O
for	O
multiple	O
testing	O
both	O
within	O
and	O
across	O
groups	O
.	O

The	O
unique	O
molecular	O
signature	O
of	O
ACP	O
was	O
defined	O
as	O
genes	O
that	O
showed	O
significant	O
differential	O
expression	O
in	O
all	O
of	O
the	O
pair	O
-	O
wise	O
comparisons	O
(	O
FDR	O
â	O
¤	O
0	O
.	O
1	O
and	O
mean	O
fold	O
difference	O
â	O
¥	O
1	O
.	O
5	O
)	O
and	O
for	O
which	O
the	O
mean	O
difference	O
was	O
in	O
the	O
same	O
direction	O
when	O
compared	O
with	O
all	O
of	O
the	O
other	O
clusters	O
(	O
i	O
.	O
e	O
.,	O
either	O
all	O
upregulated	O
or	O
all	O
downregulated	O
in	O
all	O
of	O
the	O
comparisons	O
with	O
respect	O
to	O
ACP	O
).	O

In	O
further	O
analyses	O
,	O
individual	O
tumor	O
gene	O
expression	O
of	O
select	O
genes	O
involved	O
in	O
putative	O
ACP	O
development	O
/	O
biology	O
were	O
extracted	O
from	O
the	O
normalized	O
dataset	O
.	O

For	O
these	O
comparisons	O
,	O
normalized	O
hybridization	O
intensity	O
values	O
for	O
a	O
selected	O
gene	O
for	O
individual	O
ACP	O
samples	O
were	O
presented	O
as	O
fold	O
-	O
difference	O
relative	O
to	O
the	O
average	O
of	O
all	O
other	O
tumor	O
and	O
normal	O
samples	O
.	O

Data	O
analysis	O
using	O
hierarchical	O
clustering	O
,	O
NIH	O
Database	O
for	O
Annotation	O
,	O
Visualization	O
,	O
and	O
Integrated	O
Discovery	O
(	O
DAVID	O
)	O
bioinformatics	O
tools	O
has	O
been	O
previously	O
described	O
.	O

Functional	O
analysis	O
of	O
genes	O
was	O
performed	O
with	O
DAVID	O
using	O
the	O
Gene	O
Ontology	O
,	O
Protein	O
Analysis	O
Through	O
Evolutionary	O
Relationships	O
(	O
PANTHER	O
)	O
Biological	O
Process	O
and	O
KEGG	O
databases	O
.	O

ACP	O
upregulated	O
genes	O
were	O
compared	O
to	O
known	O
targets	O
of	O
FDA	O
approved	O
and	O
other	O
oncology	O
drugs	O
that	O
had	O
reached	O
clinical	O
trial	O
stage	O
,	O
as	O
published	O
in	O
the	O
literature	O
and	O
compiled	O
in	O
Ingenuityâ	O
	O
s	O
KnowledgeBase	O
(	O
Ingenuity	O
Systems	O
,	O
www	O
.	O
ingenuity	O
.	O
com	O
).	O

Oncology	O
drug	O
target	O
gene	O
expression	O
in	O
individual	O
ACP	O
samples	O
(	O
nâ	O
=	O
â	O
	O
15	O
)	O
was	O
compared	O
to	O
all	O
other	O
tumor	O
and	O
normal	O
tissue	O
combined	O
and	O
assigned	O
percentile	O
scores	O
.	O

Drug	O
target	O
genes	O
that	O
were	O
consistently	O
highly	O
expressed	O
(>	O
66th	O
percentile	O
)	O
in	O
all	O
ACP	O
samples	O
were	O
identified	O
,	O
and	O
then	O
ranked	O
according	O
to	O
the	O
highest	O
average	O
percentile	O
expression	O
.	O

Western	O
blot	O
validation	O
of	O
functional	O
isoforms	O
of	O
putative	O
drug	O
targets	O
Protein	O
levels	O
of	O
a	O
selection	O
of	O
putative	O
drug	O
target	O
genes	O
in	O
ACP	O
were	O
examined	O
by	O
Western	O
blot	O
analysis	O
to	O
validate	O
the	O
results	O
of	O
microarray	O
analysis	O
.	O

Snap	O
frozen	O
tumor	O
samples	O
were	O
homogenized	O
in	O
RIPA	O
buffer	O
(	O
Sigma	O
)	O
supplemented	O
with	O
protease	O
and	O
phosphatase	O
inhibitors	O
(	O
Roche	O
).	O

This	O
study	O
utilized	O
6	O
ACP	O
samples	O
and	O
3	O
each	O
of	O
AT	O
/	O
RT	O
,	O
EPN	O
,	O
GBM	O
,	O
MED	O
,	O
PA	O
and	O
normal	O
brain	O
(	O
obtained	O
from	O
autopsy	O
material	O
).	O

Proteins	O
samples	O
(	O
30Â	O
Î¼g	O
)	O
were	O
resolved	O
on	O
a	O
26	O
well	O
Criterion	O
Gel	O
(	O
BioRad	O
)	O
and	O
transferred	O
to	O
Immobilon	O
PVDF	O
membrane	O
(	O
Millipore	O
).	O

Membranes	O
were	O
probed	O
with	O
antibodies	O
to	O
SHH	O
(	O
Millipore	O
#	O
06	O
-	O
1106	O
;	O
1	O
:	O
1000	O
),	O
MMP9	O
(	O
Cell	O
Signaling	O
#	O
3852	O
;	O
1	O
:	O
1000	O
),	O
MMP12	O
(	O
R	O
&	O
D	O
Systems	O
#	O
AF917	O
;	O
1	O
:	O
1000	O
)	O
and	O
Actin	O
(	O
Cell	O
Signaling	O
#	O
12262	O
;	O
1	O
:	O
10	O
,	O
000	O
).	O

Results	O
Identification	O
of	O
potential	O
drug	O
targets	O
and	O
ACP	O
signature	O
genes	O
Caption	O
(	O
TABLE	O
-	O
WRAP	O
):	O
TABLE	O
2	O
Top	O
20	O
therapeutic	O
target	O
genes	O
overexpressed	O
in	O
ACP	O
compared	O
to	O
normal	O
brain	O
tissues	O
and	O
a	O
variety	O
of	O
CNS	O
and	O
peripheral	O
malignancies	O
Symbol	O
Gene	O
name	O
Average	O
percentile	O
#	O
of	O
ACP	O
>	O
66th	O
%-	O
ile	O
Therapeutic	O
agents	O
Fold	O
p	O
-	O
Value	O
MMP12	O
matrix	O
metallopeptidase	O
12	O
99	O
.	O
4	O
15	O
AZD1236	O
820	O
3	O
.	O
03E	O
-	O
49	O
SHH	O
sonic	O
hedgehog	O
homolog	O
98	O
.	O
9	O
15	O
Erismodegib	O
,	O
Vismodegib	O
96	O
.	O
8	O
1	O
.	O
48E	O
-	O
48	O
IL2RB	O
interleukin	O
2	O
receptor	O
,	O
beta	O
96	O
.	O
7	O
15	O
Denileukin	O
diftitox	O
12	O
.	O
4	O
4	O
.	O
87E	O
-	O
23	O
LCK	O
lymphocyte	O
-	O
specific	O
protein	O
tyrosine	O
kinase	O
95	O
.	O
2	O
15	O
Dasatinib	O
,	O
Pazopanib	O
5	O
.	O
50	O
8	O
.	O
24E	O
-	O
16	O
EPHA2	O
EPH	O
receptor	O
A2	O
95	O
.	O
1	O
15	O
Dasatinib	O
,	O
Regorafenib	O
16	O
.	O
6	O
6	O
.	O
8E	O
-	O
16	O
AREG	O
Amphiregulin	O
93	O
.	O
9	O
15	O
Cetuximab	O
20	O
.	O
8	O
4	O
.	O
82E	O
-	O
17	O
PIK3CD	O
phosphoinositide	O
-	O
3	O
-	O
kinase	O
,	O
catalytic	O
,	O
delta	O
93	O
.	O
8	O
15	O
Idelalisib	O
6	O
.	O
79	O
3	O
.	O
55E	O
-	O
10	O
IL6R	O
interleukin	O
6	O
receptor	O
91	O
.	O
9	O
15	O
Siltuximab	O
6	O
.	O
13	O
7	O
.	O
06E	O
-	O
8	O
MMP9	O
matrix	O
metallopeptidase	O
9	O
91	O
.	O
6	O
15	O
AZD1236	O
41	O
.	O
0	O
9	O
.	O
79E	O
-	O
14	O
EPCAM	O
epithelial	O
cell	O
adhesion	O
molecule	O
90	O
.	O
7	O
15	O
Tucotuzumab	O
celmoleukin	O
87	O
.	O
4	O
2	O
.	O
01E	O
-	O
11	O
SRC	O
v	O
-	O
src	O
sarcoma	O
(	O
Schmidt	O
-	O
Ruppin	O
A	O
-	O
2	O
)	O
viral	O
oncogene	O
homolog	O
89	O
.	O
9	O
15	O
Bosutinib	O
,	O
Dasatinib	O
2	O
.	O
47	O
3	O
.	O
71e	O
-	O
7	O
MUC1	O
mucin	O
1	O
89	O
.	O
3	O
15	O
HuHMFG1	O
6	O
.	O
30	O
1	O
.	O
27E	O
-	O
7	O
ERBB3	O
v	O
-	O
erb	O
-	O
b2	O
erythroblastic	O
leukemia	O
viral	O
oncogene	O
homolog	O
3	O
86	O
.	O
7	O
15	O
Lapatinib	O
22	O
.	O
8	O
4	O
.	O
19E	O
-	O
08	O
TNFSF11	O
tumor	O
necrosis	O
factor	O
(	O
ligand	O
)	O
superfamily	O
,	O
member	O
11	O
91	O
.	O
7	O
14	O
Denosumab	O
5	O
.	O
17	O
4	O
.	O
28E	O
-	O
8	O
MAPK14	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
14	O
91	O
.	O
3	O
14	O
Regorafenib	O
2	O
.	O
65	O
2	O
.	O
49E	O
-	O
8	O
PTGS2	O
prostaglandin	O
-	O
endoperoxide	O
synthase	O
2	O
85	O
.	O
6	O
14	O
Lenalidomide	O
10	O
.	O
5	O
9	O
.	O
23E	O
-	O
7	O
RRAS	O
related	O
RAS	O
viral	O
(	O
r	O
-	O
ras	O
)	O
oncogene	O
homolog	O
85	O
.	O
4	O
14	O
Sorafenib	O
3	O
.	O
61	O
2	O
.	O
32E	O
-	O
5	O
PSMB1	O
proteasome	O
(	O
prosome	O
,	O
macropain	O
)	O
subunit	O
,	O
beta	O
type	O
,	O
1	O
83	O
.	O
8	O
14	O
Carfilzomib	O
1	O
.	O
45	O
5	O
.	O
85E	O
-	O
5	O
EGFR	O
epidermal	O
growth	O
factor	O
receptor	O
83	O
.	O
4	O
14	O
Cetuximab	O
,	O
Erlotinib	O
,	O
Gefitinib	O
,	O
Lapatinib	O
,	O
etc	O
.	O

7	O
.	O
57	O
5	O
.	O
99E	O
-	O
05	O
CD52	O
CD52	O
molecule	O
86	O
.	O
3	O
13	O
Alemtuzumab	O
8	O
.	O
85	O
4	O
.	O
51E	O
-	O
12	O
Caption	O
(	O
Fig	O
):	O
FIG	O
1	O
Gene	O
expression	O
of	O
potential	O
targets	O
for	O
therapeutic	O
intervention	O
in	O
ACP	O
.	O

Expression	O
of	O
the	O
indicated	O
genes	O
in	O
ACP	O
relative	O
to	O
a	O
broad	O
range	O
of	O
pediatric	O
and	O
adult	O
brain	O
tumor	O
types	O
:	O
atypical	O
teratoid	O
/	O
rhabdoid	O
tumor	O
(	O
AT	O
/	O
RT	O
),	O
choroid	O
plexus	O
papilloma	O
(	O
CPP	O
),	O
ependymoma	O
(	O
EPN	O
),	O
glioblastoma	O
multiforme	O
(	O
GBM	O
),	O
medulloblastoma	O
(	O
MED	O
),	O
meningioma	O
(	O
MEN	O
),	O
pilocytic	O
astrocytoma	O
(	O
PA	O
),	O
primitive	O
neuroectodermal	O
tumor	O
(	O
PNET	O
);	O
peripheral	O
pediatric	O
solid	O
tumors	O
:	O
malignant	O
peripheral	O
nerve	O
sheath	O
tumors	O
(	O
MPNST	O
),	O
rhabdomyosarcoma	O
(	O
RMS	O
);	O
in	O
addition	O
to	O
malignant	O
(	O
pituitary	O
adenoma	O
)	O
and	O
normal	O
pituitary	O
(	O
PT	O
and	O
N_P	O
respectively	O
);	O
and	O
normal	O
brain	O
and	O
choroid	O
plexus	O
(	O
N_B	O
and	O
N_CP	O
respectively	O
).	O

Dasatinib	O
targets	O
,	O
LCK	O
(	O
lymphocyte	O
-	O
specific	O
protein	O
tyrosine	O
kinase	O
),	O
EPHA2	O
(	O
ephrin	O
type	O
-	O
A	O
receptor	O
2	O
)	O
and	O
SRC	O
(	O
SRC	O
proto	O
-	O
oncogene	O
,	O
non	O
-	O
receptor	O
tyrosine	O
kinase	O
)	O
(	O
a	O
).	O

Sonic	O
hedgehog	O
homolog	O
(	O
b	O
).	O

Matrix	O
metalloproteases	O
9	O
&	O
12	O
(	O
c	O
).	O

EGF	O
pathway	O
genes	O
(	O
d	O
).	O

Values	O
are	O
expressed	O
as	O
log2	O
gene	O
expression	O
.	O

Horizontal	O
red	O
bars	O
represent	O
the	O
mean	O
,	O
and	O
error	O
bars	O
represent	O
standard	O
error	O
of	O
the	O
mean	O
(	O
SEM	O
)	O
Caption	O
(	O
Fig	O
):	O
FIG	O
2	O
Overexpression	O
of	O
active	O
protein	O
isoforms	O
for	O
SHH	O
,	O
MMP9	O
and	O
MMP12	O
in	O
ACP	O
relative	O
to	O
other	O
common	O
pediatric	O
brain	O
tumors	O
and	O
normal	O
brain	O
.	O

Western	O
blot	O
analysis	O
was	O
used	O
to	O
determine	O
latent	O
preforms	O
and	O
cleaved	O
active	O
isoforms	O
of	O
the	O
indicated	O
proteins	O
.	O

(	O
Abbr	O
:	O
AT	O
/	O
RT	O
,	O
atypical	O
teratoid	O
/	O
rhabdoid	O
tumor	O
;	O
EPN	O
,	O
ependymoma	O
;	O
GBM	O
,	O
glioblastoma	O
;	O
MED	O
,	O
medulloblastoma	O
;	O
PA	O
,	O
pilocytic	O
astrocytoma	O
;	O
Norm	O
,	O
normal	O
brain	O
)	O
The	O
Î²	O
-	O
catenin	O
and	O
BRAF	O
mutational	O
status	O
of	O
each	O
tumor	O
sample	O
is	O
presented	O
in	O
TableÂ	O
1	O
.	O

To	O
explore	O
the	O
clinical	O
relevance	O
of	O
our	O
human	O
pediatric	O
ACP	O
transcriptomic	O
data	O
,	O
we	O
screened	O
the	O
ACP	O
signature	O
for	O
upregulation	O
of	O
genes	O
associated	O
with	O
potential	O
oncological	O
drug	O
targets	O
for	O
the	O
treatment	O
of	O
these	O
tumors	O
.	O

Genes	O
with	O
high	O
expression	O
in	O
ACP	O
samples	O
(	O
nâ	O
=	O
â	O
	O
15	O
)	O
versus	O
all	O
other	O
normal	O
and	O
neoplastic	O
tissue	O
samples	O
(	O
nâ	O
=	O
â	O
	O
195	O
)	O
were	O
compared	B
to	O
known	O
targets	O
of	O
oncology	O
drugs	O
as	O
published	O
in	O
the	O
literature	O
and	O
compiled	O
in	O
IPA	O
KnowledgeBase	O
.	O

This	O
approach	O
identified	O
13	O
drug	O
target	O
transcripts	O
that	O
were	O
consistently	O
overexpressed	O
greater	O
than	O
the	O
66th	O
percentile	O
in	O
ACP	O
(	O
TableÂ	O
2	O
).	O

Three	O
of	O
the	O
13	O
consistently	O
elevated	O
drug	O
target	O
genes	O
,	O
LCK	O
(	O
lymphocyte	O
-	O
specific	O
protein	O
tyrosine	O
kinase	O
)	O
(	O
5	O
.	O
5	O
fold	O
change	O
(	O
FC	O
)	O
in	O
ACP	O
versus	O
all	O
other	O
samples	O
combined	O
,	O
pâ	O
=	O
â	O
	O
8	O
.	O
2â	O
	O
Ã	O
	O
â	O
	O
10â	O
	O
16	O
),	O
EPHA2	O
(	O
ephrin	O
type	O
-	O
A	O
receptor	O
2	O
)	O
(	O
FCâ	O
=	O
â	O
	O
16	O
.	O
6	O
,	O
pâ	O
=	O
â	O
	O
6	O
.	O
8â	O
	O
Ã	O
	O
â	O
	O
10â	O
	O
16	O
)	O
and	O
SRC	O
(	O
SRC	O
proto	O
-	O
oncogene	O
,	O
non	O
-	O
receptor	O
tyrosine	O
kinase	O
)	O
(	O
FCâ	O
=	O
â	O
	O
2	O
.	O
5	O
,	O
pâ	O
=	O
â	O
	O
3	O
.	O
7â	O
	O
Ã	O
	O
â	O
	O
10â	O
	O
7	O
),	O
are	O
targets	O
of	O
a	O
single	O
FDA	O
-	O
approved	O
drug	O
,	O
dasatinib	O
(	O
Fig	O
.	O
Â	O
1a	O
).	O

Other	O
combinations	O
of	O
genes	O
overexpressed	O
by	O
ACP	O
that	O
could	O
be	O
targeted	O
by	O
a	O
single	O
drug	O
were	O
identified	O
.	O

SHH	O
(	O
sonic	O
hedgehog	O
homolog	O
)	O
was	O
shown	O
to	O
be	O
highly	O
expressed	O
(	O
FCâ	O
=	O
â	O
	O
96	O
.	O
9	O
,	O
pâ	O
=	O
â	O
	O
1	O
.	O
5â	O
	O
Ã	O
	O
â	O
	O
10â	O
	O
48	O
)	O
by	O
ACP	O
in	O
this	O
study	O
(	O
Fig	O
.	O
Â	O
1b	O
),	O
which	O
is	O
consistent	O
with	O
a	O
recently	O
developed	O
mouse	O
model	O
of	O
ACP	O
and	O
is	O
the	O
focus	O
of	O
oncology	O
drug	O
development	O
for	O
a	O
number	O
of	O
tumor	O
types	O
.	O

SHH	O
is	O
translated	O
as	O
an	O
inactive	O
precursor	O
45Â	O
kDa	O
protein	O
that	O
is	O
cleaved	O
to	O
generate	O
an	O
active	O
19Â	O
kDa	O
isoform	O
.	O

As	O
a	O
putative	O
drug	O
target	O
in	O
ACP	O
,	O
we	O
measured	O
the	O
levels	O
of	O
precursor	O
and	O
active	O
isoforms	O
for	O
SHH	O
by	O
Western	O
blot	O
analysis	O
.	O

Isoform	O
levels	O
were	O
compared	O
to	O
a	O
panel	O
of	O
other	B
pediatric	O
brain	O
tumor	O
types	O
and	O
normal	O
brain	O
.	O

This	O
revealed	O
that	O
although	O
the	O
inactive	O
precursor	O
is	O
expressed	O
broadly	O
across	O
all	O
tumor	O
types	O
,	O
the	O
active	O
isoform	O
is	O
present	O
at	O
high	O
levels	O
only	O
in	O
ACP	O
(	O
Fig	O
.	O
Â	O
2	O
).	O

ACP	O
was	O
also	O
found	O
to	O
overexpress	O
MMP9	O
(	O
FCâ	O
=	O
â	O
	O
41	O
.	O
0	O
,	O
pâ	O
=	O
â	O
	O
9	O
.	O
8â	O
	O
Ã	O
	O
â	O
	O
10â	O
	O
14	O
)	O
and	O
,	O
more	O
strikingly	O
,	O
MMP12	O
(	O
FCâ	O
=	O
â	O
	O
819	O
.	O
7	O
,	O
pâ	O
=	O
â	O
	O
3	O
.	O
0â	O
	O
Ã	O
	O
â	O
	O
10â	O
	O
49	O
)	O
(	O
Fig	O
.	O
Â	O
1c	O
),	O
which	O
are	O
both	O
inhibited	O
by	O
AZD1236	O
,	O
a	O
drug	O
originally	O
tested	O
as	O
a	O
treatment	O
for	O
chronic	O
obstructive	O
pulmonary	O
disease	O
,	O
but	O
more	O
recently	O
investigated	O
as	O
an	O
antitumor	O
agent	O
.	O

Like	O
SHH	O
,	O
MMP9	O
and	O
12	O
are	O
translated	O
as	O
inactive	O
precursor	O
proteins	O
(	O
92	O
and	O
55Â	O
kDa	O
respectively	O
)	O
that	O
are	O
cleaved	O
to	O
generate	O
active	O
isoforms	O
(	O
84	O
and	O
43	O
/	O
22Â	O
kDa	O
,	O
respectively	O
).	O

MMP	O
isoform	O
levels	O
were	O
compared	O
to	O
a	O
panel	O
of	O
other	O
pediatric	O
brain	O
tumor	O
types	O
and	O
normal	O
brain	O
.	O

The	O
latent	O
precursor	O
of	O
MMP9	O
was	O
identified	O
in	O
all	O
tumor	O
types	O
but	O
not	O
normal	O
brain	O
,	O
whereas	O
the	O
active	O
isoform	O
was	O
only	O
observed	O
in	O
ACP	O
(	O
Fig	O
.	O
Â	O
2	O
).	O

Both	O
the	O
active	O
and	O
inactive	O
isoforms	O
of	O
MMP12	O
were	O
restricted	O
to	O
ACP	O
(	O
Fig	O
.	O
Â	O
2	O
).	O

ACP	O
additionally	O
overexpressed	O
AREG	O
(	O
FCâ	O
=	O
â	O
	O
20	O
.	O
9	O
,	O
pâ	O
=	O
â	O
	O
4	O
.	O
8â	O
	O
Ã	O
	O
â	O
	O
10â	O
	O
17	O
),	O
EGFR	O
(	O
FCâ	O
=	O
â	O
	O
7	O
.	O
6	O
,	O
pâ	O
=	O
â	O
	O
6	O
.	O
0â	O
	O
Ã	O
	O
â	O
	O
10â	O
	O
5	O
)	O
and	O
ERBB3	O
(	O
FCâ	O
=	O
â	O
	O
22	O
.	O
8	O
,	O
pâ	O
=	O
â	O
	O
4	O
.	O
2â	O
	O
Ã	O
	O
â	O
	O
10â	O
	O
8	O
)	O
(	O
Fig	O
.	O
Â	O
1d	O
).	O

Each	O
of	O
these	O
is	O
a	O
target	O
of	O
the	O
numerous	O
EGFR	O
/	O
ERBB	O
pathway	O
inhibiting	O
drugs	O
(	O
cetuximab	O
,	O
erlotinib	O
,	O
lapatinib	O
).	O

Transcriptome	O
microarray	O
clustering	O
analyses	O
Caption	O
(	O
Fig	O
):	O
FIG	O
3	O
Transcriptome	O
cluster	O
analysis	O
reveals	O
similarities	O
between	O
ACP	O
,	O
meningioma	O
and	O
rhabdomyosarcoma	O
,	O
with	O
no	O
relationship	O
to	O
adult	O
pituitary	O
or	O
pituitary	O
adenoma	O
.	O

Unbiased	O
hierarchical	O
clustering	O
analysis	O
of	O
a	O
panel	O
of	O
craniopharyngioma	O
tumor	O
samples	O
compared	O
to	O
other	O
pediatric	O
tumors	O
,	O
normal	O
brain	O
tissue	O
,	O
pituitary	O
tissue	O
and	O
adult	O
pituitary	O
adenomas	O
.	O

The	O
top	O
30Â	O
%	O
most	O
variant	O
genes	O
,	O
were	O
used	O
to	O
generate	O
the	O
clustering	O
dendrogram	O
above	O
.	O

(	O
AT	O
/	O
RT	O
,	O
atypical	O
teratoid	O
/	O
rhabdoid	O
tumor	O
;	O
CPP	O
,	O
choroid	O
plexus	O
papilloma	O
;	O
MPNST	O
,	O
malignant	O
peripheral	O
nerve	O
sheath	O
tumor	O
;	O
GBM	O
,	O
glioblastoma	O
multiforme	O
)	O
Unbiased	O
hierarchical	O
clustering	O
of	O
ACP	O
gene	O
expression	O
data	O
with	O
data	O
from	O
the	O
panel	O
of	O
normal	O
and	O
neoplastic	O
CNS	O
samples	O
and	O
some	O
non	O
-	O
CNS	O
pediatric	O
tumor	O
types	O
(	O
as	O
used	O
above	O
)	O
afforded	O
us	O
further	O
insights	O
into	O
the	O
biology	O
of	O
ACP	O
.	O

ACP	O
samples	O
did	O
not	O
group	O
with	O
the	O
cluster	O
containing	O
both	O
normal	O
and	O
neoplastic	O
pituitary	O
(	O
Fig	O
.	O
Â	O
3	O
).	O

Surprisingly	O
,	O
ACP	O
formed	O
a	O
distinct	O
cluster	O
within	O
a	O
larger	O
cluster	O
containing	O
MEN	O
,	O
MPNST	O
and	O
RMS	O
,	O
a	O
histologically	O
heterogeneous	O
group	O
of	O
tumors	O
derived	O
from	O
various	O
tissue	O
types	O
.	O

While	B
it	O
is	O
perhaps	O
not	O
unexpected	O
that	O
a	O
non	O
-	O
neural	O
tumor	O
like	O
ACP	O
clusters	O
within	O
this	O
group	O
of	O
non	O
-	O
neural	O
tumors	O
,	O
the	O
fact	O
that	O
this	O
cluster	O
lies	O
within	O
the	O
larger	O
neuro	O
-	O
epithelial	O
tumor	O
and	O
normal	O
brain	O
cluster	O
and	O
not	O
with	O
the	O
pituitary	O
tissues	O
is	O
difficult	O
to	O
interpret	O
.	O

This	O
raises	O
the	O
possibility	O
that	O
ACP	O
may	O
have	O
a	O
completely	O
different	B
origin	O
than	B
has	O
been	O
hypothesized	O
;	O
it	O
is	O
more	O
likely	O
however	B
that	O
it	O
has	O
differentiated	O
in	O
such	O
a	O
way	O
that	O
it	O
shares	O
a	O
convergent	O
expression	O
profile	O
in	O
common	O
with	O
these	O
tumors	O
not	O
due	O
to	O
a	O
common	O
tissue	O
of	O
origin	O
.	O

Further	O
analysis	O
of	O
the	O
gene	O
expression	O
signatures	O
responsible	O
for	O
these	O
groupings	O
as	O
well	O
as	O
comparisons	O
with	O
papillary	O
craniopharyngioma	O
and	O
head	O
and	O
neck	O
cancers	O
may	O
give	O
insight	O
into	O
the	O
nature	O
of	O
these	O
groupings	O
.	O

Gene	O
expression	O
signature	O
recapitulates	O
ACP	O
histopathological	O
characteristics	O
Caption	O
(	O
TABLE	O
-	O
WRAP	O
):	O
TABLE	O
3	O
Enriched	O
ontology	O
terms	O
associated	O
with	O
ACP	O
-	O
exclusive	O
genes	O
.	O

Limma	O
identified	O
384	O
genes	O
that	O
were	O
exclusively	O
expressed	O
in	O
ACP	O
compared	O
to	O
a	O
normal	O
brain	O
tissues	O
and	O
a	O
variety	O
of	O
CNS	O
and	O
peripheral	O
malignancies	O
.	O

DAVID	O
was	O
used	O
to	O
identify	O
23	O
enriched	O
ontologies	O
(	O
FDRâ	O
<	O
â	O
	O
0	O
.	O
005	O
)	O
that	O
are	O
shown	O
ranked	O
according	O
to	O
fold	O
enrichment	O
.	O

Abbreviation	O
:	O
Ontology	O
ID	O
prefix	O
GO	O
,	O
Gene	O
ontology	O
biological	O
process	O
;	O
BP	O
,	O
panther	O
biological	O
process	O
;	O
HSA	O
,	O
KEGG	O
pathway	O
;	O
FDR	O
,	O
Benjamini	O
false	O
discovery	O
rate	O
adjusted	O
p	O
-	O
value	O
Ontology	O
term	O
ID	O
Fold	O
enrichment	O
p	O
-	O
Value	O
FDR	O
Biomineral	O
formation	O
GO	O
:	O
31214	O
13	O
.	O
38	O
2	O
.	O
53E	O
-	O
07	O
5	O
.	O
50E	O
-	O
05	O
Odontogenesis	O
of	O
dentine	O
-	O
containing	O
tooth	O
GO	O
:	O
42475	O
11	O
.	O
28	O
5	O
.	O
50E	O
-	O
06	O
8	O
.	O
69E	O
-	O
04	O
Epidermis	O
development	O
GO	O
:	O
8544	O
11	O
.	O
06	O
3	O
.	O
10E	O
-	O
27	O
2	O
.	O
70E	O
-	O
24	O
Ectoderm	O
development	O
GO	O
:	O
7398	O
10	O
.	O
78	O
2	O
.	O
62E	O
-	O
28	O
4	O
.	O
55E	O
-	O
25	O
Epidermal	O
cell	O
differentiation	O
GO	O
:	O
9913	O
9	O
.	O
17	O
6	O
.	O
27E	O
-	O
08	O
1	O
.	O
56E	O
-	O
05	O
Keratinocyte	O
differentiation	O
GO	O
:	O
30216	O
9	O
.	O
17	O
2	O
.	O
74E	O
-	O
07	O
5	O
.	O
29E	O
-	O
05	O
Odontogenesis	O
GO	O
:	O
42476	O
9	O
.	O
17	O
5	O
.	O
23E	O
-	O
06	O
9	O
.	O
09E	O
-	O
04	O
Epithelial	O
cell	O
differentiation	O
GO	O
:	O
30855	O
8	O
.	O
43	O
5	O
.	O
25E	O
-	O
13	O
3	O
.	O
04E	O
-	O
10	O
Skeletal	O
development	O
BP	O
:	O
201	O
5	O
.	O
81	O
7	O
.	O
85E	O
-	O
07	O
1	O
.	O
96E	O
-	O
05	O
Epithelium	O
development	O
GO	O
:	O
60429	O
5	O
.	O
57	O
1	O
.	O
46E	O
-	O
10	O
6	O
.	O
33E	O
-	O
08	O
Bone	O
development	O
GO	O
:	O
60348	O
5	O
.	O
37	O
1	O
.	O
42E	O
-	O
05	O
0	O
.	O
00205	O
Ossification	O
GO	O
:	O
1503	O
5	O
.	O
26	O
4	O
.	O
46E	O
-	O
05	O
0	O
.	O
00515	O
Cell	O
structure	O
BP	O
:	O
286	O
3	O
.	O
72	O
2	O
.	O
38E	O
-	O
14	O
2	O
.	O
98E	O
-	O
12	O
Cell	O
adhesion	O
-	O
mediated	O
signaling	O
BP	O
:	O
120	O
3	O
.	O
66	O
4	O
.	O
34E	O
-	O
08	O
1	O
.	O
36E	O
-	O
06	O
Cytokine	O
-	O
cytokine	O
receptor	O
interaction	O
HSA	O
:	O
4060	O
3	O
.	O
38	O
5	O
.	O
13E	O
-	O
05	O
0	O
.	O
00557	O
Skeletal	O
system	O
development	O
GO	O
:	O
1501	O
3	O
.	O
28	O
2	O
.	O
06E	O
-	O
05	O
0	O
.	O
00274	O
Cell	O
structure	O
and	O
motility	O
BP	O
:	O
285	O
2	O
.	O
85	O
2	O
.	O
68E	O
-	O
13	O
1	O
.	O
68E	O
-	O
11	O
Cell	O
adhesion	O
GO	O
:	O
7155	O
2	O
.	O
83	O
4	O
.	O
39E	O
-	O
08	O
1	O
.	O
52E	O
-	O
05	O
Biological	O
adhesion	O
GO	O
:	O
22610	O
2	O
.	O
82	O
4	O
.	O
48E	O
-	O
08	O
1	O
.	O
30E	O
-	O
05	O
Cell	O
communication	O
BP	O
:	O
274	O
2	O
.	O
46	O
6	O
.	O
08E	O
-	O
10	O
2	O
.	O
53E	O
-	O
08	O
Cell	O
adhesion	O
BP	O
:	O
124	O
2	O
.	O
30	O
1	O
.	O
57E	O
-	O
04	O
0	O
.	O
00280	O
Regulation	O
of	O
cell	O
proliferation	O
GO	O
:	O
42127	O
2	O
.	O
24	O
3	O
.	O
69E	O
-	O
05	O
0	O
.	O
00457	O
Signal	O
transduction	O
BP	O
:	O
102	O
1	O
.	O
43	O
1	O
.	O
21E	O
-	O
04	O
0	O
.	O
00251	O
Caption	O
(	O
Fig	O
):	O
FIG	O
4	O
Expression	O
of	O
the	O
indicated	O
genes	O
in	O
pediatric	O
ACP	O
.	O

p63	O
gene	O
expression	O
in	O
the	O
indicated	O
tumor	O
and	O
normal	O
tissue	O
types	O
(	O
a	O
).	O

Wnt	O
pathway	O
(	O
b	O
)	O
and	O
Î²	O
-	O
catenin	O
(	O
TCF	O
/	O
LEF	O
)	O
target	O
gene	O
expression	O
(	O
c	O
).	O

Genes	O
at	O
chromosome	O
4p5	O
locus	O
(	O
d	O
).	O

Values	O
are	O
expressed	O
as	O
log2	O
(	O
a	O
)	O
or	O
as	O
fold	O
-	O
difference	O
of	O
individual	O
ACP	O
samples	O
relative	O
to	O
the	O
average	O
of	O
all	O
other	O
tumor	O
and	O
normal	O
samples	O
(	O
b	O
-	O
d	O
)	O
In	O
a	O
series	O
of	O
pair	O
-	O
wise	O
comparisons	O
(	O
limma	O
)	O
with	O
normal	O
brain	O
from	O
a	O
range	O
of	O
anatomic	O
sites	O
(	O
including	O
pituitary	O
)	O
and	O
other	O
brain	O
(	O
AT	O
/	O
RT	O
,	O
CPP	O
,	O
EPN	O
,	O
GBM	O
,	O
PA	O
,	O
MED	O
,	O
MEN	O
,	O
PNET	O
),	O
pituitary	O
(	O
PT	O
)	O
and	O
peripheral	O
solid	O
tumors	O
of	O
childhood	O
(	O
MPNST	O
,	O
RMS	O
)	O
we	O
identified	O
genes	O
that	O
were	O
overexpressed	O
by	O
ACP	O
in	O
all	O
comparisons	O
(	O
FDR	O
pâ	O
<	O
â	O
	O
0	O
.	O
05	O
).	O

These	O
384	O
ACP	O
signature	O
genes	O
were	O
then	O
examined	O
for	O
enrichment	O
(	O
FDRâ	O
<	O
â	O
	O
0	O
.	O
005	O
)	O
of	O
gene	O
ontology	O
terms	O
curated	O
by	O
Gene	O
Ontology	O
(	O
biological	O
processes	O
),	O
Panther	O
(	O
biological	O
processes	O
)	O
and	O
KEGG	O
(	O
pathways	O
)	O
databases	O
using	O
DAVID	O
.	O

The	O
majority	O
of	O
ontologic	O
terms	O
were	O
comprised	O
of	O
ectodermal	O
development	O
-	O
related	O
genes	O
(	O
odontogenic	O
,	O
epidermal	O
,	O
epithelial	O
development	O
)	O
(	O
TableÂ	O
3	O
).	O

Morphologic	O
characteristics	O
of	O
odontogenesis	O
in	O
ACP	O
range	O
from	O
deposits	O
of	O
calcium	O
,	O
which	O
are	O
evident	O
on	O
an	O
x	O
-	O
ray	O
,	O
to	O
development	O
of	O
whole	O
teeth	O
.	O

Specific	O
genes	O
contributing	O
to	O
odontogenesis	O
signature	O
include	O
DLX2	O
,	O
ODAM	O
,	O
AMBN	O
,	O
AMELX	O
,	O
ENAM	O
,	O
TP63	O
,	O
EDAR	O
,	O
SHH	O
,	O
FGF4	O
.	O

Epidermal	O
morphology	O
is	O
also	O
a	O
defining	O
histological	O
feature	O
of	O
ACP	O
,	O
which	O
is	O
presumed	O
to	O
develop	O
from	O
nests	O
of	O
epithelium	O
derived	O
from	O
Rathkeâ	O
	O
s	O
cleft	O
,	O
with	O
further	O
development	O
of	O
non	O
-	O
viable	O
wet	O
keratin	O
â	O
	O
ghost	O
cellsâ	O
	O
that	O
resemble	O
polyhedral	O
,	O
anucleated	O
corneocytes	O
(	O
final	O
step	O
of	O
keratinocyte	O
differentiation	O
).	O

The	O
ACP	O
genes	O
that	O
were	O
highly	O
expressed	O
within	O
these	O
epidermal	O
ontologies	O
include	O
numerous	O
keratins	O
(	O
KRT5	O
,	O
KRT13	O
,	O
KRT14	O
,	O
KRT15	O
,	O
KRT16	O
,	O
KRT31	O
,	O
KRT34	O
,	O
KRT85	O
)	O
and	O
laminins	O
(	O
LAMA3	O
,	O
LAMC2	O
).	O

TP63	O
expression	O
is	O
also	O
extraordinarily	O
high	O
in	O
ACP	O
(	O
Fig	O
.	O
Â	O
4a	O
);	O
as	O
a	O
regulator	O
of	O
odontogenic	O
,	O
epidermal	O
and	O
keratinocyte	O
development	O
,	O
and	O
in	O
regulation	O
of	O
stemness	O
,	O
p63	O
may	O
play	O
a	O
critical	O
role	O
in	O
ACP	O
development	O
and	O
morphogenesis	O
.	O

We	O
also	O
found	O
that	O
a	O
cluster	O
of	O
odontogenic	O
,	O
cytokine	O
and	O
EGF	O
family	O
proteins	O
at	O
Chromosome	O
4p5	O
was	O
highly	O
overexpressed	O
(	O
as	O
much	O
as	O
4	O
,	O
000	O
fold	O
)	O
in	O
ACP	O
(	O
Fig	O
.	O
Â	O
4d	O
).	O

The	O
genetic	O
relevance	O
of	O
the	O
high	O
levels	O
of	O
expression	O
at	O
this	O
locus	O
is	O
unclear	O
.	O

Wnt	O
pathway	O
genes	O
are	O
expressed	O
homogeneously	O
and	O
not	O
at	O
abnormally	O
high	O
levels	O
in	O
ACP	O
(	O
Fig	O
.	O
Â	O
4b	O
),	O
with	O
the	O
exception	O
of	O
the	O
transcription	O
factor	O
(	O
TCF	O
)/	O
lymphoid	O
enhancer	O
-	O
binding	O
factor	O
(	O
LEF	O
)	O
targets	O
LEF1	O
and	O
WNT5A	O
.	O

However	B
,	O
consistent	O
with	O
the	O
hypothesis	O
that	O
aberrant	O
Wnt	O
signaling	O
(	O
via	O
mutant	O
Î²	O
-	O
catenin	O
)	O
is	O
responsible	O
for	O
the	O
pathogenesis	O
of	O
ACP	O
,	O
Î²	O
-	O
catenin	O
/	O
TCF	O
/	O
LEF	O
target	O
genes	O
are	O
overexpressed	O
an	O
average	O
of	O
32	O
fold	O
over	O
the	O
other	O
samples	O
(	O
Fig	O
.	O
Â	O
4c	O
).	O

Caption	O
(	O
Fig	O
):	O
FIG	O
5	O
Expression	O
of	O
the	O
indicated	O
developmental	O
and	O
cancer	O
-	O
related	O
genes	O
in	O
individual	O
pediatric	O
ACP	O
samples	O
.	O

Epidermal	O
growth	O
factor	O
(	O
EGF	O
)	O
family	O
genes	O
(	O
a	O
).	O

Genes	O
involved	O
in	O
pituitary	O
development	O
(	O
b	O
).	O

Developmental	O
genes	O
from	O
the	O
Notch	O
(	O
c	O
),	O
Six	O
transcription	O
factor	O
(	O
d	O
),	O
Sonic	O
hedgehog	O
(	O
Shh	O
)	O
(	O
e	O
),	O
Bone	O
morphogenetic	O
protein	O
(	O
BMP	O
)	O
and	O
Fibroblast	O
growth	O
factor	O
(	O
FGF	O
)	O
(	O
f	O
)	O
families	O
.	O

Values	O
expressed	O
are	O
fold	O
-	O
difference	O
of	O
individual	O
ACP	O
samples	O
relative	O
to	O
the	O
average	O
of	O
all	O
other	O
tumor	O
and	O
normal	O
samples	O
The	O
epigenetic	O
profile	O
of	O
ACP	O
may	O
also	O
give	O
some	O
insight	O
into	O
the	O
developmental	O
origins	O
of	O
this	O
disease	O
.	O

Genes	O
involved	O
in	O
pituitary	O
development	O
(	O
Fig	O
.	O
Â	O
5a	O
)	O
are	O
not	O
highly	O
expressed	O
with	O
the	O
exception	O
of	O
PITX1	O
&	O
2	O
which	O
are	O
established	O
TCF	O
/	O
LEF	O
targets	O
.	O

Critical	O
developmental	O
and	O
survival	O
pathway	O
gene	O
expression	O
patterns	O
reveal	O
a	O
potential	O
role	O
for	O
EGFR	O
,	O
Six	O
family	O
transcription	O
factors	O
,	O
Shh	O
and	O
FGFs	O
in	O
ACP	O
pathogenesis	O
(	O
Fig	O
.	O
Â	O
5bâ	O
	O
f	O
).	O

Discussion	O
Identification	O
of	O
potential	O
therapeutic	O
targets	O
in	O
our	O
transcriptomic	O
analysis	O
confirmed	O
findings	O
of	O
previous	O
studies	O
that	O
had	O
identified	O
SHH	O
and	O
EGFR	O
pathway	O
activity	O
in	O
ACP	O
and	O
provide	O
further	O
evidence	O
that	O
therapies	O
targeting	O
these	O
pathways	O
could	O
be	O
used	O
successfully	O
in	O
treating	O
ACP	O
.	O

Transcriptomic	O
analysis	O
of	O
ACP	O
generated	O
in	O
a	O
mouse	O
model	O
demonstrated	O
high	O
levels	O
of	O
SHH	O
gene	O
expression	O
,	O
suggesting	O
a	O
mitogenic	O
autocrine	O
/	O
paracrine	O
loop	O
.	O

A	O
subsequent	O
study	O
identified	O
upregulation	O
of	O
members	O
of	O
the	O
SHH	O
signaling	O
pathway	O
in	O
human	O
specimens	O
.	O

In	O
vitro	O
and	O
xenotransplant	O
model	O
studies	O
have	O
demonstrated	O
that	O
EGFR	O
activation	O
is	O
responsible	O
for	O
driving	O
growth	O
and	O
migration	O
in	O
ACP	O
.	O

The	O
proven	O
clinical	O
utility	O
of	O
EGFR	O
inhibition	O
in	O
the	O
treatment	O
of	O
cancer	O
makes	O
EGFR	O
targeted	O
drugs	O
an	O
attractive	O
approach	O
to	O
ACP	O
treatment	O
.	O

Our	O
identification	O
of	O
high	O
levels	O
of	O
EGFR	O
ligand	O
AREG	O
provide	O
a	O
potential	O
mechanism	O
for	O
EGFR	O
activation	O
in	O
ACP	O
that	O
warrants	O
further	O
exploration	O
.	O

Furthermore	O
,	O
AREG	O
has	O
been	O
implicated	O
as	O
a	O
paracrine	O
/	O
juxtacrine	O
regulator	O
of	O
cell	O
survival	O
in	O
other	O
cancers	O
and	O
epidermal	O
cell	O
types	O
.	O

It	O
has	O
also	O
recently	O
been	O
suggested	O
that	O
ACP	O
may	O
be	O
paracrine	O
in	O
nature	O
(	O
i	O
.	O
e	O
.	O

the	O
CTNNB1	O
mutant	O
cells	O
may	O
promote	O
the	O
proliferation	O
of	O
another	O
cell	O
type	O
that	O
actually	O
populates	O
the	O
tumor	O
).	O

This	O
hypothesis	O
could	O
explain	O
the	O
extensive	O
intratumoral	O
heterogeneity	O
in	O
ACP	O
and	O
perhaps	O
the	O
difficulty	O
we	O
and	O
others	O
have	O
found	O
in	O
obtaining	O
â	O
	O
pureâ	O
	O
tumor	O
samples	O
to	O
accurately	O
identify	O
CTNNB1	O
mutations	O
.	O

We	O
also	O
identified	O
a	O
number	O
of	O
additional	O
novel	O
potential	O
drug	O
targets	O
.	O

One	O
group	O
,	O
including	O
LCK	O
,	O
EPHA2	O
and	O
SRC	O
,	O
is	O
targeted	O
by	O
the	O
kinase	O
inhibitor	O
dasatinib	O
.	O

Hundreds	O
of	O
trials	O
are	O
now	O
underway	O
using	O
dasatinib	O
to	O
treat	O
a	O
wide	O
variety	O
of	O
cancers	O
beyond	O
the	O
few	O
for	O
which	O
it	O
currently	O
has	O
FDA	O
approval	O
.	O

A	O
second	O
group	O
of	O
targets	O
we	O
identified	O
are	O
extracellular	O
proteases	O
,	O
of	O
which	O
many	O
were	O
strongly	O
represented	O
in	O
our	O
analysis	O
;	O
two	O
in	O
particular	O
,	O
MMPs	O
9	O
and	O
12	O
,	O
are	O
targeted	O
by	O
the	O
drug	O
AZD1236	O
.	O

MMP12	O
,	O
which	O
we	O
found	O
expressed	O
at	O
very	O
high	O
levels	O
,	O
is	O
a	O
proteolytic	O
factor	O
that	O
may	O
contribute	O
to	O
the	O
significant	O
invasive	O
phenotype	O
that	O
is	O
a	O
hallmark	O
of	O
ACP	O
.	O

Previous	O
studies	O
have	O
attempted	O
to	O
correlate	O
proteinase	O
activity	O
with	O
biological	O
course	O
in	O
ACP	O
including	O
a	O
study	O
that	O
confirmed	O
the	O
presence	O
of	O
MMP9	O
by	O
immunohistochemistry	O
.	O

The	O
results	O
of	O
this	O
transcriptomic	O
study	O
of	O
human	O
pediatric	O
ACP	O
shed	O
further	O
light	O
on	O
the	O
biology	O
of	O
this	O
tumor	O
,	O
reflect	O
the	O
odontogenic	O
and	O
epithelial	O
characteristics	O
in	O
the	O
pathology	O
of	O
ACP	O
and	O
recapitulate	O
the	O
origins	O
of	O
ACP	O
from	O
oral	O
ectoderm	O
.	O

The	O
origins	O
of	O
ACP	O
have	O
long	O
been	O
the	O
subject	O
of	O
speculation	O
due	O
to	O
the	O
oddity	O
of	O
their	O
morphology	O
and	O
location	O
.	O

Many	O
consider	O
ACP	O
to	O
be	O
a	O
congenital	O
midline	O
developmental	O
malformation	O
,	O
but	B
the	O
(	O
albeit	B
infrequent	O
)	O
occurrence	O
of	O
ACP	O
in	O
late	O
adulthood	O
and	O
variable	O
presentation	O
are	O
difficult	O
to	O
reconcile	O
with	O
this	O
hypothesis	O
.	O

The	O
recognition	O
that	O
Î²	O
-	O
catenin	O
dysregulation	O
is	O
responsible	O
for	O
ACP	O
have	O
led	O
to	O
two	O
conflicting	B
mouse	O
models	B
for	O
the	O
formation	O
of	O
ACP	O
â	O
	O
in	O
mice	O
an	O
ACP	O
-	O
like	O
tumor	O
can	O
develop	O
from	O
targeted	O
CTNNB1	O
mutations	O
in	O
either	O
pituitary	O
oral	O
ectoderm	O
precursors	O
in	O
developing	O
mice	O
embryos	O
or	O
in	O
pituitary	O
stem	O
cells	O
in	O
post	O
-	O
natal	O
mice	O
.	O

The	O
data	O
presented	O
here	O
are	O
consistent	O
with	O
the	O
theory	O
that	O
ACP	O
is	O
a	O
congenital	O
malformation	O
that	O
develops	O
from	O
the	O
improper	O
closure	O
of	O
the	O
craniophyrangeal	O
duct	O
from	O
the	O
oral	O
ectoderm	O
-	O
derived	O
remnants	O
of	O
Rathkeâ	O
	O
s	O
pouch	O
(	O
TableÂ	O
3	O
).	O

However	B
,	O
these	O
data	O
are	O
not	O
completely	O
inconsistent	B
with	O
the	O
hypothesis	O
that	O
ACP	O
arises	O
from	O
an	O
anterior	O
pituitary	O
stem	O
cell	O
that	O
transdifferentiates	O
toward	O
an	O
oral	O
epithelial	O
phenotype	O
.	O

Further	O
analysis	O
of	O
more	O
ACP	O
samples	O
,	O
including	O
adult	O
ACP	O
,	O
in	O
addition	O
to	O
transcriptomic	O
studies	O
of	O
neuropathologically	O
distinct	O
cell	O
subtypes	O
present	O
within	O
ACP	O
tumors	O
will	O
contribute	O
to	O
our	O
understanding	O
of	O
how	O
these	O
tumors	O
form	O
and	O
perhaps	O
how	O
to	O
better	O
treat	O
them	O
.	O

Conclusions	O
Current	O
standard	O
therapy	O
for	O
ACP	O
is	O
surgery	O
and	O
radiation	O
,	O
both	O
of	O
which	O
lead	O
to	O
high	O
morbidity	O
in	O
this	O
sensitive	O
region	O
of	O
the	O
brain	O
,	O
especially	O
in	O
children	O
,	O
in	O
whom	O
these	O
morbidities	O
become	O
a	O
lifelong	O
and	O
life	O
-	O
altering	O
disease	O
.	O

Intracystic	O
delivery	O
of	O
therapeutic	O
agents	O
(	O
interferon	O
-	O
alpha	O
,	O
bleomycin	O
or	O
Ytrrium90	O
)	O
has	O
shown	O
some	O
efficacy	O
in	O
treating	O
ACP	O
,	O
but	O
this	O
approach	O
is	O
limited	O
by	O
the	O
requirement	O
of	O
a	O
single	O
cyst	O
in	O
the	O
presenting	O
tumor	O
and	O
requires	O
stereotactic	O
surgery	O
to	O
place	O
a	O
catheter	O
and	O
Ommaya	O
reservoir	O
for	O
delivery	O
.	O

Systemic	O
therapy	O
could	O
more	O
safely	O
and	O
more	O
effectively	O
treat	O
children	O
with	O
ACP	O
.	O

However	B
,	O
progress	O
has	O
been	O
hindered	O
by	O
the	O
absence	O
of	O
in	O
vitro	O
or	O
in	O
vivo	O
models	O
of	O
this	O
tumor	O
that	O
would	O
enable	O
the	O
unbiased	O
screening	O
of	O
drug	O
libraries	O
.	O

This	O
study	O
forms	O
the	O
basis	O
for	O
further	O
studies	O
with	O
rational	O
therapies	O
for	O
ACP	O
.	O

The	O
recent	O
development	O
of	O
ACP	O
xenotransplants	O
in	O
immune	O
deficient	O
mice	O
will	O
enable	O
pre	O
-	O
clinical	O
testing	O
of	O
these	O
rationally	O
selected	O
targeted	O
therapies	O
,	O
providing	O
further	O
rationale	O
for	O
small	O
studies	O
on	O
efficacy	O
in	O
augmenting	O
surgery	O
and	O
radiation	O
or	O
in	O
treating	O
recurrent	O
ACP	O
.	O

These	O
efforts	O
,	O
combined	O
with	O
further	O
collaborations	O
between	O
centers	O
and	O
consortiums	O
will	O
provide	O
the	O
foundation	O
for	O
a	O
randomized	O
clinical	O
trial	O
using	O
targeted	O
agents	O
to	O
treat	O
ACP	O
in	O
the	O
near	O
future	O
.	O

Competing	O
interests	O
The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authorsâ	O
	O
contributions	O
JMG	O
,	O
AMD	O
,	O
BKK	O
-	O
D	O
,	O
LG	O
,	O
NF	O
and	O
TCH	O
designed	O
the	O
study	O
.	O

AMD	O
,	O
VMA	O
,	O
AMG	O
,	O
BKK	O
-	O
D	O
,	O
MH	O
,	O
and	O
TCH	O
collected	O
and	O
processed	O
the	O
tumor	O
samples	O
.	O

JMG	O
,	O
AMD	O
,	O
DKB	O
,	O
VMA	O
,	O
KKR	O
,	O
AMG	O
conducted	O
the	O
experiments	O
.	O

JMG	O
,	O
AMD	O
,	O
DKB	O
and	O
TCH	O
performed	O
the	O
transcriptomic	O
data	O
analysis	O
.	O

JMJ	O
,	O
RCEA	O
and	O
AR	O
provided	O
tumor	O
samples	O
.	O

JMG	O
,	O
AMD	O
and	O
TCH	O
drafted	O
the	O
manuscript	O
with	O
editorial	O
input	O
from	O
all	O
authors	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Molecular	O
and	O
cellular	O
pathogenesis	O
of	O
adamantinomatous	O
craniopharyngioma	O
Abstract	O
Adamantinomatous	O
craniopharyngiomas	O
(	O
ACPs	O
)	O
are	O
the	O
most	O
common	O
pituitary	O
tumours	O
in	O
children	O
.	O

Although	O
histologically	O
benign	O
,	O
these	O
are	O
clinically	O
aggressive	O
tumours	O
,	O
difficult	O
to	O
manage	O
and	O
associated	O
with	O
poor	O
quality	O
of	O
life	O
for	O
the	O
patients	O
.	O

Several	O
human	O
and	O
mouse	O
studies	O
have	O
provided	O
unequivocal	O
evidence	O
that	O
the	O
overâ	O
	O
activation	O
of	O
the	O
WNT	O
/	O
Î²â	O
	O
catenin	O
signalling	O
pathway	O
underlies	O
the	O
molecular	O
aetiology	O
of	O
these	O
tumours	O
.	O

Recently	O
,	O
research	O
using	O
genetically	O
modified	O
mouse	O
models	O
of	O
human	O
ACP	O
have	O
revealed	O
a	O
critical	O
and	O
unexpected	O
nonâ	O
	O
cell	O
autonomous	O
role	O
for	O
pituitary	O
stem	O
cells	O
in	O
ACP	O
tumourigenesis	O
,	O
which	O
has	O
expanded	O
the	O
cancer	O
stem	O
cell	O
paradigm	O
.	O

As	O
the	O
result	O
of	O
this	O
basic	O
research	O
,	O
the	O
pathogenesis	O
of	O
ACP	O
is	O
being	O
unveiled	O
,	O
with	O
promising	O
implications	O
for	O
the	O
development	O
of	O
novel	O
treatments	O
against	O
these	O
childhood	O
neoplasms	O
.	O

These	O
benign	O
tumours	O
may	O
additionally	O
represent	O
a	O
unique	O
model	O
to	O
provide	O
insights	O
into	O
the	O
initial	O
steps	O
of	O
oncogenesis	O
.	O

Introduction	O
Adamantinomatous	O
craniopharyngiomas	O
(	O
ACPs	O
)	O
are	O
nonâ	O
	O
hormone	O
secreting	O
sellar	O
tumours	O
that	O
mostly	O
affect	O
children	O
under	O
15	O
,	O
but	O
can	O
be	O
diagnosed	O
at	O
any	O
age	O
,	O
with	O
a	O
second	O
peak	O
of	O
incidence	O
in	O
adults	O
between	O
50	O
and	O
74	O
years	O
.	O

The	O
clinical	O
relevance	O
of	O
ACP	O
is	O
not	O
their	O
associated	O
mortality	O
,	O
which	O
is	O
usually	O
low	O
when	O
properly	O
managed	O
,	O
but	B
their	O
high	O
morbidity	O
due	O
to	O
serious	O
endocrinological	O
disturbances	O
and	O
tendency	O
to	O
infiltrate	O
locally	O
and	O
aggressively	O
into	O
the	O
hypothalamus	O
and	O
visual	O
tracts	O
.	O

Currently	O
,	O
there	O
are	O
no	O
specific	O
treatments	O
against	O
these	O
tumours	O
,	O
only	O
surgery	O
and	O
/	O
or	O
radiotherapy	O
,	O
but	B
these	O
are	O
not	O
curative	O
and	O
patients	O
often	O
experience	O
tumour	O
recurrence	O
.	O

Consequences	O
of	O
the	O
tumour	O
and	O
its	O
treatment	O
are	O
long	O
lasting	O
and	O
associated	O
with	O
poor	O
quality	O
of	O
life	O
for	O
the	O
survivors	O
,	O
making	O
many	O
clinicians	O
consider	O
human	O
ACP	O
as	O
a	O
chronic	O
disease	O
[	O
1	O
,	O
2	O
].	O

This	O
review	O
aims	O
to	O
discuss	O
the	O
pathogenesis	O
of	O
human	O
craniopharyngioma	O
from	O
an	O
embryological	O
perspective	O
,	O
arguing	O
that	O
the	O
majority	O
of	O
human	O
ACPs	O
are	O
developmental	O
tumours	O
.	O

It	O
will	O
present	O
results	O
obtained	O
from	O
human	O
and	O
mouse	O
studies	O
,	O
highlighting	O
the	O
implications	O
of	O
data	O
derived	O
from	O
current	O
research	O
using	O
validated	O
mouse	O
models	O
for	O
these	O
human	O
neoplasms	O
.	O

In	O
particular	O
,	O
it	O
will	O
provide	O
an	O
overview	O
on	O
the	O
critical	O
findings	O
that	O
have	O
helped	O
delineate	O
the	O
early	O
cellular	O
and	O
molecular	O
mechanisms	O
resulting	O
in	O
development	O
of	O
ACP	O
,	O
with	O
a	O
particular	O
emphasis	O
on	O
the	O
role	O
of	O
pituitary	O
stem	O
cells	O
.	O

For	O
inâ	O
	O
depth	O
analysis	O
of	O
the	O
clinical	O
aspects	O
of	O
human	O
ACP	O
,	O
such	O
as	O
treatments	O
and	O
patient	O
management	O
,	O
readers	O
are	O
directed	O
to	O
the	O
other	O
reviews	O
on	O
these	O
topics	O
[	O
1	O
,	O
3	O
,	O
4	O
,	O
5	O
,	O
6	O
,	O
7	O
,	O
8	O
,	O
9	O
,	O
10	O
,	O
11	O
,	O
12	O
].	O

Pathology	O
of	O
human	O
ACP	O
Human	O
ACPs	O
are	O
cystic	O
tumours	O
located	O
either	O
within	O
or	O
above	O
the	O
sellar	O
region	O
,	O
frequently	O
compromising	O
the	O
hypothalamus	O
,	O
pituitary	O
gland	O
,	O
pituitary	O
stalk	O
and	O
optic	O
chiasm	O
.	O

The	O
histopathology	O
of	O
these	O
tumours	O
is	O
characterized	O
by	O
the	O
formation	O
of	O
a	O
peripheral	O
basal	O
cell	O
layer	O
of	O
palisading	O
epithelium	O
,	O
loose	O
aggregates	O
of	O
epithelial	O
stellate	O
cells	O
,	O
nodules	O
of	O
anucleated	O
ghost	O
cells	O
with	O
brightly	O
eosinophilic	O
cytoplasm	O
termed	O
wet	O
keratin	O
,	O
large	O
areas	O
of	O
regressive	O
changes	O
,	O
that	O
is	O
,	O
hemosiderin	O
deposits	O
,	O
cholesterol	O
clefts	O
,	O
multinucleated	O
foreignâ	O
	O
body	O
giant	O
cells	O
,	O
inflammation	O
and	O
calcifications	O
[	O
13	O
,	O
14	O
,	O
15	O
,	O
16	O
].	O

A	O
histopathological	O
hallmark	O
of	O
human	O
ACP	O
is	O
the	O
presence	O
of	O
cells	O
showing	O
nucleoâ	O
	O
cytoplasmic	O
accumulation	O
of	O
Î²â	O
	O
catenin	O
,	O
which	O
often	O
gather	O
to	O
form	O
whorlâ	O
	O
like	O
structures	O
close	O
to	O
the	O
invasive	O
front	O
(	O
hereby	O
referred	O
to	O
as	O
â	O
	O
cell	O
clustersâ	O
)	O
[	O
9	O
,	O
17	O
,	O
18	O
,	O
19	O
,	O
20	O
]	O
(	O
Figureâ	O
	O
1	O
).	O

These	O
are	O
clearly	O
a	O
minority	O
of	O
cells	O
and	O
are	O
distributed	O
evenly	O
throughout	O
the	O
tumour	O
.	O

These	O
Î²â	O
	O
cateninâ	O
	O
accumulating	O
cluster	O
cells	O
show	O
activation	O
of	O
the	O
WNT	O
/	O
Î²â	O
	O
catenin	O
pathway	O
as	O
evidenced	O
by	O
the	O
expression	O
of	O
pathway	O
targets	O
such	O
as	O
AXIN2	O
,	O
LEF1	O
and	O
BMP4	O
[	O
18	O
,	O
21	O
,	O
22	O
].	O

They	O
distinctly	O
express	O
stem	O
cell	O
markers	O
[	O
23	O
]	O
and	O
the	O
tight	O
junction	O
protein	O
Claudinâ	O
	O
1	O
[	O
24	O
].	O

The	O
presence	O
of	O
these	O
clusters	O
is	O
a	O
hallmark	O
that	O
differentiates	O
human	O
ACP	O
from	O
any	O
other	O
tumour	O
of	O
the	O
sellar	O
region	O
,	O
including	O
the	O
papillary	O
type	O
of	O
craniopharyngioma	O
[	O
25	O
].	O

Caption	O
(	O
Fig	O
):	O
FIG	O
1	O
Histomorphological	O
features	O
of	O
mouse	O
and	O
human	O
ACP	O
.	O

(	O
A	O
)	O
Haematoxylin	O
and	O
eosin	O
staining	O
of	O
mouse	O
and	O
human	O
tumours	O
showing	O
the	O
presence	O
of	O
microcystic	O
changes	O
(	O
stellate	O
reticulum	O
;	O
arrows	O
)	O
and	O
whorlâ	O
	O
like	O
nodular	O
structures	O
(	O
cell	O
clusters	O
;	O
arrowheads	O
).	O

(	O
B	O
)	O
Immunohistochemistry	O
with	O
a	O
specific	O
antiâ	O
	O
Î²â	O
	O
catenin	O
antibody	O
showing	O
the	O
presence	O
of	O
cell	O
clusters	O
with	O
nucleoâ	O
	O
cytoplasmic	O
accumulation	O
of	O
Î²â	O
	O
catenin	O
.	O

Reproduced	O
with	O
permission	O
from	O
PNAS	O
(	O
Gastonâ	O
	O
Massuet	O
etâ	O
	O
al	O
.,	O
PNAS	O
USA	O
2011	O
,	O
vol	O
.	O

108	O
,	O
number	O
28	O
,	O
pp	O
11482â	O
	O
11487	O
).	O

The	O
cell	O
of	O
origin	O
of	O
human	O
ACP	O
remains	O
unknown	O
.	O

The	O
pattern	O
of	O
expression	O
of	O
cytokeratins	O
is	O
consistent	O
with	O
oral	O
epithelial	O
origin	O
,	O
and	O
it	O
is	O
generally	O
believed	O
that	O
these	O
neoplasms	O
derive	O
from	O
remnants	O
of	O
Rathke	O
'	O
s	O
pouch	O
,	O
the	O
embryological	O
primordium	O
of	O
the	O
anterior	O
pituitary	O
[	O
26	O
,	O
27	O
].	O

WNT	O
/	O
Î²â	O
	O
catenin	O
signalling	O
is	O
required	O
for	O
normal	O
development	O
of	O
the	O
pituitary	O
gland	O
The	O
pituitary	O
gland	O
is	O
a	O
master	O
endocrine	O
organ	O
that	O
regulates	O
essential	O
physiological	O
processes	O
including	O
growth	O
,	O
reproduction	O
,	O
metabolism	O
and	O
stress	O
response	O
.	O

The	O
mature	O
gland	O
,	O
consisting	O
of	O
the	O
anterior	O
and	O
posterior	O
pituitary	O
(	O
AP	O
and	O
PP	O
,	O
respectively	O
),	O
starts	O
to	O
develop	O
around	O
9	O
.	O
0	O
days	O
post	O
coitum	O
(	O
dpc	O
)	O
in	O
mice	O
and	O
around	O
week	O
4	O
in	O
humans	O
from	O
two	O
distinct	O
germ	O
layers	O
(	O
Figureâ	O
	O
2	O
).	O

The	O
AP	O
derives	O
from	O
Rathke	O
'	O
s	O
pouch	O
,	O
a	O
region	O
of	O
the	O
oral	O
epithelium	O
of	O
the	O
early	O
embryo	O
that	O
contains	O
the	O
undifferentiated	O
precursors	O
of	O
all	O
of	O
the	O
hormoneâ	O
	O
producing	O
endocrine	O
cells	O
of	O
the	O
mature	O
pituitary	O
as	O
well	O
as	O
tissueâ	O
	O
specific	O
pituitary	O
stem	O
cells	O
of	O
the	O
adult	O
organ	O
[	O
28	O
].	O

The	O
PP	O
is	O
of	O
neural	O
origin	O
and	O
originates	O
from	O
a	O
diverticulum	O
at	O
the	O
floor	O
of	O
the	O
prospective	O
hypothalamus	O
called	O
the	O
infundibulum	O
.	O

The	O
PP	O
is	O
hypocellular	O
and	O
contains	O
the	O
axons	O
of	O
the	O
oxytocin	O
and	O
arginine	O
vasopressin	O
neurons	O
of	O
the	O
hypothalamus	O
.	O

The	O
PP	O
is	O
connected	O
to	O
the	O
hypothalamus	O
through	O
the	O
pituitary	O
stalk	O
,	O
which	O
comprises	O
the	O
portal	O
vessels	O
and	O
hypothalamic	O
axons	O
.	O

Caption	O
(	O
Fig	O
):	O
FIG	O
2	O
Cartoon	O
showing	O
mouse	O
pituitary	O
development	O
from	O
9	O
.	O
5	O
to	O
18	O
.	O

5â	O
	O
dpc	O
.	O

Rathke	O
'	O
s	O
pouch	O
(	O
RP	O
)	O
forms	O
at	O
9	O
.	O
5â	O
	O
dpc	O
as	O
an	O
evagination	O
of	O
the	O
oral	O
ectoderm	O
(	O
OE	O
)	O
at	O
the	O
boundary	O
between	O
OE	O
and	O
pharyngeal	O
endoderm	O
(	O
PE	O
).	O

The	O
epithelium	O
of	O
RP	O
contains	O
the	O
undifferentiated	O
progenitors	O
that	O
give	O
rise	O
to	O
all	O
hormoneâ	O
	O
producing	O
cells	O
at	O
the	O
end	O
of	O
gestation	O
.	O

By	O
11	O
.	O
5â	O
	O
dpc	O
,	O
RP	O
pinches	O
off	O
from	O
the	O
oral	O
ectoderm	O
and	O
establishes	O
contacts	O
with	O
the	O
infundibulum	O
(	O
INF	O
),	O
a	O
recess	O
of	O
the	O
floor	O
of	O
the	O
diencephalon	O
(	O
DI	O
).	O

RP	O
progenitors	O
proliferate	O
rapidly	O
from	O
9	O
.	O
5â	O
	O
dpc	O
and	O
the	O
progeny	O
migrates	O
ventrally	O
and	O
initiates	O
differentiation	O
to	O
populate	O
the	O
primordium	O
of	O
the	O
anterior	O
lobe	O
(	O
AL	O
)	O
of	O
the	O
pituitary	O
.	O

The	O
presumptive	O
intermediate	O
lobe	O
(	O
IL	O
)	O
is	O
indicated	O
.	O

At	O
18	O
.	O
5â	O
	O
dpc	O
,	O
just	O
prior	O
to	O
birth	O
,	O
the	O
pituitary	O
comprises	O
the	O
posterior	O
lobe	O
(	O
PP	O
),	O
of	O
neural	O
origin	O
,	O
and	O
the	O
anterior	O
pituitary	O
(	O
AP	O
),	O
derived	O
from	O
the	O
anterior	O
and	O
intermediate	O
lobes	O
.	O

The	O
pituitary	O
is	O
located	O
between	O
the	O
hypothalamus	O
(	O
Hyp	O
)	O
and	O
the	O
basosphenoid	O
bone	O
(	O
BS	O
).	O

(	O
Figure	O
courtesy	O
of	O
Dr	O
C	O
.	O
L	O
.	O

Andoniadou	O
.)	O

Normal	O
morphogenesis	O
and	O
differentiation	O
of	O
the	O
pituitary	O
gland	O
are	O
regulated	O
by	O
the	O
activity	O
of	O
several	O
transcriptional	O
factors	O
and	O
signalling	O
pathways	O
[	O
29	O
,	O
30	O
,	O
31	O
].	O

One	O
of	O
these	O
pathways	O
is	O
WNT	O
/	O
Î²â	O
	O
catenin	O
,	O
a	O
major	O
regulator	O
of	O
several	O
cellular	O
processes	O
during	O
organogenesis	O
and	O
adulthood	O
[	O
32	O
,	O
33	O
].	O

The	O
activity	O
of	O
the	O
WNT	O
/	O
Î²â	O
	O
catenin	O
pathway	O
is	O
controlled	O
by	O
the	O
stability	O
of	O
Î²â	O
	O
catenin	O
,	O
a	O
transcriptional	O
activator	O
lacking	O
a	O
DNA	O
binding	O
domain	O
.	O

In	O
the	O
absence	O
of	O
WNT	O
ligands	O
,	O
Î²â	O
	O
catenin	O
is	O
phosphorylated	O
by	O
a	O
destruction	O
complex	O
and	O
degraded	O
rapidly	O
,	O
via	O
the	O
ubiquitination	O
pathway	O
,	O
preventing	O
its	O
stabilization	O
and	O
the	O
activation	O
of	O
the	O
pathway	O
.	O

Binding	O
of	O
WNT	O
ligands	O
to	O
their	O
receptors	O
disrupts	O
the	O
destruction	O
complex	O
,	O
preventing	O
the	O
phosphorylation	O
of	O
Î²â	O
	O
catenin	O
and	O
its	O
subsequent	O
ubiquitination	O
and	O
degradation	O
.	O

Stabilized	O
Î²â	O
	O
catenin	O
can	O
translocate	O
into	O
the	O
nucleus	O
and	O
interact	O
with	O
DNAâ	O
	O
binding	O
transcription	O
factors	O
of	O
the	O
TCF	O
/	O
LEF	O
family	O
to	O
activate	O
the	O
expression	O
of	O
target	O
genes	O
of	O
the	O
pathway	O
(	O
Figureâ	O
	O
3	O
).	O

Caption	O
(	O
Fig	O
):	O
FIG	O
3	O
WNT	O
/	O
Î²â	O
	O
catenin	O
signalling	O
pathway	O
.	O

(	O
A	O
)	O
In	O
the	O
absence	O
of	O
WNT	O
ligands	O
,	O
Î²â	O
	O
catenin	O
is	O
trapped	O
in	O
a	O
destruction	O
complex	O
formed	O
by	O
Axin	O
,	O
APC	O
and	O
GSK3Î²	O
and	O
phosphorylated	O
in	O
specific	O
residues	O
encoded	O
by	O
exon	O
3	O
of	O
CTNNB1	O
.	O

This	O
results	O
in	O
rapid	O
degradation	O
of	O
Î²â	O
	O
catenin	O
and	O
,	O
consequentially	O
,	O
the	O
repression	O
of	O
target	O
genes	O
brought	O
about	O
by	O
the	O
interaction	O
of	O
TCF	O
/	O
LEF1	O
with	O
coâ	O
	O
repressors	O
[	O
e	O
.	O
g	O
.	O

groucho	O
(	O
Gro	O
)/	O
TLE	O
family	O
members	O
].	O

(	O
B	O
)	O
Binding	O
of	O
WNT	O
ligands	O
to	O
the	O
Frizzled	O
(	O
FZD	O
)	O
receptors	O
and	O
ist	O
coâ	O
	O
receptors	O
LRP	O
leads	O
to	O
the	O
activation	O
of	O
dishevelled	O
(	O
DVL	O
)	O
and	O
recruitment	O
to	O
the	O
cytoplasmic	O
membrane	O
of	O
both	O
DVL	O
and	O
Axin	O
.	O

This	O
causes	O
the	O
dysruption	O
of	O
the	O
destruction	O
complex	O
,	O
releasing	O
Î²â	O
	O
catenin	O
,	O
which	O
cannot	O
be	O
efficiently	O
phosphorylated	O
or	O
degraded	O
.	O

The	O
stabilisation	O
of	O
Î²â	O
	O
catenin	O
results	O
in	O
increased	O
cytoplasmic	O
protein	O
levels	O
and	O
eventually	O
nuclear	O
translocation	O
,	O
where	O
its	O
interaction	O
with	O
TCF	O
/	O
LEF1	O
factors	O
mediates	O
the	O
expression	O
of	O
target	O
genes	O
oft	O
he	O
pathway	O
.	O

(	O
C	O
)	O
Expression	O
of	O
a	O
stable	O
form	O
of	O
Î²â	O
	O
catenin	O
lacking	O
the	O
amino	O
acids	O
encoded	O
by	O
exon	O
3	O
of	O
CTNNB1	O
(	O
small	O
red	O
circle	O
in	O
BCAT	O
)	O
results	O
in	O
protein	O
stabilisation	O
as	O
mutant	O
Î²â	O
	O
catenin	O
cannot	O
be	O
properly	O
phosphorylated	O
or	O
degraded	O
.	O

This	O
causes	O
the	O
activation	O
of	O
the	O
WNT	O
/	O
Î²â	O
	O
catenin	O
pathway	O
in	O
a	O
cellâ	O
	O
autonomous	O
manner	O
in	O
the	O
absence	O
of	O
WNT	O
ligands	O
.	O

(	O
Figure	O
courtesy	O
of	O
Dr	O
C	O
.	O
L	O
.	O

Andoniadou	O
.)	O

Genetic	O
studies	O
in	O
mice	O
have	O
demonstrated	O
the	O
requirement	O
of	O
this	O
pathway	O
for	O
normal	O
pituitary	O
morphogenesis	O
and	O
differentiation	O
.	O

WNT	O
/	O
Î²â	O
	O
catenin	O
is	O
necessary	O
for	O
terminal	O
differentiation	O
of	O
hormoneâ	O
	O
producing	O
cells	O
at	O
late	O
stages	O
of	O
pituitary	O
development	O
,	O
while	O
it	O
must	O
be	O
inhibited	O
at	O
early	O
stages	O
to	O
establish	O
normal	O
proliferation	O
of	O
Rathke	O
'	O
s	O
pouch	O
progenitors	O
[	O
34	O
,	O
35	O
,	O
36	O
,	O
37	O
,	O
38	O
,	O
39	O
].	O

Supporting	O
this	O
notion	O
,	O
the	O
upâ	O
	O
regulation	O
of	O
the	O
WNT	O
/	O
Î²â	O
	O
catenin	O
pathway	O
in	O
Rathke	O
'	O
s	O
pouch	O
(	O
RP	O
)	O
progenitors	O
leads	O
to	O
dramatic	O
pituitary	O
hyperplasia	O
,	O
ectopic	O
pituitary	O
tissue	O
in	O
the	O
oropharyngeal	O
cavity	O
and	O
perinatal	O
death	O
in	O
80	O
%	O
of	O
pups	O
.	O

In	O
addition	O
,	O
somatotroph	O
,	O
lactotroph	O
and	O
thyrotroph	O
differentiation	O
is	O
impaired	O
[	O
21	O
].	O

This	O
genetically	O
modified	O
mouse	O
model	O
harbours	O
a	O
mutated	O
form	O
of	O
Î²â	O
	O
catenin	O
that	O
is	O
transcriptionally	O
active	O
,	O
but	O
lacks	O
the	O
amino	O
acids	O
encoded	O
by	O
exon	O
3	O
of	O
Ctnnb1	O
(	O
the	O
gene	O
encoding	O
Î²â	O
	O
catenin	O
),	O
preventing	O
its	O
phosphorylation	O
and	O
subsequent	O
degradation	O
,	O
and	O
leading	O
to	O
the	O
overâ	O
	O
activation	O
of	O
the	O
WNT	O
/	O
Î²â	O
	O
catenin	O
pathway	O
[	O
40	O
].	O

Overâ	O
	O
activation	O
of	O
the	O
WNT	O
/	O
Î²â	O
	O
catenin	O
pathway	O
underlies	O
the	O
molecular	O
aetiology	O
of	O
human	O
and	O
mouse	O
ACP	O
An	O
interesting	O
observation	O
of	O
the	O
previously	O
described	O
embryonic	O
mouse	O
line	O
(	O
hereby	O
referred	O
to	O
as	O
the	O
â	O
	O
embryonic	O
ACP	O
modelâ	O
)	O
is	O
that	O
the	O
remaining	O
20	O
%	O
of	O
the	O
pups	O
survive	O
weaning	O
but	O
show	O
variable	O
growth	O
defects	O
and	O
fully	O
penetrant	O
pituitary	O
tumours	O
,	O
with	O
a	O
median	O
survival	O
of	O
around	O
11	O
weeks	O
of	O
age	O
[	O
21	O
].	O

Histopathological	O
analyses	O
have	O
revealed	O
characteristic	O
hallmarks	O
of	O
human	O
ACP	O
such	O
as	O
large	O
cysts	O
,	O
cell	O
clusters	O
with	O
nucleoâ	O
	O
cytoplasmic	O
accumulation	O
of	O
Î²â	O
	O
catenin	O
and	O
expression	O
of	O
Axin2	O
,	O
Lef1	O
and	O
Bmp4	O
,	O
indicating	O
the	O
activation	O
of	O
the	O
Wnt	O
/	O
Î²â	O
	O
catenin	O
pathway	O
[	O
21	O
,	O
25	O
,	O
41	O
].	O

These	O
neoplastic	O
cells	O
do	O
not	O
express	O
markers	O
of	O
proliferation	O
or	O
pituitary	O
hormones	O
and	O
are	O
negative	O
for	O
synaptophysin	O
,	O
a	O
marker	O
of	O
neurons	O
and	O
endocrine	O
cells	O
(	O
Figureâ	O
	O
4	O
and	O
data	O
not	O
shown	O
)	O
[	O
21	O
,	O
42	O
,	O
43	O
].	O

Therefore	O
,	O
cluster	O
cells	O
in	O
mouse	O
and	O
human	O
ACPs	O
have	O
exited	O
the	O
cell	O
cycle	O
,	O
are	O
undifferentiated	O
and	O
possibly	O
not	O
of	O
either	O
neural	O
or	O
endocrine	O
origin	O
.	O

However	B
,	O
contrary	B
to	O
the	O
human	O
counterpart	O
,	O
mouse	O
ACPs	O
do	O
not	O
show	O
wet	O
keratin	O
or	O
calcification	O
,	O
suggesting	O
speciesâ	O
	O
specific	O
differences	B
between	O
mouse	O
and	O
human	O
ACPs	O
.	O

Critically	O
,	O
human	O
ACPs	O
develop	O
over	O
years	O
,	O
but	O
mouse	O
ACPs	O
develop	O
in	O
a	O
period	O
of	O
weeks	O
.	O

Despite	B
these	O
differences	B
,	O
the	O
mouse	O
tumours	O
are	O
more	O
similar	O
to	O
human	O
ACP	O
than	O
to	O
any	O
other	O
tumour	O
of	O
the	O
sellar	O
region	O
including	O
pituitary	O
adenoma	O
,	O
Rathke	O
'	O
s	O
cleft	O
cysts	O
and	O
even	O
the	O
papillary	O
type	O
of	O
craniopharyngioma	O
.	O

Caption	O
(	O
Fig	O
):	O
FIG	O
4	O
Cluster	O
cells	O
in	O
mouse	O
and	O
human	O
ACP	O
do	O
not	O
express	O
Ki67	O
or	O
SOX9	O
.	O

Double	O
immunofluorescent	O
staining	O
against	O
Î²â	O
	O
catenin	O
(	O
green	O
)	O
and	O
the	O
proliferative	O
marker	O
Ki67	O
or	O
the	O
transcription	O
factor	O
SOX9	O
(	O
red	O
).	O

Reproduced	O
with	O
permission	O
from	O
PNAS	O
(	O
Gastonâ	O
	O
Massuet	O
etâ	O
	O
al	O
.,	O
PNAS	O
USA	O
2011	O
,	O
vol	O
.	O

108	O
,	O
number	O
28	O
,	O
pp	O
11482â	O
	O
11487	O
).	O

Mutations	O
in	O
CTNNB1	O
have	O
been	O
identified	O
in	O
most	O
of	O
the	O
human	O
ACP	O
samples	O
analysed	O
[	O
17	O
,	O
19	O
,	O
20	O
,	O
44	O
,	O
45	O
,	O
46	O
].	O

These	O
are	O
mostly	O
restricted	O
to	O
exon	O
3	O
and	O
result	O
in	O
the	O
substitution	O
or	O
deletion	O
of	O
the	O
critical	O
regulatory	O
amino	O
acids	O
that	O
control	O
stabilization	O
of	O
the	O
protein	O
,	O
predicted	O
to	O
lead	O
to	O
its	O
nucleocytoplasmic	O
accumulation	O
and	O
overâ	O
	O
activation	O
of	O
the	O
WNT	O
/	O
Î²â	O
	O
catenin	O
pathway	O
[	O
21	O
,	O
22	O
,	O
25	O
,	O
41	O
,	O
47	O
].	O

Human	O
mutations	O
are	O
functionally	O
equivalent	O
to	O
the	O
mutated	O
Î²â	O
	O
catenin	O
expressed	O
in	O
the	O
embryonic	O
ACP	O
model	O
.	O

Together	O
,	O
the	O
human	O
and	O
mouse	O
studies	O
have	O
provided	O
robust	O
evidence	O
for	O
a	O
role	O
of	O
CTNNB1	O
mutations	O
and	O
the	O
overâ	O
	O
activation	O
of	O
the	O
WNT	O
/	O
Î²â	O
	O
catenin	O
pathway	O
in	O
the	O
molecular	O
aetiology	O
of	O
ACP	O
.	O

Childhoodâ	O
	O
onset	O
ACP	O
is	O
likely	O
to	O
be	O
a	O
tumour	O
of	O
embryonic	O
origin	O
Further	O
molecular	O
and	O
genetic	O
studies	O
using	O
the	O
embryonic	O
ACP	O
mouse	O
model	O
have	O
revealed	O
two	O
interesting	O
findings	O
on	O
the	O
pathogenesis	O
of	O
human	O
ACPs	O
,	O
in	O
particular	O
,	O
of	O
childhoodâ	O
	O
onset	O
ACP	O
.	O

First	O
,	O
genetic	O
approaches	O
in	O
mice	O
have	O
demonstrated	O
that	O
tumours	O
form	O
only	O
when	O
oncogenic	O
Î²â	O
	O
catenin	O
is	O
expressed	O
in	O
Rathke	O
'	O
s	O
pouch	O
undifferentiated	O
precursors	O
,	O
but	O
not	O
when	O
committed	O
progenitors	O
or	O
fully	O
differentiated	O
hormoneâ	O
	O
producing	O
cells	O
are	O
targeted	O
.	O

Second	O
,	O
analyses	O
of	O
mouse	O
embryos	O
at	O
different	O
stages	O
of	O
development	O
have	O
revealed	O
that	O
Î²â	O
	O
cateninâ	O
	O
accumulating	O
cell	O
clusters	O
with	O
a	O
similar	O
gene	O
expression	O
profile	O
to	O
the	O
human	O
clusters	O
are	O
present	O
in	O
the	O
pituitary	O
gland	O
of	O
the	O
embryonic	O
ACP	O
model	O
by	O
the	O
end	O
of	O
gestation	O
[	O
21	O
].	O

Are	O
these	O
conclusions	O
applicable	O
to	O
the	O
human	O
tumours	O
?	O

The	O
similarities	O
between	O
the	O
mouse	O
and	O
human	O
clusters	O
are	O
remarkable	O
,	O
not	O
only	O
morphologically	O
but	O
also	O
at	O
the	O
molecular	O
level	O
,	O
strongly	O
suggesting	O
that	O
they	O
represent	O
equivalent	O
structures	O
in	O
mouse	O
and	O
human	O
ACPs	O
.	O

In	O
fact	O
,	O
whole	O
transcriptome	O
gene	O
expression	O
profiling	O
of	O
the	O
mouse	O
cluster	O
cells	O
has	O
revealed	O
numerous	O
genes	O
/	O
pathways	O
that	O
are	O
dysregulated	O
in	O
the	O
mouse	O
and	O
also	O
in	O
the	O
human	O
tumours	O
[	O
42	O
].	O

The	O
possibility	O
that	O
ACP	O
patients	O
may	O
have	O
cell	O
clusters	O
in	O
the	O
pituitary	O
gland	O
is	O
supported	O
by	O
clinical	O
evidence	O
.	O

In	O
a	O
retrospective	O
analysis	O
of	O
90	O
children	O
diagnosed	O
with	O
ACP	O
(	O
median	O
age	O
at	O
diagnosis	O
8	O
.	O
3	O
years	O
),	O
Muller	O
and	O
colleagues	O
have	O
reported	O
a	O
significant	O
decrease	O
in	O
height	O
score	O
at	O
10â	O
	O
12	O
months	O
of	O
age	O
that	O
persisted	O
until	O
the	O
diagnosis	O
of	O
ACP	O
[	O
48	O
].	O

Of	O
note	O
,	O
somatotrophs	O
are	O
clearly	O
defective	O
in	O
the	O
embryonic	O
ACP	O
model	O
by	O
the	O
end	O
of	O
gestation	O
and	O
postnatally	O
resulting	O
in	O
dwarfism	O
[	O
21	O
].	O

Therefore	O
,	O
it	O
is	O
tempting	O
to	O
suggest	O
that	O
clusters	O
may	O
develop	O
embryologically	O
in	O
human	O
patients	O
and	O
may	O
be	O
present	O
in	O
the	O
pituitary	O
gland	O
of	O
the	O
newborn	O
prior	O
to	O
the	O
appearance	O
of	O
any	O
tumour	O
mass	O
.	O

In	O
fact	O
,	O
foetal	O
ACP	O
was	O
recently	O
diagnosed	O
in	O
a	O
18	O
week	O
human	O
foetus	O
[	O
49	O
].	O

Pituitary	O
stem	O
cells	O
play	O
a	O
critical	O
role	O
in	O
the	O
pathogenesis	O
of	O
ACP	O
The	O
presence	O
of	O
tissueâ	O
	O
specific	O
stem	O
cells	O
has	O
been	O
demonstrated	O
in	O
several	O
organs	O
including	O
the	O
brain	O
,	O
gastrointestinal	O
tract	O
,	O
skin	O
,	O
bone	O
marrow	O
and	O
skeletal	O
muscle	O
among	O
others	O
.	O

These	O
cells	O
can	O
selfâ	O
	O
renew	O
,	O
express	O
markers	O
associated	O
with	O
stemness	O
(	O
e	O
.	O
g	O
.	O

Sox2	O
)	O
and	O
can	O
give	O
rise	O
to	O
progeny	O
able	O
to	O
differentiate	O
and	O
contribute	O
to	O
tissue	O
homeostasis	O
as	O
well	O
as	O
regeneration	O
[	O
32	O
,	O
50	O
].	O

The	O
existence	O
of	O
similar	O
cells	O
in	O
the	O
adult	O
murine	O
pituitary	O
gland	O
has	O
been	O
long	O
suspected	O
[	O
51	O
],	O
but	O
not	O
fully	O
demonstrated	O
until	O
recently	O
,	O
by	O
using	O
genetic	O
tracing	O
in	O
the	O
mouse	O
[	O
52	O
,	O
53	O
].	O

Pituitary	O
stem	O
cells	O
express	O
the	O
transcription	O
factors	O
SOX2	O
and	O
SOX9	O
and	O
are	O
capable	O
of	O
differentiating	O
into	O
all	O
of	O
the	O
hormoneâ	O
	O
producing	O
cells	O
to	O
contribute	O
to	O
organ	O
homeostasis	O
and	O
regeneration	O
.	O

In	O
the	O
adult	O
human	O
pituitary	O
,	O
SOX2	O
+	O
ve	O
cells	O
have	O
also	O
been	O
identified	O
,	O
suggesting	O
that	O
stem	O
cells	O
may	O
also	O
exist	O
in	O
the	O
human	O
organ	O
[	O
54	O
].	O

Tissueâ	O
	O
specific	O
stem	O
cells	O
can	O
be	O
the	O
origin	O
of	O
cancer	O
,	O
a	O
concept	O
that	O
has	O
fuelled	O
the	O
cancer	O
stem	O
cell	O
(	O
CSC	O
)	O
paradigm	O
.	O

This	O
proposes	O
that	O
within	O
tumours	O
and	O
cancers	O
,	O
there	O
is	O
a	O
minority	O
of	O
transformed	O
cells	O
capable	O
of	O
selfâ	O
	O
renewing	O
and	O
generate	O
the	O
progeny	O
that	O
populate	O
the	O
tumour	O
bulk	O
.	O

As	O
CSCs	O
may	O
be	O
particularly	O
resistant	O
to	O
chemotherapy	O
and	O
radiation	O
,	O
it	O
is	O
thought	O
that	O
they	O
can	O
be	O
responsible	O
for	O
cancer	O
evolution	O
,	O
recurrence	O
and	O
metastasis	O
,	O
raising	O
a	O
significant	O
interest	O
in	O
the	O
oncology	O
field	O
as	O
potential	O
targets	O
for	O
novel	O
specific	O
therapies	O
[	O
55	O
,	O
56	O
,	O
57	O
,	O
58	O
,	O
59	O
,	O
60	O
].	O

The	O
presence	O
of	O
CSCs	O
in	O
pituitary	O
tumours	O
,	O
and	O
specifically	O
in	O
human	O
ACP	O
,	O
has	O
recently	O
been	O
investigated	O
using	O
genetic	O
approaches	O
.	O

A	O
mouse	O
model	O
was	O
generated	O
by	O
activating	O
the	O
WNT	O
/	O
Î²â	O
	O
catenin	O
pathway	O
exclusively	O
in	O
SOX2	O
+	O
ve	O
adult	O
pituitary	O
stem	O
cells	O
[	O
52	O
].	O

These	O
mice	O
,	O
referred	O
to	O
as	O
the	O
â	O
	O
adult	O
ACP	O
modelâ	O
,	O
also	O
develop	O
pituitary	O
tumours	O
that	O
are	O
composed	O
of	O
synaptophysinâ	O
	O
negative	O
and	O
undifferentiated	O
(	O
i	O
.	O
e	O
.	O

neither	O
endocrine	O
nor	O
neural	O
)	O
tumour	O
cells	O
.	O

Importantly	O
,	O
these	O
tumours	O
contain	O
Î²â	O
	O
cateninâ	O
	O
accumulating	O
cell	O
clusters	O
,	O
indicating	O
a	O
significant	O
resemblance	O
to	O
both	O
human	O
ACP	O
and	O
the	O
embryonic	O
model	O
previously	O
described	O
.	O

Taking	O
into	O
consideration	O
this	O
mouse	O
research	O
,	O
it	O
could	O
be	O
speculated	O
that	O
mutations	O
in	O
CTNNB1	O
in	O
SOX2	O
+	O
ve	O
stem	O
cells	O
of	O
the	O
mature	O
adult	O
pituitary	O
are	O
the	O
cause	O
of	O
adulthoodâ	O
	O
onset	O
ACP	O
in	O
humans	O
,	O
while	B
the	O
same	O
mutations	O
in	O
undifferentiated	O
RP	O
progenitors	O
may	O
lead	O
to	O
childhoodâ	O
	O
onset	O
ACP	O
.	O

Further	O
molecular	O
characterization	O
of	O
adult	O
and	O
childhood	O
ACP	O
may	O
help	O
resolve	O
this	O
hypothesis	O
.	O

It	O
was	O
important	O
to	O
address	O
whether	B
the	O
mutated	O
SOX2	O
+	O
ve	O
cells	O
in	O
the	O
adult	O
ACP	O
model	O
were	O
CSCs	O
.	O

To	O
address	O
this	O
important	O
question	O
,	O
SOX2	O
+	O
ve	O
stem	O
cells	O
have	O
been	O
targeted	O
to	O
simultaneously	O
express	O
oncogenic	O
mutant	O
Î²â	O
	O
catenin	O
and	O
yellow	O
fluorescent	O
protein	O
(	O
YFP	O
).	O

If	O
normal	O
SOX2	O
+	O
ve	O
cells	O
were	O
transformed	O
into	O
CSCs	O
due	O
to	O
the	O
expression	O
of	O
oncogenic	O
Î²â	O
	O
catenin	O
,	O
the	O
tumour	O
would	O
be	O
expected	O
to	O
contain	O
YFP	O
+	O
progeny	O
cells	O
.	O

Surprisingly	O
,	O
tumours	O
do	O
not	O
express	O
YFP	O
,	O
indicating	O
that	O
the	O
cell	O
of	O
origin	O
of	O
mouse	O
ACP	O
is	O
not	O
a	O
targeted	O
SOX2	O
+	O
ve	O
cell	O
(	O
Figureâ	O
	O
5	O
)	O
[	O
52	O
].	O

The	O
targeted	O
SOX2	O
+	O
ve	O
cells	O
proliferate	O
transiently	O
due	O
to	O
the	O
overâ	O
	O
activation	O
of	O
the	O
WNT	O
/	O
Î²â	O
	O
catenin	O
pathway	O
;	O
but	O
soon	O
after	O
this	O
burst	O
of	O
cell	O
division	O
,	O
they	O
exit	O
the	O
cell	O
cycle	O
and	O
form	O
cell	O
clusters	O
with	O
nucleoâ	O
	O
cytoplasmic	O
accumulation	O
of	O
Î²â	O
	O
catenin	O
,	O
like	O
those	O
observed	O
in	O
human	O
ACP	O
.	O

Two	O
conclusions	O
can	O
be	O
drawn	O
from	O
these	O
studies	O
:	O
(	O
i	O
)	O
SOX2	O
+	O
ve	O
stem	O
cells	O
are	O
not	O
the	O
cell	O
of	O
origin	O
of	O
ACP	O
;	O
however	B
,	O
they	O
are	O
the	O
origin	O
of	O
the	O
typical	O
cell	O
clusters	O
that	O
characterize	O
these	O
neoplasms	O
;	O
(	O
ii	O
)	O
mutated	O
SOX2	O
+	O
ve	O
cells	O
expressing	O
oncogenic	O
Î²â	O
	O
catenin	O
are	O
not	O
CSCs	O
according	O
to	O
the	O
classical	O
definition	O
of	O
the	O
CSC	O
paradigm	O
,	O
since	O
their	O
descendants	O
do	O
not	O
colonize	O
the	O
tumours	O
,	O
rather	B
they	O
induced	O
tumours	O
in	O
a	O
nonâ	O
	O
cell	O
autonomous	O
manner	O
.	O

Caption	O
(	O
Fig	O
):	O
FIG	O
5	O
The	O
progeny	O
of	O
SOX2	O
+	O
pituitary	O
stem	O
cells	O
give	O
rise	O
to	O
the	O
cell	O
clusters	O
but	O
are	O
not	O
the	O
cellâ	O
	O
ofâ	O
	O
origin	O
of	O
mouse	O
ACP	O
.	O

Double	O
immunofluorescence	O
staining	O
reveals	O
the	O
presence	O
of	O
a	O
Î²â	O
	O
cateninâ	O
	O
accumulating	O
tumour	O
(	O
asterisk	O
)	O
that	O
is	O
YFP	O
â	O
	O
ve	O
.	O

Note	O
that	O
YFP	O
â	O
	O
ve	O
tumour	O
is	O
adjacent	O
to	O
YFP	O
+	O
ve	O
cell	O
clusters	O
showing	O
nucleoâ	O
	O
cytoplasmic	O
Î²â	O
	O
catenin	O
accumulation	O
(	O
arrowheads	O
).	O

Reproduced	O
with	O
permission	O
from	O
Elsevier	O
(	O
Andoniadou	O
etâ	O
	O
al	O
.,	O
Cell	O
Stem	O
Cell	O
2013	O
,	O
vol	O
.	O

13	O
,	O
issue	O
4	O
,	O
pp	O
433â	O
	O
445	O
).	O

A	O
paracrine	O
model	O
for	O
the	O
involvement	O
of	O
pituitary	O
stem	O
cells	O
in	O
tumourigenesis	O
If	B
murine	O
ACP	O
tumours	O
are	O
not	O
derived	O
from	O
the	O
mutated	O
SOX2	O
+	O
ve	O
stem	O
cells	O
in	O
a	O
cellâ	O
	O
autonomous	O
manner	O
,	O
what	O
is	O
the	O
mechanism	O
underlying	O
tumour	O
formation	O
?	O

Molecular	O
analyses	O
have	O
provided	O
some	O
interesting	O
and	O
provocative	O
insights	O
into	O
this	O
question	O
.	O

Using	O
genetic	O
approaches	O
,	O
the	O
cluster	O
cells	O
have	O
been	O
isolated	O
from	O
the	O
embryonic	O
mouse	O
model	O
and	O
their	O
gene	O
expression	O
profiled	O
in	O
comparison	O
with	O
the	O
nonâ	O
	O
cluster	O
tumour	O
cells	O
to	O
identify	O
dysregulated	O
genes	O
/	O
pathways	O
[	O
42	O
].	O

The	O
studies	O
have	O
revealed	O
that	O
cluster	O
cells	O
function	O
like	O
signalling	O
centres	O
by	O
expressing	O
a	O
great	O
variety	O
of	O
secreted	O
proteins	O
including	O
members	O
of	O
the	O
fibroblast	O
growth	O
factor	O
(	O
FGF	O
),	O
transforming	O
growth	O
factor	O
beta	O
(	O
TGFÎ²	O
),	O
epithelial	O
growth	O
factor	O
(	O
EGF	O
)	O
and	O
sonic	O
hedgehog	O
(	O
SHH	O
)	O
pathways	O
.	O

In	O
addition	O
,	O
several	O
chemokines	O
and	O
cytokines	O
as	O
well	O
as	O
their	O
receptors	O
,	O
which	O
are	O
critical	O
mediators	O
of	O
inflammation	O
,	O
are	O
also	O
upâ	O
	O
regulated	O
in	O
the	O
mouse	O
clusters	O
.	O

Of	O
interest	O
,	O
proteins	O
with	O
proâ	O
	O
inflammatory	O
properties	O
have	O
been	O
identified	O
in	O
the	O
cystic	O
fluid	O
of	O
human	O
ACP	O
,	O
suggesting	O
that	O
ACP	O
may	O
be	O
an	O
inflammationâ	O
	O
driven	O
tumour	O
[	O
13	O
,	O
14	O
,	O
15	O
,	O
16	O
].	O

Many	O
of	O
these	O
factors	O
have	O
been	O
shown	O
to	O
be	O
expressed	O
in	O
several	O
tumours	O
/	O
cancers	O
and	O
play	O
critical	O
roles	O
in	O
tumour	O
biology	O
[	O
61	O
,	O
62	O
,	O
63	O
,	O
64	O
,	O
65	O
].	O

Normal	O
embryogenesis	O
relies	O
heavily	O
on	O
signalling	O
centres	O
.	O

Broadly	O
speaking	O
,	O
normal	O
organogenesis	O
including	O
pituitary	O
morphogenesis	O
is	O
brought	O
about	O
by	O
the	O
activities	O
of	O
cells	O
with	O
instructive	O
properties	O
that	O
secrete	O
signals	O
(	O
i	O
.	O
e	O
.	O

signalling	O
centres	O
)	O
and	O
those	O
of	O
surrounding	O
cells	O
,	O
which	O
respond	O
to	O
those	O
signals	O
.	O

In	O
mouse	O
ACP	O
,	O
Î²â	O
	O
cateninâ	O
	O
accumulating	O
cell	O
clusters	O
secrete	O
factors	O
affecting	O
the	O
tissue	O
microenvironment	O
in	O
a	O
paracrine	O
manner	O
,	O
promoting	O
cell	O
transformation	O
and	O
tumourigenesis	O
.	O

In	O
this	O
paracrine	O
model	O
of	O
involvement	O
of	O
stem	O
cells	O
in	O
tumourigenesis	O
,	O
the	O
cell	O
sustaining	O
the	O
oncogenic	O
mutation	O
and	O
the	O
cell	O
of	O
origin	O
of	O
the	O
tumours	O
are	O
different	B
[	O
52	O
]	O
(	O
Figureâ	O
	O
6	O
).	O

Caption	O
(	O
Fig	O
):	O
FIG	O
6	O
Paracrine	O
model	O
of	O
involvement	O
of	O
pituitary	O
stem	O
cells	O
in	O
tumourigenesis	O
.	O

When	O
targeted	O
to	O
express	O
oncogenic	O
Î²â	O
	O
catenin	O
,	O
SOX2	O
+	O
ve	O
cells	O
(	O
green	O
)	O
accumulate	O
nucleoâ	O
	O
cytoplasmic	O
Î²â	O
	O
catenin	O
,	O
proliferate	O
transiently	O
and	O
stop	O
dividing	O
forming	O
clusters	O
.	O

Clusters	O
secrete	O
signals	O
to	O
the	O
surrounding	O
cells	O
to	O
induce	O
cell	O
transformation	O
and	O
tumour	O
growth	O
from	O
a	O
cell	O
that	O
is	O
not	O
derived	O
from	O
the	O
targeted	O
SOX2	O
+	O
ve	O
stem	O
cell	O
.	O

Reproduced	O
with	O
permission	O
from	O
Elsevier	O
(	O
Andoniadou	O
etâ	O
	O
al	O
.,	O
Cell	O
Stem	O
Cell	O
2013	O
,	O
vol	O
.	O

13	O
,	O
issue	O
4	O
,	O
pp	O
433â	O
	O
445	O
).	O

An	O
important	O
question	O
is	O
to	O
what	O
extent	O
these	O
findings	O
are	O
relevant	O
to	O
human	O
ACP	O
.	O

Several	O
lines	O
of	O
evidence	O
support	O
the	O
view	O
that	O
the	O
pathogenesis	O
of	O
mouse	O
and	O
human	O
ACP	O
are	O
very	O
similar	O
:	O
(	O
i	O
)	O
recent	O
research	O
using	O
a	O
xenograft	O
model	O
of	O
human	O
ACP	O
in	O
immunosuppressed	O
mice	O
has	O
shown	O
that	O
the	O
activities	O
of	O
the	O
clusters	O
are	O
critical	O
to	O
regulate	O
cell	O
behaviour	O
in	O
the	O
invasive	O
front	O
of	O
the	O
tumours	O
[	O
66	O
];	O
(	O
ii	O
)	O
human	O
clusters	O
also	O
express	O
FGFs	O
,	O
TGFÎ²s	O
,	O
SHH	O
,	O
chemokine	O
receptors	O
and	O
other	O
secreted	O
factors	O
capable	O
of	O
modifying	O
the	O
tumour	O
microenvironment	O
and	O
promoting	O
tumour	O
growth	O
[	O
22	O
,	O
42	O
,	O
67	O
,	O
68	O
];	O
(	O
iii	O
)	O
cluster	O
cells	O
in	O
the	O
human	O
tumours	O
are	O
nonâ	O
	O
proliferative	O
,	O
undifferentiated	O
(	O
i	O
.	O
e	O
.	O

neither	O
endocrine	O
not	O
neural	O
)	O
and	O
express	O
markers	O
associated	O
with	O
stem	O
cells	O
[	O
21	O
,	O
23	O
];	O
(	O
iv	O
)	O
cell	O
clusters	O
are	O
present	O
in	O
the	O
majority	O
of	O
human	O
ACP	O
,	O
even	O
in	O
very	O
large	O
and	O
advanced	O
tumours	O
,	O
suggesting	O
that	O
their	O
activities	O
must	O
be	O
required	O
for	O
growth	O
and	O
/	O
or	O
survival	O
of	O
tumour	O
cells	O
.	O

If	B
this	O
was	O
not	O
the	O
case	O
,	O
it	O
would	O
be	O
difficult	O
to	O
explain	O
why	O
the	O
tumour	O
ends	O
up	O
killing	O
all	O
of	O
the	O
normal	O
pituitary	O
tissue	O
,	O
but	B
sparing	O
a	O
limited	O
population	O
of	O
nonâ	O
	O
dividing	O
cells	O
forming	O
clusters	O
.	O

Whether	B
the	O
paracrine	O
signals	O
of	O
the	O
clusters	O
may	O
also	O
be	O
required	O
for	O
the	O
initial	O
transformation	O
of	O
the	O
cell	O
of	O
origin	O
of	O
the	O
tumour	O
is	O
an	O
important	O
question	O
that	O
requires	O
further	O
research	O
.	O

Moreover	O
,	O
it	O
is	O
possible	O
that	O
the	O
paracrine	O
model	O
may	O
be	O
applicable	O
to	O
other	B
pituitary	O
tumours	O
and	O
human	O
cancers	O
as	O
published	O
evidence	O
suggests	O
its	O
broader	O
implications	O
in	O
the	O
oncology	O
field	O
[	O
69	O
,	O
70	O
,	O
71	O
,	O
72	O
,	O
73	O
,	O
74	O
].	O

Conclusions	O
and	O
open	O
questions	O
The	O
pathogenesis	O
of	O
human	O
ACP	O
is	O
being	O
revealed	O
and	O
several	O
dysregulated	O
genes	O
and	O
pathways	O
have	O
been	O
identified	O
,	O
which	O
may	O
impact	O
the	O
diagnosis	O
,	O
prognosis	O
and	O
treatment	O
of	O
patients	O
in	O
the	O
years	O
to	O
come	O
.	O

It	O
is	O
established	O
that	O
mutations	O
in	O
CTNNB1	O
resulting	O
in	O
the	O
overâ	O
	O
activation	O
of	O
the	O
WNT	O
/	O
Î²â	O
	O
catenin	O
pathway	O
underlie	O
the	O
aetiology	O
of	O
ACP	O
,	O
but	B
many	O
questions	O
remain	O
unanswered	O
.	O

Why	O
are	O
the	O
tumourigenic	O
effects	O
of	O
mutant	O
Î²â	O
	O
catenin	O
restricted	O
only	O
to	O
Rathke	O
'	O
s	O
pouch	O
embryonic	O
precursors	O
and	O
adult	O
pituitary	O
stem	O
cells	O
?	O

Research	O
from	O
mouse	O
models	O
has	O
demonstrated	O
that	O
only	O
these	O
undifferentiated	O
cells	O
are	O
able	O
to	O
induce	O
tumours	O
when	O
targeted	O
with	O
oncogenicÎ²â	O
	O
catenin	O
.	O

This	O
is	O
likely	O
to	O
be	O
the	O
case	O
in	O
human	O
ACP	O
,	O
when	O
taking	O
into	O
account	O
the	O
similarities	O
in	O
the	O
pathogenesis	O
and	O
the	O
possibility	O
that	O
childhoodâ	O
	O
onset	O
ACP	O
is	O
likely	O
to	O
be	O
a	O
developmental	O
tumour	O
.	O

Which	O
is	O
the	O
cell	O
of	O
origin	O
of	O
the	O
tumours	O
?	O

It	O
is	O
puzzling	O
that	O
mutated	O
SOX2	O
+	O
ve	O
stem	O
cells	O
in	O
the	O
adult	O
pituitary	O
are	O
not	O
the	O
cell	O
of	O
origin	O
of	O
the	O
tumours	O
in	O
the	O
mouse	O
as	O
it	O
would	O
be	O
expected	O
according	O
to	O
the	O
CSC	O
paradigm	O
.	O

Instead	O
they	O
induce	O
tumours	O
in	O
a	O
nonâ	O
	O
cell	O
autonomous	O
manner	O
by	O
activating	O
a	O
secretory	O
phenotype	O
with	O
tumourâ	O
	O
inducing	O
potential	O
.	O

Whether	B
cluster	O-
cells	O-
may	O-
or	I
may	O
be	O
not	I
the	O
origin	O
of	O
human	O
ACP	O
requires	O
detailed	O
molecular	O
analyses	O
.	O

Of	O
note	O
,	O
Holsken	O
etâ	O
	O
al	O
.	O

(	O
2009	O
)	O
revealed	O
the	O
presence	O
of	O
different	O
CTNNB1	O
mutations	O
inside	O
and	O
outside	O
the	O
clusters	O
in	O
50	O
%	O
of	O
the	O
human	O
ACP	O
analysed	O
,	O
suggesting	O
the	O
existence	O
of	O
tumour	O
heterogeneity	O
as	O
described	O
in	O
mouse	O
ACP	O
[	O
22	O
].	O

Which	O
are	O
the	O
dysregulated	O
pathways	O
in	O
human	O
ACP	O
?	O

Mouse	O
and	O
human	O
studies	O
have	O
discovered	O
several	O
pathways	O
that	O
are	O
dysregulated	O
in	O
ACP	O
,	O
but	O
nonâ	B
	O
biased	O
largeâ	O
	O
scale	O
gene	O
expression	O
analyses	O
of	O
human	O
ACP	O
are	O
needed	O
to	O
identify	O
other	B
targetable	O
pathways	O
and	O
novel	O
biomarkers	O
capable	O
of	O
predicting	O
tumour	O
behaviour	O
such	O
as	O
infiltrative	O
potential	O
and	O
recurrence	O
.	O

Could	O
the	O
study	O
of	O
these	O
benign	O
tumours	O
provide	O
novel	O
insights	O
into	O
the	O
origin	O
of	O
cancer	O
?	O

If	B
cancer	O
is	O
considered	O
as	O
the	O
malignant	O
progression	O
of	O
a	O
preâ	O
	O
malignant	O
lesion	O
,	O
then	O
benign	O
tumours	O
offer	O
a	O
window	O
of	O
opportunity	O
to	O
better	O
understand	O
the	O
early	O
steps	O
of	O
cell	O
transformation	O
and	O
tumour	O
initiation	O
.	O

Such	O
knowledge	O
is	O
needed	O
if	B
we	O
aim	O
to	O
improve	O
early	O
diagnosis	O
and	O
to	O
develop	O
treatments	O
,	O
which	O
eliminate	O
tumour	O
cells	O
at	O
more	O
vulnerable	O
stages	O
of	O
cancer	O
progression	O
.	O

The	O
paracrine	O
mechanism	O
described	O
using	O
the	O
adult	O
ACP	O
model	O
has	O
broadened	O
our	O
knowledge	O
on	O
how	O
adult	O
stem	O
cells	O
contribute	O
to	O
tumourigenesis	O
beyond	O
the	O
classical	O
CSC	O
paradigm	O
.	O

Future	O
research	O
is	O
required	O
to	O
dissect	O
this	O
model	O
further	O
and	O
to	O
assess	O
its	O
impact	O
in	O
the	O
cancer	O
field	O
.	O

Conflict	O
of	O
interest	O
The	O
author	O
declares	O
no	O
conflict	O
of	O
interest	O
.	O

Tumour	O
compartment	O
transcriptomics	O
demonstrates	O
the	O
activation	O
of	O
inflammatory	O
and	O
odontogenic	O
programmes	O
in	O
human	O
adamantinomatous	O
craniopharyngioma	O
and	O
identifies	O
the	O
MAPK	O
/	O
ERK	O
pathway	O
as	O
a	O
novel	O
therapeutic	O
target	O
Abstract	O
Adamantinomatous	O
craniopharyngiomas	O
(	O
ACPs	O
)	O
are	O
clinically	O
challenging	O
tumours	O
,	O
the	O
majority	O
of	O
which	O
have	O
activating	O
mutations	O
in	O
CTNNB1	O
.	O

They	O
are	O
histologically	O
complex	O
,	O
showing	O
cystic	O
and	O
solid	O
components	O
,	O
the	O
latter	O
comprised	O
of	O
different	O
morphological	O
cell	O
types	O
(	O
e	O
.	O
g	O
.	O

Î²	O
-	O
catenin	O
-	O
accumulating	O
cluster	O
cells	O
and	O
palisading	O
epithelium	O
),	O
surrounded	O
by	O
a	O
florid	O
glial	O
reaction	O
with	O
immune	O
cells	O
.	O

Here	O
,	O
we	O
have	O
carried	O
out	O
RNA	O
sequencing	O
on	O
18	O
ACP	O
samples	O
and	O
integrated	O
these	O
data	O
with	O
an	O
existing	O
ACP	O
transcriptomic	O
dataset	O
.	O

No	O
studies	O
so	O
far	O
have	O
examined	O
the	O
patterns	O
of	O
gene	O
expression	O
within	O
the	O
different	O
cellular	O
compartments	O
of	O
the	O
tumour	O
.	O

To	O
achieve	O
this	O
goal	O
,	O
we	O
have	O
combined	O
laser	O
capture	O
microdissection	O
with	O
computational	O
analyses	O
to	O
reveal	O
groups	O
of	O
genes	O
that	O
are	O
associated	O
with	O
either	O
epithelial	O
tumour	O
cells	O
(	O
clusters	O
and	O
palisading	O
epithelium	O
),	O
glial	O
tissue	O
or	O
immune	O
infiltrate	O
.	O

We	O
use	O
these	O
human	O
ACP	O
molecular	O
signatures	O
and	O
RNA	O
-	O
Seq	O
data	O
from	O
two	O
ACP	O
mouse	O
models	O
to	O
reveal	O
that	O
cell	O
clusters	O
are	O
molecularly	O
analogous	O
to	O
the	O
enamel	O
knot	O
,	O
a	O
critical	O
signalling	O
centre	O
controlling	O
normal	O
tooth	O
morphogenesis	O
.	O

Supporting	O
this	O
finding	O
,	O
we	O
show	O
that	O
human	O
cluster	O
cells	O
express	O
high	O
levels	O
of	O
several	O
members	O
of	O
the	O
FGF	O
,	O
TGFB	O
and	O
BMP	O
families	O
of	O
secreted	O
factors	O
,	O
which	O
signal	O
to	O
neighbouring	O
cells	O
as	O
evidenced	O
by	O
immunostaining	O
against	O
the	O
phosphorylated	O
proteins	O
pERK1	O
/	O
2	O
,	O
pSMAD3	O
and	O
pSMAD1	O
/	O
5	O
/	O
9	O
in	O
both	O
human	O
and	O
mouse	O
ACP	O
.	O

We	O
reveal	O
that	O
inhibiting	O
the	O
MAPK	O
/	O
ERK	O
pathway	O
with	O
trametinib	O
,	O
a	O
clinically	O
approved	O
MEK	O
inhibitor	O
,	O
results	O
in	O
reduced	O
proliferation	O
and	O
increased	O
apoptosis	O
in	O
explant	O
cultures	O
of	O
human	O
and	O
mouse	O
ACP	O
.	O

Finally	O
,	O
we	O
analyse	O
a	O
prominent	O
molecular	O
signature	O
in	O
the	O
glial	O
reactive	O
tissue	O
to	O
characterise	O
the	O
inflammatory	O
microenvironment	O
and	O
uncover	O
the	O
activation	O
of	O
inflammasomes	O
in	O
human	O
ACP	O
.	O

We	O
validate	O
these	O
results	O
by	O
immunostaining	O
against	O
immune	O
cell	O
markers	O
,	O
cytokine	O
ELISA	O
and	O
proteome	O
analysis	O
in	O
both	O
solid	O
tumour	O
and	O
cystic	O
fluid	O
from	O
ACP	O
patients	O
.	O

Our	O
data	O
support	O
a	O
new	O
molecular	O
paradigm	O
for	O
understanding	O
ACP	O
tumorigenesis	O
as	O
an	O
aberrant	O
mimic	O
of	O
natural	O
tooth	O
development	O
and	O
opens	O
new	O
therapeutic	O
opportunities	O
by	O
revealing	O
the	O
activation	O
of	O
the	O
MAPK	O
/	O
ERK	O
and	O
inflammasome	O
pathways	O
in	O
human	O
ACP	O
.	O

Electronic	O
supplementary	O
material	O
The	O
online	O
version	O
of	O
this	O
article	O
(	O
10	O
.	O
1007	O
/	O
s00401	O
-	O
018	O
-	O
1830	O
-	O
2	O
)	O
contains	O
supplementary	O
material	O
,	O
which	O
is	O
available	O
to	O
authorized	O
users	O
.	O

Introduction	O
Adamantinomatous	O
craniopharyngioma	O
(	O
ACP	O
)	O
is	O
the	O
most	O
common	O
tumour	O
of	O
the	O
sellar	O
region	O
in	O
children	O
.	O

Despite	O
being	O
cytologically	O
benign	O
,	O
ACPs	O
display	O
clinically	O
aggressive	O
behaviour	O
such	O
as	O
destruction	O
of	O
the	O
pituitary	O
gland	O
and	O
invasion	O
of	O
the	O
hypothalamus	O
and	O
visual	O
pathways	O
,	O
altogether	O
leading	O
to	O
chronic	O
severe	O
morbidity	O
and	O
increased	O
mortality	O
during	O
long	O
-	O
term	O
follow	O
-	O
up	O
.	O

ACPs	O
are	O
histologically	O
complex	O
tumours	O
with	O
variable	O
cystic	O
,	O
calcified	O
and	O
solid	O
components	O
.	O

They	O
frequently	O
invade	O
adjacent	O
tissues	O
with	O
infiltrating	O
finger	O
-	O
like	O
structures	O
surrounded	O
by	O
a	O
florid	O
glial	O
and	O
inflammatory	O
reactive	O
tissue	O
.	O

A	O
pathognomonic	O
feature	O
of	O
ACP	O
is	O
the	O
presence	O
of	O
anuclear	O
ghost	O
cells	O
,	O
also	O
known	O
as	O
â	O
	O
wet	O
keratinâ	O
,	O
while	B
other	B
common	O
features	O
include	O
calcification	O
and	O
cholesterol	O
clefts	O
.	O

The	O
majority	O
of	O
ACPs	O
have	O
somatic	O
activating	O
mutations	O
in	O
CTNNB1	O
,	O
the	O
gene	O
encoding	O
Î²	O
-	O
catenin	O
.	O

However	B
,	O
nucleo	O
-	O
cytoplasmic	O
accumulation	O
of	O
Î²	O
-	O
catenin	O
is	O
limited	O
to	O
only	O
a	O
small	O
proportion	O
of	O
cells	O
,	O
often	O
correlating	O
with	O
epithelial	O
whorl	O
-	O
like	O
structures	O
(	O
referred	O
to	O
as	O
Î²	O
-	O
catenin	O
-	O
accumulating	O
cell	O
clusters	O
),	O
or	O
in	O
single	O
cells	O
throughout	O
the	O
tumour	O
.	O

As	O
expected	O
,	O
these	O
regions	O
correlate	O
with	O
WNT	O
pathway	O
activation	O
,	O
evidenced	O
by	O
the	O
expression	O
of	O
pathway	O
target	O
genes	O
(	O
e	O
.	O
g	O
.	O

AXIN2	O
and	O
LEF1	O
).	O

In	B
contrast	I
,	O
in	O
other	B
histological	O
compartments	O
such	O
as	O
the	O
palisading	O
epithelium	O
or	O
stellate	O
reticulum	O
,	O
Î²	O
-	O
catenin	O
expression	O
is	O
limited	O
to	O
the	O
cell	O
membrane	O
and	O
activation	O
of	O
the	O
WNT	O
pathway	O
is	O
less	O
pronounced	O
.	O

The	O
similarities	O
between	O
ACP	O
and	O
both	O
normal	O
tooth	O
development	O
and	O
odontogenic	O
tumours	O
have	O
been	O
recognised	O
for	O
decades	O
,	O
on	O
the	O
basis	O
of	O
their	O
comparable	O
histopathology	O
and	O
co	O
-	O
expression	O
of	O
enamel	O
proteins	O
,	O
proteinases	O
and	O
some	O
keratins	O
,	O
as	O
well	O
as	O
the	O
occasional	O
identification	O
of	O
fully	O
formed	O
teeth	O
in	O
ACP	O
.	O

However	B
,	O
the	O
molecular	O
mechanisms	O
underlying	O
these	O
commonalities	O
are	O
not	O
well	O
understood	O
.	O

Insight	O
into	O
the	O
functional	O
significance	O
of	O
the	O
Î²	O
-	O
catenin	O
-	O
accumulating	O
cell	O
clusters	O
has	O
been	O
provided	O
by	O
studies	O
conducted	O
in	O
murine	O
ACP	O
models	O
,	O
where	O
a	O
degradation	O
-	O
resistant	O
(	O
activated	O
)	O
form	O
of	O
Î²	O
-	O
catenin	O
is	O
expressed	O
in	O
either	O
Rathkeâ	O
	O
s	O
pouch	O
derivatives	O
(	O
Hesx1Cre	O
/+/	O
Ctnnb1lox	O
(	O
ex3	O
)/+	O
mouse	O
line	O
;	O
ACP	O
embryonic	O
model	O
)	O
or	O
Sox2	O
-	O
expressing	O
adult	O
pituitary	O
stem	O
cells	O
(	O
Sox2CreERT2	O
/+/	O
Ctnnb1lox	O
(	O
ex3	O
)/+	O
mouse	O
line	O
;	O
ACP	O
inducible	O
model	O
).	O

Evidence	O
gathered	O
from	O
both	O
models	B
suggests	O
these	O
clusters	O
act	O
in	O
a	O
paracrine	O
manner	O
,	O
driving	O
tumour	O
growth	O
and	O
/	O
or	O
invasion	O
into	O
surrounding	O
tissues	O
through	O
the	O
secretion	O
of	O
a	O
wide	O
range	O
of	O
factors	O
(	O
e	O
.	O
g	O
.	O

SHH	O
,	O
FGFs	O
,	O
BMPs	O
,	O
TGFB1	O
;	O
as	O
well	O
as	O
pro	O
-	O
inflammatory	O
mediators	O
such	O
IL1	O
,	O
IL6	O
and	O
other	O
CXC	O
and	O
CC	O
chemokines	O
).	O

This	O
hypothesis	O
is	O
consistent	O
with	O
their	O
location	O
at	O
the	O
leading	O
edge	O
of	O
tissue	O
invasion	O
in	O
human	O
tumours	O
.	O

These	O
findings	O
have	O
raised	O
interest	O
in	O
discovering	O
therapeutic	O
approaches	O
targeting	O
these	O
clusters	O
and	O
highlighted	O
a	O
need	O
to	O
better	O
understand	O
the	O
pathways	O
and	O
cellular	O
processes	O
active	O
both	O
within	O
clusters	O
and	O
the	O
responding	O
tissues	O
.	O

Two	O
recent	O
publications	O
have	O
analysed	O
mRNA	O
expression	O
microarray	O
profiles	O
of	O
ACPs	O
,	O
comparing	O
either	O
with	O
other	B
tumour	O
types	O
and	O
control	O
tissues	O
,	O
or	O
with	O
the	O
BRAF	O
mutation	O
-	O
driven	O
papillary	O
craniopharyngioma	O
(	O
PCP	O
)	O
subtype	O
.	O

These	O
studies	O
have	O
highlighted	O
the	O
differences	B
between	O
ACP	O
and	O
PCP	O
and	O
identified	O
a	O
number	O
of	O
potential	O
therapeutic	O
targets	O
using	O
differential	O
expression	O
analysis	O
,	O
many	O
of	O
these	O
previously	O
anticipated	O
by	O
studies	O
using	O
the	O
murine	O
models	O
.	O

However	B
,	O
correlation	O
between	O
dysregulated	O
gene	O
pathways	O
in	O
human	O
ACP	O
and	O
tumour	O
architecture	O
has	O
been	O
limited	O
to	O
the	O
analyses	O
of	O
specific	O
proteins	O
by	O
immunostaining	O
.	O

Revealing	O
which	O
pathways	O
are	O
dysregulated	O
in	O
specific	O
tumour	O
cellular	O
compartments	O
is	O
important	O
to	O
increase	O
our	O
understanding	O
of	O
the	O
pathogenesis	O
of	O
human	O
ACP	O
.	O

Additionally	O
,	O
it	O
is	O
a	O
necessary	O
step	O
to	O
determine	O
which	O
cells	O
are	O
likely	O
to	O
be	O
susceptible	O
to	O
specific	O
targeted	O
therapies	O
,	O
helping	O
predict	O
possible	O
outcomes	O
.	O

For	O
instance	O
,	O
pancreatic	O
ductal	O
cell	O
carcinoma	O
(	O
PDCA	O
)	O
epithelial	O
cells	O
secrete	O
SHH	O
and	O
activate	O
the	O
pathway	O
in	O
the	O
tumours	O
,	O
but	O
its	O
targeted	O
inhibition	O
in	O
mouse	O
models	O
and	O
patients	O
causes	O
disruption	O
of	O
the	O
host	O
-	O
derived	O
stroma	O
with	O
little	O
effect	O
on	O
the	O
cancer	O
epithelial	O
cells	O
,	O
resulting	O
in	O
rapid	O
disease	O
progression	O
and	O
increased	O
aggressiveness	O
.	O

In	O
this	O
manuscript	O
,	O
we	O
have	O
performed	O
a	O
comprehensive	O
gene	O
expression	O
study	O
of	O
18	O
human	O
ACPs	O
combining	O
whole	O
-	O
tumour	O
RNA	O
-	O
Seq	O
with	O
transcriptomics	O
of	O
laser	O
capture	O
microdissected	O
tumour	O
cellular	O
components	O
to	O
reveal	O
the	O
molecular	O
signatures	O
of	O
specific	O
tumour	O
cell	O
compartments	O
.	O

We	O
complement	O
this	O
gene	O
expression	O
study	O
with	O
proteome	O
analysis	O
and	O
ELISA	O
of	O
both	O
tumour	O
and	O
cystic	O
fluid	O
from	O
ACP	O
patients	O
.	O

Our	O
data	O
provide	O
a	O
molecular	O
rationale	O
for	O
the	O
resemblance	O
of	O
ACP	O
and	O
tooth	O
development	O
and	O
highlight	O
a	O
complex	O
signalling	O
cascade	O
orchestrated	O
by	O
the	O
cluster	O
cells	O
.	O

Of	O
clinical	O
relevance	O
,	O
we	O
identify	O
the	O
MAPK	O
/	O
ERK	O
pathway	O
and	O
inflammasome	O
signalling	O
as	O
potentially	O
targetable	O
pathways	O
and	O
provide	O
preclinical	O
evidence	O
supporting	O
the	O
use	O
of	O
MEK	O
inhibitors	O
against	O
human	O
ACP	O
.	O

Materials	O
and	O
methods	O
Human	O
tumour	O
and	O
pituitary	O
samples	O
Anonymised	O
archival	O
frozen	O
and	O
formalin	O
-	O
fixed	O
paraffin	O
-	O
embedded	O
(	O
FFPE	O
)	O
specimens	O
of	O
ACP	O
and	O
non	O
-	O
functioning	O
pituitary	O
adenoma	O
(	O
NFPA	O
)	O
were	O
identified	O
in	O
the	O
local	O
pathology	O
archive	O
,	O
through	O
the	O
Childhoodâ	O
	O
s	O
Cancer	O
and	O
Leukaemia	O
Group	O
Tissue	O
Bank	O
,	O
Brain	O
UK	O
and	O
from	O
collaborators	O
.	O

Fetal	O
pituitary	O
tissue	O
(	O
19Â	O
weeks	O
corrected	O
gestational	O
age	O
)	O
was	O
accessed	O
through	O
the	O
Human	O
Developmental	O
Biology	O
Resource	O
(	O
HDBR	O
).	O

Further	O
details	O
can	O
be	O
found	O
in	O
Suppl	O
.	O

Materials	O
and	O
Methods	O
(	O
Online	O
Resource	O
1	O
).	O

Laser	O
capture	O
microdissection	O
(	O
LCM	O
)	O
Two	O
cases	O
(	O
JA004	O
,	O
JA029	O
)	O
were	O
used	O
for	O
LCM	O
because	O
they	O
contained	O
easily	O
definable	O
histological	O
features	O
(	O
clusters	O
,	O
palisading	O
epithelium	O
and	O
glial	O
reaction	O
)	O
and	O
cryopreserved	O
tissue	O
of	O
sufficient	O
quality	O
was	O
available	O
.	O

Further	O
details	O
can	O
be	O
found	O
in	O
Suppl	O
.	O

Materials	O
and	O
Methods	O
(	O
Online	O
Resource	O
1	O
).	O

RNA	O
sequencing	O
For	O
human	O
ACP	O
samples	O
sequencing	O
was	O
performed	O
by	O
UCL	O
Genomics	O
.	O

Murine	O
ACP	O
samples	O
were	O
sequenced	O
by	O
the	O
Oxford	O
Wellcome	O
Trust	O
Centre	O
for	O
Human	O
Genetics	O
.	O

Further	O
details	O
can	O
be	O
found	O
in	O
Suppl	O
.	O

Materials	O
and	O
Methods	O
(	O
Online	O
Resource	O
1	O
).	O

Immunostaining	O
of	O
histological	O
sections	O
Immunohistochemistry	O
and	O
immunofluorescence	O
staining	O
was	O
performed	O
as	O
previously	O
described	O
.	O

Antibody	O
details	O
can	O
be	O
found	O
in	O
Suppl	O
.	O

Materials	O
and	O
Methods	O
(	O
Online	O
Resource	O
1	O
).	O

Ex	O
vivo	O
culture	O
of	O
mouse	O
and	O
human	O
tumours	O
Ex	O
vivo	O
culture	O
of	O
neoplastic	O
pituitaries	O
was	O
performed	O
as	O
described	O
in	O
the	O
presence	O
of	O
either	O
trametinib	O
at	O
2	O
or	O
20Â	O
nM	O
(	O
Mekinist	O
)	O
or	O
DMSO	O
(	O
vehicle	O
control	O
).	O

Histological	O
analysis	O
was	O
performed	O
after	O
18Â	O
h	O
.	O
Small	O
pieces	O
of	O
human	O
ACP	O
(	O
around	O
1â	O
	O
2Â	O
mm3	O
)	O
were	O
cultured	O
in	O
identical	O
conditions	O
.	O

The	O
proportion	O
of	O
Ki67	O
positive	O
and	O
cleaved	O
caspase	O
-	O
3	O
cells	O
in	O
the	O
ex	O
vivo	O
culture	O
experiments	O
was	O
calculated	O
as	O
an	O
index	O
out	O
of	O
the	O
total	O
DAPI	O
-	O
stained	O
nuclei	O
.	O

Over	O
150	O
,	O
000Â	O
DAPI	O
nuclei	O
were	O
counted	O
from	O
six	O
histological	O
sections	O
per	O
pituitary	O
in	O
a	O
total	O
of	O
six	O
neoplastic	O
pituitaries	O
.	O

Three	O
human	O
tumours	O
were	O
used	O
in	O
the	O
ex	O
vivo	O
experiments	O
and	O
the	O
Ki	O
-	O
67	O
and	O
cleaved	O
caspase	O
-	O
3	O
index	O
calculated	O
as	O
described	O
above	O
from	O
four	O
histological	O
sections	O
per	O
tumour	O
(	O
over	O
192	O
,	O
000Â	O
cells	O
counted	O
).	O

Cytokine	O
multiplex	O
ELISA	O
Levels	O
of	O
TNF	O
-	O
Î	O
±,	O
IFN	O
-	O
Î³	O
,	O
IL	O
-	O
1Î²	O
,	O
IL	O
-	O
6	O
.	O

IL	O
-	O
8	O
,	O
IL	O
-	O
10	O
and	O
IL	O
-	O
18	O
were	O
measured	O
in	O
ACP	O
tumour	O
and	O
ACP	O
cystic	O
fluid	O
using	O
a	O
Meso	O
Scale	O
Discovery	O
(	O
MSD	O
)	O
multiplex	O
kit	O
(	O
Meso	O
Scale	O
Diagnostics	O
)	O
as	O
per	O
the	O
manufacturerâ	O
	O
s	O
instructions	O
.	O

For	O
solid	O
tumours	O
,	O
protein	O
lysates	O
were	O
extracted	O
from	O
pieces	O
of	O
fresh	O
frozen	O
ACP	O
.	O

Briefly	O
,	O
6	O
-	O
to	O
28	O
-	O
mg	O
samples	O
were	O
placed	O
in	O
250Â	O
Î¼l	O
of	O
lysis	O
buffer	O
(	O
150Â	O
mM	O
NaCl	O
,	O
20Â	O
mM	O
Tris	O
pH	O
7	O
.	O
5	O
,	O
1Â	O
mM	O
EDTA	O
,	O
1Â	O
mM	O
EGTA	O
,	O
1	O
%	O
Triton	O
,	O
with	O
Protease	O
Inhibitor	O
(	O
Roche	O
),	O
1Â	O
mM	O
sodium	O
orthovanadate	O
and	O
25Â	O
mM	O
sodium	O
fluoride	O
).	O

Samples	O
were	O
sonicated	O
on	O
ice	O
and	O
left	O
for	O
30Â	O
min	O
at	O
4Â	O
Â	O
°	O
C	O
,	O
followed	O
by	O
centrifugation	O
at	O
20	O
,	O
000g	O
for	O
10Â	O
min	O
and	O
collection	O
of	O
supernatant	O
.	O

Protein	O
concentrations	O
were	O
quantified	O
by	O
Bradford	O
assay	O
.	O

Cytokine	O
levels	O
were	O
normalised	O
against	O
total	O
protein	O
added	O
to	O
the	O
ELISA	O
.	O

Results	O
Samples	O
and	O
RNA	O
sequencing	O
data	O
analysis	O
Caption	O
(	O
Fig	O
):	O
FIG	O
1	O
Bioinformatics	O
analysis	O
of	O
gene	O
expression	O
profiling	O
of	O
human	O
ACP	O
whole	O
tumours	O
identifies	O
modules	O
of	O
genes	O
potentially	O
associated	O
with	O
specific	O
tumour	O
cell	O
compartments	O
.	O

a	O
Representative	O
histology	O
of	O
ACP	O
samples	O
showing	O
and	O
areas	O
of	O
tumour	O
(	O
T	O
),	O
reactive	O
glial	O
tissue	O
(	O
G	O
),	O
wet	O
keratin	O
/	O
ghost	O
cells	O
(	O
WK	O
),	O
epithelial	O
whorls	O
(	O
C	O
)	O
(	O
epithelial	O
whorls	O
referred	O
to	O
in	O
this	O
paper	O
as	O
clusters	O
),	O
palisading	O
epithelium	O
(	O
PE	O
)	O
and	O
stellate	O
reticulum	O
(	O
SR	O
).	O

Immunohistochemistry	O
using	O
antibodies	O
against	O
Î²	O
-	O
catenin	O
(	O
Î²	O
-	O
cat	O
)	O
on	O
case	O
JA029	O
showing	O
clusters	O
of	O
cells	O
with	O
nuclear	O
-	O
cytoplasmic	O
accumulation	O
.	O

Scale	O
bars	O
400Â	O
Î¼m	O
(	O
top	O
left	O
panel	O
),	O
100Â	O
Î¼m	O
(	O
other	O
three	O
panels	O
).	O

b	O
Scatterplot	O
revealing	O
a	O
significant	O
correlation	O
between	O
CTNNB1	O
mutation	O
frequency	O
and	O
histologically	O
assessed	O
tumour	O
content	O
.	O

#	O
case	O
JA011	O
;	O
*	O
case	O
JA005	O
;	O
controls	O
:	O
fetal	O
pituitaries	O
and	O
NFPA	O
tissues	O
.	O

See	O
Suppl	O
.	O

Table	O
1	O
(	O
Online	O
Resource	O
2	O
)	O
for	O
sample	O
details	O
.	O

c	O
Principal	O
component	O
analysis	O
plot	O
showing	O
the	O
separation	O
between	O
adamantinomatous	O
craniopharyngioma	O
(	O
ACP	O
),	O
non	O
-	O
functioning	O
pituitary	O
adenoma	O
(	O
NFPA	O
)	O
and	O
control	O
fetal	O
pituitary	O
tissues	O
(	O
fetal	O
).	O

d	O
Bar	O
plot	O
of	O
selected	O
statistically	O
significant	O
and	O
differentially	O
expressed	O
genes	O
,	O
as	O
assessed	O
by	O
DESeq2	O
,	O
in	O
ACP	O
tumours	O
compared	O
with	O
control	O
fetal	O
tissue	O
.	O

Higher	O
than	O
0	O
means	O
higher	O
expression	O
in	O
ACP	O
and	O
lower	O
than	O
0	O
means	O
higher	O
in	O
control	O
tissue	O
.	O

The	O
most	O
up	O
-	O
regulated	O
genes	O
in	O
ACP	O
tumours	O
are	O
keratins	O
.	O

Other	O
up	O
-	O
regulated	O
genes	O
include	O
WNTs	O
and	O
WNT	O
pathway	O
targets	O
(	O
e	O
.	O
g	O
.	O

NOTUM	O
,	O
AXIN2	O
,	O
LEF1	O
),	O
genes	O
known	O
to	O
be	O
expressed	O
in	O
ACP	O
(	O
e	O
.	O
g	O
.	O

FGFs	O
,	O
BMPs	O
)	O
and	O
previously	O
suggested	O
therapeutic	O
targets	O
(	O
SHH	O
,	O
MMP12	O
,	O
MMP9	O
,	O
EGFR	O
).	O

Pituitary	O
transcription	O
factors	O
(	O
LHX3	O
,	O
POU1F1	O
)	O
and	O
pituitary	O
hormones	O
(	O
e	O
.	O
g	O
.	O

FSHB	O
,	O
GH1	O
,	O
TSHB	O
)	O
are	O
up	O
-	O
regulated	O
in	O
controls	O
.	O

See	O
Suppl	O
.	O

TableÂ	O
3	O
(	O
Online	O
Resource	O
5	O
)	O
for	O
details	O
.	O

Error	O
barsâ	O
=	O
â	O
	O
1	O
standard	O
error	O
,	O
***	O
adjusted	O
p	O
value	O
<	O
â	O
	O
1â	O
	O
Ã	O
	O
â	O
	O
10â	O
	O
9	O
.	O

e	O
Multidimensional	O
scaling	O
plot	O
of	O
expression	O
patterns	O
of	O
the	O
5000	O
most	O
differentially	O
expressed	O
genes	O
included	O
in	O
the	O
weighted	O
gene	O
co	O
-	O
expression	O
network	O
analysis	O
(	O
WGCNA	O
)	O
analysis	O
.	O

The	O
colour	O
of	O
each	O
gene	O
indicates	O
it	O
membership	O
to	O
a	O
co	O
-	O
expressed	O
gene	O
expression	O
module	O
.	O

f	O
Heatmap	O
of	O
correlations	O
between	O
each	O
moduleâ	O
	O
s	O
gene	O
expression	O
profile	O
and	O
phenotypic	O
information	O
.	O

Scale	O
bar	O
indicate	O
r	O
value	O
â	O
	O
â	O
	O
1	O
to	O
+	O
â	O
	O
1	O
.	O

For	O
instance	O
,	O
the	O
brown	O
module	O
shows	O
a	O
strong	O
correlation	O
with	O
tumour	O
content	O
and	O
mutational	O
frequency	O
,	O
whilst	B
the	O
blue	O
module	O
correlates	O
with	O
the	O
presence	O
of	O
glial	O
reactive	O
tissue	O
and	O
GFAP	O
A	O
total	O
of	O
18	O
primary	O
ACP	O
samples	O
and	O
six	O
control	O
tissues	O
(	O
three	O
fetal	O
pituitaries	O
and	O
three	O
non	O
-	O
functioning	O
pituitary	O
adenomas	O
,	O
NFPA	O
)	O
were	O
analysed	O
by	O
RNA	O
-	O
Seq	O
.	O

We	O
chose	O
fetal	O
pituitaries	O
as	O
control	O
sample	O
because	O
ACP	O
is	O
thought	O
to	O
derive	O
from	O
remnants	O
of	O
Rathkeâ	O
	O
s	O
pouch	O
,	O
the	O
primordium	O
of	O
the	O
anterior	O
pituitary	O
.	O

RNA	O
quality	O
from	O
post	O
-	O
mortem	O
normal	O
adult	O
pituitaries	O
was	O
inadequate	O
for	O
RNA	O
sequencing	O
.	O

As	O
NFPA	O
are	O
tumours	O
containing	O
cells	O
similar	O
to	O
the	O
normal	O
adult	O
pituitary	O
and	O
are	O
known	O
to	O
cluster	O
with	O
normal	O
pituitary	O
tissue	O
on	O
expression	O
analysis	O
,	O
these	O
were	O
also	O
used	O
as	O
controls	O
.	O

Activating	O
mutations	O
in	O
exon	O
3	O
of	O
CTNNB1	O
were	O
identified	O
in	O
all	O
of	O
the	O
ACP	O
cases	O
,	O
except	O
for	O
JA011	O
and	O
JA005	O
,	O
with	O
a	O
mutation	O
allele	O
frequency	O
ranging	O
between	O
6	O
%	O
and	O
48	O
%	O
[	O
Suppl	O
.	O

TableÂ	O
1	O
(	O
Online	O
Resource	O
2	O
)].	O

Targeted	O
DNA	O
sequencing	O
of	O
an	O
adjacent	O
frozen	O
sample	O
of	O
case	O
JA011	O
revealed	O
a	O
CTNNB1	O
p	O
.	O
Gly34Arg	O
mutation	O
with	O
a	O
variant	O
allele	O
frequency	O
of	O
4	O
.	O
7	O
%	O
[	O
Suppl	O
.	O

TableÂ	O
1	O
(	O
Online	O
Resource	O
2	O
)].	O

There	O
was	O
insufficient	O
material	O
to	O
perform	O
targeted	O
sequencing	O
on	O
JA005	O
.	O

Immunohistochemistry	O
against	O
Î²	O
-	O
catenin	O
in	O
case	O
JA005	O
failed	O
to	O
identify	O
cells	O
,	O
which	O
accumulated	O
the	O
protein	O
and	O
analysis	O
of	O
RNA	O
data	O
did	O
not	O
reveal	O
mutations	O
in	O
other	O
CTNNB1	O
exons	O
[	O
Suppl	O
.	O

TableÂ	O
1	O
(	O
Online	O
Resource	O
2	O
)].	O

The	O
allelic	O
frequencies	O
of	O
mutant	O
CTNNB1	O
significantly	O
correlated	O
with	O
the	O
estimated	O
histological	O
tumour	O
content	O
(	O
râ	O
=	O
â	O
	O
0	O
.	O
88	O
,	O
pâ	O
=	O
â	O
	O
6	O
.	O
61â	O
	O
Ã	O
	O
â	O
	O
10â	O
	O
8	O
)	O
and	O
were	O
consistent	O
with	O
the	O
presence	O
of	O
a	O
heterozygous	O
mutation	O
within	O
all	O
tumour	O
cells	O
[	O
Suppl	O
.	O

TableÂ	O
1	O
(	O
Online	O
Resource	O
2	O
);	O
Fig	O
.	O
Â	O
1b	O
].	O

Principal	O
component	O
analysis	O
(	O
PCA	O
)	O
and	O
clustering	O
confirmed	O
the	O
separation	O
of	O
tumours	O
(	O
including	O
JA005	O
and	O
JA011	O
)	O
from	O
controls	O
[	O
Fig	O
.	O
Â	O
1c	O
;	O
Suppl	O
.	O

Fig	O
.	O
Â	O
1a	O
(	O
Online	O
Resource	O
3	O
)].	O

Differential	O
gene	O
expression	O
revealed	O
that	O
a	O
total	O
of	O
6099	O
genes	O
were	O
significantly	O
expressed	O
at	O
higher	O
levels	O
in	O
tumours	O
versus	O
controls	O
,	O
while	O
5211	O
genes	O
were	O
higher	O
in	O
controls	O
versus	O
tumours	O
(	O
adjusted	O
p	O
value	O
<	O
â	O
	O
0	O
.	O
1	O
)	O
[	O
Suppl	O
.	O

TableÂ	O
2a	O
(	O
Online	O
Resource	O
4	O
)].	O

The	O
genes	O
and	O
ontology	O
pathways	O
found	O
to	O
be	O
dysregulated	O
in	O
our	O
dataset	O
are	O
consistent	O
with	O
published	O
RNA	O
and	O
immunohistochemical	O
expression	O
studies	O
and	O
demonstrate	O
that	O
these	O
results	O
are	O
robust	O
and	O
biologically	O
meaningful	O
[	O
Fig	O
.	O
Â	O
1d	O
;	O
Suppl	O
.	O

TableÂ	O
2a	O
,	O
b	O
(	O
Online	O
Resource	O
4	O
)	O
and	O
Suppl	O
.	O

TableÂ	O
3	O
(	O
Online	O
Resource	O
5	O
)].	O

Computational	O
modular	O
analysis	O
and	O
transcriptomics	O
of	O
laser	O
capture	O
microdissected	O
tumour	O
cells	O
reveal	O
the	O
molecular	O
signatures	O
of	O
specific	O
cellular	O
compartments	O
Next	O
,	O
we	O
aimed	O
to	O
further	O
dissect	O
the	O
molecular	O
signatures	O
obtained	O
from	O
the	O
RNA	O
-	O
Seq	O
data	O
and	O
establish	O
if	B
these	O
correlated	O
with	O
particular	O
tumour	O
characteristics	O
including	O
diagnosis	O
,	O
percentage	O
of	O
tumour	O
content	O
,	O
CTNNB1	O
mutation	O
allele	O
frequency	O
and	O
the	O
presence	O
of	O
specific	O
histological	O
features	O
.	O

Weighted	O
gene	O
co	O
-	O
expression	O
network	O
analysis	O
(	O
WGCNA	O
)	O
was	O
used	O
to	O
describe	O
the	O
correlation	O
patterns	O
among	O
genes	O
across	O
samples	O
,	O
resulting	O
in	O
the	O
identification	O
of	O
12	O
distinct	O
patterns	O
of	O
gene	O
expression	O
(	O
modules	O
),	O
which	O
were	O
assigned	O
a	O
colour	O
identifier	O
(	O
Fig	O
.	O
Â	O
1e	O
).	O

Three	O
major	O
distinct	O
patterns	O
of	O
gene	O
expression	O
across	O
the	O
samples	O
were	O
determined	O
:	O
(	O
1	O
)	O
the	O
brown	O
module	O
,	O
consisting	O
of	O
genes	O
relating	O
to	O
epithelial	O
differentiation	O
and	O
whose	O
expression	O
correlated	O
with	O
percentage	O
tumour	O
content	O
and	O
CTNNB1	O
mutation	O
allele	O
frequency	O
[	O
Fig	O
.	O
Â	O
1f	O
;	O
Suppl	O
.	O

TableÂ	O
4a	O
,	O
e	O
(	O
Online	O
Resource	O
6	O
);	O
Suppl	O
.	O

Fig	O
.	O
Â	O
2a	O
(	O
Online	O
Resource	O
3	O
)];	O
(	O
2	O
)	O
the	O
blue	O
and	O
turquoise	O
modules	O
,	O
containing	O
genes	O
involved	O
in	O
nervous	O
system	O
development	O
,	O
whose	O
expression	O
correlated	O
with	O
the	O
presence	O
of	O
reactive	O
glial	O
tissue	O
[	O
Fig	O
.	O
Â	O
1f	O
;	O
Suppl	O
.	O

TableÂ	O
4a	O
,	O
j	O
,	O
l	O
(	O
Online	O
Resource	O
6	O
);	O
Suppl	O
.	O

Fig	O
.	O
Â	O
3a	O
,	O
b	O
(	O
Online	O
Resource	O
3	O
)];	O
(	O
3	O
)	O
the	O
magenta	O
module	O
,	O
including	O
inflammation	O
-	O
related	O
genes	O
whose	O
expression	O
correlated	O
with	O
immune	O
cell	O
markers	O
such	O
as	O
CD14	O
[	O
Fig	O
.	O
Â	O
1f	O
;	O
Suppl	O
.	O

TableÂ	O
4a	O
,	O
k	O
(	O
online	O
Resource	O
6	O
);	O
Suppl	O
.	O

Fig	O
.	O
Â	O
2d	O
(	O
Online	O
Resource	O
3	O
)].	O

Further	O
details	O
of	O
other	O
identified	O
modules	O
are	O
presented	O
in	O
Suppl	O
.	O

Results	O
(	O
Online	O
Resource	O
1	O
),	O
Suppl	O
.	O

Figs	O
.	O
Â	O
2â	O
	O
4	O
(	O
Online	O
Resource	O
3	O
)	O
and	O
Suppl	O
.	O

TableÂ	O
4	O
(	O
Online	O
Resource	O
6	O
).	O

WGCNA	O
of	O
the	O
human	O
ACP	O
microarray	O
data	O
published	O
by	O
Gump	O
et	O
al	O
.	O

also	O
showed	O
moderate	O
preservation	O
of	O
the	O
major	O
modules	O
with	O
our	O
datasets	O
[	O
Suppl	O
.	O

Results	O
(	O
Online	O
Resource	O
1	O
)],	O
suggesting	O
that	O
the	O
molecular	O
signatures	O
of	O
the	O
main	O
cellular	O
types	O
within	O
ACP	O
samples	O
(	O
i	O
.	O
e	O
.	O

tumour	O
epithelium	O
,	O
reactive	O
glial	O
tissue	O
and	O
inflammatory	O
infiltrate	O
)	O
may	O
be	O
contained	O
in	O
specific	O
modules	O
.	O

Caption	O
(	O
Fig	O
):	O
FIG	O
2	O
Gene	O
profiling	O
of	O
laser	O
capture	O
microdissected	O
tumour	O
cells	O
confirms	O
the	O
WGCNA	O
,	O
identifying	O
modules	O
associated	O
with	O
tumour	O
cell	O
compartments	O
and	O
revealing	O
novel	O
ACP	O
genes	O
.	O

a	O
Scheme	O
of	O
the	O
experimental	O
approach	O
.	O

Histological	O
sections	O
of	O
tumour	O
samples	O
JA004	O
and	O
JA029	O
were	O
subjected	O
to	O
laser	O
capture	O
microdissection	O
(	O
LCM	O
)	O
to	O
isolate	O
Î²	O
-	O
catenin	O
-	O
accumulating	O
cell	O
clusters	O
(	O
C	O
),	O
palisading	O
epithelium	O
(	O
PE	O
)	O
and	O
glial	O
reactive	O
tissue	O
(	O
G	O
).	O

Biological	O
duplicates	O
were	O
performed	O
for	O
clusters	O
and	O
palisading	O
epithelium	O
in	O
case	O
JA004	O
.	O

RNA	O
was	O
purified	O
from	O
each	O
of	O
these	O
tumour	O
cell	O
compartments	O
,	O
amplified	O
and	O
sequenced	O
.	O

b	O
Principal	O
component	O
analysis	O
reveals	O
grouping	O
of	O
the	O
data	O
from	O
laser	O
capture	O
microdissected	O
samples	O
.	O

c	O
Gene	O
set	O
enrichment	O
analysis	O
revealing	O
the	O
enrichment	O
of	O
an	O
inflammatory	O
signature	O
in	O
microdissected	O
glial	O
reactive	O
tissue	O
relative	O
to	O
tumour	O
tissue	O
(	O
i	O
.	O
e	O
.	O

genes	O
included	O
in	O
clusters	O
plus	O
palisading	O
epithelium	O
),	O
whilst	O
a	O
WNT	O
signalling	O
expression	O
signature	O
is	O
associated	O
with	O
the	O
microdissected	O
tumour	O
tissue	O
.	O

Enrichment	O
for	O
WNT	O
signalling	O
was	O
stronger	O
in	O
the	O
clusters	O
relative	O
to	O
both	O
PE	O
and	O
glial	O
tissue	O
.	O

d	O
Gene	O
set	O
enrichment	O
analysis	O
showing	O
the	O
enrichment	O
of	O
the	O
brown	O
module	O
genes	O
with	O
a	O
signature	O
of	O
tumour	O
cell	O
compartments	O
(	O
i	O
.	O
e	O
.	O

genes	O
including	O
in	O
cluster	O
cells	O
plus	O
palisading	O
epithelium	O
).	O

In	B
contrast	I
,	O
both	O
the	O
blue	O
and	O
turquoise	O
module	O
genes	O
are	O
predominantly	O
expressed	O
by	O
reactive	O
glia	O
.	O

e	O
Double	O
immunofluorescence	O
staining	O
revealing	O
the	O
expression	O
of	O
BCL11B	O
and	O
TP63	O
in	O
the	O
epithelial	O
components	O
of	O
the	O
tumour	O
,	O
including	O
palisading	O
epithelium	O
(	O
PE	O
)	O
and	O
Î²	O
-	O
catenin	O
accumulating	O
clusters	O
(	O
C	O
),	O
but	O
not	O
in	O
reactive	O
glial	O
tissue	O
(	O
G	O
).	O

NES	O
normalised	O
enrichment	O
score	O
,	O
FDR	O
false	O
discovery	O
rate	O
.	O

Scale	O
bars	O
100Â	O
Î¼m	O
To	O
validate	O
the	O
WGCNA	O
results	O
,	O
we	O
profiled	O
specific	O
cellular	O
compartments	O
of	O
human	O
ACP	O
,	O
through	O
the	O
isolation	O
of	O
cluster	O
cells	O
,	O
palisading	O
epithelium	O
and	O
reactive	O
glial	O
tissue	O
by	O
laser	O
capture	O
microdissection	O
(	O
LCM	O
)	O
(	O
Fig	O
.	O
Â	O
2a	O
,	O
b	O
).	O

As	O
a	O
result	O
of	O
the	O
rarity	O
of	O
suitable	O
tissue	O
,	O
we	O
performed	O
this	O
experiment	O
using	O
only	O
two	O
human	O
ACP	O
tumours	O
,	O
nonetheless	O
RNA	O
-	O
Seq	O
data	O
was	O
robust	O
and	O
representative	O
of	O
the	O
isolated	O
cell	O
compartments	O
.	O

For	O
instance	O
,	O
gene	O
set	O
enrichment	O
analysis	O
(	O
GSEA	O
)	O
confirmed	O
the	O
enrichment	O
of	O
a	O
WNT	O
signalling	O
expression	O
signature	O
in	O
tumour	O
tissue	O
(	O
i	O
.	O
e	O
.	O

clusters	O
plus	O
palisading	O
epithelium	O
,	O
PE	O
)	O
when	O
compared	O
with	O
glial	O
reactive	O
tissue	O
(	O
normalised	O
enrichment	O
score	O
(	O
NES	O
)	O
â	O
=	O
â	O
	O
1	O
.	O
52	O
,	O
false	O
discovery	O
rate	O
(	O
FDR	O
)	O
â	O
=	O
â	O
	O
0	O
.	O
106	O
),	O
whilst	B
an	O
inflammatory	O
response	O
signature	O
was	O
associated	O
with	O
the	O
glial	O
reactive	O
tissue	O
(	O
NESâ	O
=	O
â	O
	O
â	O
	O
â	O
	O
1	O
.	O
87	O
,	O
FDRâ	O
=	O
â	O
	O
0	O
.	O
03	O
)	O
(	O
Fig	O
.	O
Â	O
2c	O
).	O

Enrichment	O
for	O
WNT	O
signalling	O
was	O
stronger	O
in	O
the	O
clusters	O
relative	O
to	O
both	O
PE	O
(	O
NESâ	O
=	O
â	O
	O
1	O
.	O
81	O
,	O
FDRâ	O
=	O
â	O
	O
0	O
.	O
013	O
)	O
and	O
glial	O
tissue	O
(	O
NESâ	O
=	O
â	O
	O
1	O
.	O
82	O
,	O
FDRâ	O
=	O
â	O
	O
0	O
.	O
004	O
),	O
in	O
agreement	O
with	O
the	O
higher	O
expression	O
of	O
WNT	O
target	O
genes	O
in	O
cluster	O
cells	O
(	O
e	O
.	O
g	O
.	O

AXIN2	O
,	O
LEF1	O
and	O
NOTUM	O
)	O
(	O
Fig	O
.	O
Â	O
2c	O
).	O

A	O
full	O
list	O
of	O
the	O
differentially	O
expressed	O
genes	O
between	O
clusters	O
,	O
palisading	O
epithelium	O
and	O
reactive	O
glia	O
is	O
shown	O
in	O
Suppl	O
.	O

TableÂ	O
2câ	O
	O
e	O
(	O
Online	O
Resource	O
4	O
).	O

By	O
systematically	O
comparing	O
the	O
molecular	O
signatures	O
obtained	O
from	O
these	O
profiling	O
experiments	O
with	O
the	O
modules	O
previously	O
described	O
,	O
we	O
confirmed	O
that	O
the	O
brown	O
module	O
genes	O
were	O
enriched	O
in	O
the	O
signature	O
of	O
tumour	O
cell	O
compartments	O
(	O
i	O
.	O
e	O
.	O

cluster	O
cells	O
and	O
palisading	O
epithelium	O
)	O
(	O
NESâ	O
=	O
â	O
	O
2	O
.	O
24	O
,	O
FDRâ	O
<	O
â	O
	O
0	O
.	O
001	O
)	O
(	O
Fig	O
.	O
Â	O
2d	O
).	O

In	B
contrast	I
,	O
both	O
the	O
blue	O
and	O
turquoise	O
module	O
genes	O
were	O
predominantly	O
expressed	O
by	O
reactive	O
glia	O
(	O
blue	O
,	O
NESâ	O
=	O
â	O
	O
â	O
	O
â	O
	O
3	O
.	O
36	O
;	O
turquoise	O
,	O
NESâ	O
=	O
â	O
	O
â	O
	O
â	O
	O
3	O
.	O
06	O
;	O
FDRâ	O
<	O
â	O
	O
0	O
.	O
001	O
)	O
(	O
Fig	O
.	O
Â	O
2d	O
).	O

Supporting	O
the	O
notion	O
that	O
these	O
modules	O
represent	O
specific	O
signatures	O
,	O
genes	O
known	O
to	O
be	O
expressed	O
in	O
tumour	O
epithelium	O
,	O
such	O
as	O
WNT	O
targets	O
(	O
e	O
.	O
g	O
.	O

AXIN2	O
,	O
NOTUM	O
),	O
FGF3	O
and	O
BMP4	O
were	O
contained	O
in	O
the	O
brown	O
module	O
[	O
Suppl	O
.	O

TableÂ	O
4a	O
(	O
Online	O
Resource	O
6	O
)].	O

Likewise	O
,	O
genes	O
known	O
to	O
be	O
expressed	O
in	O
the	O
glial	O
reactive	O
tissue	O
,	O
such	O
as	O
GFAP	O
,	O
S100B	O
and	O
NKX2	O
.	O
2	O
were	O
contained	O
in	O
the	O
blue	O
and	O
turquoise	O
modules	O
[	O
Suppl	O
.	O

TableÂ	O
4a	O
(	O
Online	O
Resource	O
6	O
)].	O

Of	O
interest	O
,	O
the	O
three	O
genes	O
with	O
the	O
strongest	O
brown	O
module	O
membership	O
score	O
(	O
a	O
measure	O
of	O
the	O
degree	O
of	O
co	O
-	O
expression	O
)	O
were	O
TP63	O
,	O
APCDD1L	O
and	O
BCL11B	O
[	O
Suppl	O
.	O

TableÂ	O
3a	O
(	O
Online	O
Resource	O
6	O
)].	O

TP63	O
has	O
previously	O
been	O
shown	O
to	O
be	O
expressed	O
in	O
the	O
tumour	O
cells	O
in	O
human	O
ACP	O
,	O
but	B
APCDD1L	O
and	O
BCL11B	O
have	O
not	O
been	O
implicated	O
in	O
ACP	O
.	O

Consistently	O
,	O
immunofluorescence	O
of	O
ACP	O
histological	O
sections	O
revealed	O
the	O
expression	O
of	O
BCL11B	O
and	O
TP63	O
exclusively	O
in	O
tumour	O
cell	O
compartments	O
,	O
including	O
clusters	O
,	O
palisading	O
epithelium	O
and	O
stellate	O
reticulum	O
,	O
but	O
not	O
within	O
surrounding	O
reactive	O
tissue	O
(	O
Fig	O
.	O
Â	O
2e	O
).	O

Similarly	O
,	O
immunofluorescence	O
revealed	O
expression	O
of	O
APCDD1L	O
mostly	O
in	O
the	O
cluster	O
cells	O
with	O
no	O
expression	O
in	O
the	O
vast	O
majority	O
of	O
the	O
glial	O
tissue	O
except	O
for	O
cells	O
adjacent	O
to	O
the	O
tumour	O
cells	O
[	O
Suppl	O
.	O

Fig	O
.	O
Â	O
5	O
(	O
Online	O
Resource	O
3	O
)].	O

This	O
is	O
in	O
agreement	O
with	O
the	O
differential	O
expression	O
analysis	O
of	O
the	O
laser	O
capture	O
microdissection	O
dataset	O
showing	O
that	O
APCDD1L	O
is	O
highly	O
expressed	O
in	O
the	O
clusters	O
versus	O
glial	O
reactive	O
tissue	O
[	O
40	O
.	O
46	O
-	O
fold	O
,	O
adjusted	O
p	O
valueâ	O
=	O
â	O
	O
0	O
.	O
12	O
;	O
Suppl	O
.	O

TableÂ	O
2e	O
(	O
Online	O
Resource	O
4	O
)].	O

Plotting	O
of	O
normalised	O
expression	O
levels	O
confirmed	O
the	O
relationship	O
of	O
these	O
brown	O
module	O
genes	O
with	O
CTNNB1	O
mutation	O
allele	O
frequency	O
,	O
further	O
supporting	O
that	O
expression	O
of	O
these	O
genes	O
is	O
enriched	O
within	O
the	O
tumour	O
cells	O
(	O
râ	O
=	O
â	O
	O
0	O
.	O
83	O
,	O
0	O
.	O
95	O
,	O
0	O
.	O
96	O
respectively	O
for	O
each	O
gene	O
,	O
pâ	O
<	O
â	O
	O
1â	O
	O
Ã	O
	O
â	O
	O
10â	O
	O
5	O
)	O
[	O
Suppl	O
.	O

Fig	O
.	O
Â	O
6	O
(	O
Online	O
Resource	O
3	O
)].	O

These	O
datasets	O
represent	O
a	O
useful	O
resource	O
for	O
the	O
identification	O
of	O
novel	O
genes	O
specifically	O
expressed	O
or	O
highly	O
enriched	O
within	O
particular	O
human	O
ACP	O
cell	O
compartments	O
.	O

Together	O
,	O
these	O
studies	O
have	O
revealed	O
the	O
molecular	O
signatures	O
of	O
the	O
tumour	O
epithelium	O
(	O
i	O
.	O
e	O
.	O

cluster	O
cells	O
and	O
palisading	O
epithelium	O
)	O
and	O
glial	O
reactive	O
tissue	O
(	O
astrocytes	O
and	O
immune	O
cells	O
).	O

Human	O
ACP	O
clusters	O
are	O
molecularly	O
analogous	O
to	O
the	O
enamel	O
knot	O
and	O
activate	O
a	O
transcriptional	O
programme	O
resembling	O
odontogenesis	O
Caption	O
(	O
Fig	O
):	O
FIG	O
3	O
ACP	O
and	O
developing	O
mammalian	O
tooth	O
share	O
common	O
molecular	O
signatures	O
.	O

a	O
Gene	O
set	O
enrichment	O
plots	O
showing	O
that	O
ACP	O
tumours	O
are	O
enriched	O
for	O
genes	O
expressed	O
by	O
ameloblasts	O
and	O
inner	O
enamel	O
epithelium	O
.	O

Results	O
obtained	O
from	O
using	O
the	O
RNA	O
dataset	O
from	O
profiling	O
whole	O
ACP	O
tumours	O
.	O

b	O
Expression	O
of	O
relevant	O
ameloblast	O
-	O
related	O
genes	O
is	O
significantly	O
expressed	O
at	O
higher	O
levels	O
in	O
whole	O
ACP	O
tumours	O
compared	O
with	O
control	O
tissues	O
(	O
fetal	O
pituitary	O
and	O
NFPA	O
).	O

See	O
Suppl	O
.	O

TableÂ	O
5	O
(	O
Online	O
Resource	O
7	O
)	O
for	O
details	O
(***	O
adjusted	O
p	O
value	O
<	O
â	O
	O
1â	O
	O
Ã	O
	O
â	O
	O
10â	O
	O
7	O
,	O
*	O
adjusted	O
p	O
valueâ	O
=	O
â	O
	O
0	O
.	O
028	O
).	O

c	O
Gene	O
set	O
enrichment	O
plots	O
showing	O
that	O
the	O
cluster	O
cells	O
are	O
enriched	O
for	O
genes	O
expressed	O
in	O
the	O
enamel	O
knot	O
whilst	O
palisading	O
epithelium	O
shows	O
a	O
signature	O
of	O
inner	O
enamel	O
epithelia	O
at	O
cap	O
stage	O
.	O

Results	O
obtained	O
from	O
using	O
the	O
RNA	O
dataset	O
from	O
profiling	O
microdissected	O
ACP	O
compartments	O
.	O

d	O
Double	O
immunofluorescent	O
staining	O
reveals	O
the	O
co	O
-	O
expression	O
of	O
p21	O
/	O
CDKN1A	O
and	O
EDAR	O
,	O
two	O
enamel	O
knot	O
markers	O
,	O
in	O
the	O
Î²	O
-	O
catenin	O
-	O
accumulating	O
clusters	O
.	O

e	O
Gene	O
set	O
enrichment	O
analysis	O
showing	O
that	O
both	O
the	O
inner	O
enamel	O
epithelium	O
and	O
ameloblast	O
gene	O
signatures	O
are	O
enriched	O
in	O
the	O
embryonic	O
mouse	O
ACP	O
model	O
compared	O
with	O
wild	O
-	O
type	O
controls	O
(	O
WT	O
).	O

f	O
Enrichment	O
plots	O
confirming	O
that	O
mouse	O
clusters	O
from	O
both	O
the	O
embryonic	O
and	O
inducible	O
ACP	O
mouse	O
models	O
show	O
a	O
molecular	O
signature	O
of	O
the	O
enamel	O
knot	O
.	O

NES	O
normalised	O
enrichment	O
score	O
,	O
FDR	O
false	O
discovery	O
rate	O
.	O

Scale	O
bars	O
100Â	O
Î¼m	O
We	O
then	O
used	O
the	O
RNA	O
data	O
from	O
profiling	O
whole	O
tumours	O
and	O
compartment	O
-	O
specific	O
molecular	O
signatures	O
obtained	O
by	O
LCM	O
to	O
explore	O
the	O
relationship	O
between	O
ACP	O
and	O
odontogenesis	O
at	O
a	O
molecular	O
level	O
.	O

The	O
brown	O
module	O
genes	O
,	O
enriched	O
in	O
the	O
signature	O
of	O
tumour	O
cell	O
compartments	O
,	O
contained	O
genes	O
related	O
to	O
odontogenesis	O
[	O
Suppl	O
.	O

TableÂ	O
4a	O
,	O
e	O
(	O
Online	O
Resource	O
6	O
].	O

GSEA	O
was	O
performed	O
using	O
sets	O
of	O
genes	O
experimentally	O
confirmed	O
to	O
be	O
expressed	O
in	O
specific	O
cell	O
types	O
during	O
tooth	O
development	O
in	O
human	O
and	O
other	O
species	O
.	O

These	O
studies	O
revealed	O
that	O
,	O
compared	O
to	O
control	O
tissues	O
(	O
fetal	O
pituitary	O
and	O
NFPA	O
),	O
human	O
ACP	O
tumours	O
(	O
based	O
on	O
whole	O
-	O
tumour	O
RNA	O
datasets	O
)	O
were	O
enriched	O
for	O
genes	O
expressed	O
in	O
both	O
ameloblasts	O
(	O
NESâ	O
=	O
â	O
	O
2	O
.	O
57	O
,	O
FDRâ	O
<	O
â	O
	O
0	O
.	O
001	O
)	O
and	O
their	O
precursors	O
,	O
the	O
inner	O
enamel	O
epithelium	O
(	O
NESâ	O
=	O
â	O
	O
2	O
.	O
79	O
,	O
FDRâ	O
<	O
â	O
	O
0	O
.	O
001	O
;	O
dataset	O
from	O
all	O
stages	O
of	O
inner	O
epithelium	O
development	O
(	O
Fig	O
.	O
Â	O
3a	O
).	O

The	O
expression	O
of	O
ameloblast	O
transcription	O
factors	O
(	O
e	O
.	O
g	O
.	O

BCL11B	O
,	O
MSX2	O
),	O
enamel	O
genes	O
(	O
ENAM	O
,	O
AMELX	O
,	O
AMELY	O
,	O
AMBN	O
)	O
and	O
proteinases	O
(	O
MMP20	O
,	O
KLK4	O
)	O
was	O
significantly	O
higher	O
in	O
human	O
ACP	O
compared	O
with	O
control	O
tissues	O
[	O
Fig	O
.	O
Â	O
3b	O
;	O
Suppl	O
.	O

TableÂ	O
5	O
(	O
Online	O
Resource	O
7	O
)].	O

In	B
contrast	I
,	O
genes	O
specifically	O
expressed	O
in	O
dental	O
mesenchyme	O
-	O
derived	O
odontoblasts	O
were	O
not	O
up	O
-	O
regulated	O
in	O
human	O
ACP	O
(	O
e	O
.	O
g	O
.	O

MSX1	O
,	O
DSPP	O
)	O
[	O
Fig	O
.	O
Â	O
3b	O
;	O
Suppl	O
.	O

TableÂ	O
5	O
(	O
Online	O
Resource	O
7	O
)].	O

By	O
comparing	O
the	O
molecular	O
signatures	O
of	O
specific	O
tumour	O
compartments	O
obtained	O
by	O
LCM	O
with	O
curated	O
gene	O
sets	O
derived	O
from	O
distinct	O
cell	O
types	O
present	O
during	O
tooth	O
development	O
,	O
we	O
identified	O
molecular	O
similarities	O
between	O
the	O
ACP	O
Î²	O
-	O
catenin	O
-	O
accumulating	O
cell	O
clusters	O
and	O
the	O
enamel	O
knot	O
,	O
a	O
critical	O
signalling	O
centre	O
within	O
the	O
developing	O
tooth	O
.	O

Gene	O
set	O
enrichment	O
analysis	O
revealed	O
a	O
significant	O
enrichment	O
of	O
the	O
enamel	O
knot	O
gene	O
signature	O
in	O
human	O
cluster	O
cells	O
when	O
compared	O
with	O
either	O
palisading	O
epithelium	O
(	O
NESâ	O
=	O
â	O
	O
1	O
.	O
90	O
,	O
FDRâ	O
=	O
â	O
	O
0	O
.	O
004	O
)	O
or	O
to	O
reactive	O
glial	O
tissue	O
(	O
NESâ	O
=	O
â	O
	O
1	O
.	O
79	O
,	O
FDRâ	O
=	O
â	O
	O
0	O
.	O
01	O
)	O
(	O
Fig	O
.	O
Â	O
3c	O
).	O

Enamel	O
knot	O
signals	O
act	O
on	O
the	O
inner	O
enamel	O
epithelium	O
at	O
the	O
cap	O
stage	O
of	O
tooth	O
development	O
to	O
control	O
proliferation	O
and	O
tooth	O
morphogenesis	O
,	O
and	O
we	O
identified	O
a	O
strong	O
enrichment	O
between	O
palisading	O
epithelium	O
and	O
cap	O
-	O
stage	O
enamel	O
epithelium	O
,	O
suggesting	O
that	O
palisading	O
and	O
enamel	O
epithelium	O
may	O
be	O
equivalent	O
structures	O
(	O
NESâ	O
=	O
â	O
	O
â	O
	O
â	O
	O
1	O
.	O
69	O
,	O
FDRâ	O
=	O
â	O
	O
0	O
.	O
008	O
)	O
(	O
Fig	O
.	O
Â	O
3c	O
).	O

We	O
validated	O
these	O
findings	O
further	O
by	O
immunofluorescence	O
against	O
p21	O
/	O
CDKN1A	O
,	O
a	O
marker	O
of	O
the	O
enamel	O
knot	O
,	O
which	O
showed	O
specific	O
signal	O
mostly	O
restricted	O
to	O
human	O
ACP	O
clusters	O
(	O
nâ	O
=	O
â	O
	O
8	O
tumour	O
samples	O
;	O
Fig	O
.	O
Â	O
3d	O
),	O
consistent	O
with	O
previous	O
reports	O
.	O

In	O
addition	O
,	O
the	O
ectodysplasin	O
receptor	O
(	O
EDAR	O
),	O
whose	O
signalling	O
pathway	O
has	O
been	O
strongly	O
implicated	O
in	O
enamel	O
knot	O
formation	O
but	O
not	O
previously	O
studied	O
in	O
ACP	O
,	O
was	O
highly	O
expressed	O
in	O
ACP	O
tumours	O
compared	O
with	O
controls	O
(	O
467	O
.	O
88	O
-	O
fold	O
;	O
adjusted	O
p	O
valueâ	O
=	O
â	O
	O
1	O
.	O
37Eâ	O
	O
29	O
)	O
and	O
in	O
Î²	O
-	O
catenin	O
clusters	O
relative	O
to	O
palisading	O
epithelium	O
(	O
10	O
.	O
85	O
-	O
fold	O
;	O
adjusted	O
p	O
valueâ	O
=	O
â	O
	O
0	O
.	O
0001	O
)	O
or	O
glial	O
reactive	O
tissue	O
(	O
357	O
.	O
05	O
-	O
fold	O
;	O
adjusted	O
p	O
valueâ	O
=	O
â	O
	O
9	O
.	O
77Eâ	O
	O
05	O
)	O
[	O
Suppl	O
.	O

TableÂ	O
2a	O
,	O
d	O
,	O
e	O
(	O
Online	O
Resource	O
4	O
)].	O

Immunofluorescence	O
confirmed	O
the	O
expression	O
of	O
EDAR	O
in	O
human	O
cluster	O
cells	O
and	O
its	O
absence	O
in	O
the	O
glial	O
reactive	O
tissue	O
,	O
further	O
confirming	O
similarities	O
between	O
ACP	O
clusters	O
and	O
the	O
enamel	O
knot	O
(	O
nâ	O
=	O
â	O
	O
5	O
human	O
tumours	O
;	O
Fig	O
.	O
Â	O
3d	O
).	O

To	O
test	O
further	O
these	O
findings	O
,	O
we	O
performed	O
RNA	O
-	O
Seq	O
on	O
three	O
Hesx1Cre	O
/+/	O
Ctnnb1lox	O
(	O
ex3	O
)/+	O
neoplastic	O
and	O
three	O
control	O
pituitaries	O
at	O
postnatal	O
day	O
1	O
(	O
P1	O
).	O

As	O
in	O
human	O
ACP	O
,	O
GSEA	O
also	O
confirmed	O
greater	O
expression	O
of	O
inner	O
enamel	O
epithelium	O
(	O
cap	O
stage	O
)	O
(	O
NESâ	O
=	O
â	O
	O
2	O
.	O
61	O
,	O
FDRâ	O
<	O
â	O
	O
0	O
.	O
001	O
)	O
and	O
ameloblast	O
(	O
NESâ	O
=	O
â	O
	O
2	O
.	O
38	O
,	O
FDRâ	O
<	O
â	O
	O
0	O
.	O
001	O
)	O
genes	O
in	O
Hesx1Cre	O
/+/	O
Ctnnb1lox	O
(	O
ex3	O
)/+	O
neoplastic	O
pituitaries	O
at	O
P1	O
compared	O
with	O
wild	O
-	O
type	O
controls	O
,	O
further	O
highlighting	O
the	O
molecular	O
relationship	O
between	O
mouse	O
ACP	O
and	O
tooth	O
development	O
[	O
Fig	O
.	O
Â	O
3e	O
;	O
Suppl	O
.	O

TableÂ	O
2f	O
(	O
Online	O
Resource	O
4	O
)].	O

Mouse	O
ACP	O
also	O
contains	O
Î²	O
-	O
catenin	O
-	O
accumulating	O
cell	O
clusters	O
,	O
and	O
we	O
have	O
previously	O
characterised	O
their	O
expression	O
profiles	O
in	O
both	O
the	O
Hesx1Cre	O
/+/	O
Ctnnb1lox	O
(	O
ex3	O
)/+	O
embryonic	O
and	O
the	O
Sox2CreERT2	O
/+/	O
Ctnnb1lox	O
(	O
ex3	O
)/+	O
inducible	O
mouse	O
models	O
of	O
ACP	O
.	O

GSEA	O
revealed	O
a	O
molecular	O
signature	O
of	O
the	O
enamel	O
knot	O
in	O
the	O
clusters	O
from	O
both	O
of	O
these	O
mouse	O
models	O
(	O
embryonic	O
model	O
,	O
NESâ	O
=	O
â	O
	O
1	O
.	O
90	O
,	O
FDRâ	O
=	O
â	O
	O
0	O
.	O
003	O
;	O
inducible	O
model	O
NESâ	O
=	O
â	O
	O
2	O
.	O
44	O
,	O
FDRâ	O
<	O
â	O
	O
0	O
.	O
001	O
)	O
(	O
Fig	O
.	O
Â	O
3f	O
).	O

Expression	O
of	O
p21	O
has	O
recently	O
been	O
reported	O
to	O
be	O
enriched	O
in	O
the	O
clusters	O
in	O
mouse	O
ACP	O
,	O
but	B
EDAR	O
immunostaining	O
was	O
inconclusive	B
,	O
possibly	O
because	O
the	O
antibody	O
does	O
not	O
recognise	O
mouse	O
EDAR	O
.	O

Together	O
,	O
these	O
results	O
reveal	O
molecular	O
analogies	O
shared	O
between	O
ACP	O
Î²	O
-	O
catenin	O
-	O
accumulating	O
clusters	O
with	O
the	O
enamel	O
knot	O
and	O
the	O
palisading	O
epithelium	O
with	O
the	O
inner	O
enamel	O
epithelium	O
.	O

Cell	O
clusters	O
orchestrate	O
paracrine	O
signalling	O
within	O
human	O
and	O
murine	O
ACP	O
The	O
molecular	O
similarities	O
between	O
human	O
clusters	O
and	O
the	O
enamel	O
knot	O
prompted	O
us	O
to	O
explore	O
further	O
whether	B
the	O
clusters	O
may	O
also	O
act	O
as	O
signalling	O
centres	O
in	O
human	O
ACP	O
tumours	O
.	O

In	O
agreement	O
with	O
this	O
notion	O
,	O
our	O
RNA	O
profiling	O
revealed	O
that	O
human	O
ACP	O
clusters	O
expressed	O
high	O
levels	O
of	O
members	O
of	O
the	O
FGF	O
,	O
BMP	O
and	O
WNT	O
families	O
of	O
secreted	O
factors	O
compared	O
with	O
either	B
palisading	O
epithelium	O
or	O
reactive	O
glia	O
[	O
Suppl	O
.	O

Fig	O
.	O
Â	O
7	O
(	O
Online	O
Resource	O
3	O
);	O
Suppl	O
.	O

TableÂ	O
2d	O
,	O
e	O
(	O
Online	O
Resource	O
4	O
)].	O

SHH	O
was	O
also	O
highly	O
expressed	O
by	O
the	O
cluster	O
cells	O
(	O
Suppl	O
.	O

Fig	O
.	O
Â	O
7a	O
),	O
as	O
previously	O
shown	O
.	O

The	O
activation	O
of	O
the	O
WNT	O
pathway	O
in	O
human	O
ACP	O
has	O
been	O
well	O
documented	O
,	O
and	O
we	O
identified	O
the	O
expression	O
of	O
several	O
WNT	O
ligands	O
(	O
e	O
.	O
g	O
.	O

WNT4	O
,	O
WNT5A	O
,	O
WNT6	O
,	O
WNT7A	O
,	O
WNT10A	O
,	O
WNT10B	O
and	O
WNT16	O
)	O
in	O
the	O
clusters	O
relative	O
to	O
the	O
palisading	O
epithelium	O
or	O
glial	O
reactive	O
tissue	O
[	O
Suppl	O
.	O

Fig	O
.	O
Â	O
7b	O
(	O
Online	O
Resource	O
3	O
);	O
Suppl	O
.	O

TableÂ	O
2d	O
,	O
e	O
(	O
Online	O
Resource	O
4	O
);	O
adjusted	O
p	O
value	O
â	O
¤	O
â	O
	O
0	O
.	O
03	O
].	O

To	O
reveal	O
the	O
cells	O
responding	O
to	O
FGF	O
,	O
TGFÎ²	O
and	O
BMP	O
factors	O
,	O
we	O
analysed	O
the	O
expression	O
of	O
the	O
ligands	O
and	O
their	O
receptors	O
in	O
our	O
human	O
RNA	O
-	O
Seq	O
datasets	O
and	O
performed	O
immunofluorescence	O
against	O
downstream	O
signalling	O
effectors	O
indicating	O
pathway	O
activation	O
.	O

Caption	O
(	O
Fig	O
):	O
FIG	O
4	O
Identification	O
of	O
the	O
activation	O
of	O
the	O
MAPK	O
/	O
ERK	O
,	O
TGFB	O
and	O
BMP	O
signalling	O
pathways	O
in	O
human	O
ACP	O
.	O

a	O
Immunohistochemistry	O
revealing	O
the	O
expression	O
of	O
phosphorylated	O
ERK1	O
/	O
2	O
(	O
pERK1	O
/	O
2	O
),	O
a	O
read	O
out	O
of	O
active	O
MAPK	O
/	O
ERK	O
pathway	O
,	O
at	O
the	O
tips	O
of	O
the	O
invading	O
tumour	O
epithelium	O
(	O
palisading	O
epithelium	O
,	O
arrows	O
in	O
a	O
,	O
aâ	O
´	O
and	O
aâ	O
	O
³â	O
	O
³	O
)	O
and	O
within	O
reactive	O
glial	O
tissue	O
(	O
G	O
;	O
arrows	O
in	O
aâ	O
	O
³	O
).	O

b	O
Double	O
immunofluorescent	O
staining	O
showing	O
pERK1	O
/	O
2	O
expression	O
in	O
the	O
palisading	O
epithelium	O
(	O
PE	O
)	O
around	O
the	O
Î²	O
-	O
catenin	O
accumulating	O
clusters	O
(	O
C	O
),	O
which	O
express	O
several	O
activating	O
ligands	O
of	O
the	O
MAPK	O
/	O
ERK	O
pathway	O
(	O
see	O
main	O
text	O
for	O
details	O
).	O

Note	O
that	O
cells	O
within	O
the	O
reactive	O
glial	O
tissue	O
(	O
G	O
)	O
are	O
also	O
pERK1	O
/	O
2	O
positive	O
.	O

c	O
Double	O
immunofluorescence	O
revealing	O
abundant	O
Ki67	O
+	O
ve	O
cells	O
in	O
the	O
palisading	O
epithelium	O
close	O
to	O
clusters	O
.	O

d	O
Double	O
immunofluorescence	O
showing	O
Ki67	O
and	O
pERK1	O
/	O
2	O
co	O
-	O
expression	O
within	O
the	O
palisading	O
epithelium	O
(	O
PE	O
).	O

e	O
Double	O
immunofluorescence	O
showing	O
pSMAD3	O
staining	O
,	O
indicating	O
activation	O
of	O
TGFÎ²	O
signalling	O
,	O
in	O
both	O
tumour	O
and	O
reactive	O
glia	O
,	O
with	O
strongest	O
signal	O
in	O
reactive	O
tissue	O
adjacent	O
to	O
tumour	O
epithelia	O
(	O
arrowhead	O
).	O

Double	O
immunofluorescence	O
reveals	O
pSMAD1	O
/	O
5	O
/	O
9	O
staining	O
,	O
indicating	O
BMP	O
signalling	O
in	O
cells	O
within	O
and	O
adjacent	O
to	O
the	O
Î²	O
-	O
catenin	O
-	O
accumulating	O
clusters	O
(	O
C	O
).	O

Note	O
the	O
absence	O
of	O
staining	O
in	O
the	O
palisading	O
epithelium	O
(	O
PE	O
).	O

Scale	O
bars	O
:	O
aâ	O
	O
aâ	O
	O
³â	O
	O
³	O
200Â	O
Î¼m	O
;	O
bâ	O
	O
f	O
100Â	O
Î¼m	O
FGFR1â	O
	O
3	O
were	O
broadly	O
expressed	O
across	O
tumour	O
and	O
glial	O
cells	O
and	O
not	O
differentially	O
expressed	O
between	O
compartments	O
[	O
Suppl	O
.	O

Fig	O
.	O
Â	O
7b	O
(	O
Online	O
Resource	O
3	O
);	O
Suppl	O
.	O

TableÂ	O
2d	O
,	O
e	O
(	O
Online	O
Resource	O
4	O
)].	O

The	O
ligands	O
FGF3	O
,	O
FGF4	O
,	O
FGF9	O
,	O
FGF12	O
,	O
FGF13	O
,	O
FGF18	O
and	O
FGF19	O
were	O
highly	O
expressed	O
in	O
the	O
clusters	O
relative	O
to	O
the	O
palisading	O
epithelium	O
or	O
the	O
glial	O
reactive	O
tissue	O
[	O
adjusted	O
p	O
value	O
â	O
¤	O
â	O
	O
0	O
.	O
1	O
;	O
Suppl	O
.	O

Fig	O
.	O
Â	O
7a	O
,	O
b	O
(	O
Online	O
Resource	O
3	O
);	O
Suppl	O
.	O

TableÂ	O
2d	O
,	O
e	O
(	O
Online	O
Resource	O
4	O
)].	O

Downstream	O
activation	O
of	O
the	O
MAPK	O
/	O
ERK	O
pathway	O
,	O
as	O
evidenced	O
by	O
phosphorylation	O
of	O
ERK1	O
/	O
2	O
,	O
was	O
identified	O
by	O
immunohistochemistry	O
and	O
immunofluorescence	O
within	O
the	O
palisading	O
epithelium	O
around	O
the	O
clusters	O
and	O
neighbouring	O
reactive	O
tissue	O
,	O
but	O
no	O
positive	O
signal	O
was	O
observed	O
in	O
the	O
clusters	O
themselves	O
(	O
Fig	O
.	O
Â	O
4a	O
,	O
b	O
,	O
d	O
).	O

Particularly	O
prominent	O
staining	O
was	O
detected	O
at	O
the	O
leading	O
edge	O
of	O
tissue	O
invasion	O
(	O
Fig	O
.	O
Â	O
4a	O
).	O

Areas	O
of	O
palisading	O
epithelium	O
around	O
the	O
clusters	O
were	O
often	O
enriched	O
for	O
the	O
proliferation	O
marker	O
Ki67	O
(	O
Fig	O
.	O
Â	O
4c	O
),	O
concurrent	O
with	O
elevated	O
pERK1	O
/	O
2	O
+	O
ve	O
staining	O
(	O
Fig	O
.	O
Â	O
4b	O
).	O

Double	O
immunofluorescence	O
of	O
three	O
human	O
ACP	O
samples	O
revealed	O
a	O
variable	O
degree	O
of	O
co	O
-	O
localisation	O
between	O
Ki67	O
and	O
pERK1	O
/	O
2	O
expression	O
(	O
Fig	O
.	O
Â	O
4d	O
)	O
(	O
tumour	O
1	O
:	O
80	O
%,	O
45	O
co	O
-	O
expressing	O
cells	O
out	O
of	O
56	O
Ki67	O
+	O
ve	O
cells	O
;	O
tumour	O
2	O
:	O
44	O
%,	O
26	O
co	O
-	O
expressing	O
/	O
59	O
Ki67	O
+	O
ve	O
cells	O
;	O
tumour	O
3	O
:	O
15	O
%,	O
5	O
co	O
-	O
expressing	O
/	O
33	O
Ki67	O
+	O
ve	O
cells	O
).	O

BMP4	O
and	O
BMP8A	O
were	O
highly	O
expressed	O
by	O
clusters	O
(	O
adjusted	O
p	O
value	O
â	O
¤	O
â	O
	O
0	O
.	O
001	O
)	O
and	O
BMPR1A	O
and	O
BMPR2	O
were	O
expressed	O
across	O
all	O
cell	O
types	O
,	O
whist	O
BMPR1B	O
was	O
highly	O
expressed	O
in	O
the	O
glial	O
reactive	O
tissue	O
(	O
adjusted	O
p	O
valueâ	O
=	O
â	O
	O
0	O
.	O
00011	O
)	O
[	O
Suppl	O
.	O

Fig	O
.	O
Â	O
7b	O
(	O
Online	O
Resource	O
3	O
);	O
Suppl	O
.	O

TableÂ	O
2d	O
,	O
e	O
(	O
Online	O
Resource	O
4	O
)].	O

Activation	O
of	O
the	O
pathway	O
,	O
as	O
evidenced	O
by	O
immunofluorescence	O
staining	O
against	O
phosphorylated	O
SMAD1	O
/	O
5	O
/	O
9	O
was	O
widely	O
present	O
in	O
tumour	O
cells	O
,	O
particularly	O
in	O
proximity	O
to	O
the	O
clusters	O
,	O
but	O
was	O
absent	O
from	O
the	O
palisading	O
epithelium	O
(	O
Fig	O
.	O
Â	O
4f	O
).	O

Other	O
members	O
of	O
the	O
TGF	O
superfamily	O
of	O
secreted	O
factors	O
,	O
such	O
as	O
TGFB1	O
-	O
3	O
,	O
as	O
well	O
as	O
their	O
receptors	O
were	O
broadly	O
expressed	O
across	O
all	O
tumour	O
compartments	O
,	O
although	O
TGFB1	O
appeared	O
non	O
-	O
significantly	O
elevated	O
in	O
clusters	O
relative	O
to	O
both	O
PE	O
(	O
4	O
.	O
9	O
-	O
fold	O
,	O
unadjusted	O
p	O
valueâ	O
=	O
â	O
	O
0	O
.	O
08	O
;	O
adjusted	O
p	O
value	O
not	O
assessed	O
because	O
of	O
inadequate	O
read	O
numbers	O
)	O
and	O
glial	O
tissue	O
(	O
9	O
.	O
5	O
-	O
fold	O
,	O
adjusted	O
p	O
valueâ	O
=	O
â	O
	O
0	O
.	O
37	O
)	O
[	O
Suppl	O
.	O

Fig	O
.	O
Â	O
7a	O
,	O
b	O
(	O
Online	O
Resource	O
3	O
);	O
Suppl	O
.	O

TableÂ	O
2d	O
,	O
e	O
(	O
Online	O
Resource	O
4	O
)].	O

Double	O
immunofluorescence	O
against	O
Î²	O
-	O
catenin	O
and	O
phospho	O
-	O
SMAD3	O
revealed	O
the	O
activation	O
of	O
the	O
TGFÎ²	O
pathway	O
in	O
tumour	O
cells	O
and	O
reactive	O
tissue	O
.	O

Increased	O
signal	O
was	O
apparent	O
within	O
areas	O
of	O
reactive	O
tissue	O
closest	O
to	O
tumour	O
cells	O
(	O
Fig	O
.	O
Â	O
4e	O
).	O

Caption	O
(	O
Fig	O
):	O
FIG	O
5	O
Identification	O
of	O
the	O
activation	O
of	O
the	O
MAPK	O
/	O
ERK	O
,	O
TGFB	O
and	O
BMP	O
signalling	O
pathways	O
in	O
the	O
ACP	O
embryonic	O
mouse	O
model	O
.	O

Double	O
immunofluorescent	O
staining	O
on	O
histological	O
sections	O
of	O
neoplastic	O
pituitaries	O
of	O
the	O
ACP	O
embryonic	O
mouse	O
model	O
at	O
postnatal	O
day	O
1	O
(	O
P1	O
).	O

Note	O
the	O
widespread	O
expression	O
of	O
pERK1	O
/	O
2	O
in	O
cells	O
around	O
the	O
Î²	O
-	O
catenin	O
-	O
accumulating	O
cell	O
clusters	O
,	O
which	O
show	O
no	O
expression	O
of	O
this	O
marker	O
.	O

pSMAD3	O
and	O
pSMAD1	O
/	O
5	O
/	O
9	O
staining	O
is	O
also	O
predominant	O
in	O
cells	O
surrounding	O
the	O
clusters	O
,	O
but	O
occasionally	O
weak	O
staining	O
is	O
observed	O
in	O
some	O
cluster	O
cells	O
(	O
arrowheads	O
).	O

Scale	O
bars	O
50Â	O
Î¼m	O
We	O
have	O
previously	O
shown	O
that	O
murine	O
clusters	O
in	O
the	O
Hesx1Cre	O
/+/	O
Ctnnb1lox	O
(	O
ex3	O
)/+	O
embryonic	O
model	O
of	O
ACP	O
also	O
express	O
several	O
genes	O
of	O
the	O
FGF	O
,	O
TGFÎ²	O
and	O
BMP	O
families	O
,	O
but	B
the	O
activation	O
of	O
these	O
pathways	O
has	O
not	O
been	O
demonstrated	O
so	O
far	O
.	O

Immunofluorescent	O
staining	O
revealed	O
strong	O
expression	O
of	O
p	O
-	O
ERK1	O
/	O
2	O
in	O
cells	O
directly	O
surrounding	O
the	O
Î²	O
-	O
catenin	O
-	O
accumulating	O
clusters	O
,	O
which	O
displayed	O
no	O
positive	O
staining	O
themselves	O
(	O
Fig	O
.	O
Â	O
5a	O
).	O

p	O
-	O
SMAD3	O
and	O
p	O
-	O
SMAD1	O
/	O
5	O
/	O
9	O
staining	O
was	O
mostly	O
observed	O
in	O
cells	O
near	O
the	O
clusters	O
,	O
with	O
some	O
cluster	O
cells	O
showing	O
weak	O
staining	O
(	O
Fig	O
.	O
Â	O
5b	O
,	O
c	O
).	O

These	O
analyses	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
human	O
and	O
murine	O
clusters	O
act	O
as	O
signalling	O
centres	O
through	O
the	O
expression	O
of	O
multiple	O
ligands	O
that	O
activate	O
the	O
SHH	O
,	O
WNT	O
,	O
MAPK	O
/	O
ERK	O
,	O
TGFÎ²	O
and	O
BMP	O
signalling	O
pathways	O
in	O
neighbouring	O
cells	O
.	O

Preclinical	O
studies	O
provide	O
support	O
for	O
an	O
important	O
role	O
of	O
the	O
MAPK	O
/	O
ERK	O
pathway	O
in	O
the	O
pathogenesis	O
of	O
both	O
human	O
and	O
mouse	O
ACP	O
To	O
further	O
understand	O
the	O
role	O
of	O
the	O
MAPK	O
/	O
ERK	O
pathway	O
in	O
human	O
ACP	O
and	O
to	O
test	O
its	O
potential	O
as	O
a	O
therapeutic	O
target	O
,	O
we	O
targeted	O
this	O
pathway	O
using	O
trametinib	O
,	O
a	O
specific	O
MEK	O
inhibitor	O
that	O
has	O
shown	O
promising	O
results	O
in	O
MAPK	O
/	O
ERK	O
-	O
driven	O
solid	O
tumours	O
and	O
currently	O
being	O
trialled	O
in	O
children	O
and	O
adolescents	O
with	O
a	O
variety	O
of	O
solid	O
tumours	O
(	O
NIH	O
-	O
NCI	O
clinical	O
trial	O
:	O
NCT02124772	O
).	O

Caption	O
(	O
Fig	O
):	O
FIG	O
6	O
Ex	O
vivo	O
inhibition	O
of	O
the	O
MAPK	O
/	O
ERK	O
pathway	O
in	O
mouse	O
ACP	O
results	O
in	O
decreased	O
proliferation	O
and	O
increased	O
apoptosis	O
of	O
tumour	O
cells	O
.	O

Neoplastic	O
pituitaries	O
of	O
the	O
ACP	O
embryonic	O
mouse	O
model	O
were	O
cultured	O
in	O
the	O
presence	O
of	O
the	O
MEK	O
inhibitor	O
trametinib	O
(	O
2	O
or	O
20Â	O
nM	O
)	O
or	O
the	O
vehicle	O
control	O
(	O
DMSO	O
)	O
for	O
18Â	O
h	O
.	O
Following	O
histological	O
processing	O
,	O
sections	O
were	O
immunostained	O
against	O
Î²	O
-	O
catenin	O
and	O
pERK1	O
/	O
2	O
(	O
readout	O
of	O
active	O
MAPK	O
/	O
ERK	O
pathway	O
;	O
a	O
),	O
Ki	O
-	O
67	O
(	O
proliferation	O
marker	O
;	O
b	O
)	O
and	O
cleaved	O
caspase	O
-	O
3	O
(	O
apoptosis	O
marker	O
;	O
c	O
).	O

Quantitative	O
analysis	O
showing	O
a	O
significant	O
dose	O
-	O
dependent	O
reduction	O
in	O
Ki	O
-	O
67	O
proliferative	O
index	O
(	O
d	O
;	O
20Â	O
nM	O
)	O
and	O
an	O
increase	O
in	O
apoptosis	O
(	O
e	O
;	O
2	O
and	O
20Â	O
nM	O
)	O
in	O
trametinib	O
-	O
treated	O
relative	O
to	O
vehicle	O
-	O
treated	O
control	O
.	O

Kruskalâ	O
	O
Wallis	O
with	O
Dunnâ	O
	O
s	O
post	O
-	O
test	O
**	O
pâ	O
<	O
â	O
	O
0	O
.	O
01	O
;	O
***	O
pâ	O
<	O
â	O
	O
0	O
.	O
001	O
.	O

Mean	O
of	O
4	O
.	O
1â	O
	O
Ã	O
	O
â	O
	O
103	O
nuclei	O
for	O
each	O
point	O
.	O

Scale	O
bars	O
50Â	O
Î¼m	O
The	O
neoplastic	O
pituitaries	O
of	O
the	O
Hesx1Cre	O
/+/	O
Ctnnb1lox	O
(	O
ex3	O
)/+	O
mice	O
at	O
postnatal	O
day	O
1	O
(	O
P1	O
)	O
contain	O
well	O
-	O
defined	O
Î²	O
-	O
catenin	O
-	O
accumulating	O
clusters	O
.	O

To	O
test	O
the	O
effects	O
of	O
trametinib	O
in	O
the	O
mouse	O
model	O
,	O
we	O
cultured	O
neoplastic	O
pituitaries	O
at	O
P1	O
in	O
the	O
presence	O
or	O
absence	O
of	O
2	O
and	O
20Â	O
nM	O
trametinib	O
for	O
18Â	O
h	O
(	O
nâ	O
=	O
â	O
	O
6	O
pituitaries	O
).	O

P1	O
neoplastic	O
pituitaries	O
resemble	O
human	O
ACP	O
more	O
closely	O
than	O
older	O
stages	O
of	O
murine	O
tumour	O
development	O
at	O
both	O
the	O
histological	O
and	O
molecular	O
levels	O
.	O

Immunofluorescence	O
revealed	O
an	O
obvious	O
decrease	O
in	O
p	O
-	O
ERK1	O
/	O
2	O
immunofluorescence	O
within	O
the	O
neoplastic	O
pituitaries	O
upon	O
trametinib	O
treatment	O
with	O
both	O
concentrations	O
,	O
which	O
was	O
more	O
apparent	O
at	O
20Â	O
nM	O
,	O
demonstrating	O
the	O
successful	O
inhibition	O
of	O
the	O
MAPK	O
/	O
ERK	O
pathway	O
(	O
Fig	O
.	O
Â	O
6a	O
).	O

Assessment	O
of	O
proliferation	O
revealed	O
a	O
significant	O
reduction	O
in	O
the	O
Ki67	O
proliferation	O
index	O
between	O
the	O
20Â	O
nM	O
trametinib	O
-	O
treated	O
and	O
vehicle	O
control	O
groups	O
(	O
vehicle	O
,	O
11	O
.	O
6	O
%	O
â	O
	O
Â	O
±	O
â	O
	O
1	O
.	O
10	O
;	O
2Â	O
nM	O
trametinib	O
,	O
10	O
.	O
7	O
%	O
â	O
	O
Â	O
±	O
â	O
	O
1	O
.	O
34	O
;	O
20Â	O
nM	O
trametinib	O
,	O
9	O
.	O
17	O
%	O
â	O
	O
Â	O
±	O
â	O
	O
1	O
.	O
27	O
;	O
meanâ	O
	O
Â	O
±	O
â	O
	O
standard	O
deviation	O
;	O
Kruskalâ	O
	O
Wallis	O
test	O
followed	O
by	O
Dunnâ	O
	O
s	O
multiple	O
comparison	O
test	O
;	O
vehicle	O
vs	O
2Â	O
nM	O
pâ	O
=	O
â	O
	O
0	O
.	O
2438	O
;	O
vehicle	O
vs	O
20Â	O
nM	O
pâ	O
=	O
â	O
	O
0	O
.	O
00018	O
)	O
(	O
Fig	O
.	O
Â	O
6b	O
).	O

Likewise	O
,	O
both	O
trametinib	O
treatments	O
resulted	O
in	O
a	O
dose	O
-	O
dependent	O
significant	O
increase	O
in	O
active	O
caspase	O
-	O
3	O
immunofluorescence	O
,	O
a	O
marker	O
of	O
apoptosis	O
(	O
vehicle	O
,	O
2	O
.	O
88	O
%	O
â	O
	O
Â	O
±	O
â	O
	O
1	O
.	O
08	O
;	O
2Â	O
nM	O
trametinib	O
,	O
5	O
.	O
15	O
%	O
â	O
	O
Â	O
±	O
â	O
	O
2	O
.	O
23	O
;	O
20Â	O
nM	O
trametinib	O
,	O
10	O
.	O
7	O
%	O
â	O
	O
Â	O
±	O
â	O
	O
2	O
.	O
35	O
;	O
meanâ	O
	O
Â	O
±	O
â	O
	O
standard	O
deviation	O
;	O
Kruskalâ	O
	O
Wallis	O
test	O
followed	O
by	O
Dunnâ	O
	O
s	O
multiple	O
comparison	O
test	O
;	O
vehicle	O
vs	O
2Â	O
nM	O
pâ	O
=	O
â	O
	O
0	O
.	O
00756	O
;	O
vehicle	O
vs	O
20Â	O
nM	O
pâ	O
=	O
â	O
	O
0	O
.	O
000002	O
)	O
(	O
Fig	O
.	O
Â	O
6c	O
).	O

Caption	O
(	O
Fig	O
):	O
FIG	O
7	O
Ex	O
vivo	O
inhibition	O
of	O
the	O
MAPK	O
/	O
ERK	O
pathway	O
in	O
human	O
ACP	O
results	O
in	O
decreased	O
proliferation	O
and	O
increased	O
apoptosis	O
of	O
tumour	O
cells	O
.	O

Small	O
pieces	O
of	O
three	O
human	O
ACP	O
tumours	O
were	O
cultured	O
in	O
the	O
presence	O
of	O
the	O
MEK	O
inhibitor	O
trametinib	O
(	O
2	O
or	O
20Â	O
nM	O
)	O
or	O
the	O
vehicle	O
control	O
(	O
DMSO	O
)	O
for	O
18Â	O
h	O
.	O
Following	O
histological	O
processing	O
,	O
sections	O
were	O
immunostained	O
against	O
Î²	O
-	O
catenin	O
and	O
pERK1	O
/	O
2	O
(	O
readout	O
of	O
active	O
MAPK	O
/	O
ERK	O
pathway	O
;	O
a	O
),	O
Ki	O
-	O
67	O
(	O
proliferation	O
marker	O
;	O
b	O
)	O
and	O
cleaved	O
caspase	O
-	O
3	O
(	O
apoptosis	O
marker	O
;	O
c	O
).	O

Quantitative	O
analysis	O
showing	O
a	O
significant	O
dose	O
-	O
dependent	O
reduction	O
in	O
Ki	O
-	O
67	O
proliferative	O
index	O
(	O
d	O
;	O
2	O
and	O
20Â	O
nM	O
)	O
and	O
an	O
increase	O
in	O
apoptosis	O
(	O
e	O
;	O
20Â	O
nM	O
)	O
in	O
trametinib	O
-	O
treated	O
relative	O
to	O
vehicle	O
-	O
treated	O
control	O
.	O

Kruskalâ	O
	O
Wallis	O
with	O
Dunnâ	O
	O
s	O
post	O
-	O
test	O
**	O
pâ	O
<	O
â	O
	O
0	O
.	O
01	O
;	O
***	O
pâ	O
<	O
â	O
	O
0	O
.	O
001	O
.	O

Mean	O
of	O
1	O
.	O
6â	O
	O
Ã	O
	O
â	O
	O
104	O
nuclei	O
for	O
each	O
point	O
.	O

Scale	O
bars	O
50Â	O
Î¼m	O
Next	O
,	O
we	O
performed	O
similar	O
ex	O
vivo	O
culture	O
experiments	O
using	O
small	O
pieces	O
of	O
human	O
ACP	O
tumours	O
,	O
which	O
were	O
cultured	O
with	O
and	O
without	O
trametinib	O
(	O
nâ	O
=	O
â	O
	O
3	O
ACP	O
tumours	O
;	O
2	O
and	O
20Â	O
nM	O
trametinib	O
or	O
vehicle	O
control	O
)	O
for	O
18Â	O
h	O
.	O
Inhibition	O
of	O
the	O
MAPK	O
/	O
ERK	O
pathway	O
was	O
revealed	O
by	O
a	O
reduction	O
of	O
p	O
-	O
ERK1	O
/	O
2	O
immunofluorescence	O
in	O
trametinib	O
-	O
treated	O
tumours	O
relative	O
to	O
vehicle	O
-	O
treated	O
controls	O
,	O
which	O
was	O
more	O
accentuated	O
at	O
20Â	O
nM	O
(	O
Fig	O
.	O
Â	O
7a	O
).	O

Immunohistochemistry	O
revealed	O
a	O
dose	O
-	O
dependent	O
,	O
significant	O
decrease	O
in	O
the	O
Ki67	O
proliferation	O
index	O
upon	O
treatment	O
with	O
trametinib	O
(	O
vehicle	O
,	O
0	O
.	O
950	O
%	O
â	O
	O
Â	O
±	O
â	O
	O
0	O
.	O
140	O
;	O
2Â	O
nM	O
trametinib	O
,	O
0	O
.	O
614	O
%	O
â	O
	O
Â	O
±	O
â	O
	O
0	O
.	O
240	O
;	O
20Â	O
nM	O
trametinib	O
,	O
0	O
.	O
551	O
%	O
â	O
	O
Â	O
±	O
â	O
	O
0	O
.	O
168	O
;	O
meanâ	O
	O
Â	O
±	O
â	O
	O
standard	O
deviation	O
;	O
Kruskalâ	O
	O
Wallis	O
test	O
followed	O
by	O
Dunnâ	O
	O
s	O
multiple	O
comparison	O
test	O
;	O
vehicle	O
vs	O
2Â	O
nM	O
pâ	O
=	O
â	O
	O
0	O
.	O
0028	O
;	O
vehicle	O
vs	O
20Â	O
nM	O
pâ	O
=	O
â	O
	O
0	O
.	O
00030	O
).	O

Similarly	O
,	O
assessment	O
of	O
apoptosis	O
uncovered	O
a	O
dose	O
-	O
dependent	O
increase	O
in	O
apoptosis	O
,	O
which	O
reached	O
significance	O
at	O
20Â	O
nM	O
(	O
vehicle	O
,	O
1	O
.	O
43	O
%	O
â	O
	O
Â	O
±	O
â	O
	O
0	O
.	O
404	O
;	O
2Â	O
nM	O
trametinib	O
,	O
1	O
.	O
99	O
%	O
â	O
	O
Â	O
±	O
â	O
	O
0	O
.	O
514	O
;	O
20Â	O
nM	O
trametinib	O
,	O
3	O
.	O
44	O
%	O
â	O
	O
Â	O
±	O
â	O
	O
1	O
.	O
56	O
;	O
meanâ	O
	O
Â	O
±	O
â	O
	O
standard	O
deviation	O
;	O
Kruskalâ	O
	O
Wallis	O
test	O
followed	O
by	O
Dunnâ	O
	O
s	O
multiple	O
comparison	O
test	O
;	O
vehicle	O
vs	O
2Â	O
nM	O
pâ	O
=	O
â	O
	O
0	O
.	O
07033	O
;	O
vehicle	O
vs	O
20Â	O
nM	O
pâ	O
=	O
â	O
	O
0	O
.	O
000052	O
).	O

Combined	O
together	O
,	O
these	O
preclinical	O
studies	O
provide	O
preliminary	O
evidence	O
for	O
a	O
potential	O
anti	O
-	O
tumoural	O
effect	O
of	O
trametinib	O
on	O
ACP	O
.	O

Specifically	O
,	O
we	O
show	O
that	O
trametinib	O
treatment	O
significantly	O
reduces	O
proliferation	O
and	O
increases	O
apoptosis	O
in	O
both	O
human	O
and	O
mouse	O
ACP	O
in	O
vitro	O
.	O

Cytokine	O
profiling	O
of	O
tumour	O
and	O
cystic	O
fluid	O
suggests	O
activation	O
of	O
the	O
inflammasomes	O
in	O
human	O
ACP	O
Caption	O
(	O
Fig	O
):	O
FIG	O
8	O
Characterisation	O
of	O
the	O
immune	O
microenvironment	O
in	O
the	O
solid	O
component	O
and	O
cystic	O
fluid	O
of	O
human	O
ACP	O
.	O

a	O
Immunohistochemistry	O
showing	O
infiltration	O
of	O
myeloid	O
(	O
CD68	O
+	O
ve	O
)	O
and	O
lymphoid	O
(	O
CD3	O
+	O
ve	O
)	O
within	O
human	O
ACP	O
tumour	O
(	O
T	O
)	O
and	O
reactive	O
glial	O
tissue	O
(	O
G	O
).	O

CD68	O
+	O
ve	O
and	O
IBA1	O
+	O
ve	O
immunostaining	O
is	O
observed	O
in	O
close	O
association	O
with	O
the	O
cholesterol	O
clefts	O
(	O
arrows	O
).	O

Likewise	O
,	O
immunohistochemistry	O
against	O
the	O
chemokine	O
CCL2	O
is	O
detected	O
near	O
the	O
cholesterol	O
clefts	O
.	O

b	O
The	O
expression	O
of	O
the	O
cytokines	O
IL18	O
,	O
IL1B	O
and	O
IL10	O
correlate	O
significantly	O
with	O
CD14	O
expression	O
,	O
a	O
marker	O
preferentially	O
expressed	O
in	O
monocytes	O
/	O
macrophages	O
,	O
in	O
the	O
24	O
samples	O
(	O
ACP	O
tumours	O
and	O
control	O
tissues	O
)	O
profiled	O
by	O
RNA	O
-	O
Seq	O
.	O

c	O
Multiplex	O
ELISA	O
quantification	O
of	O
cytokine	O
protein	O
expression	O
within	O
the	O
solid	O
tumour	O
(	O
nâ	O
=	O
â	O
	O
8	O
tumours	O
;	O
left	O
)	O
and	O
cystic	O
fluid	O
(	O
nâ	O
=	O
â	O
	O
10	O
samples	O
;	O
right	O
).	O

IL8	O
,	O
IL18	O
,	O
IL6	O
and	O
IL1B	O
are	O
the	O
highest	O
expressed	O
cytokines	O
in	O
the	O
solid	O
tumour	O
.	O

In	O
the	O
cystic	O
fluid	O
,	O
levels	O
of	O
IL6	O
and	O
IL8	O
are	O
the	O
highest	O
,	O
but	O
all	O
the	O
other	O
cytokines	O
are	O
also	O
detected	O
.	O

For	O
solid	O
tumour	O
values	O
were	O
normalised	O
against	O
total	O
protein	O
and	O
for	O
cystic	O
fluid	O
samples	O
against	O
volume	O
.	O

The	O
blue	O
dots	O
represent	O
the	O
value	O
obtained	O
of	O
each	O
cytokine	O
for	O
each	O
sample	O
and	O
the	O
red	O
dots	O
represent	O
the	O
median	O
.	O

Scale	O
bars	O
100Â	O
Î¼m	O
Our	O
transcriptional	O
analysis	O
of	O
whole	O
ACP	O
tumours	O
exposed	O
another	O
major	O
pattern	O
of	O
gene	O
expression	O
,	O
the	O
magenta	O
module	O
,	O
which	O
correlated	O
with	O
immune	O
cell	O
markers	O
and	O
was	O
enriched	O
for	O
immune	O
system	O
genes	O
[	O
Fig	O
.	O
Â	O
1f	O
;	O
Suppl	O
.	O

TableÂ	O
4a	O
,	O
k	O
(	O
Online	O
Resource	O
6	O
);	O
Suppl	O
.	O

Fig	O
.	O
Â	O
2d	O
(	O
Online	O
Resource	O
3	O
)].	O

Supporting	O
this	O
finding	O
,	O
immunohistochemistry	O
against	O
CD68	O
and	O
CD3	O
revealed	O
myeloid	O
-	O
derived	O
(	O
CD68	O
+	O
ve	O
)	O
and	O
lymphoid	O
-	O
derived	O
(	O
CD3	O
+	O
ve	O
)	O
cells	O
variably	O
infiltrating	O
the	O
reactive	O
glial	O
and	O
tumour	O
epithelial	O
compartments	O
within	O
human	O
ACP	O
(	O
Fig	O
.	O
Â	O
8a	O
).	O

Of	O
note	O
,	O
myeloid	O
cells	O
,	O
as	O
evidenced	O
by	O
immunohistochemistry	O
for	O
CD68	O
or	O
IBA1	O
,	O
were	O
frequently	O
observed	O
in	O
close	O
association	O
with	O
the	O
cholesterol	O
clefts	O
(	O
Fig	O
.	O
Â	O
8a	O
).	O

In	O
addition	O
,	O
cytokine	O
-	O
encoding	O
genes	O
were	O
highly	O
up	O
-	O
regulated	O
in	O
ACP	O
whole	O
tumours	O
compared	O
with	O
controls	O
[	O
Suppl	O
.	O

TableÂ	O
6	O
(	O
Online	O
Resource	O
8	O
)].	O

The	O
expression	O
of	O
IL1B	O
,	O
IL18	O
and	O
IL10	O
correlated	O
significantly	O
with	O
the	O
immune	O
infiltrate	O
and	O
inflammatory	O
cell	O
markers	O
,	O
particularly	O
CD14	O
and	O
CD68	O
(	O
râ	O
>	O
â	O
	O
0	O
.	O
73	O
,	O
pâ	O
<	O
â	O
	O
1â	O
	O
Ã	O
	O
â	O
	O
10â	O
	O
5	O
),	O
as	B
opposed	I
to	I
CTNNB1	O
mutation	O
allele	O
frequency	O
[	O
Fig	O
.	O
Â	O
8b	O
;	O
Suppl	O
.	O

TableÂ	O
6	O
(	O
Online	O
Resource	O
8	O
)].	O

This	O
suggests	O
that	O
cytokine	O
expression	O
predominantly	O
derived	O
from	O
immune	O
rather	B
than	O
tumour	O
cells	O
.	O

The	O
presence	O
of	O
cytokines	O
in	O
the	O
ACP	O
tumours	O
was	O
also	O
assessed	O
by	O
multiplex	O
ELISA	O
against	O
IL1B	O
,	O
IL6	O
,	O
IL8	O
(	O
CXCL8	O
),	O
IL10	O
,	O
IL18	O
,	O
TNF	O
(	O
TNFÎ	O
±)	O
and	O
IFNG	O
(	O
IFNÎ³	O
),	O
which	O
revealed	O
the	O
expression	O
of	O
all	O
of	O
these	O
but	O
IFNG	O
in	O
protein	O
lysates	O
from	O
eight	O
human	O
ACPs	O
(	O
Fig	O
.	O
Â	O
8c	O
).	O

This	O
is	O
in	O
line	O
with	O
recent	O
findings	O
.	O

Immunohistochemistry	O
against	O
IL1B	O
,	O
IL6	O
and	O
IL8	O
did	O
not	O
yield	O
reliable	O
results	O
in	O
our	O
hands	O
using	O
different	B
antibodies	O
.	O

The	O
cystic	O
fluid	O
of	O
ACP	O
has	O
been	O
shown	O
to	O
contain	O
inflammatory	O
modulators	O
.	O

To	O
explore	O
the	O
protein	O
composition	O
in	O
greater	O
detail	O
,	O
comprehensive	O
proteome	O
analysis	O
was	O
completed	O
on	O
cystic	O
fluid	O
from	O
six	O
ACP	O
patients	O
[	O
Suppl	O
.	O

Materials	O
and	O
Methods	O
(	O
Online	O
Resource	O
1	O
)].	O

To	O
obtain	O
greater	O
depth	O
in	O
the	O
proteome	O
coverage	O
,	O
samples	O
of	O
fluid	O
were	O
first	O
subjected	O
to	O
a	O
combinatorial	O
peptide	O
bead	O
equalisation	O
[	O
Suppl	O
.	O

Fig	O
.	O
Â	O
8a	O
(	O
Online	O
Resource	O
3	O
)].	O

In	O
total	O
,	O
461	O
proteins	O
were	O
identified	O
in	O
all	O
samples	O
,	O
using	O
an	O
FDR	O
of	O
1	O
%	O
and	O
requiring	O
at	O
least	O
two	O
unique	O
peptides	O
for	O
each	O
protein	O
[	O
Suppl	O
.	O

TableÂ	O
7	O
(	O
Online	O
Resource	O
9	O
)].	O

The	O
overall	O
proteome	O
profile	O
of	O
all	O
six	O
cystic	O
fluid	O
samples	O
was	O
similar	O
[	O
Suppl	O
.	O

Fig	O
.	O
Â	O
8b	O
(	O
Online	O
Resource	O
3	O
)],	O
covering	O
an	O
excess	O
of	O
five	O
orders	O
of	O
magnitude	O
.	O

The	O
most	O
abundant	O
proteins	O
included	O
albumin	O
and	O
several	O
inflammation	O
-	O
associated	O
proteins	O
such	O
as	O
apolipoproteins	O
,	O
particularly	O
APOA1	O
and	O
APOA2	O
,	O
complement	O
system	O
proteins	O
and	O
immunoglobulins	O
[	O
Suppl	O
.	O

Fig	O
.	O
Â	O
8c	O
(	O
Online	O
Resource	O
3	O
].	O

Ontology	O
analysis	O
revealed	O
an	O
enrichment	O
for	O
terms	O
related	O
to	O
immune	O
/	O
defence	O
response	O
,	O
inflammation	O
and	O
sterol	O
metabolism	O
[	O
Suppl	O
.	O

Fig	O
.	O
Â	O
8d	O
(	O
Online	O
Resource	O
3	O
)].	O

Cytokines	O
were	O
not	O
detected	O
in	O
the	O
proteome	O
analysis	O
,	O
almost	O
certainly	O
attributable	O
to	O
their	O
very	O
low	O
concentrations	O
.	O

We	O
used	O
multiplex	O
ELISA	O
to	O
demonstrate	O
the	O
presence	O
of	O
IL1B	O
,	O
IL6	O
,	O
IL8	O
,	O
IL10	O
,	O
IL18	O
,	O
TNF	O
and	O
IFNG	O
in	O
the	O
cystic	O
fluid	O
and	O
whole	O
ACP	O
tumour	O
protein	O
lysates	O
(	O
Fig	O
.	O
Â	O
8c	O
).	O

Caption	O
(	O
Fig	O
):	O
FIG	O
9	O
Activation	O
of	O
the	O
inflammasomes	O
underlies	O
the	O
ACP	O
inflammatory	O
response	O
.	O

a	O
Gene	O
set	O
enrichment	O
plots	O
showing	O
that	O
human	O
ACP	O
tumours	O
are	O
enriched	O
for	O
genes	O
expressed	O
by	O
macrophages	O
,	O
chondrocytes	O
and	O
uterine	O
muscle	O
cells	O
exposed	O
to	O
IL1B	O
in	O
culture	O
conditions	O
.	O

b	O
Gene	O
set	O
enrichment	O
plots	O
reveal	O
a	O
molecular	O
signature	O
of	O
atherosclerotic	O
plaques	O
in	O
human	O
ACP	O
.	O

Results	O
are	O
based	O
on	O
data	O
obtained	O
from	O
RNA	O
-	O
Seq	O
profiles	O
from	O
whole	O
ACP	O
tumours	O
and	O
control	O
tissues	O
(	O
fetal	O
pituitaries	O
and	O
NFPA	O
).	O

c	O
The	O
levels	O
of	O
IL6	O
,	O
IL8	O
and	O
TNFÎ	O
±	O
protein	O
correlate	O
with	O
levels	O
of	O
IL1B	O
in	O
human	O
ACP	O
cystic	O
fluid	O
(	O
nâ	O
=	O
â	O
	O
10	O
cystic	O
fluid	O
samples	O
;	O
determined	O
by	O
ELISA	O
).	O

NES	O
normalised	O
enrichment	O
score	O
,	O
FDR	O
false	O
discovery	O
rate	O
The	O
cytokine	O
profile	O
identified	O
in	O
the	O
ACP	O
RNA	O
-	O
Seq	O
dataset	O
,	O
in	O
particular	O
the	O
significantly	O
higher	O
expression	O
of	O
IL1A	O
(	O
18	O
.	O
1	O
-	O
fold	O
),	O
IL18	O
(	O
14	O
.	O
8	O
-	O
fold	O
),	O
TNF	O
(	O
10	O
.	O
4	O
-	O
fold	O
)	O
and	O
IL1B	O
(	O
7	O
-	O
fold	O
)	O
in	O
human	O
ACP	O
tumours	O
relative	O
to	O
controls	O
,	O
was	O
suggestive	O
of	O
inflammasome	O
activation	O
[	O
Suppl	O
.	O

TableÂ	O
6	O
(	O
Online	O
Resource	O
8	O
)].	O

Inflammasomes	O
are	O
innate	O
danger	O
-	O
associated	O
pattern	O
recognition	O
protein	O
complexes	O
that	O
activate	O
and	O
up	O
-	O
regulate	O
IL1	O
family	O
members	O
,	O
particularly	O
IL1B	O
and	O
IL18	O
.	O

This	O
subsequently	O
drives	O
a	O
pro	O
-	O
inflammatory	O
response	O
through	O
secondary	O
expression	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
including	O
IL6	O
,	O
IL8	O
,	O
TNF	O
and	O
chemokines	O
(	O
e	O
.	O
g	O
.	O

CCL2	O
).	O

Several	O
genes	O
encoding	O
core	O
inflammasome	O
components	O
were	O
all	O
significantly	O
expressed	O
at	O
higher	O
levels	O
in	O
ACP	O
tumours	O
compared	O
with	O
control	O
tissues	O
,	O
including	O
NLRP1	O
(	O
6	O
.	O
4	O
-	O
fold	O
),	O
NLRP3	O
(	O
4	O
.	O
8	O
-	O
fold	O
),	O
NLRC4	O
(	O
4	O
.	O
8	O
-	O
fold	O
),	O
CASP1	O
(	O
5	O
-	O
fold	O
)	O
and	O
PYCARD	O
(	O
4	O
-	O
fold	O
)	O
[	O
Suppl	O
.	O

TableÂ	O
2a	O
(	O
Online	O
Resource	O
4	O
)].	O

Moreover	O
,	O
GSEA	O
highlighted	O
a	O
significant	O
enrichment	O
of	O
the	O
IL1B	O
response	O
signature	O
in	O
ACP	O
tumours	O
using	O
three	O
independent	O
datasets	O
of	O
genes	O
up	O
-	O
regulated	O
upon	O
IL1B	O
treatment	O
(	O
NESâ	O
=	O
â	O
	O
1	O
.	O
79	O
,	O
2	O
.	O
25	O
,	O
2	O
.	O
66	O
,	O
respectively	O
;	O
FDRsâ	O
<	O
â	O
	O
0	O
.	O
001	O
)	O
(	O
Fig	O
.	O
Â	O
9a	O
).	O

Complementing	O
the	O
mRNA	O
expression	O
data	O
,	O
protein	O
levels	O
of	O
the	O
downstream	O
cytokines	O
IL6	O
,	O
IL8	O
and	O
TNF	O
correlated	O
with	O
the	O
protein	O
levels	O
of	O
IL1B	O
in	O
ACP	O
cystic	O
fluid	O
,	O
supporting	O
a	O
role	O
of	O
IL1B	O
in	O
activating	O
the	O
inflammasomes	O
(	O
IL6	O
,	O
râ	O
=	O
â	O
	O
0	O
.	O
91	O
,	O
pâ	O
=	O
â	O
	O
0	O
.	O
0002	O
;	O
IL8	O
,	O
râ	O
=	O
â	O
	O
0	O
.	O
95	O
,	O
pâ	O
=	O
â	O
	O
2	O
.	O
4â	O
	O
Ã	O
	O
â	O
	O
10â	O
	O
5	O
;	O
TNFÎ	O
±,	O
râ	O
=	O
â	O
	O
0	O
.	O
96	O
,	O
pâ	O
=	O
â	O
	O
1	O
.	O
41â	O
	O
Ã	O
	O
â	O
	O
10â	O
	O
5	O
)	O
(	O
Fig	O
.	O
Â	O
9c	O
).	O

Having	O
shown	O
an	O
expression	O
profile	O
,	O
at	O
both	O
the	O
mRNA	O
and	O
protein	O
levels	O
,	O
supportive	O
of	O
the	O
activation	O
of	O
inflammasomes	O
in	O
human	O
ACP	O
,	O
we	O
sought	O
to	O
explore	O
the	O
similarities	O
of	O
this	O
molecular	O
signature	O
with	O
that	O
caused	O
by	O
other	O
inflammasome	O
activators	O
.	O

Cholesterol	O
and	O
other	O
crystals	O
(	O
e	O
.	O
g	O
.	O

uric	O
acid	O
crystals	O
)	O
are	O
established	O
activators	O
of	O
inflammasomes	O
,	O
which	O
mediate	O
inflammation	O
and	O
are	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
atherosclerosis	O
and	O
arthropathies	O
(	O
e	O
.	O
g	O
.	O

gout	O
).	O

The	O
ACP	O
inflammatory	O
cytokine	O
profile	O
was	O
similar	O
to	O
that	O
seen	O
in	O
gout	O
,	O
specifically	O
regarding	O
the	O
high	O
levels	O
of	O
IL1B	O
,	O
IL6	O
and	O
IL18	O
.	O

Interestingly	O
,	O
we	O
observed	O
strong	O
expression	O
of	O
the	O
inflammasome	O
-	O
induced	O
chemokine	O
CCL2	O
in	O
association	O
with	O
cholesterol	O
clefts	O
(	O
Fig	O
.	O
Â	O
8a	O
),	O
while	O
GSEA	O
revealed	O
a	O
significant	O
enrichment	O
of	O
an	O
atherosclerotic	O
plaque	O
gene	O
signature	O
in	O
ACP	O
tumours	O
relative	O
to	O
control	O
tissues	O
(	O
NESâ	O
=	O
â	O
	O
2	O
.	O
12	O
,	O
FDRâ	O
<	O
â	O
	O
0	O
.	O
001	O
)	O
(	O
Fig	O
.	O
Â	O
9b	O
).	O

Together	O
,	O
these	O
results	O
suggest	O
an	O
activation	O
of	O
the	O
inflammasomes	O
in	O
human	O
ACP	O
and	O
identify	O
cholesterol	O
as	O
a	O
possible	O
activator	O
.	O

Discussion	O
Caption	O
(	O
Fig	O
):	O
FIG	O
10	O
Schematic	O
summary	O
of	O
the	O
findings	O
.	O

Molecular	O
and	O
histological	O
relationships	O
between	O
ACP	O
pathogenesis	O
and	O
tooth	O
development	O
.	O

The	O
enamel	O
knot	O
and	O
the	O
Î²	O
-	O
catenin	O
-	O
accumulating	O
clusters	O
,	O
which	O
both	O
have	O
similar	O
expression	O
profiles	O
and	O
comparable	O
histology	O
,	O
act	O
as	O
signalling	O
hubs	O
through	O
the	O
secretion	O
of	O
a	O
several	O
growth	O
factors	O
acting	O
in	O
an	O
autocrine	O
and	O
/	O
or	O
paracrine	O
manner	O
on	O
the	O
surrounding	O
cells	O
,	O
i	O
.	O
e	O
.	O

the	O
enamel	O
epithelium	O
/	O
dental	O
mesenchyme	O
in	O
the	O
forming	O
tooth	O
or	O
the	O
palisading	O
epithelium	O
,	O
stellate	O
reticulum	O
and	O
glial	O
reactive	O
tissue	O
in	O
ACP	O
.	O

Reciprocal	O
signalling	O
from	O
surrounding	O
tissues	O
to	O
the	O
enamel	O
knot	O
and	O
clusters	O
is	O
indicated	O
by	O
double	O
-	O
headed	O
arrows	O
.	O

In	O
the	O
glial	O
reactive	O
tissue	O
,	O
cholesterol	O
crystals	O
activate	O
the	O
inflammasomes	O
resulting	O
in	O
the	O
secretion	O
of	O
IL1B	O
,	O
which	O
in	O
turn	O
acts	O
on	O
the	O
local	O
immune	O
effector	O
cells	O
to	O
drive	O
an	O
inflammatory	O
response	O
In	O
this	O
study	O
,	O
we	O
have	O
revealed	O
the	O
molecular	O
signatures	O
of	O
different	O
compartments	O
in	O
human	O
ACP	O
,	O
including	O
the	O
Î²	O
-	O
catenin	O
-	O
accumulating	O
cell	O
clusters	O
,	O
palisading	O
epithelium	O
,	O
glial	O
tissue	O
and	O
the	O
immune	O
microenvironment	O
.	O

Through	O
these	O
analyses	O
,	O
we	O
have	O
identified	O
and	O
validated	O
the	O
expression	O
of	O
novel	O
ACP	O
genes	O
,	O
demonstrated	O
the	O
molecular	O
similarities	O
between	O
human	O
ACP	O
and	O
tooth	O
development	O
,	O
revealed	O
the	O
MAPK	O
/	O
ERK	O
pathway	O
and	O
inflammasome	O
signalling	O
as	O
two	O
novel	O
targetable	O
pathways	O
and	O
importantly	O
,	O
provided	O
preliminary	O
data	O
supporting	O
the	O
use	O
of	O
MEK	O
inhibitors	O
against	O
human	O
ACP	O
.	O

A	O
schematic	O
summary	O
of	O
the	O
findings	O
of	O
this	O
research	O
is	O
shown	O
in	O
Fig	O
.	O
Â	O
10	O
.	O

We	O
provide	O
a	O
rationale	O
that	O
explains	O
the	O
long	O
-	O
standing	O
observation	O
of	O
the	O
histological	O
similarities	O
of	O
ACP	O
tumours	O
with	O
tooth	O
development	O
and	O
odontogenic	O
tumours	O
.	O

We	O
show	O
that	O
ACP	O
Î²	O
-	O
catenin	O
-	O
accumulating	O
clusters	O
and	O
the	O
enamel	O
knots	O
of	O
developing	O
teeth	O
are	O
molecularly	O
analogous	O
structures	O
,	O
as	O
are	O
ACP	O
palisading	O
epithelium	O
and	O
dental	O
inner	O
enamel	O
epithelium	O
.	O

These	O
pairs	O
share	O
a	O
molecular	O
signature	O
and	O
activate	O
similar	O
genetic	O
programmes	O
.	O

Through	O
the	O
use	O
of	O
mouse	O
models	O
of	O
ACP	O
,	O
we	O
show	O
that	O
the	O
expression	O
of	O
oncogenic	O
Î²	O
-	O
catenin	O
leading	O
to	O
the	O
activation	O
of	O
the	O
WNT	O
pathway	O
is	O
sufficient	O
to	O
induce	O
enamel	O
epithelial	O
/	O
ameloblast	O
-	O
like	O
gene	O
expression	O
and	O
enamel	O
knot	O
-	O
like	O
cluster	O
formation	O
in	O
Rathkeâ	O
	O
s	O
pouch	O
derivatives	O
.	O

Importantly	O
,	O
when	O
the	O
same	O
degradation	O
-	O
resistant	O
form	O
of	O
Ctnnb1	O
(	O
Ctnnb1lox	O
(	O
ex3	O
))	O
is	O
activated	O
in	O
the	O
enamel	O
epithelia	O
under	O
the	O
control	O
of	O
the	O
Krt14	O
or	O
Sox2	O
promoters	O
,	O
the	O
result	O
is	O
continuous	O
tooth	O
formation	O
,	O
with	O
the	O
presence	O
of	O
multiple	O
enamel	O
knots	O
and	O
with	O
morphological	O
similarities	O
to	O
ACP	O
.	O

Of	O
note	O
,	O
fully	O
formed	O
teeth	O
including	O
dentin	O
are	O
occasionally	O
seen	O
in	O
human	O
ACP	O
.	O

Analogous	O
to	O
the	O
developing	O
tooth	O
,	O
we	O
highlight	O
a	O
complex	O
system	O
of	O
paracrine	O
signalling	O
occurring	O
between	O
tissue	O
compartments	O
,	O
centred	O
on	O
ACP	O
clusters	O
.	O

We	O
characterise	O
the	O
FGF	O
,	O
MAPK	O
/	O
ERK	O
,	O
TGFÎ²	O
,	O
BMP	O
and	O
EDAR	O
signalling	O
pathways	O
in	O
ACP	O
.	O

The	O
importance	O
for	O
many	O
of	O
these	O
genes	O
and	O
pathways	O
has	O
been	O
functionally	O
explored	O
in	O
the	O
developing	O
tooth	O
,	O
where	O
their	O
manipulation	O
alters	O
the	O
number	O
of	O
teeth	O
and	O
/	O
or	O
their	O
morphogenesis	O
.	O

As	O
the	O
consequences	O
of	O
gene	O
inactivation	O
have	O
been	O
more	O
extensively	O
studied	O
in	O
the	O
tooth	O
development	O
field	O
,	O
it	O
is	O
plausible	O
to	O
speculate	O
that	O
this	O
knowledge	O
may	O
inform	O
on	O
the	O
genes	O
/	O
pathways	O
that	O
may	O
be	O
more	O
relevant	O
in	O
the	O
pathogenesis	O
of	O
human	O
ACP	O
.	O

Illustrating	O
this	O
concept	O
,	O
we	O
show	O
that	O
ex	O
vivo	O
MEK	O
inhibition	O
with	O
trametinib	O
results	O
in	O
decreased	O
proliferation	O
increased	O
apoptosis	O
in	O
both	O
mouse	O
and	O
human	O
ACP	O
.	O

Likewise	O
,	O
individuals	O
with	O
Costello	O
syndrome	O
,	O
a	O
condition	O
that	O
results	O
from	O
germline	O
activating	O
mutations	O
in	O
HRAS	O
leading	O
to	O
the	O
over	O
-	O
activation	O
of	O
the	O
MAPK	O
/	O
ERK	O
pathway	O
,	O
show	O
defective	O
enamel	O
mineralisation	O
with	O
increased	O
number	O
,	O
proliferation	O
and	O
irregular	O
orientation	O
of	O
ameloblasts	O
.	O

This	O
phenotype	O
can	O
be	O
rescued	O
by	O
MEK	O
inhibition	O
in	O
murine	O
models	O
of	O
Costello	O
syndrome	O
.	O

We	O
show	O
that	O
MAPK	O
/	O
ERK	O
pathway	O
inhibition	O
ex	O
vivo	O
using	O
trametinib	O
is	O
associated	O
with	O
decreased	O
proliferation	O
and	O
increased	O
apoptosis	O
in	O
both	O
mouse	O
and	O
human	O
ACP	O
,	O
suggesting	O
that	O
other	O
pathways	O
of	O
importance	O
during	O
tooth	O
development	O
may	O
also	O
be	O
relevant	O
in	O
the	O
context	O
of	O
ACP	O
pathogenesis	O
.	O

Future	O
preclinical	O
studies	O
in	O
both	O
genetic	O
and	O
patient	O
-	O
derived	O
xenograft	O
mouse	O
models	O
of	O
ACP	O
will	O
assess	O
the	O
effects	O
of	O
trametinib	O
treatment	O
in	O
tumour	O
development	O
.	O

Finally	O
,	O
we	O
highlight	O
that	O
inflammasome	O
activation	O
may	O
underlie	O
the	O
inflammation	O
observed	O
in	O
human	O
ACP	O
,	O
and	O
identify	O
that	O
cholesterol	O
crystals	O
may	O
be	O
a	O
potential	O
inflammasome	O
activator	O
(	O
Fig	O
.	O
Â	O
10	O
).	O

This	O
finding	O
could	O
have	O
important	O
therapeutic	O
consequences	O
.	O

Prevention	O
of	O
inflammasome	O
activation	O
by	O
the	O
use	O
of	O
IL1R	O
inhibitors	O
(	O
e	O
.	O
g	O
.	O

anakinra	O
)	O
has	O
been	O
remarkably	O
effective	O
in	O
several	O
autoinflammatory	O
diseases	O
,	O
most	O
notably	O
in	O
cryopyrin	O
-	O
associated	O
periodic	O
syndromes	O
(	O
CAPS	O
),	O
gout	O
and	O
atherosclerotic	O
disease	O
.	O

Inhibitors	O
such	O
as	O
anakinra	O
are	O
used	O
in	O
routine	O
clinical	O
practice	O
,	O
including	O
in	O
paediatrics	O
,	O
and	O
are	O
known	O
to	O
cross	O
the	O
blood	O
brain	O
barrier	O
and	O
improve	O
neuroinflammation	O
in	O
patients	O
with	O
severe	O
CAPS	O
.	O

The	O
ability	O
to	O
measure	O
downstream	O
cytokines	O
e	O
.	O
g	O
.	O

IL6	O
and	O
IL8	O
within	O
cystic	O
fluid	O
offers	O
an	O
opportunity	O
to	O
develop	O
biomarkers	O
of	O
therapy	O
response	O
to	O
anakinra	O
and	O
other	O
similar	O
drugs	O
.	O

In	O
summary	O
,	O
we	O
reveal	O
a	O
detailed	O
molecular	O
rationale	O
underpinning	O
the	O
resemblance	O
of	O
ACP	O
to	O
tooth	O
development	O
and	O
odontogenic	O
tumours	O
,	O
and	O
additionally	O
,	O
we	O
provide	O
evidence	O
from	O
preclinical	O
testing	O
of	O
the	O
use	O
of	O
novel	O
targeted	O
therapies	O
in	O
ACP	O
,	O
opening	O
the	O
door	O
for	O
biologically	O
driven	O
studies	O
in	O
human	O
patients	O
.	O

Electronic	O
supplementary	O
material	O
Below	O
is	O
the	O
link	O
to	O
the	O
electronic	O
supplementary	O
material	O
.	O

Electronic	O
supplementary	O
material	O
The	O
online	O
version	O
of	O
this	O
article	O
(	O
10	O
.	O
1007	O
/	O
s00401	O
-	O
018	O
-	O
1830	O
-	O
2	O
)	O
contains	O
supplementary	O
material	O
,	O
which	O
is	O
available	O
to	O
authorized	O
users	O
.	O

Funding	O
J	O
.	O
R	O
.	O
A	O
.	O

is	O
a	O
Cancer	O
Research	O
UK	O
Clinical	O
Research	O
Training	O
Fellow	O
.	O

Funding	O
for	O
this	O
research	O
was	O
provided	O
by	O
Cancer	O
Research	O
UK	O
,	O
the	O
Childrenâ	O
	O
s	O
Cancer	O
and	O
Leukaemia	O
Group	O
,	O
Children	O
with	O
Cancer	O
UK	O
(	O
15	O
/	O
190	O
),	O
MRC	O
(	O
MR	O
/	O
M125	O
/	O
1	O
),	O
the	O
Brain	O
Tumour	O
Charity	O
(	O
SIGNAL	O
and	O
EVEREST	O
),	O
Great	O
Ormond	O
Street	O
Hospital	O
Childrenâ	O
	O
s	O
Charity	O
and	O
the	O
National	O
Institute	O
of	O
Health	O
Research	O
Biomedical	O
Research	O
Centre	O
at	O
Great	O
Ormond	O
Street	O
Hospital	O
for	O
Children	O
NHS	O
Foundation	O
Trust	O
and	O
University	O
College	O
London	O
.	O

S	O
.	O
H	O
.	O

is	O
supported	O
by	O
a	O
Wellcome	O
Trust	O
PhD	O
Fellowship	O
.	O

J	O
.	O
R	O
.	O
A	O
.	O

is	O
supported	O
by	O
a	O
Cancer	O
Research	O
UK	O
Clinical	O
Research	O
Training	O
Fellowship	O
.	O

J	O
.	O
P	O
.	O
M	O
.-	O
B	O
.	O

is	O
a	O
Great	O
Ormond	O
Street	O
Hospital	O
for	O
Childrenâ	O
	O
s	O
Charity	O
Principal	O
Investigator	O
.	O

Compliance	O
with	O
ethical	O
standards	O
Conflict	O
of	O
interest	O
P	O
.	O
B	O
.	O

has	O
received	O
institutional	O
grants	O
from	O
SOBI	O
,	O
Roche	O
and	O
Novartis	O
;	O
consultancy	O
fees	O
from	O
Roche	O
;	O
and	O
lecturing	O
fees	O
from	O
SOBI	O
and	O
Novartis	O
.	O

The	O
other	O
authors	O
declare	O
that	O
they	O
have	O
no	O
conflict	O
of	O
interest	O
.	O

Targeting	O
IL	O
-	O
6	O
Is	O
a	O
Potential	O
Treatment	O
for	O
Primary	O
Cystic	O
Craniopharyngioma	O
Abstract	O
Adamantinomatous	O
craniopharyngioma	O
(	O
ACP	O
)	O
makes	O
up	O
between	O
6	O
and	O
8	O
%	O
of	O
pediatric	O
brain	O
tumors	O
and	O
is	O
the	O
most	O
common	O
pediatric	O
tumor	O
arising	O
in	O
the	O
sellar	O
/	O
suprasellar	O
region	O
of	O
the	O
brain	O
.	O

The	O
10	O
-	O
year	O
survival	O
for	O
patients	O
diagnosed	O
with	O
craniopharyngioma	O
ranges	O
between	O
64	O
and	O
92	O
%,	O
but	O
complicating	O
factors	O
such	O
as	O
location	O
,	O
common	O
cyst	O
formation	O
,	O
and	O
potential	O
hypothalamic	O
infiltration	O
cause	O
significant	O
morbidity	O
in	O
this	O
population	O
.	O

There	O
are	O
a	O
number	O
of	O
therapeutic	O
options	O
for	O
children	O
with	O
ACP	O
,	O
including	O
surgery	O
,	O
radiation	O
,	O
and	O
cyst	O
directed	O
therapies	O
such	O
as	O
interferon	O
and	O
bleomycin	O
.	O

Research	O
has	O
raised	O
concerns	O
regarding	O
the	O
efficacy	O
and	O
side	O
effects	O
associated	O
with	O
these	O
conventional	O
therapies	O
,	O
as	O
well	O
as	O
with	O
the	O
difficulty	O
in	O
treating	O
recurrent	O
cystic	O
ACP	O
.	O

Evidence	O
from	O
our	O
group	O
and	O
others	O
has	O
shown	O
that	O
the	O
cystic	O
and	O
solid	O
tumor	O
components	O
of	O
craniopharyngioma	O
have	O
high	O
levels	O
of	O
IL	O
-	O
6R	O
and	O
IL	O
-	O
6	O
,	O
providing	O
a	O
potential	O
target	O
for	O
therapy	O
.	O

Tocilizumab	O
,	O
a	O
humanized	O
monoclonal	O
antibody	O
,	O
acts	O
against	O
soluble	O
and	O
membrane	O
bound	O
IL	O
-	O
6R	O
,	O
and	O
has	O
been	O
widely	O
utilized	O
in	O
pediatric	O
patients	O
.	O

Two	O
patients	O
with	O
recurrent	O
cystic	O
ACP	O
were	O
offered	O
systemically	O
administered	O
tocilizumab	O
or	O
a	O
combination	O
of	O
tocilizumab	O
and	O
bevacizumab	O
on	O
a	O
compassionate	O
use	O
basis	O
.	O

Both	O
patients	O
'	O
tumors	O
had	O
a	O
significant	O
response	O
,	O
with	O
decreased	O
cyst	O
burden	O
,	O
supporting	O
the	O
assertion	B
that	O
tocilizumab	O
with	O
or	O
without	O
bevacizumab	O
may	O
be	O
an	O
option	O
for	O
patients	O
suffering	O
from	O
cystic	O
ACP	O
.	O

Introduction	O
Adamantinomatous	O
craniopharyngioma	O
(	O
ACP	O
)	O
is	O
a	O
neurologically	O
devastating	O
chronic	O
disease	O
with	O
morbidity	O
that	O
far	O
outweighs	O
the	O
mortality	O
risk	O
.	O

It	O
comprises	O
6â	O
	O
8	O
%	O
of	O
pediatric	O
brain	O
tumors	O
and	O
is	O
the	O
most	O
common	O
tumor	O
of	O
the	O
sellar	O
/	O
suprasellar	O
region	O
in	O
children	O
.	O

ACP	O
is	O
among	O
a	O
growing	O
number	O
of	O
pediatric	O
brain	O
tumors	O
in	O
which	O
tumor	O
growth	O
can	O
often	O
be	O
controlled	O
with	O
10	O
-	O
year	O
survival	O
ranging	O
between	O
64	O
and	O
92	O
%	O
however	O
,	O
ACP	O
'	O
s	O
suprasellar	O
location	O
and	O
propensity	O
for	O
cyst	O
formation	O
[	O
present	O
in	O
~	O
90	O
%	O
]	O
and	O
hypothalamic	O
infiltration	O
predispose	O
many	O
children	O
to	O
a	O
life	O
of	O
severe	O
disability	O
.	O

As	O
such	O
,	O
ACP	O
has	O
been	O
associated	O
with	O
the	O
lowest	O
quality	O
of	O
life	O
scores	O
of	O
any	O
pediatric	O
brain	O
tumor	O
.	O

Therapeutic	O
modalities	O
for	O
children	O
with	O
ACP	O
include	O
maximally	O
-	O
safe	O
surgery	O
,	O
radiation	O
,	O
and	O
cyst	O
-	O
directed	O
therapies	O
,	O
such	O
as	O
interferon	O
and	O
bleomycin	O
.	O

None	O
of	O
these	O
approaches	O
,	O
however	O
,	O
are	O
directed	O
against	O
unique	O
biological	O
characteristics	O
of	O
ACP	O
.	O

Furthermore	O
,	O
after	O
many	O
years	O
of	O
use	O
,	O
each	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
shortcomings	O
regarding	O
clinical	O
efficacy	O
and	O
/	O
or	O
side	O
effects	O
especially	O
when	O
observed	O
within	O
the	O
framework	O
of	O
ACP	O
as	O
a	O
chronic	O
disease	O
.	O

Basic	O
science	O
research	O
in	O
ACP	O
has	O
demonstrated	O
a	O
single	O
recurrent	O
somatic	O
mutation	O
of	O
the	O
CTNNB1	O
gene	O
,	O
which	O
leads	O
to	O
WNT	O
pathway	O
activation	O
.	O

This	O
mutation	O
is	O
,	O
unfortunately	O
,	O
not	O
currently	O
therapeutically	O
targetable	O
and	O
is	O
present	O
in	O
a	O
minority	O
of	O
ACP	O
cells	O
,	O
suggesting	O
additional	O
pathogenic	O
drivers	O
.	O

Work	O
using	O
recently	O
developed	O
genetically	O
engineered	O
mouse	O
models	O
(	O
GEMMs	O
)	O
of	O
ACP	O
indicates	O
that	O
the	O
tumor	O
arises	O
from	O
precursors	O
of	O
the	O
anterior	O
pituitary	O
gland	O
or	O
Rathke	O
'	O
s	O
Pouch	O
hence	O
,	O
ACP	O
may	O
not	O
reside	O
within	O
an	O
immunoprivileged	O
location	O
behind	O
the	O
blood	O
-	O
brain	O
barrier	O
[	O
BBB	O
].	O

Further	O
work	O
suggests	O
that	O
a	O
unique	O
paracrine	O
mechanism	O
drives	O
pathological	O
tumor	O
behavior	O
by	O
cells	O
that	O
lack	O
the	O
CTNNB1	O
mutation	O
.	O

This	O
assertion	O
is	O
supported	O
by	O
work	O
describing	O
both	O
the	O
pediatric	O
ACP	O
transcriptome	O
and	O
inflammatory	O
milieu	O
,	O
which	O
indicates	O
a	O
proinflammatory	O
environment	O
in	O
ACP	O
tissue	O
and	O
cyst	O
fluid	O
.	O

These	O
studies	O
demonstrated	O
highly	O
upregulated	O
levels	O
of	O
IL	O
-	O
6R	O
and	O
IL	O
-	O
6	O
in	O
cyst	O
fluid	O
and	O
solid	O
tumor	O
tissue	O
.	O

While	B
the	O
precise	O
mechanism	O
of	O
paracrine	O
signaling	O
is	O
not	O
yet	O
known	O
,	O
IL	O
-	O
6	O
/	O
IL	O
-	O
6R	O
blockade	O
may	O
hold	O
therapeutic	O
relevance	O
for	O
ACP	O
.	O

Tocilizumab	O
,	O
a	O
humanized	O
monoclonal	O
antibody	O
against	O
soluble	O
and	O
membrane	O
bound	O
IL	O
-	O
6R	O
,	O
is	O
approved	O
by	O
the	O
U	O
.	O
S	O
.	O
Food	O
and	O
Drug	O
Administration	O
for	O
systemic	O
administration	O
in	O
pediatric	O
patients	O
age	O
>	O
2	O
years	O
.	O

Indications	O
include	O
the	O
treatment	O
of	O
systemic	O
juvenile	O
idiopathic	O
arthritis	O
,	O
polyarticular	O
juvenile	O
idiopathic	O
arthritis	O
,	O
and	O
cytokine	O
release	O
syndrome	O
following	O
chimeric	O
cntigen	O
ceceptor	O
(	O
CAR	O
)	O
T	O
-	O
cell	O
therapy	O
for	O
acute	O
lymphoblastic	O
leukemia	O
.	O

There	O
is	O
substantial	O
experience	O
with	O
this	O
well	O
-	O
tolerated	O
medication	O
in	O
the	O
pediatric	O
oncology	O
community	O
.	O

Adverse	O
events	O
associated	O
with	O
tocilizumab	O
are	O
infection	O
,	O
neutropenia	O
,	O
thrombocytopenia	O
,	O
and	O
elevated	O
liver	O
enzymes	O
.	O

This	O
report	O
discusses	O
the	O
management	O
of	O
two	O
patients	O
with	O
cystic	O
ACP	O
who	O
failed	O
first	O
line	O
cystic	O
-	O
directed	O
therapies	O
and	O
were	O
eventually	O
offered	O
systemic	O
administration	O
of	O
the	O
IL	O
-	O
6R	O
antibody	O
,	O
tocilizumab	O
,	O
on	O
a	O
compassionate	O
use	O
basis	O
.	O

Primary	O
patient	O
samples	O
were	O
obtained	O
from	O
Children	O
'	O
s	O
Hospital	O
Colorado	O
and	O
collected	O
in	O
accordance	O
with	O
local	O
and	O
Federal	O
human	O
research	O
protection	O
guidelines	O
and	O
institutional	O
review	O
board	O
regulations	O
.	O

The	O
protocol	O
was	O
approved	O
by	O
the	O
Colorado	O
Multiple	O
Institutional	O
Review	O
Board	O
(	O
COMIRB	O
95â	O
	O
500	O
).	O

Written	O
informed	O
consent	O
was	O
obtained	O
for	O
all	O
specimens	O
and	O
clinical	O
information	O
collected	O
.	O

Case	O
1	O
Presentation	O
A	O
3	O
-	O
year	O
-	O
old	O
male	O
presented	O
to	O
the	O
Emergency	O
Department	O
after	O
hitting	O
his	O
head	O
during	O
a	O
fall	O
from	O
a	O
crib	O
.	O

CT	O
scan	O
revealed	O
a	O
suprasellar	O
mass	O
with	O
extensive	O
cysts	O
extending	O
throughout	O
the	O
right	O
middle	O
and	O
bilateral	O
posterior	O
cranial	O
fossae	O
,	O
as	O
well	O
as	O
to	O
the	O
atrium	O
of	O
the	O
right	O
lateral	O
ventricle	O
.	O

MRI	O
(	O
Figure	O
1A	O
)	O
confirmed	O
the	O
findings	O
,	O
which	O
were	O
most	O
consistent	O
with	O
the	O
diagnosis	O
of	O
craniopharyngioma	O
.	O

MRI	O
-	O
based	O
manual	O
segmentation	O
software	O
Aquarius	O
(	O
iNtuition	O
,	O
TeraRecon	O
,	O
Forest	O
City	O
,	O
CA	O
)	O
was	O
used	O
to	O
measure	O
tumor	O
volumes	O
showing	O
primary	O
cystic	O
disease	O
with	O
minimal	O
solid	O
tumor	O
component	O
(	O
Figure	O
1	O
,	O
graph	O
).	O

The	O
patient	O
'	O
s	O
medical	O
history	O
included	O
premature	O
birth	O
at	O
34	O
weeks	O
.	O

He	O
demonstrated	O
normal	O
growth	O
and	O
development	O
until	O
13	O
months	O
of	O
age	O
when	O
he	O
experienced	O
speech	O
and	O
motor	O
regression	O
.	O

He	O
regained	O
some	O
motor	O
skills	O
prior	O
to	O
his	O
presentation	O
but	O
continued	O
to	O
experience	O
mild	O
to	O
moderate	O
speech	O
delay	O
.	O

Caption	O
(	O
Fig	O
):	O
FIG	O
1	O
Cyst	O
volume	O
(	O
cm3	O
)	O
in	O
response	O
to	O
treatment	O
course	O
for	O
patient	O
1	O
.	O

(	O
A	O
)	O
Diagnostic	O
MRis	O
.	O

(	O
B	O
)	O
Early	O
response	O
to	O
interferon	O
.	O

(	O
C	O
)	O
Response	O
at	O
end	O
of	O
bleomycin	O
.	O

(	O
D	O
)	O
Best	O
response	O
to	O
tocilizumab	O
alone	O
.	O

(	O
E	O
)	O
Best	O
response	O
to	O
tocilizumab	O
and	O
bevacizumab	O
.	O

(	O
F	O
)	O
Six	O
months	O
off	O
all	O
therapy	O
.	O

(	O
G	O
)	O
Most	O
recent	O
scan	O
.	O

(	O
H	O
)	O
Cyst	O
volume	O
(	O
cm3	O
)	O
in	O
response	O
to	O
treatment	O
course	O
.	O

A	O
cyst	O
catheter	O
was	O
placed	O
into	O
the	O
dominant	O
right	O
temporal	O
cyst	O
.	O

Three	O
days	O
after	O
discharge	O
,	O
he	O
developed	O
significant	O
facial	O
and	O
scalp	O
swelling	O
accompanied	O
by	O
vomiting	O
.	O

This	O
swelling	O
was	O
ultimately	O
attributed	O
to	O
cyst	O
fluid	O
tracking	O
along	O
the	O
outside	O
of	O
the	O
catheter	O
and	O
under	O
the	O
Ommaya	O
reservoir	O
into	O
the	O
subcutaneous	O
soft	O
tissues	O
.	O

He	O
was	O
successfully	O
treated	O
with	O
a	O
course	O
of	O
oral	O
dexamethasone	O
.	O

Approximately	O
6	O
weeks	O
following	O
placement	O
,	O
he	O
was	O
treated	O
with	O
intracystic	O
IFN	O
-	O
Î	O
±	O
according	O
to	O
previously	O
utilized	O
protocols	O
.	O

Overall	O
cyst	O
volume	O
initially	O
decreased	O
(	O
Figure	O
1B	O
)	O
however	O
,	O
after	O
4	O
months	O
of	O
therapy	O
,	O
the	O
cystic	O
component	O
began	O
to	O
increase	O
in	O
size	O
.	O

The	O
patient	O
was	O
transitioned	O
to	O
intracystic	O
bleomycin	O
therapy	O
and	O
received	O
3	O
units	O
/	O
10	O
mls	O
three	O
times	O
per	O
week	O
for	O
a	O
total	O
of	O
14	O
doses	O
.	O

Following	O
5	O
weeks	O
of	O
intracystic	O
bleomycin	O
,	O
he	O
presented	O
emergently	O
with	O
new	O
onset	O
left	O
VI	O
and	O
VII	O
cranial	O
nerve	O
palsies	O
.	O

MRI	O
demonstrated	O
new	O
edema	O
involving	O
the	O
left	O
pons	O
,	O
middle	O
cerebellar	O
peduncle	O
,	O
and	O
anterior	O
right	O
cerebellar	O
hemisphere	O
,	O
in	O
continuity	O
with	O
one	O
wall	O
of	O
the	O
cyst	O
receiving	O
bleomycin	O
(	O
Figure	O
1C	O
).	O

Bleomycin	O
therapy	O
was	O
discontinued	O
,	O
and	O
the	O
patient	O
was	O
treated	O
with	O
dexamethasone	O
,	O
resulting	O
in	O
full	O
recovery	O
of	O
CN	O
VI	O
and	O
partial	O
recovery	O
of	O
CN	O
VII	O
function	O
,	O
with	O
residual	O
mild	O
facial	O
asymmetry	O
and	O
weakness	O
.	O

The	O
patient	O
remained	O
off	O
of	O
therapy	O
with	O
routine	O
MRI	O
scanning	O
to	O
monitor	O
for	O
disease	O
progression	O
.	O

During	O
the	O
initial	O
7	O
months	O
,	O
there	O
was	O
radiographic	O
improvement	O
of	O
the	O
cystic	O
portions	O
of	O
his	O
lesion	O
however	O
,	O
imaging	O
at	O
14	O
months	O
off	O
therapy	O
demonstrated	O
progression	O
of	O
his	O
cystic	O
disease	O
(	O
Figure	O
1	O
,	O
graph	O
).	O

Given	O
his	O
young	O
age	O
and	O
the	O
large	O
potential	O
radiation	O
field	O
,	O
the	O
risks	O
of	O
radiation	O
therapy	O
were	O
thought	O
to	O
outweigh	B
the	O
benefit	O
,	O
and	O
he	O
was	O
offered	O
treatment	O
with	O
tociliziumab	O
(	O
12	O
mg	O
/	O
kg	O
IV	O
q2	O
weeks	O
)	O
on	O
a	O
compassionate	O
use	O
basis	O
,	O
which	O
he	O
received	O
for	O
6	O
months	O
and	O
tolerated	O
well	O
.	O

Imaging	O
6	O
months	O
following	O
the	O
start	O
of	O
therapy	O
demonstrated	O
a	O
decrease	O
in	O
volume	O
of	O
some	O
cysts	O
and	O
an	O
apparent	O
slowing	O
of	O
expansion	O
of	O
others	O
(	O
Figure	O
1D	O
).	O

Following	O
an	O
additional	O
3	O
months	O
of	O
therapy	O
,	O
the	O
patient	O
was	O
admitted	O
to	O
the	O
Emergency	O
Department	O
for	O
seizure	O
episodes	O
coincident	O
with	O
the	O
collapse	O
of	O
multiple	O
cysts	O
,	O
although	O
it	O
could	O
not	O
be	O
definitively	O
determined	O
that	O
the	O
seizures	O
were	O
related	O
to	O
the	O
cyst	O
collapse	O
.	O

He	O
underwent	O
a	O
complete	O
workup	O
for	O
evaluation	O
of	O
his	O
seizures	O
and	O
was	O
found	O
to	O
have	O
normal	O
metabolic	O
labs	O
,	O
no	O
evidence	O
of	O
vascular	O
changes	O
,	O
and	O
no	O
residual	O
edema	O
from	O
his	O
previous	O
bleomycin	O
treatment	O
.	O

EEG	O
evidence	O
shows	O
seizures	O
arise	O
in	O
the	O
right	O
temporal	O
region	O
which	O
is	O
associated	O
with	O
significant	O
cystic	O
disease	O
burden	O
and	O
felt	O
to	O
be	O
the	O
underlying	O
cause	O
of	O
his	O
seizures	O
.	O

His	O
seizures	O
were	O
controlled	O
with	O
levetiracetam	O
and	O
he	O
continued	O
treatment	O
with	O
tocilizumab	O
.	O

Following	O
8	O
months	O
of	O
therapy	O
,	O
MRI	O
showed	O
evidence	O
of	O
progression	O
of	O
the	O
cystic	O
component	O
of	O
his	O
ACP	O
(	O
Figure	O
1	O
,	O
graph	O
).	O

The	O
patient	O
experienced	O
increased	O
headaches	O
and	O
required	O
intensified	O
supportive	O
care	O
including	O
narcotic	O
pain	O
medication	O
to	O
support	O
his	O
pain	O
control	O
needs	O
.	O

Treatment	O
options	O
were	O
discussed	O
including	O
surgery	O
and	O
radiation	O
,	O
but	O
both	O
options	O
were	O
deemed	O
to	O
have	O
significant	O
morbidity	O
risks	O
by	O
the	O
family	O
,	O
and	O
they	O
requested	O
an	O
alternative	O
chemotherapy	O
plan	O
.	O

At	O
this	O
time	O
,	O
an	O
attempt	O
to	O
treat	O
his	O
disease	O
with	O
combination	O
bevacizumab	O
and	O
tocilizumab	O
was	O
initiated	O
.	O

Bevacizumab	O
was	O
added	O
as	O
potential	O
additional	O
cyst	O
directed	O
therapy	O
.	O

Systemic	O
IV	O
tocilizumab	O
in	O
combination	O
with	O
IV	O
bevacizumab	O
every	O
2	O
weeks	O
was	O
generally	O
well	O
tolerated	O
.	O

There	O
were	O
three	O
delays	O
in	O
therapy	O
of	O
2	O
weeks	O
for	O
the	O
first	O
two	O
delays	O
and	O
4	O
weeks	O
for	O
the	O
third	O
delay	O
due	O
to	O
neutropenia	O
(	O
CTCAE	O
v5	O
,	O
Grade	O
3	O
).	O

There	O
were	O
no	O
fevers	O
or	O
signs	O
of	O
systemic	O
illness	O
associated	O
with	O
these	O
episodes	O
.	O

In	O
total	O
,	O
he	O
received	O
14	O
months	O
of	O
combination	O
therapy	O
over	O
28	O
months	O
with	O
MRIs	O
showing	O
a	O
significant	O
decrease	O
in	O
cystic	O
disease	O
(	O
Figure	O
1E	O
).	O

Following	O
multiple	O
scans	O
with	O
stable	O
disease	O
,	O
the	O
primary	O
oncologist	O
and	O
family	O
elected	O
for	O
a	O
therapy	O
break	O
with	O
routine	O
tumor	O
surveillance	O
.	O

Three	O
months	O
off	O
of	O
therapy	O
,	O
an	O
MRI	O
showed	O
a	O
minimal	O
increase	O
in	O
some	O
cystic	O
components	O
while	O
the	O
remainder	O
of	O
the	O
solid	O
and	O
cystic	O
components	O
remained	O
unchanged	O
.	O

Six	O
months	O
off	O
therapy	O
the	O
patient	O
was	O
seen	O
in	O
the	O
Emergency	O
Department	O
with	O
seizure	O
activity	O
.	O

At	O
this	O
time	O
,	O
an	O
MRI	O
demonstrated	O
an	O
overall	O
increase	O
in	O
his	O
cystic	O
mass	O
(	O
Figure	O
1F	O
).	O

Bevacizumab	O
and	O
tocilizumab	O
were	O
re	O
-	O
initiated	O
with	O
a	O
significant	O
decrease	O
in	O
cystic	O
disease	O
following	O
4	O
months	O
of	O
therapy	O
.	O

The	O
patient	O
has	O
remained	O
on	O
combination	O
therapy	O
for	O
13	O
months	O
(	O
Figure	O
1G	O
),	O
to	O
date	O
,	O
and	O
his	O
seizures	O
are	O
controlled	O
with	O
levetiracetam	O
.	O

Case	O
2	O
Presentation	O
A	O
7	O
-	O
year	O
-	O
old	O
male	O
presented	O
with	O
a	O
1	O
month	O
-	O
long	O
history	O
of	O
nausea	O
and	O
vomiting	O
.	O

A	O
head	O
CT	O
was	O
performed	O
for	O
concern	O
for	O
increased	O
intracranial	O
pressure	O
and	O
demonstrated	O
a	O
large	O
cystic	O
frontal	O
mass	O
that	O
crossed	O
the	O
midline	O
,	O
with	O
perilesional	O
edema	O
.	O

His	O
past	O
medical	O
history	O
was	O
significant	O
for	O
a	O
diagnosis	O
of	O
â	O
	O
lazy	O
eyeâ	O
	O
1	O
year	O
previously	O
and	O
short	O
stature	O
(	O
later	O
determined	O
to	O
be	O
due	O
to	O
growth	O
hormone	O
deficiency	O
).	O

Family	O
history	O
was	O
unremarkable	O
.	O

MRI	O
brain	O
demonstrated	O
a	O
large	O
cystic	O
sellar	O
/	O
suprasellar	O
mass	O
,	O
most	O
consistent	O
with	O
craniopharyngioma	O
(	O
Figure	O
2A	O
).	O

MRI	O
volume	O
measures	O
as	O
with	O
Case	O
1	O
demonstrated	O
primary	O
cystic	O
disease	O
with	O
minimal	O
solid	O
tumor	O
component	O
(	O
Figure	O
2	O
,	O
graph	O
).	O

Initial	O
surgical	O
management	O
included	O
stereotactic	O
cyst	O
catheter	O
placement	O
with	O
concomitant	O
drainage	O
of	O
~	O
50	O
mL	O
of	O
â	O
	O
machine	O
oilâ	O
-	O
like	O
cyst	O
fluid	O
.	O

His	O
initial	O
post	O
-	O
operative	O
course	O
was	O
uneventful	O
.	O

Caption	O
(	O
Fig	O
):	O
FIG	O
2	O
Cyst	O
volume	O
(	O
cm3	O
)	O
in	O
response	O
to	O
treatment	O
course	O
for	O
patient	O
2	O
.	O

(	O
A	O
)	O
Diagnostic	O
MRis	O
.	O

(	O
B	O
)	O
Scan	O
immediately	O
before	O
ommaya	O
reservoir	O
replacement	O
.	O

(	O
C	O
)	O
Scan	O
immediately	O
stopping	O
bleomycin	O
for	O
right	O
frontal	O
lobe	O
edema	O
.	O

(	O
D	O
)	O
Scan	O
while	O
on	O
Tocilizumab	O
.	O

(	O
E	O
)	O
Patient	O
two	O
cyst	O
volume	O
(	O
cm3	O
)	O
in	O
response	O
to	O
treatment	O
course	O
.	O

The	O
patient	O
returned	O
to	O
the	O
outpatient	O
clinic	O
for	O
weekly	O
cyst	O
aspiration	O
.	O

Three	O
months	O
after	O
catheter	O
placement	O
,	O
MRI	O
demonstrated	O
an	O
increase	O
in	O
cyst	O
size	O
(	O
Figure	O
2B	O
),	O
and	O
repositioning	O
of	O
the	O
catheter	O
was	O
undertaken	O
.	O

Resumption	O
of	O
scheduled	O
cyst	O
aspiration	O
again	O
led	O
to	O
a	O
decrease	O
in	O
the	O
cyst	O
size	O
(	O
Figure	O
2	O
,	O
graph	O
).	O

However	O
,	O
due	O
to	O
the	O
need	O
for	O
continued	O
cyst	O
aspiration	O
,	O
and	O
the	O
position	O
of	O
the	O
tumor	O
,	O
which	O
appeared	O
amenable	O
to	O
gross	O
surgical	O
excision	O
,	O
craniotomy	O
for	O
tumor	O
removal	O
was	O
undertaken	O
.	O

At	O
surgery	O
,	O
the	O
cyst	O
wall	O
was	O
densely	O
adherent	O
to	O
the	O
anterior	O
cerebral	O
vessels	O
,	O
and	O
subtotal	O
resection	O
was	O
achieved	O
.	O

The	O
patient	O
was	O
treated	O
with	O
focal	O
radiation	O
(	O
54	O
Gy	O
in	O
30	O
fractions	O
)	O
but	O
was	O
noted	O
to	O
have	O
rapid	O
cyst	O
recurrence	O
during	O
radiation	O
.	O

Following	O
completion	O
of	O
radiation	O
,	O
a	O
cyst	O
catheter	O
was	O
replaced	O
.	O

The	O
patient	O
was	O
treated	O
with	O
intracystic	O
bleomycin	O
,	O
which	O
resulted	O
in	O
an	O
initial	O
decrease	O
in	O
cyst	O
size	O
.	O

However	O
,	O
after	O
1	O
month	O
,	O
the	O
patient	O
developed	O
new	O
onset	O
lethargy	O
,	O
and	O
imaging	O
demonstrated	O
right	O
frontal	O
lobe	O
edema	O
adjacent	O
to	O
the	O
cyst	O
wall	O
(	O
Figure	O
2C	O
).	O

He	O
was	O
treated	O
with	O
dexamethasone	O
and	O
cessation	O
of	O
bleomycin	O
with	O
resolution	O
of	O
his	O
symptoms	O
.	O

The	O
patient	O
was	O
offered	O
systemic	O
tocilizumab	O
(	O
12	O
mg	O
/	O
kg	O
IV	O
q2	O
weeks	O
)	O
on	O
a	O
compassionate	O
use	O
basis	O
.	O

After	O
6	O
months	O
of	O
therapy	O
,	O
the	O
cyst	O
exhibited	O
a	O
partial	O
response	O
with	O
measurements	O
improved	O
from	O
26	O
Ã	O
	O
28	O
Ã	O
	O
27	O
mm	O
(	O
AP	O
Ã	O
	O
TRV	O
Ã	O
	O
CC	O
)	O
to	O
18	O
Ã	O
	O
24	O
Ã	O
	O
18	O
mm	O
(	O
AP	O
Ã	O
	O
TRV	O
Ã	O
	O
CC	O
)	O
(	O
Figure	O
2D	O
).	O

He	O
has	O
had	O
no	O
significant	O
adverse	O
effects	O
,	O
no	O
new	O
neurologic	O
sequela	O
and	O
no	O
hospitalizations	O
.	O

Therapy	O
was	O
discontinued	O
after	O
seven	O
months	O
,	O
and	O
he	O
continues	O
on	O
an	O
MRI	O
monitoring	O
plan	O
.	O

Discussion	O
Here	O
we	O
report	O
the	O
first	O
use	O
of	O
tocilizumab	O
alone	O
or	O
in	O
combination	O
with	O
bevacizumab	O
for	O
the	O
treatment	O
of	O
cystic	O
ACP	O
in	O
pediatric	O
patients	O
.	O

The	O
biological	O
basis	O
for	O
this	O
was	O
based	O
on	O
recent	O
studies	O
that	O
demonstrated	O
elevated	O
IL	O
-	O
6R	O
levels	O
and	O
IL	O
-	O
6	O
transcript	O
levels	O
in	O
ACP	O
cyst	O
fluid	O
and	O
solid	O
tissue	O
,	O
respectively	O
.	O

The	O
patient	O
in	O
case	O
1	O
had	O
known	O
elevated	O
IL	O
-	O
6	O
in	O
cyst	O
fluid	O
prior	O
to	O
therapy	O
with	O
tocilizumab	O
and	O
level	O
were	O
in	O
line	O
with	O
other	O
samples	O
tested	O
(	O
Figure	O
3	O
).	O

Case	O
2	O
had	O
confirmation	O
of	O
elevated	O
IL	O
-	O
6	O
in	O
pre	O
-	O
therapy	O
cyst	O
fluid	O
after	O
initiation	O
of	O
therapy	O
.	O

In	O
addition	O
,	O
genetically	O
engineered	O
mouse	O
models	O
of	O
ACP	O
induced	O
by	O
mutation	O
in	O
anterior	O
pituitary	O
progenitors	O
faithfully	O
recapitulate	O
many	O
histological	O
and	O
biological	O
characteristics	O
of	O
human	O
ACP	O
implying	O
that	O
the	O
tumor	O
may	O
arise	O
from	O
tissue	O
that	O
lacks	O
blood	O
-	O
brain	O
barrier	O
protection	O
.	O

Thus	O
,	O
systemically	O
administered	O
therapy	O
may	O
achieve	O
sufficient	O
tissue	O
levels	O
at	O
the	O
site	O
of	O
the	O
lesion	O
.	O

In	O
both	O
cases	O
presented	O
,	O
the	O
cystic	O
portion	O
of	O
tumor	O
responded	O
,	O
further	O
supporting	O
the	O
potential	O
relevance	O
of	O
this	O
therapy	O
in	O
children	O
with	O
cystic	O
ACP	O
.	O

Caption	O
(	O
Fig	O
):	O
FIG	O
3	O
IL	O
-	O
6	O
Levels	O
at	O
diagnosis	O
for	O
patient	O
1	O
,	O
patient	O
2	O
,	O
a	O
group	O
of	O
ACP	O
Patients	O
,	O
and	O
a	O
group	O
of	O
pilocytic	O
astrocytoma	O
.	O

The	O
IL	O
-	O
6	O
levels	O
(	O
pg	O
/	O
mL	O
)	O
found	O
in	O
the	O
cystic	O
fluid	O
of	O
patient	O
1	O
and	O
patient	O
2	O
at	O
diagnosis	O
as	O
well	O
as	O
a	O
group	O
of	O
6	O
craniopharyngioma	O
patients	O
and	O
a	O
group	O
of	O
5	O
patients	O
with	O
pilocytic	O
astrocytoma	O
.	O

Current	O
therapies	O
for	O
pediatric	O
ACP	O
can	O
cause	O
significant	O
morbidity	O
,	O
and	O
safer	O
,	O
more	O
effective	O
treatment	O
is	O
needed	O
.	O

Research	O
is	O
expanding	O
these	O
options	O
to	O
include	O
a	O
number	O
of	O
biologic	O
approaches	O
.	O

This	O
includes	O
the	O
potential	O
to	O
target	O
beta	O
-	O
catenin	O
and	O
the	O
use	O
of	O
MEK	O
inhibitors	O
.	O

Here	O
we	O
propose	O
new	O
potential	O
agents	O
,	O
tocilizumab	O
alone	O
or	O
in	O
combination	O
with	O
bevacizumab	O
.	O

Since	O
Patient	O
1	O
progressed	O
on	O
tocilizumab	O
alone	O
,	O
bevacizumab	O
was	O
added	O
as	O
a	O
cyst	O
targeted	O
therapy	O
.	O

Bevacizumab	O
,	O
a	O
monoclonal	O
antibody	O
that	O
binds	O
to	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
resulting	O
in	O
inhibition	O
of	O
new	O
blood	O
vessel	O
formation	O
.	O

No	O
research	O
has	O
been	O
done	O
on	O
the	O
use	O
of	O
bevacizumab	O
in	O
ACP	O
patients	O
,	O
but	O
one	O
small	O
case	O
series	O
reviewed	O
the	O
use	O
of	O
bevacizumab	O
in	O
three	O
patients	O
with	O
pilocytic	O
astrocytoma	O
(	O
PA	O
),	O
another	O
predominantly	O
cystic	O
tumor	O
,	O
and	O
found	O
that	O
all	O
three	O
patients	O
tolerated	O
the	O
therapy	O
well	O
and	O
resulted	O
in	O
a	O
decrease	O
cyst	O
volumes	O
.	O

Bevacizumab	O
has	O
also	O
been	O
shown	O
recently	O
to	O
have	O
clinical	O
and	O
radiographic	O
effects	O
in	O
adult	O
PA	O
patients	O
and	O
has	O
been	O
shown	O
to	O
be	O
a	O
safe	O
and	O
tolerated	O
therapy	O
in	O
pediatric	O
patients	O
with	O
PA	O
and	O
other	O
forms	O
of	O
low	O
-	O
grade	O
glioma	O
.	O

Overall	O
,	O
the	O
patients	O
presented	O
tolerated	O
therapy	O
well	O
without	O
significant	O
side	O
effects	O
or	O
complications	O
other	O
than	O
isolated	O
Grade	O
3	O
neutropenia	O
without	O
associated	O
infections	O
.	O

These	O
two	O
case	O
studies	O
suggest	O
that	O
the	O
combination	O
use	O
of	O
systemically	O
administered	O
tocilizumab	O
and	O
bevacizumab	O
may	O
be	O
effective	O
in	O
pediatric	O
patients	O
with	O
primarily	O
cystic	O
craniopharyngioma	O
.	O

Future	O
evaluation	O
of	O
this	O
combination	O
of	O
this	O
drug	O
is	O
needed	O
to	O
further	O
evaluate	O
the	O
potential	O
of	O
these	O
drugs	O
in	O
the	O
management	O
of	O
ACP	O
.	O

Author	O
Contributions	O
SG	O
did	O
primary	O
case	O
reviews	O
and	O
writing	O
of	O
original	O
draft	O
of	O
manuscript	O
.	O

DM	O
provided	O
MRI	O
analysis	O
and	O
figures	O
.	O

AD	O
and	O
NF	O
provided	O
laboratory	O
data	O
.	O

ND	O
and	O
LH	O
provided	O
patient	O
care	O
and	O
manuscript	O
preparation	O
.	O

TH	O
and	O
JM	O
provided	O
primary	O
patient	O
care	O
,	O
conceptualization	O
,	O
manuscript	O
preparation	O
,	O
and	O
project	O
management	O
.	O

Conflict	O
of	O
Interest	O
Statement	O
The	O
authors	O
declare	O
that	O
the	O
research	O
was	O
conducted	O
in	O
the	O
absence	O
of	O
any	O
commercial	O
or	O
financial	O
relationships	O
that	O
could	O
be	O
construed	O
as	O
a	O
potential	O
conflict	O
of	O
interest	O
.	O

Funding	O
.	O

The	O
Morgan	O
Adams	O
Foundation	O
(	O
SG	O
,	O
NF	O
,	O
LH	O
,	O
TH	O
,	O
and	O
JM	O
).	O

Additional	O
funding	O
to	O
TH	O
by	O
NCI	O
R03	O
CA235200	O
,	O
GN	O
-	O
000522â	O
	O
The	O
Brain	O
Tumor	O
Charity	O
,	O
NCI	O
R03	O
CA212800	O
.	O

The	O
Inflammatory	O
Milieu	O
of	O
Adamantinomatous	O
Craniopharyngioma	O
and	O
Its	O
Implications	O
for	O
Treatment	O
Abstract	O
Pediatric	O
Adamantinomatous	O
Craniopharyngiomas	O
(	O
ACPs	O
)	O
are	O
histologically	O
benign	O
brain	O
tumors	O
that	O
often	O
follow	O
an	O
aggressive	O
clinical	O
course	O
.	O

Their	O
suprasellar	O
location	O
leaves	O
them	O
in	O
close	O
proximity	O
to	O
critical	O
neurological	O
and	O
vascular	O
structures	O
and	O
often	O
results	O
in	O
significant	O
neuroendocrine	O
morbidity	O
.	O

Current	O
treatment	O
paradigms	O
,	O
involving	O
surgical	O
resection	O
and	O
radiotherapy	O
,	O
confer	O
significant	O
morbidity	O
to	O
patients	O
and	O
there	O
is	O
an	O
obvious	O
need	O
to	O
discover	O
effective	O
and	O
safe	O
alternative	O
treatments	O
.	O

Recent	O
years	O
have	O
witnessed	O
significant	O
efforts	O
to	O
fully	O
detail	O
the	O
genomic	O
,	O
transcriptomic	O
and	O
proteomic	O
make	O
-	O
up	O
of	O
these	O
tumors	O
,	O
in	O
an	O
attempt	O
to	O
identify	O
potential	O
therapeutic	O
targets	O
.	O

These	O
studies	O
have	O
resulted	O
in	O
ever	O
mounting	O
evidence	O
that	O
inflammatory	O
processes	O
and	O
the	O
immune	O
response	O
play	O
a	O
critical	O
role	O
in	O
the	O
pathogenesis	O
of	O
both	O
the	O
solid	O
and	O
cystic	O
portion	O
of	O
ACPs	O
.	O

Several	O
inflammatory	O
and	O
immune	O
markers	O
have	O
been	O
identified	O
in	O
both	O
the	O
cyst	O
fluid	O
and	O
solid	O
tumor	O
tissue	O
of	O
ACP	O
.	O

Due	O
to	O
the	O
existence	O
of	O
effective	O
agents	O
that	O
target	O
them	O
,	O
IL	O
-	O
6	O
and	O
immune	O
checkpoint	O
inhibitors	O
seem	O
to	O
present	O
the	O
most	O
likely	O
immediate	O
candidates	O
for	O
clinical	O
trials	O
of	O
targeted	O
immune	O
-	O
related	O
therapy	O
in	O
ACP	O
.	O

If	O
effective	O
,	O
such	O
agents	O
may	O
result	O
in	O
a	O
paradigm	O
shift	B
in	O
treatment	O
that	O
ultimately	O
reduces	O
morbidity	O
and	O
results	O
in	O
better	O
outcomes	O
for	O
our	O
patients	O
.	O

1	O
.	O

Introduction	O
Pediatric	O
Adamantinomatous	O
Craniopharyngiomas	O
(	O
ACPs	O
)	O
are	O
histologically	O
benign	O
brain	O
tumors	O
that	O
often	O
follow	O
an	O
aggressive	O
clinical	O
course	O
.	O

The	O
tumors	O
are	O
most	O
commonly	O
centered	O
in	O
the	O
suprasellar	O
region	O
and	O
are	O
believed	O
to	O
develop	O
from	O
remnants	O
of	O
Rathkeâ	O
	O
s	O
pouch	O
.	O

Radiologically	O
and	O
grossly	O
,	O
these	O
tumors	O
appear	O
as	O
mixed	O
solid	O
and	O
cystic	O
lesions	O
often	O
with	O
areas	O
of	O
calcification	O
(	O
Figure	O
1	O
).	O

Histologically	O
,	O
ACPs	O
are	O
heterogeneous	O
tumors	O
of	O
epithelial	O
origin	O
.	O

The	O
classic	O
features	O
consist	O
of	O
palisading	O
epithelium	O
,	O
stellate	O
cells	O
,	O
nodules	O
of	O
anuclear	O
â	O
	O
ghost	O
cellsâ	O
	O
and	O
â	O
	O
wet	O
keratinâ	O
	O
as	O
well	O
as	O
large	O
areas	O
of	O
regressive	O
changes	O
(	O
i	O
.	O
e	O
.,	O
inflammation	O
and	O
calcifications	O
,	O
multinucleated	O
giant	O
cells	O
,	O
hemosiderin	O
deposits	O
,	O
cholesterol	O
clefts	O
)	O
(	O
Figure	O
2	O
).	O

Their	O
proximity	O
to	O
critical	O
neurological	O
and	O
vascular	O
structures	O
often	O
confers	O
significant	O
neuroendocrine	O
morbidity	O
on	O
patients	O
.	O

Surgery	O
remains	O
the	O
primary	O
treatment	O
strategy	O
,	O
but	O
can	O
result	O
in	O
significant	O
morbidity	O
,	O
specifically	O
damage	O
to	O
the	O
hypothalamus	O
,	O
pituitary	O
and	O
optic	O
apparatus	O
,	O
which	O
results	O
in	O
long	O
-	O
term	O
sequelae	O
that	O
can	O
greatly	O
impact	O
a	O
childâ	O
	O
s	O
quality	O
of	O
life	O
.	O

In	O
an	O
era	O
of	O
personalized	O
medicine	O
and	O
targeted	O
therapies	O
,	O
ACP	O
remains	O
resistant	O
to	O
such	O
advances	O
.	O

On	B
the	I
other	I
hand	I
,	O
recent	O
case	O
reports	O
of	O
the	O
response	O
of	O
papillary	O
craniopharyngioma	O
,	O
a	O
different	O
tumor	O
of	O
the	O
suprasellar	O
region	O
,	O
to	O
BRAF	O
inhibitors	O
have	O
elucidated	O
the	O
great	O
potential	O
of	O
targeted	O
therapies	O
in	O
treating	O
these	O
tumors	O
.	O

As	O
a	O
result	O
,	O
recent	O
years	O
have	O
witnessed	O
significant	O
efforts	O
to	O
fully	O
elucidate	O
the	O
genomic	O
,	O
transcriptomic	O
and	O
proteomic	O
make	O
-	O
up	O
of	O
ACP	O
in	O
an	O
attempt	O
to	O
identify	O
potential	O
therapeutic	O
targets	O
for	O
the	O
treatment	O
of	O
this	O
disease	O
.	O

1	O
.	O
1	O
.	O

The	O
Central	O
Role	O
of	O
WNT	O
Pathway	O
Overactivation	O
in	O
the	O
Tumorigenesis	O
of	O
ACP	O
The	O
one	O
consistent	O
genomic	O
mutation	O
that	O
appears	O
to	O
be	O
present	O
in	O
the	O
majority	O
,	O
if	O
not	O
all	O
,	O
of	O
ACPs	O
is	O
an	O
activation	O
mutation	O
in	O
the	O
CTNNB1	O
gene	O
of	O
the	O
WNT	O
/	O
wingless	O
pathway	O
.	O

Most	O
commonly	O
this	O
involves	O
a	O
point	O
mutation	O
in	O
exon	O
3	O
of	O
the	O
CTNNB1	O
gene	O
.	O

A	O
number	O
of	O
studies	O
have	O
demonstrated	O
various	O
different	B
mutations	O
,	O
most	O
commonly	O
involving	O
serine	O
or	O
threonine	O
phosphorylation	O
sites	O
encoded	O
by	O
exon	O
3	O
.	O

Ordinarily	O
,	O
and	O
in	O
the	O
absence	O
of	O
WNT	O
activation	O
,	O
beta	O
-	O
catenin	O
is	O
marked	O
for	O
destruction	O
by	O
a	O
destruction	O
complex	O
consisting	O
of	O
AXIN	O
,	O
glycogen	O
synthase	O
kinase	O
-	O
3Î²	O
(	O
GSK3Î²	O
),	O
and	O
APC	O
,	O
among	O
other	O
proteins	O
.	O

This	O
complex	O
binds	O
to	O
and	O
phosphorylates	O
specific	O
residues	O
encoded	O
by	O
exon	O
3	O
of	O
CTNNB1	O
and	O
results	O
in	O
degradation	O
of	O
the	O
protein	O
.	O

In	O
the	O
presence	O
of	O
WNT	O
activation	O
,	O
WNT	O
ligands	O
bind	O
to	O
Frizzled	O
and	O
its	O
co	O
-	O
receptor	O
LRP	O
(	O
Low	O
-	O
density	O
lipoprotein	O
receptor	O
-	O
related	O
protein	O
)	O
at	O
the	O
cell	O
membrane	O
.	O

This	O
in	O
turn	O
leads	O
to	O
the	O
activation	O
of	O
Disheveled	O
(	O
DVL	O
)	O
and	O
the	O
binding	O
of	O
AXIN	O
at	O
the	O
cell	O
membrane	O
.	O

Consequently	O
,	O
the	O
normal	O
destruction	O
complex	O
is	O
broken	O
up	O
and	O
beta	O
-	O
catenin	O
is	O
released	O
.	O

Eventually	O
this	O
stabilized	O
beta	O
-	O
catenin	O
will	O
accumulate	O
in	O
first	O
the	O
cytoplasm	O
,	O
and	O
subsequently	O
the	O
nucleus	O
resulting	O
in	O
the	O
expression	O
of	O
WNT	O
pathway	O
target	O
genes	O
.	O

In	O
the	O
pathological	O
state	O
present	O
in	O
ACP	O
,	O
the	O
various	O
point	O
mutations	O
prevent	O
the	O
binding	O
of	O
GSK3Î²	O
to	O
beta	O
-	O
catenin	O
,	O
and	O
the	O
subsequent	O
phosphorylation	O
of	O
the	O
serine	O
and	O
threonine	O
residues	O
.	O

This	O
results	O
in	O
a	O
degradation	O
-	O
resistant	O
form	O
of	O
beta	O
-	O
catenin	O
,	O
resulting	O
in	O
aberrant	O
nuclear	O
accumulation	O
of	O
the	O
protein	O
in	O
certain	O
cells	O
within	O
the	O
tumor	O
.	O

In	O
the	O
nucleus	O
,	O
beta	O
-	O
catenin	O
acts	O
as	O
a	O
transcription	O
factor	O
,	O
leading	O
to	O
overactivation	O
of	O
the	O
WNT	O
/	O
beta	O
-	O
catenin	O
pathway	O
.	O

Although	B
this	O
aberrant	O
overactivation	O
of	O
the	O
WNT	O
pathway	O
is	O
thought	O
to	O
be	O
crucial	O
in	O
the	O
pathogenesis	O
of	O
ACPs	O
,	O
the	O
resulting	O
nuclear	O
accumulation	O
of	O
beta	O
-	O
catenin	O
is	O
only	O
observed	O
in	O
a	O
minority	O
of	O
cells	O
,	O
specifically	O
in	O
whorl	O
like	O
epithelial	O
cell	O
clusters	O
(	O
Figure	O
1D	O
).	O

These	O
cells	O
are	O
thought	O
to	O
be	O
crucial	O
in	O
the	O
tumorigenesis	O
of	O
ACP	O
and	O
various	O
mechanisms	O
have	O
been	O
proposed	O
as	O
to	O
how	O
they	O
may	O
drive	O
tumor	O
growth	O
(	O
Figure	O
2	O
).	O

One	O
such	O
theory	O
involves	O
a	O
paracrine	O
mechanism	O
whereby	O
these	O
cell	O
clusters	O
induce	O
tumor	O
growth	O
by	O
expressing	O
a	O
large	O
array	O
of	O
growth	O
factors	O
,	O
chemokines	O
,	O
and	O
cytokines	O
and	O
act	O
as	O
a	O
kind	O
of	O
signaling	O
center	O
that	O
promotes	O
tumor	O
progression	O
.	O

It	O
has	O
also	O
been	O
hypothesized	O
that	O
the	O
nuclear	O
accumulation	O
of	O
beta	O
-	O
catenin	O
and	O
overactivation	O
of	O
the	O
WNT	O
pathway	O
in	O
these	O
cell	O
clusters	O
might	O
also	O
play	O
a	O
crucial	O
role	O
in	O
the	O
invasion	O
of	O
adjacent	O
structures	O
(	O
e	O
.	O
g	O
.	O

hypothalamus	O
and	O
pituitary	O
)	O
in	O
ACP	O
.	O

Microscopically	O
,	O
a	O
digitate	O
invasion	O
/	O
growth	O
pattern	O
into	O
structures	O
such	O
as	O
the	O
hypothalamus	O
can	O
be	O
seen	O
and	O
is	O
thought	O
to	O
be	O
an	O
important	O
factor	O
in	O
the	O
neuro	O
-	O
endocrine	O
disorders	O
frequently	O
seen	O
in	O
children	O
with	O
ACP	O
.	O

In	O
addition	O
,	O
this	O
invasive	O
nature	O
can	O
preclude	O
the	O
neurosurgeon	O
from	O
obtaining	O
a	O
gross	O
total	O
resection	O
at	O
the	O
time	O
of	O
surgery	O
leading	O
to	O
tumor	O
recurrence	O
and	O
a	O
more	O
aggressive	O
clinical	O
course	O
.	O

HÃ	O
¶	O
lsken	O
et	O
al	O
.	O

noted	O
that	O
beta	O
-	O
catenin	O
accumulating	O
whorls	O
/	O
clusters	O
are	O
found	O
at	O
the	O
tips	O
of	O
these	O
invading	O
projections	O
of	O
tumor	O
and	O
hypothesized	O
that	O
this	O
may	O
suggest	O
a	O
role	O
for	O
these	O
clusters	O
in	O
the	O
promotion	O
of	O
tumor	O
invasion	O
.	O

In	O
addition	O
,	O
Apps	O
et	O
al	O
.	O

used	O
micro	O
-	O
CT	O
to	O
produce	O
3	O
-	O
D	O
models	O
of	O
ACP	O
tumor	O
samples	O
.	O

Using	O
this	O
novel	O
technique	O
,	O
they	O
visualized	O
cell	O
clusters	O
in	O
tumor	O
protrusions	O
into	O
surrounding	O
tissue	O
.	O

In	O
a	O
separate	O
paper	O
,	O
the	O
same	O
group	O
used	O
laser	O
capture	O
microdissection	O
to	O
separate	O
out	O
these	O
cell	O
clusters	O
and	O
analyze	O
their	O
transcriptomic	O
profiles	O
.	O

They	O
found	O
that	O
these	O
cell	O
clusters	O
express	O
high	O
levels	O
of	O
the	O
FGF	O
,	O
BMP	O
and	O
WNT	O
families	O
of	O
secreted	O
factors	O
and	O
were	O
able	O
to	O
demonstrate	O
downstream	O
activation	O
of	O
the	O
MAPK	O
/	O
ERK	O
that	O
was	O
particularly	O
prominent	O
at	O
the	O
tips	O
of	O
the	O
invading	O
tumor	O
epithelium	O
.	O

These	O
facts	O
lend	O
further	O
credence	O
to	O
the	O
theory	O
that	O
these	O
clusters	O
drive	O
tumor	O
invasion	O
in	O
a	O
paracrine	O
manner	O
.	O

HÃ	O
¶	O
lsken	O
et	O
al	O
.	O

cultured	O
a	O
total	O
of	O
6	O
ACP	O
samples	O
and	O
measured	O
their	O
invasion	O
capacity	O
via	O
two	O
methods	O
,	O
namely	O
Boyden	O
chamber	O
assays	O
,	O
and	O
wound	O
-	O
healing	O
assays	O
.	O

They	O
then	O
suppressed	O
beta	O
-	O
catenin	O
expression	O
in	O
the	O
samples	O
by	O
introducing	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
directed	O
against	O
the	O
CTNNB1	O
gene	O
and	O
repeated	O
the	O
assays	O
.	O

They	O
found	O
that	O
after	O
treatment	O
with	O
the	O
siRNA	O
the	O
accumulation	O
of	O
beta	O
-	O
catenin	O
was	O
significantly	O
reduced	O
and	O
resulted	O
in	O
a	O
significant	O
decrease	O
in	O
tumor	O
cell	O
migration	O
and	O
invasion	O
capacity	O
.	O

They	O
also	O
demonstrated	O
that	O
the	O
treatment	O
with	O
siRNA	O
resulted	O
in	O
the	O
reduced	O
expression	O
of	O
the	O
Fascin	O
protein	O
.	O

Fascin	O
is	O
a	O
member	O
of	O
the	O
actin	O
cross	O
-	O
linking	O
family	O
of	O
proteins	O
and	O
plays	O
a	O
crucial	O
role	O
in	O
cell	O
-	O
matrix	O
adhesion	O
,	O
cell	O
migration	O
,	O
and	O
remodeling	O
of	O
the	O
cell	O
cytoskeleton	O
/	O
architecture	O
.	O

In	O
addition	O
,	O
the	O
aberrant	O
overexpression	O
of	O
the	O
Fascin	O
protein	O
has	O
been	O
demonstrated	O
in	O
a	O
number	O
of	O
cancers	O
,	O
including	O
oral	O
squamous	O
cell	O
carcinoma	O
,	O
and	O
prostate	O
cancer	O
.	O

HÃ	O
¶	O
lsken	O
et	O
al	O
.	O

demonstrated	O
that	O
the	O
beta	O
-	O
catenin	O
accumulating	O
cells	O
in	O
ACP	O
also	O
over	O
expressed	O
Fascin	O
.	O

They	O
then	O
showed	O
that	O
treatment	O
with	O
the	O
siRNA	O
lead	O
to	O
a	O
decrease	O
in	O
not	O
only	O
beta	O
-	O
catenin	O
accumulation	O
,	O
but	O
also	O
Fascin	O
levels	O
.	O

They	O
proposed	O
that	O
this	O
increase	O
in	O
Fascin	O
expression	O
may	O
represent	O
the	O
mechanism	O
by	O
which	O
WNT	O
overactivation	O
in	O
these	O
ACP	O
cells	O
may	O
increase	O
tumor	O
cell	O
migration	O
and	O
invasion	O
into	O
adjacent	O
structures	O
.	O

Given	O
the	O
seemingly	O
crucial	O
role	O
of	O
WNT	O
overactivation	O
in	O
ACPs	O
,	O
targeting	O
the	O
WNT	O
pathway	O
would	O
appear	O
to	O
represent	O
an	O
attractive	O
strategy	O
for	O
tackling	O
these	O
tumors	O
.	O

The	O
WNT	O
pathway	O
has	O
been	O
shown	O
to	O
play	O
a	O
crucial	O
role	O
in	O
a	O
number	O
of	O
cancers	O
such	O
as	O
colorectal	O
cancers	O
,	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
,	O
and	O
chronic	O
myeloid	O
leukemia	O
.	O

This	O
has	O
resulted	O
in	O
significant	O
efforts	O
to	O
better	O
understand	O
the	O
pathway	O
and	O
to	O
develop	O
therapies	O
that	O
target	O
it	O
.	O

Despite	B
all	O
these	O
efforts	O
,	O
no	O
drug	O
targeting	O
the	O
WNT	O
pathway	O
has	O
been	O
approved	O
.	O

The	O
reasons	O
for	O
the	O
difficulty	O
in	O
targeting	O
the	O
WNT	O
pathway	O
are	O
legion	O
and	O
complex	O
but	O
one	O
major	O
area	O
of	O
concern	O
is	O
the	O
important	O
role	O
the	O
pathway	O
plays	O
in	O
the	O
maintenance	O
of	O
normal	O
stem	O
cells	O
for	O
tissue	O
regeneration	O
.	O

The	O
potential	O
issues	O
that	O
may	O
arise	O
with	O
WNT	O
pathway	O
targeting	O
was	O
illustrated	O
by	O
Zhong	O
et	O
al	O
.	O

who	O
demonstrated	O
significant	O
intestinal	O
toxicity	O
associated	O
with	O
tankyrase	O
inhibitors	O
in	O
mice	O
.	O

Due	O
to	O
the	O
difficulties	O
that	O
have	O
been	O
encountered	O
in	O
targeting	O
the	O
WNT	O
pathway	O
in	O
more	O
aggressive	O
cancers	O
,	O
it	O
seems	O
likely	O
that	O
such	O
therapies	O
with	O
acceptable	O
efficacy	O
and	O
toxicity	O
will	O
remain	O
elusive	O
for	O
some	O
time	O
to	O
come	O
.	O

It	O
is	O
unlikely	O
such	O
a	O
therapy	O
will	O
become	O
a	O
viable	O
option	O
in	O
the	O
treatment	O
of	O
ACP	O
in	O
the	O
near	O
future	O
and	O
as	O
a	O
result	O
,	O
the	O
need	O
to	O
discover	O
other	O
effective	O
therapies	O
has	O
become	O
imperative	O
.	O

ACP	O
is	O
a	O
very	O
rare	O
disease	O
and	O
developing	O
novel	O
therapies	O
specifically	O
for	O
this	O
tumor	O
type	O
is	O
currently	O
not	O
practical	O
or	O
realistic	O
.	O

As	O
a	O
result	O
,	O
much	O
work	O
has	O
focused	O
on	O
identifying	O
alternative	B
targets	O
with	O
extant	O
treatments	O
,	O
which	O
may	O
offer	O
better	O
results	O
in	O
the	O
treatment	O
of	O
ACP	O
.	O

These	O
efforts	O
have	O
resulted	O
in	O
the	O
identification	O
of	O
multiple	O
molecular	O
pathways	O
involved	O
in	O
the	O
pathogenesis	O
of	O
ACP	O
.	O

A	O
number	O
of	O
these	O
pathways	O
result	O
in	O
the	O
upregulation	O
of	O
pro	O
-	O
inflammatory	O
/	O
immune	O
genes	O
that	O
may	O
be	O
amenable	O
to	O
targeted	O
therapies	O
.	O

The	O
immune	O
/	O
inflammatory	O
cells	O
seen	O
in	O
ACP	O
samples	O
are	O
varied	O
and	O
can	O
include	O
CD4	O
-	O
T	O
-	O
Lymphocytes	O
,	O
CD20	O
-	O
B	O
-	O
Lymphocytes	O
,	O
CD	O
-	O
68	O
-	O
Macrophages	O
,	O
and	O
CD	O
-	O
56	O
-	O
NK	O
cells	O
.	O

The	O
presence	O
of	O
all	O
these	O
cells	O
is	O
not	O
consistent	O
among	O
all	O
ACP	O
samples	O
and	O
this	O
fact	O
is	O
reflective	O
of	O
the	O
histologically	O
heterogeneous	O
nature	O
of	O
these	O
tumors	O
.	O

Work	O
is	O
ongoing	O
to	O
investigate	O
whether	B
these	O
pathways	O
may	O
present	O
potential	O
therapeutic	O
targets	O
and	O
ultimately	O
leads	O
to	O
better	O
outcomes	O
and	O
reduced	O
morbidity	O
for	O
patients	O
.	O

The	O
following	O
is	O
a	O
review	O
of	O
the	O
evidence	O
that	O
highlights	O
the	O
potential	O
importance	O
of	O
the	O
inflammatory	O
/	O
immune	O
response	O
in	O
the	O
generation	O
of	O
these	O
tumors	O
and	O
the	O
potential	O
in	O
targeting	O
these	O
pathways	O
in	O
the	O
treatment	O
of	O
this	O
often	O
-	O
devastating	O
disease	O
.	O

1	O
.	O
2	O
.	O

The	O
role	O
of	O
the	O
Inflammatory	O
Response	O
in	O
Generating	O
the	O
Cystic	O
Compartment	O
in	O
ACP	O
ACPs	O
often	O
have	O
large	O
cystic	O
components	O
that	O
contribute	O
to	O
the	O
adverse	O
clinical	O
outcomes	O
associated	O
with	O
the	O
disease	O
(	O
Figure	O
3	O
).	O

Their	O
large	O
size	O
and	O
at	O
times	O
rapid	O
growth	O
can	O
injure	O
or	O
exert	O
mass	O
effect	O
on	O
critical	O
adjacent	O
structures	O
,	O
such	O
as	O
the	O
pituitary	O
,	O
the	O
hypothalamus	O
,	O
the	O
optic	O
apparatus	O
and	O
third	O
ventricle	O
,	O
which	O
may	O
necessitate	O
urgent	O
surgical	O
intervention	O
to	O
preserve	O
function	O
and	O
prevent	O
morbidity	O
and	O
mortality	O
.	O

As	O
a	O
result	O
,	O
a	O
better	O
understanding	O
of	O
the	O
pathogenesis	O
of	O
ACP	O
cysts	O
and	O
the	O
development	O
of	O
better	O
treatments	O
to	O
limit	O
their	O
growth	O
is	O
clearly	O
desirable	O
.	O

Numerous	O
studies	O
have	O
analyzed	O
the	O
content	O
of	O
these	O
cysts	O
and	O
the	O
results	O
of	O
these	O
studies	O
have	O
demonstrated	O
a	O
significant	O
inflammatory	O
content	O
within	O
them	O
.	O

A	O
summary	O
of	O
some	O
of	O
these	O
papers	O
is	O
presented	O
in	O
Table	O
1	O
.	O

Some	O
of	O
the	O
first	O
work	O
examining	O
the	O
role	O
of	O
inflammation	O
in	O
ACP	O
pathogenesis	O
was	O
carried	O
out	O
by	O
Mori	O
et	O
al	O
.	O

who	O
demonstrated	O
highly	O
elevated	O
levels	O
of	O
IL	O
-	O
6	O
in	O
the	O
cyst	O
fluid	O
of	O
15	O
pediatric	O
ACPs	O
and	O
posited	O
that	O
IL	O
-	O
6	O
plays	O
an	O
important	O
role	O
in	O
the	O
inflammatory	O
reaction	O
associated	O
with	O
ACPs	O
.	O

Another	O
study	O
that	O
demonstrated	O
the	O
role	O
played	O
by	O
the	O
inflammatory	O
response	O
in	O
the	O
generation	O
of	O
the	O
ACP	O
cyst	O
was	O
that	O
by	O
Pettorini	O
et	O
al	O
..	O

Using	O
high	O
-	O
performance	O
liquid	O
chromatography	O
and	O
mass	O
spectrometry	O
to	O
analyze	O
cyst	O
fluid	O
from	O
6	O
patients	O
,	O
they	O
found	O
high	O
levels	O
of	O
alpha	O
defensins	O
1â	O
	O
3	O
,	O
proteins	O
that	O
are	O
present	O
in	O
neutrophils	O
and	O
are	O
involved	O
in	O
the	O
inflammatory	O
-	O
mediated	O
response	O
.	O

Furthermore	O
,	O
their	O
group	O
demonstrated	O
that	O
these	O
levels	O
were	O
significantly	O
reduced	O
after	O
treatment	O
with	O
intracystic	O
interferon	O
alpha	O
(	O
IFN	O
-	O
alpha	O
).	O

They	O
posited	O
that	O
the	O
detection	O
of	O
these	O
proteins	O
suggested	O
that	O
the	O
innate	O
immune	O
response	O
was	O
playing	O
a	O
critical	O
role	O
in	O
cyst	O
generation	O
and	O
that	O
a	O
possible	O
mechanism	O
of	O
action	O
of	O
IFN	O
-	O
alpha	O
in	O
treating	O
the	O
cyst	O
was	O
via	O
an	O
immune	O
-	O
modulatory	O
effect	O
.	O

A	O
later	O
study	O
by	O
the	O
same	O
group	O
performed	O
more	O
extensive	O
proteomic	O
analysis	O
on	O
nineteen	O
patient	O
samples	O
.	O

In	O
this	O
study	O
,	O
they	O
used	O
reverse	O
phase	O
liquid	O
chromatography	O
in	O
conjunction	O
with	O
high	O
resolution	O
ESI	O
-	O
I	O
TQ	O
-	O
Orbitrap	O
mass	O
spectrometry	O
to	O
analyze	O
ACP	O
cyst	O
fluid	O
from	O
nineteen	O
children	O
.	O

In	O
addition	O
to	O
again	O
revealing	O
elevated	O
levels	O
of	O
alpha	O
-	O
defensins	O
(	O
that	O
again	O
were	O
reduced	O
after	O
treatment	O
with	O
IFN	O
-	O
alpha	O
),	O
they	O
also	O
demonstrated	O
elevated	O
levels	O
of	O
several	O
other	O
proteins	O
of	O
inflammation	O
.	O

Specifically	O
,	O
these	O
included	O
alpha2	O
-	O
HS	O
-	O
glycoprotein	O
,	O
alpha1	O
-	O
antichymotrypsin	O
and	O
apolipoproteins	O
.	O

In	O
another	O
study	O
,	O
Donson	O
et	O
al	O
.	O

used	O
cytometric	O
bead	O
analysis	O
to	O
measure	O
the	O
concentration	O
of	O
24	O
cytokines	O
and	O
11	O
chemokines	O
in	O
cyst	O
fluid	O
from	O
five	O
pediatric	O
ACPs	O
and	O
five	O
pediatric	O
pilocytic	O
astrocytomas	O
(	O
PAs	O
).	O

Their	O
analysis	O
demonstrated	O
that	O
six	O
cytokines	O
were	O
present	O
at	O
statistically	O
significant	O
increased	O
levels	O
in	O
ACPs	O
versus	O
PAs	O
.	O

These	O
cytokines	O
included	O
IL	O
-	O
6	O
,	O
IL	O
-	O
10	O
,	O
CXCL8	O
(	O
IL	O
-	O
8	O
),	O
and	O
CXCL1	O
(	O
GRO	O
).	O

Of	O
these	O
,	O
levels	O
of	O
IL	O
-	O
6	O
demonstrated	O
the	O
greatest	O
difference	O
between	O
ACPs	O
and	O
PAs	O
.	O

Apps	O
et	O
al	O
.	O

also	O
demonstrated	O
similar	O
findings	O
when	O
analyzing	O
the	O
protein	O
content	O
of	O
ACP	O
cyst	O
fluid	O
.	O

They	O
analyzed	O
the	O
content	O
of	O
cyst	O
fluid	O
from	O
6	O
patients	O
with	O
ACP	O
using	O
multiplex	O
ELISA	O
(	O
Enzyme	O
-	O
linked	O
immunsorbent	O
assay	O
).	O

They	O
found	O
that	O
the	O
cyst	O
fluid	O
contained	O
several	O
proteins	O
associated	O
with	O
inflammation	O
,	O
such	O
as	O
apolipoproteins	O
,	O
complement	O
system	O
proteins	O
and	O
immunoglobulins	O
.	O

In	O
addition	O
,	O
their	O
analysis	O
revealed	O
the	O
presence	O
of	O
cytokines	O
such	O
as	O
IL	O
-	O
1B	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
,	O
IL	O
-	O
10	O
,	O
IL	O
-	O
18	O
as	O
well	O
as	O
TNF	O
(	O
Tumor	O
necrosis	O
factor	O
)	O
and	O
Interferon	O
gamma	O
.	O

Further	O
evidence	O
for	O
the	O
role	O
of	O
inflammation	O
in	O
the	O
genesis	O
of	O
the	O
cystic	O
component	O
in	O
ACPs	O
is	O
provided	O
by	O
the	O
efficacy	O
of	O
treatment	O
with	O
IFN	O
-	O
alpha	O
.	O

IFN	O
-	O
alpha	O
has	O
been	O
used	O
with	O
varying	O
degrees	O
of	O
success	O
in	O
the	O
treatment	O
of	O
multiple	O
cancers	O
.	O

The	O
mechanism	O
of	O
action	O
in	O
the	O
treatment	O
of	O
neoplasms	O
is	O
complex	O
and	O
multifaceted	O
but	O
likely	O
involves	O
the	O
stimulation	O
of	O
an	O
anti	O
-	O
cancer	O
immune	O
response	O
.	O

The	O
use	O
of	O
intracystic	O
IFN	O
-	O
alpha	O
in	O
the	O
treatment	O
of	O
cystic	O
ACP	O
has	O
been	O
established	O
for	O
several	O
years	O
and	O
numerous	O
studies	O
have	O
demonstrated	O
its	O
safety	O
and	O
efficacy	O
.	O

The	O
treatment	O
involves	O
the	O
surgical	O
placement	O
of	O
a	O
catheter	O
within	O
the	O
cyst	O
with	O
the	O
position	O
of	O
the	O
catheter	O
confirmed	O
radiologically	O
prior	O
to	O
the	O
administration	O
of	O
the	O
drug	O
.	O

This	O
method	O
of	O
treatment	O
has	O
been	O
shown	O
to	O
delay	O
disease	O
progression	O
and	O
can	O
allow	O
the	O
clinical	O
team	O
to	O
delay	O
a	O
more	O
definitive	O
treatment	O
via	O
surgical	O
resection	O
and	O
radiotherapy	O
.	O

Such	O
a	O
delay	O
is	O
often	O
desirable	O
,	O
as	O
it	O
by	O
may	O
allow	O
a	O
childâ	O
	O
s	O
developing	O
brain	O
to	O
mature	O
further	O
prior	O
to	O
undergoing	O
inherently	O
risky	O
surgery	O
and	O
radiation	O
therapy	O
.	O

The	O
mechanism	O
of	O
action	O
of	O
intracystic	O
IFN	O
-	O
alpha	O
in	O
treating	O
ACP	O
has	O
not	O
been	O
confirmed	O
but	O
,	O
as	O
in	O
other	B
cancers	O
,	O
is	O
likely	O
to	O
involve	O
an	O
immunomodulatory	O
effect	O
.	O

Indeed	O
,	O
the	O
previously	O
mentioned	O
proteomic	O
analyses	O
would	O
seem	O
to	O
lend	O
significant	O
weight	O
to	O
this	O
argument	O
.	O

1	O
.	O
3	O
.	O

The	O
Solid	O
Component	O
of	O
ACP	O
Also	O
Demonstrates	O
Elevated	O
Levels	O
of	O
Several	O
Inflammatory	O
Markers	O
Multiple	O
studies	O
have	O
also	O
identified	O
high	O
levels	O
of	O
cytokines	O
and	O
inflammatory	O
markers	O
in	O
the	O
solid	O
component	O
of	O
ACPs	O
,	O
lending	O
further	O
support	O
to	O
the	O
theory	O
that	O
inflammation	O
plays	O
a	O
critical	O
role	O
in	O
pathogenesis	O
.	O

Gump	O
et	O
al	O
.	O

used	O
micro	O
-	O
array	O
data	O
to	O
demonstrate	O
elevated	O
levels	O
of	O
IL	O
-	O
6R	O
in	O
ACP	O
relative	O
to	O
other	O
pediatric	O
brain	O
tumors	O
.	O

Subsequently	O
,	O
Donson	O
et	O
al	O
.,	O
utilized	O
detailed	O
transcriptomic	O
analysis	O
to	O
demonstrate	O
increased	O
expression	O
of	O
pro	O
-	O
inflammatory	O
mediators	O
in	O
ACP	O
solid	O
tumor	O
tissue	O
including	O
IL	O
-	O
6	O
,	O
CXCL1	O
,	O
CLCL8	O
,	O
CXCR2	O
,	O
IL	O
-	O
10	O
and	O
IDO	O
-	O
1	O
.	O

Separate	O
work	O
by	O
Martelli	O
et	O
al	O
.	O

used	O
advanced	O
proteomics	O
to	O
investigate	O
the	O
protein	O
signature	O
in	O
ACP	O
.	O

In	O
addition	O
to	O
identifying	O
beta	O
-	O
catenin	O
and	O
its	O
related	O
proteins	O
in	O
solid	O
tumor	O
tissue	O
from	O
seven	O
patients	O
,	O
their	O
analysis	O
also	O
identified	O
the	O
presence	O
of	O
increased	O
levels	O
of	O
alpha	O
-	O
defensins	O
1â	O
	O
4	O
.	O

As	O
previously	O
stated	O
,	O
these	O
proteins	O
are	O
neutrophil	O
-	O
derived	O
proteins	O
that	O
play	O
an	O
important	O
role	O
in	O
the	O
innate	O
immune	O
response	O
and	O
in	O
inflammation	O
.	O

Their	O
detection	O
in	O
the	O
solid	O
portion	O
of	O
ACP	O
again	O
seems	O
to	O
confirm	O
that	O
the	O
inflammatory	O
response	O
plays	O
an	O
important	O
role	O
in	O
ACP	O
tumorigenesis	O
.	O

A	O
recent	O
paper	O
by	O
Apps	O
et	O
al	O
.	O

used	O
transcriptome	O
analysis	O
of	O
tumor	O
tissue	O
from	O
18	O
patients	O
to	O
identify	O
a	O
pattern	O
of	O
elevated	O
expression	O
of	O
several	O
immune	O
cell	O
markers	O
and	O
immune	O
system	O
genes	O
in	O
ACP	O
.	O

Furthermore	O
,	O
their	O
analysis	O
used	O
immunohistochemistry	O
to	O
reveal	O
the	O
presence	O
of	O
both	O
myeloid	O
-	O
derived	O
and	O
lymphoid	O
-	O
derived	O
cells	O
infiltrating	O
both	O
the	O
reactive	O
glial	O
and	O
tumor	O
epithelial	O
compartments	O
in	O
the	O
ACP	O
samples	O
.	O

They	O
also	O
found	O
that	O
multiple	O
cytokine	O
encoding	O
genes	O
were	O
highly	O
upregulated	O
in	O
ACP	O
and	O
that	O
the	O
expression	O
of	O
such	O
genes	O
correlated	O
with	O
the	O
immune	O
infiltrate	O
and	O
inflammatory	O
cell	O
markers	O
.	O

This	O
would	O
suggest	O
that	O
this	O
upregulated	O
cytokine	O
expression	O
is	O
mostly	O
derived	O
from	O
the	O
infiltrating	O
immune	O
cells	O
rather	B
than	O
from	O
the	O
tumor	O
cells	O
that	O
are	O
over	O
expressing	O
beta	O
-	O
catenin	O
.	O

Finally	O
,	O
they	O
also	O
utilized	O
multiplex	O
ELISA	O
to	O
analyze	O
protein	O
lysates	O
from	O
eight	O
patient	O
ACP	O
samples	O
and	O
this	O
analysis	O
revealed	O
the	O
expression	O
of	O
IL	O
-	O
1B	O
,	O
Il	O
-	O
6	O
,	O
IL	O
-	O
8	O
,	O
IL	O
-	O
10	O
,	O
IL	O
-	O
18	O
,	O
and	O
TNF	O
-	O
alpha	O
in	O
all	O
the	O
samples	O
.	O

1	O
.	O
4	O
.	O

Immune	O
Checkpoint	O
Inhibitors	O
and	O
Their	O
Potential	O
Use	O
in	O
ACP	O
Immune	O
checkpoint	O
inhibitors	O
have	O
shown	O
promise	O
in	O
the	O
treatment	O
of	O
a	O
number	O
of	O
cancers	O
.	O

Specifically	O
,	O
inhibition	O
of	O
the	O
programmed	O
cell	O
death	O
protein	O
(	O
PD1	O
)	O
and	O
its	O
ligand	O
(	O
PD	O
-	O
L1	O
)	O
with	O
the	O
agents	O
,	O
nivolumab	O
and	O
pembrolizumab	O
,	O
has	O
resulted	O
in	O
improved	O
survival	O
in	O
cancers	O
including	O
melanoma	O
and	O
non	O
-	O
small	O
cell	O
lung	O
adenocarcinoma	O
.	O

The	O
availability	O
of	O
these	O
agents	O
and	O
their	O
relatively	O
favorable	O
side	O
effect	O
profile	O
has	O
resulted	O
in	O
numerous	O
studies	O
investigating	O
their	O
efficacy	O
in	O
various	O
cancers	O
/	O
tumor	O
types	O
.	O

PD	O
-	O
1	O
is	O
an	O
important	O
protein	O
involved	O
in	O
inhibitory	O
immune	O
signaling	O
and	O
is	O
an	O
essential	O
regulator	O
of	O
the	O
adaptive	O
immune	O
response	O
.	O

In	O
cancers	O
,	O
PD	O
-	O
1	O
-	O
expressing	O
tumor	O
-	O
infiltrating	O
T	O
cells	O
can	O
be	O
disabled	O
by	O
PD	O
-	O
L1	O
expressed	O
on	O
the	O
surfaces	O
of	O
tumor	O
cells	O
themselves	O
or	O
alternatively	O
by	O
PD	O
-	O
L1	O
on	O
the	O
surface	O
of	O
other	O
infiltrating	O
immune	O
cells	O
.	O

The	O
binding	O
of	O
PD	O
-	O
1	O
to	O
its	O
ligand	O
results	O
in	O
the	O
suppression	O
of	O
the	O
immune	O
response	O
to	O
the	O
cancer	O
cells	O
.	O

Checkpoint	O
Inhibitors	O
reverse	O
this	O
process	O
and	O
allow	O
T	O
cells	O
to	O
once	O
again	O
attack	O
the	O
cancer	O
.	O

Predicting	O
the	O
response	O
of	O
a	O
particular	O
tumor	O
or	O
cancer	O
to	O
PD1	O
inhibitors	O
such	O
as	O
nivolumab	O
and	O
pembrolizumab	O
is	O
difficult	O
and	O
Taube	O
et	O
al	O
.	O

aimed	O
to	O
identify	O
those	O
factors	O
that	O
best	O
predicted	O
a	O
robust	O
and	O
meaningful	O
response	O
to	O
therapy	O
.	O

In	O
a	O
prior	O
study	O
by	O
the	O
same	O
group	O
they	O
found	O
that	O
anti	O
-	O
PD	O
-	O
1	O
therapy	O
produced	O
an	O
objective	O
response	O
in	O
20â	O
	O
25	O
%	O
of	O
patients	O
with	O
treatment	O
-	O
resistant	O
NSCLC	O
,	O
renal	O
cell	O
carcinoma	O
and	O
melanoma	O
and	O
that	O
PD	O
-	O
L1	O
expression	O
by	O
tumor	O
cells	O
seemed	O
to	O
be	O
associated	O
with	O
a	O
response	O
to	O
therapy	O
.	O

In	O
their	O
follow	O
up	O
study	O
they	O
aimed	O
to	O
further	O
investigate	O
various	O
factors	O
that	O
might	O
predict	O
a	O
response	O
to	O
anti	O
-	O
PD	O
-	O
1	O
therapy	O
including	O
PD	O
-	O
L1	O
expression	O
by	O
tumor	O
cells	O
,	O
PD	O
-	O
L1	O
expression	O
by	O
infiltrating	O
immune	O
cells	O
,	O
PD	O
-	O
L2	O
expression	O
by	O
tumor	O
cells	O
and	O
other	O
tumor	O
microenvironment	O
factors	O
.	O

They	O
found	O
that	O
in	O
their	O
cohort	O
only	O
the	O
expression	O
of	O
PD	O
-	O
L1	O
by	O
tumor	O
cells	O
correlated	O
with	O
both	O
an	O
objective	O
response	O
(	O
as	O
defined	O
by	O
the	O
â	O
	O
Response	O
evaluation	O
criteria	O
in	O
Solid	O
Tumorsâ	O
	O
or	O
RECIST	O
criteria	O
)	O
and	O
clinical	O
benefit	O
(	O
p	O
=	O
0	O
.	O
025	O
and	O
0	O
.	O
005	O
respectively	O
).	O

The	O
correlation	O
of	O
the	O
expression	O
of	O
PD	O
-	O
L1	O
by	O
infiltrating	O
immune	O
cells	O
with	O
a	O
clinical	O
response	O
did	O
not	O
reach	O
statistical	O
significance	O
although	O
the	O
correlation	O
with	O
clinical	O
benefit	O
was	O
statistically	O
significant	O
(	O
p	O
=	O
0	O
.	O
038	O
).	O

Of	O
note	O
,	O
expression	O
of	O
the	O
PD	O
-	O
1	O
receptor	O
on	O
tumor	O
infiltrating	O
lymphocytes	O
(	O
TILs	O
),	O
expression	O
of	O
PD	O
-	O
L2	O
by	O
tumor	O
cells	O
or	O
TILs	O
,	O
and	O
other	O
microenvironment	O
immune	O
factors	O
did	O
not	O
correlate	O
with	O
outcomes	O
.	O

In	O
addition	O
,	O
it	O
is	O
important	O
to	O
reiterate	O
that	O
even	O
in	O
those	O
tumors	O
expressing	O
PD	O
-	O
L1	O
on	O
tumor	O
cells	O
,	O
only	O
39	O
%	O
of	O
patients	O
(	O
9	O
out	O
of	O
23	O
)	O
had	O
an	O
objective	O
response	O
.	O

That	O
being	O
said	O
,	O
these	O
therapies	O
have	O
provided	O
an	O
option	O
for	O
patients	O
with	O
aggressive	O
and	O
treatment	O
-	O
resistant	O
cancers	O
for	O
whom	O
previously	O
there	O
were	O
few	O
if	O
any	O
good	O
options	O
.	O

Due	O
to	O
the	O
efficacy	O
of	O
immune	O
checkpoint	O
inhibitors	O
more	O
and	O
more	O
work	O
is	O
being	O
undertaken	O
to	O
identify	O
other	O
cancers	O
and	O
tumors	O
that	O
may	O
be	O
amenable	O
to	O
such	O
therapy	O
including	O
craniopharyngiomas	O
.	O

Recent	O
work	O
by	O
Coy	O
et	O
al	O
.	O

demonstrated	O
the	O
expression	O
of	O
PD	O
-	O
L1	O
in	O
epithelial	O
cells	O
lining	O
the	O
cysts	O
and	O
intrinsic	O
PD	O
-	O
1	O
expression	O
in	O
the	O
beta	O
-	O
catenin	O
over	O
expressing	O
whorl	O
-	O
like	O
epithelial	O
cell	O
clusters	O
in	O
ACP	O
.	O

As	O
previously	O
discussed	O
,	O
these	O
clusters	O
are	O
thought	O
to	O
play	O
a	O
pivotal	O
role	O
in	O
tumor	O
growth	O
in	O
ACP	O
via	O
a	O
number	O
of	O
mechanisms	O
,	O
rendering	O
targeting	O
of	O
PD	O
-	O
1	O
as	O
an	O
attractive	O
potential	O
therapy	O
.	O

Another	O
study	O
by	O
Witt	O
et	O
al	O
.	O

also	O
demonstrated	O
elevated	O
PD	O
-	O
L1	O
expression	O
in	O
ACP	O
.	O

As	O
mentioned	O
above	O
,	O
numerous	O
previous	O
studies	O
on	O
other	B
solid	O
cancers	O
have	O
demonstrated	O
that	O
the	O
expression	O
of	O
PD	O
-	O
L1	O
can	O
be	O
predictive	O
of	O
the	O
response	O
to	O
the	O
PD	O
-	O
1	O
/	O
PD	O
-	O
L1	O
inhibitors	O
.	O

Again	O
,	O
as	O
previously	O
mentioned	O
,	O
such	O
a	O
finding	O
far	O
from	O
guarantees	O
a	O
response	O
and	O
in	O
these	O
landmark	O
papers	O
they	O
found	O
that	O
even	O
in	O
patients	O
that	O
expressed	O
PD	O
-	O
L1	O
on	O
tumor	O
cells	O
,	O
the	O
response	O
rate	O
to	O
the	O
treatment	O
was	O
only	O
39	O
%.	O

In	O
addition	O
,	O
Witt	O
et	O
al	O
.	O

nicely	O
demonstrated	O
,	O
using	O
T	O
cell	O
exhaustion	O
testing	O
of	O
various	O
types	O
of	O
ependymomas	O
,	O
that	O
elevated	O
PD	O
-	O
L1	O
expression	O
in	O
tumors	O
can	O
be	O
indicative	O
of	O
either	B
tumor	O
adaptations	O
to	O
hide	O
from	O
the	O
innate	O
immune	O
response	O
or	O
due	O
to	O
normal	O
T	O
-	O
cell	O
antigen	O
-	O
activation	O
,	O
a	O
known	O
function	O
of	O
PD	O
-	O
1	O
.	O

In	O
their	O
study	O
they	O
utilized	O
functional	O
T	O
cell	O
exhaustion	O
assays	O
that	O
stimulate	O
T	O
cells	O
via	O
exposure	O
to	O
Phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)/	O
ionomycin	O
.	O

Subsequent	O
to	O
stimulations	O
their	O
group	O
used	O
a	O
Milliplex	O
Map	O
Kit	O
(	O
Millipore	O
)	O
to	O
measure	O
the	O
concentration	O
of	O
several	O
cytokines	O
including	O
IFN	O
-	O
gamma	O
.	O

They	O
found	O
that	O
infiltrating	O
T	O
-	O
cells	O
in	O
RELA	O
fusion	O
supratentorial	O
ependymoma	O
did	O
not	O
secrete	O
IFN	O
-	O
gamma	O
.	O

They	O
concluded	O
that	O
this	O
suggested	O
that	O
in	O
the	O
case	O
of	O
RELA	O
fusion	O
ependymoma	O
,	O
the	O
increased	O
expression	O
of	O
PD	O
-	O
1	O
/	O
PD	O
-	O
L1	O
results	O
in	O
the	O
exhaustion	O
of	O
infiltrating	O
T	O
-	O
cells	O
and	O
immune	O
evasion	O
by	O
the	O
tumor	O
.	O

On	O
the	O
contrary	B
,	O
they	O
found	O
that	O
in	O
group	O
B	O
ependymomas	O
(	O
which	O
also	O
express	O
high	O
levels	O
of	O
PD	O
-	O
1	O
),	O
infiltrating	O
T	O
-	O
cells	O
were	O
,	O
in	O
fact	O
,	O
capable	O
of	O
secreting	O
IFN	O
-	O
gamma	O
after	O
stimulation	O
with	O
PMA	O
/	O
ionomycin	O
.	O

They	O
posited	O
that	O
in	O
these	O
tumors	O
,	O
elevated	O
expression	O
of	O
PD	O
-	O
1	O
was	O
representative	O
of	O
normal	O
T	O
-	O
cell	O
activation	O
in	O
response	O
to	O
the	O
tumor	O
.	O

As	O
such	O
,	O
although	O
the	O
findings	O
by	O
Coy	O
et	O
al	O
.	O

of	O
elevated	O
PD	O
-	O
1	O
/	O
PD	O
-	O
L1	O
expression	O
in	O
ACP	O
are	O
exciting	O
and	O
may	O
result	O
in	O
an	O
alternative	B
treatment	O
strategy	O
in	O
resistant	O
and	O
multiply	O
recurrent	O
cases	O
,	O
further	O
investigation	O
is	O
necessary	O
to	O
fully	O
elucidate	O
the	O
implications	O
of	O
this	O
increased	O
PD	O
-	O
1	O
/	O
PD	O
-	O
L1	O
expression	O
in	O
ACP	O
before	O
any	O
widespread	O
implementation	O
.	O

1	O
.	O
5	O
.	O

CTLA	O
-	O
4	O
Inhibition	O
and	O
Its	O
Potential	O
Use	O
in	O
the	O
Treatment	O
of	O
ACP	O
The	O
other	B
major	O
group	O
of	O
immune	O
checkpoint	O
inhibitors	O
that	O
have	O
become	O
increasingly	O
utilized	O
in	O
cancer	O
are	O
the	O
CTLA	O
-	O
4	O
inhibitors	O
of	O
which	O
ipilimumab	O
is	O
the	O
classic	O
example	O
.	O

One	O
of	O
the	O
first	O
major	O
studies	O
to	O
demonstrate	O
the	O
efficacy	O
of	O
these	O
agents	O
was	O
that	O
by	O
Hodi	O
et	O
al	O
.	O

in	O
2010	O
.	O

In	O
their	O
study	O
they	O
randomized	O
676	O
patients	O
with	O
stage	O
3	O
or	O
4	O
treatment	O
-	O
resistant	O
melanoma	O
to	O
treatment	O
with	O
ipilimumab	O
plus	O
glycoprotein	O
100	O
(	O
gp100	O
)	O
or	O
gp100	O
alone	O
.	O

They	O
demonstrated	O
a	O
statistically	O
significant	O
,	O
although	O
modest	O
benefit	O
,	O
in	O
terms	O
of	O
survival	O
for	O
patients	O
in	O
the	O
ipilimumab	O
group	O
.	O

Subsequent	O
work	O
by	O
Ji	O
et	O
al	O
.	O

aimed	O
to	O
elucidate	O
what	O
specific	O
factors	O
might	O
be	O
predictive	O
of	O
response	O
to	O
treatment	O
with	O
CTLA	O
-	O
4	O
blockade	O
.	O

This	O
group	O
utilized	O
gene	O
expression	O
profiling	O
to	O
demonstrate	O
that	O
in	O
pre	O
-	O
treatment	O
samples	O
of	O
patients	O
with	O
metastatic	O
melanoma	O
a	O
higher	O
baseline	O
expression	O
of	O
immune	O
related	O
genes	O
was	O
predictive	O
of	O
an	O
increased	O
response	O
to	O
treatment	O
with	O
ipilimumab	O
.	O

Specifically	O
,	O
they	O
analyzed	O
the	O
gene	O
expression	O
in	O
tumor	O
samples	O
from	O
45	O
patients	O
with	O
melanoma	O
both	O
before	O
,	O
and	O
three	O
weeks	O
after	O
treatment	O
with	O
ipilimumab	O
.	O

They	O
found	O
that	O
tumors	O
that	O
had	O
increased	O
expression	O
of	O
immune	O
related	O
genes	O
pre	O
-	O
treatment	O
,	O
were	O
more	O
likely	O
to	O
respond	O
to	O
the	O
therapy	O
.	O

Indeed	O
,	O
when	O
they	O
clustered	O
genes	O
based	O
on	O
biological	O
functions	O
and	O
examined	O
the	O
differential	O
expression	O
of	O
these	O
groups	O
of	O
genes	O
between	O
responders	O
and	O
non	O
-	O
responders	O
,	O
they	O
demonstrated	O
that	O
genes	O
related	O
to	O
the	O
inflammatory	O
response	O
were	O
those	O
that	O
were	O
most	O
differentially	O
expressed	O
between	O
the	O
two	O
groups	O
.	O

This	O
led	O
their	O
group	O
to	O
conclude	O
that	O
a	O
â	O
	O
pre	O
-	O
existing	O
immune	O
-	O
active	O
tumor	O
microenvironment	O
might	O
favor	O
clinical	O
response	O
to	O
ipilimumabâ	O
.	O

As	O
previously	O
stated	O
,	O
ACPs	O
have	O
been	O
shown	O
to	O
harbor	O
a	O
significant	O
inflammatory	O
/	O
immune	O
component	O
in	O
both	O
the	O
solid	O
and	O
cystic	O
component	O
and	O
there	O
is	O
mounting	O
evidence	O
that	O
this	O
pro	O
-	O
inflammatory	O
environment	O
plays	O
an	O
active	O
role	O
in	O
tumorigenesis	O
.	O

A	O
2017	O
study	O
by	O
Donson	O
et	O
al	O
.	O

utilized	O
various	O
methods	O
to	O
demonstrate	O
upregulation	O
of	O
several	O
pro	O
-	O
inflammatory	O
genes	O
in	O
both	O
the	O
solid	O
and	O
cystic	O
component	O
of	O
these	O
tumors	O
.	O

This	O
begs	O
the	O
question	O
,	O
could	O
the	O
use	O
of	O
a	O
CTLA	O
-	O
4	O
inhibitor	O
such	O
as	O
ipilimumab	O
lead	O
to	O
improved	O
outcomes	O
in	O
ACP	O
?	O

Furthermore	O
,	O
recent	O
trials	O
have	O
demonstrated	O
that	O
combining	O
different	B
types	O
of	O
immune	O
checkpoint	O
inhibitors	O
can	O
lead	O
to	O
a	O
survival	O
advantage	O
for	O
patients	O
with	O
treatment	O
refractory	O
cancers	O
.	O

Specifically	O
,	O
combining	O
ant	O
-	O
PD1	O
and	O
anti	O
-	O
CTLA	O
-	O
4	O
therapy	O
can	O
result	O
in	O
improved	O
survival	O
in	O
treatment	O
-	O
resistant	O
metastatic	O
melanoma	O
,	O
renal	O
cell	O
carcinoma	O
and	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
.	O

Given	O
the	O
expression	O
of	O
PD	O
-	O
L1	O
and	O
the	O
significant	O
immune	O
cell	O
and	O
inflammatory	O
milieu	O
present	O
in	O
ACP	O
,	O
the	O
use	O
of	O
such	O
combinations	O
in	O
the	O
treatment	O
of	O
this	O
disease	O
would	O
appear	O
promising	O
.	O

As	O
a	O
result	O
,	O
a	O
lot	O
of	O
work	O
remains	O
to	O
be	O
done	O
to	O
fully	O
elucidate	O
the	O
potential	O
of	O
such	O
treatments	O
in	O
ACP	O
.	O

Given	O
the	O
often	O
-	O
aggressive	O
clinical	O
course	O
,	O
and	O
devastating	O
effects	O
this	O
disease	O
can	O
have	O
on	O
patientâ	O
	O
s	O
quality	O
of	O
life	O
such	O
potential	O
is	O
surely	O
worth	O
investigating	O
.	O

1	O
.	O
6	O
.	O

The	O
Role	O
of	O
Senescence	O
and	O
the	O
Senescence	O
Associated	O
Secretory	O
Phenotype	O
(	O
SASP	O
)	O
in	O
the	O
Pathogenesis	O
of	O
ACP	O
In	O
the	O
normal	O
physiological	O
state	O
,	O
cellular	O
senescence	O
develops	O
in	O
response	O
to	O
both	O
extracellular	O
and	O
intracellular	O
stressors	O
and	O
pushes	O
the	O
cell	O
into	O
cell	O
cycle	O
arrest	O
.	O

This	O
prevents	O
propagation	O
of	O
the	O
damaged	O
cell	O
and	O
,	O
when	O
this	O
occurs	O
in	O
the	O
context	O
of	O
cancer	O
,	O
can	O
ultimately	O
result	O
in	O
tumor	O
suppression	O
.	O

Paradoxically	B
,	O
senescent	O
cells	O
can	O
go	O
on	O
to	O
develop	O
secretory	O
functions	O
that	O
result	O
in	O
changes	O
to	O
the	O
cellular	O
microenvironment	O
and	O
may	O
ultimately	O
promote	O
tumor	O
growth	O
.	O

Senescent	O
cells	O
can	O
persist	O
in	O
a	O
metabolically	O
active	O
state	O
,	O
ultimately	O
developing	O
what	O
is	O
termed	O
the	O
Senescence	O
Associated	O
Secretory	O
Phenotype	O
(	O
SASP	O
).	O

In	O
such	O
a	O
state	O
,	O
cells	O
can	O
secrete	O
a	O
variety	O
of	O
interleukins	O
,	O
inflammatory	O
cytokines	O
,	O
growth	O
factors	O
,	O
and	O
proteases	O
,	O
which	O
can	O
affect	O
the	O
surrounding	O
cells	O
and	O
tumor	O
microenvironment	O
.	O

SASP	O
factors	O
include	O
pro	O
-	O
inflammatory	O
mediators	O
such	O
as	O
IL	O
-	O
6	O
,	O
IL	O
-	O
1	O
,	O
certain	O
Matrix	O
Metalloproteinases	O
,	O
and	O
various	O
chemokines	O
.	O

Of	O
these	O
,	O
Rodier	O
et	O
al	O
.	O

found	O
that	O
IL	O
-	O
6	O
was	O
the	O
most	O
important	O
in	O
allowing	O
senescent	O
cells	O
to	O
promote	O
cell	O
invasion	O
.	O

Gonzalez	O
-	O
Meljem	O
et	O
al	O
.	O

demonstrated	O
that	O
the	O
SASP	O
plays	O
a	O
prominent	O
role	O
in	O
both	O
genetically	O
engineered	O
mouse	O
models	O
of	O
ACP	O
and	O
human	O
ACP	O
.	O

They	O
used	O
gene	O
set	O
enrichment	O
analysis	O
(	O
GSEA	O
)	O
to	O
demonstrate	O
that	O
beta	O
-	O
catenin	O
accumulating	O
cluster	O
cells	O
in	O
the	O
mouse	O
models	O
of	O
ACP	O
had	O
gene	O
expression	O
profiles	O
that	O
were	O
significantly	O
enriched	O
for	O
SASP	O
genes	O
.	O

Similarly	O
,	O
they	O
utilized	O
ELISA	O
cytokine	O
arrays	O
to	O
demonstrate	O
that	O
multiple	O
SASP	O
associated	O
proteins	O
such	O
as	O
IL	O
-	O
6	O
,	O
IL	O
-	O
1a	O
,	O
MMP2	O
,	O
MMP3	O
,	O
CXCL1	O
,	O
and	O
CXCL11	O
were	O
all	O
upregulated	O
in	O
the	O
murine	O
cluster	O
cells	O
.	O

In	O
addition	O
,	O
other	B
studies	O
,	O
such	O
as	O
those	O
by	O
Gump	O
et	O
al	O
.,	O
and	O
Apps	O
et	O
al	O
.,	O
used	O
various	O
techniques	O
to	O
demonstrate	O
the	O
overexpression	O
of	O
several	O
of	O
these	O
proteins	O
in	O
human	O
ACP	O
.	O

Meljem	O
et	O
al	O
.	O

then	O
used	O
laser	O
-	O
capture	O
microdissection	O
and	O
RNA	O
sequencing	O
to	O
analyze	O
the	O
molecular	O
signature	O
of	O
the	O
beta	O
-	O
catenin	O
accumulating	O
cell	O
clusters	O
in	O
human	O
ACP	O
.	O

They	O
performed	O
hierarchical	O
clustering	O
analysis	O
that	O
demonstrated	O
similar	O
molecular	O
profiles	O
between	O
the	O
cluster	O
cells	O
from	O
the	O
mouse	O
models	O
and	O
those	O
from	O
human	O
ACP	O
.	O

Subsequent	O
GSEA	O
of	O
human	O
clusters	O
also	O
demonstrated	O
a	O
strong	O
SASP	O
signature	O
.	O

They	O
thus	O
concluded	O
that	O
the	O
human	O
and	O
mouse	O
clusters	O
represent	O
equivalent	O
structures	O
and	O
share	O
a	O
common	O
senescent	O
molecular	O
signature	O
.	O

Given	O
the	O
critical	O
role	O
that	O
these	O
cell	O
clusters	O
are	O
thought	O
to	O
play	O
in	O
ACP	O
tumorigenesis	O
,	O
they	O
posited	O
that	O
the	O
SASP	O
may	O
play	O
a	O
critical	O
role	O
in	O
the	O
pathogenesis	O
of	O
ACP	O
.	O

This	O
paper	O
aimed	O
to	O
demonstrate	O
the	O
critical	O
role	O
played	O
by	O
inflammation	O
in	O
the	O
pathogenesis	O
of	O
ACP	O
.	O

Given	O
that	O
human	O
ACPs	O
seem	O
to	O
harbor	O
a	O
very	O
strong	O
SASP	O
signature	O
and	O
the	O
SASP	O
induces	O
a	O
strong	O
pro	O
-	O
inflammatory	O
state	O
,	O
it	O
is	O
very	O
possible	O
that	O
the	O
SASP	O
plays	O
a	O
critical	O
role	O
in	O
producing	O
the	O
pro	O
-	O
inflammatory	O
milieu	O
and	O
invasive	O
nature	O
of	O
ACP	O
.	O

Trials	O
examining	O
the	O
use	O
of	O
senolytic	O
drugs	O
are	O
currently	O
in	O
their	O
incipient	O
stages	O
and	O
it	O
is	O
possible	O
that	O
such	O
therapies	O
may	O
provide	O
an	O
attractive	O
treatment	O
strategy	O
for	O
ACP	O
in	O
the	O
future	O
.	O

2	O
.	O

Conclusions	O
A	O
significant	O
and	O
growing	O
body	O
of	O
evidence	O
points	O
to	O
a	O
critical	O
role	O
in	O
the	O
activation	O
of	O
inflammation	O
and	O
the	O
immune	O
response	O
in	O
the	O
pathogenesis	O
of	O
ACP	O
.	O

Multiple	O
studies	O
have	O
demonstrated	O
high	O
levels	O
of	O
inflammatory	O
markers	O
and	O
cytokines	O
in	O
both	O
ACP	O
cyst	O
fluid	O
and	O
solid	O
tumor	O
.	O

Many	O
of	O
these	O
employed	O
advanced	O
genomic	O
,	O
proteomic	O
and	O
transcriptomic	O
techniques	O
to	O
demonstrate	O
expression	O
of	O
multiple	O
genes	O
involved	O
in	O
the	O
inflammatory	O
and	O
immune	O
response	O
in	O
these	O
tumors	O
.	O

A	O
number	O
of	O
these	O
markers	O
represent	O
attractive	O
potential	O
targets	O
for	O
directed	O
therapy	O
in	O
the	O
treatment	O
of	O
ACP	O
.	O

Specifically	O
,	O
due	O
to	O
existing	O
experience	O
combined	O
with	O
proven	O
efficacy	O
in	O
other	O
cancers	O
and	O
diseases	O
,	O
IL	O
-	O
6	O
and	O
the	O
immune	O
checkpoint	O
inhibitors	O
(	O
anti	O
-	O
PD	O
-	O
1	O
/	O
PD	O
-	O
L1	O
and	O
anti	O
-	O
CTLA	O
-	O
4	O
)	O
may	O
represent	O
particularly	O
good	O
targets	O
/	O
therapies	O
.	O

Similarly	O
,	O
combinations	O
of	O
such	O
agents	O
have	O
proven	O
very	O
effective	O
in	O
prolonging	O
survival	O
in	O
malignant	O
cancer	O
such	O
as	O
melanoma	O
,	O
renal	O
cell	O
carcinoma	O
and	O
non	O
-	O
small	O
-	O
cell	O
lung	O
cancer	O
that	O
were	O
failing	O
more	O
traditional	O
treatment	O
.	O

Such	O
combination	O
therapy	O
may	O
also	O
present	O
a	O
potential	O
therapeutic	O
strategy	O
in	O
the	O
management	O
of	O
recurrent	O
and	O
treatment	O
-	O
resistant	O
ACP	O
.	O

In	O
addition	O
,	O
these	O
agents	O
might	O
also	O
be	O
combined	O
with	O
agents	O
that	O
do	O
not	O
specifically	O
interact	O
with	O
inflammatory	O
/	O
immune	O
processes	O
(	O
e	O
.	O
g	O
.,	O
MEK	O
inhibition	O
).	O

In	O
fact	O
,	O
Apps	O
et	O
al	O
.	O

demonstrated	O
that	O
MAPK	O
/	O
ERK	O
pathway	O
likely	O
plays	O
a	O
pivotal	O
role	O
in	O
the	O
pathogenesis	O
of	O
both	O
murine	O
and	O
human	O
ACP	O
.	O

In	O
addition	O
,	O
they	O
showed	O
that	O
treating	O
human	O
ACP	O
with	O
trametinib	O
ex	O
vivo	O
resulted	O
in	O
decreased	O
proliferation	O
and	O
increased	O
apoptosis	O
.	O

Finally	O
,	O
recent	O
work	O
has	O
also	O
demonstrated	O
the	O
pivotal	O
role	O
played	O
by	O
senescence	O
and	O
the	O
SASP	O
in	O
the	O
pathogenesis	O
of	O
these	O
tumors	O
.	O

It	O
is	O
possible	O
that	O
the	O
strong	O
SASP	O
signature	O
drives	O
much	O
of	O
the	O
inflammation	O
seen	O
in	O
ACP	O
,	O
and	O
that	O
targeting	O
SASP	O
associated	O
pathways	O
may	O
provide	O
an	O
effective	O
treatment	O
strategy	O
in	O
the	O
future	O
.	O

Due	O
to	O
the	O
benign	O
histological	O
nature	O
of	O
the	O
disease	O
,	O
it	O
is	O
likely	O
that	O
initial	O
clinical	O
trials	O
of	O
such	O
agents	O
will	O
be	O
reserved	O
for	O
patients	O
with	O
recurrent	O
or	O
progressive	O
disease	O
.	O

In	O
addition	O
,	O
due	O
to	O
the	O
rarity	O
of	O
the	O
disease	O
and	O
the	O
scarcity	O
of	O
tumor	O
tissue	O
it	O
is	O
vital	O
that	O
pediatric	O
centers	O
continue	O
to	O
work	O
together	O
to	O
share	O
knowledge	O
and	O
tissue	O
in	O
an	O
effort	O
to	O
accelerate	O
the	O
development	O
of	O
safe	O
and	O
efficacious	O
treatments	O
.	O

Such	O
efforts	O
will	O
hopefully	O
result	O
in	O
improved	O
outcomes	O
for	O
children	O
suffering	O
from	O
this	O
chronic	O
and	O
often	O
devastating	O
disease	O
.	O

Finally	O
,	O
other	B
advanced	O
techniques	O
are	O
being	O
developed	O
that	O
continue	O
to	O
enhance	O
our	O
ability	O
to	O
better	O
diagnose	O
,	O
and	O
identify	O
biomarkers	O
in	O
oncologic	O
diseases	O
that	O
may	O
result	O
in	O
the	O
development	O
of	O
better	O
therapeutics	O
.	O

It	O
is	O
possible	O
that	O
such	O
techniques	O
if	B
applied	O
to	O
ACPs	O
could	O
result	O
in	O
significant	O
advances	O
in	O
the	O
diagnosis	O
and	O
treatment	O
of	O
ACP	O
in	O
the	O
future	O
.	O

Author	O
Contributions	O
R	O
.	O
W	O
.	O

as	O
the	O
first	O
author	O
was	O
primarily	O
responsible	O
for	O
drafting	O
the	O
article	O
manuscript	O
.	O

E	O
.	O
P	O
.	O

also	O
helped	O
draft	O
the	O
manuscript	O
and	O
helped	O
with	O
editing	O
the	O
final	O
submission	O
.	O

A	O
.	O
G	O
.	O
provided	O
the	O
pathology	O
figures	O
and	O
the	O
descriptions	O
of	O
the	O
same	O
.	O

T	O
.	O
H	O
.	O

acted	O
as	O
the	O
lead	O
author	O
and	O
guided	O
the	O
direction	O
of	O
the	O
manuscript	O
as	O
well	O
as	O
being	O
the	O
primary	O
editor	O
of	O
the	O
final	O
submission	O
.	O

All	O
authors	O
have	O
read	O
and	O
agreed	O
to	O
the	O
published	O
version	O
of	O
the	O
manuscript	O
.	O

Funding	O
No	O
external	O
funding	O
was	O
received	O
for	O
the	O
production	O
of	O
this	O
research	O
.	O

Conflicts	O
of	O
Interest	O
The	O
authors	O
declare	O
no	O
conflict	O
of	O
interest	O
.	O

Caption	O
(	O
Fig	O
):	O
FIG	O
1	O
Classic	O
histopathological	O
findings	O
in	O
adamantinomatous	O
craniopharyngioma	O
:	O
(	O
A	O
)	O
H	O
&	O
E	O
stained	O
sections	O
showing	O
an	O
epithelial	O
tumor	O
with	O
palisading	O
cells	O
with	O
aggregates	O
of	O
â	O
	O
wetâ	O
	O
keratin	O
;	O
(	O
B	O
)	O
higher	O
magnification	O
view	O
demonstrating	O
keratinized	O
â	O
	O
ghost	O
cellsâ	O
;	O
(	O
C	O
)	O
Higher	O
magnification	O
view	O
demonstrating	O
calcifications	O
and	O
stellate	O
reticulum	O
;	O
(	O
D	O
)	O
Immunohistochemical	O
staining	O
for	O
Beta	O
-	O
catenin	O
that	O
is	O
nuclear	O
positive	O
in	O
a	O
subset	O
of	O
tumor	O
cells	O
.	O

(	O
E	O
)	O
The	O
surrounding	O
brain	O
parenchyma	O
shows	O
extensive	O
gliosis	O
with	O
Rosenthal	O
fibers	O
.	O

Caption	O
(	O
Fig	O
):	O
FIG	O
2	O
Computed	O
Tomography	O
(	O
Left	O
)	O
andMagnetic	O
resonance	O
Imaging	O
(	O
Right	O
)	O
images	O
from	O
the	O
same	O
patient	O
of	O
a	O
classic	O
example	O
of	O
an	O
adamantinomatous	O
craniopharyngioma	O
.	O

This	O
typical	O
tumor	O
is	O
centered	O
in	O
the	O
suprasellar	O
region	O
with	O
mixed	O
solid	O
and	O
cystic	O
areas	O
as	O
well	O
as	O
areas	O
of	O
calcification	O
as	O
seen	O
on	O
the	O
CT	O
.	O
Caption	O
(	O
Fig	O
):	O
FIG	O
3	O
Example	O
of	O
an	O
adamantinomatous	O
craniopharyngioma	O
with	O
a	O
massive	O
cystic	O
component	O
.	O

Caption	O
(	O
TABLE	O
-	O
WRAP	O
):	O
TABLE	O
1	O
Key	O
studies	O
that	O
have	O
demonstrated	O
the	O
key	O
role	O
of	O
the	O
inflammatory	O
/	O
immune	O
response	O
in	O
the	O
pathogenesis	O
of	O
adamantinomatous	O
craniopharyngioma	O
.	O

Study	O
Summary	O
of	O
Study	O
Findings	O
Kilday	O
et	O
al	O
.	O

2017	O
Multinational	O
study	O
assessing	O
the	O
efficacy	O
of	O
intra	O
-	O
cystic	O
IFN	O
-	O
alpha	O
in	O
treating	O
ACP	O
Demonstrated	O
a	O
progression	O
free	O
survival	O
advantage	O
for	O
intracystic	O
IFN	O
-	O
alpha	O
Pettorini	O
et	O
al	O
.	O

2010	O
Identified	O
the	O
presence	O
of	O
alpha	O
-	O
defensins	O
1â	O
	O
3	O
in	O
ACP	O
cyst	O
fluid	O
Demonstrated	O
the	O
importance	O
of	O
inflammation	O
the	O
genesis	O
of	O
ACP	O
cysts	O
Gump	O
et	O
al	O
.	O

2015	O
Used	O
mRNA	O
microarray	O
analysis	O
to	O
identify	O
the	O
overexpression	O
of	O
multiple	O
inflammatory	O
markers	O
in	O
ACP	O
relative	O
to	O
other	O
tumors	O
Identifies	O
IL6R	O
and	O
IL2RB	O
to	O
be	O
overexpressed	O
in	O
ACP	O
relative	O
to	O
normal	O
brain	O
and	O
other	O
tumors	O
Donson	O
et	O
al	O
.	O

2017	O
Identified	O
elevated	O
levels	O
of	O
severeal	O
inflammatory	O
markers	O
in	O
both	O
ACP	O
cyst	O
fluid	O
and	O
solid	O
tumor	O
Overexpressed	O
inflammatory	O
markers	O
identified	O
included	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
,	O
CXCL1	O
,	O
and	O
IL	O
-	O
10	O
Apps	O
et	O
al	O
.	O

2018	O
Used	O
various	O
methods	O
including	O
RNA	O
sequencing	O
to	O
identify	O
activation	O
of	O
the	O
inflammasome	O
in	O
ACP	O
cyst	O
fluid	O
and	O
solid	O
tumor	O
Imflamatory	O
genes	O
that	O
were	O
overexpressed	O
included	O
IL	O
-	O
1B	O
,	O
IL	O
-	O
18	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
,	O
IL	O
-	O
10	O
Coy	O
et	O
al	O
.	O

2018	O
demonstrated	O
the	O
expression	O
of	O
PD	O
-	O
L1	O
in	O
epithelial	O
cells	O
lining	O
the	O
cysts	O
and	O
intrinsic	O
PD	O
-	O
1	O
expression	O
in	O
the	O
beta	O
-	O
catenin	O
over	O
expressing	O
whorl	O
-	O
like	O
epithelial	O
cell	O
clusters	O
in	O
ACP	O
The	O
first	O
paper	O
to	O
demonstrate	O
that	O
immune	O
checkpoint	O
inhibitors	O
may	O
play	O
a	O
role	O
in	O
ACP	O
treatments	O

Transcriptional	O
analyses	O
of	O
adult	O
and	O
pediatric	O
adamantinomatous	O
craniopharyngioma	O
reveals	O
similar	O
expression	O
signatures	O
regarding	O
potential	O
therapeutic	O
targets	O
Abstract	O
Adamantinomatous	O
craniopharyngioma	O
(	O
ACP	O
)	O
is	O
a	O
biologically	O
benign	O
but	O
clinically	O
aggressive	O
lesion	O
that	O
has	O
a	O
significant	O
impact	O
on	O
quality	O
of	O
life	O
.	O

The	O
incidence	O
of	O
the	O
disease	O
has	O
a	O
bimodal	O
distribution	O
,	O
with	O
peaks	O
occurring	O
in	O
children	O
and	O
older	O
adults	O
.	O

Our	O
group	O
previously	O
published	O
the	O
results	O
of	O
a	O
transcriptome	O
analysis	O
of	O
pediatric	O
ACPs	O
that	O
identified	O
several	O
genes	O
that	O
were	O
consistently	O
overexpressed	O
relative	O
to	O
other	O
pediatric	O
brain	O
tumors	O
and	O
normal	O
tissue	O
.	O

We	O
now	O
present	O
the	O
results	O
of	O
a	O
transcriptome	O
analysis	O
comparing	O
pediatric	O
to	O
adult	O
ACP	O
to	O
identify	O
biological	O
differences	O
between	O
these	O
groups	O
that	O
may	O
provide	O
novel	O
therapeutic	O
insights	O
or	O
support	O
the	O
assertion	O
that	O
potential	O
therapies	O
identified	O
through	O
the	O
study	O
of	O
pediatric	O
ACP	O
may	O
also	O
have	O
a	O
role	O
in	O
adult	O
ACP	O
.	O

Using	O
our	O
compiled	O
transcriptome	O
dataset	O
of	O
27	O
pediatric	O
and	O
9	O
adult	O
ACPs	O
,	O
obtained	O
through	O
the	O
Advancing	O
Treatment	O
for	O
Pediatric	O
Craniopharyngioma	O
Consortium	O
,	O
we	O
interrogated	O
potential	O
age	O
-	O
related	O
transcriptional	O
differences	O
using	O
several	O
rigorous	O
mathematical	O
analyses	O
.	O

These	O
included	O
:	O
canonical	O
differential	O
expression	O
analysis	O
;	O
divisive	O
,	O
agglomerative	O
,	O
and	O
probabilistic	O
based	O
hierarchical	O
clustering	O
;	O
information	O
theory	O
based	O
characterizations	O
;	O
and	O
the	O
deep	O
learning	O
approach	O
,	O
HD	O
Spot	O
.	O

Our	O
work	O
indicates	O
that	O
there	O
is	O
no	O
therapeutically	O
relevant	O
difference	O
in	O
ACP	O
gene	O
expression	O
based	O
on	O
age	O
.	O

As	O
such	O
,	O
potential	O
therapeutic	O
targets	O
identified	O
in	O
pediatric	O
ACP	O
are	O
also	O
likely	O
to	O
have	O
relvance	O
for	O
adult	O
patients	O
.	O

Introduction	O
Adamantinomatous	O
craniopharyngioma	O
(	O
ACP	O
)	O
is	O
a	O
histologically	O
benign	O
brain	O
tumor	O
that	O
arises	O
in	O
the	O
sellar	O
/	O
suprasellar	O
region	O
.	O

Despite	O
being	O
a	O
WHO	O
grade	O
I	O
lesion	O
,	O
ACP	O
often	O
follows	O
a	O
clinically	O
aggressive	O
course	O
and	O
has	O
been	O
associated	O
with	O
the	O
worst	O
quality	O
of	O
life	O
outcomes	O
of	O
any	O
pediatric	O
brain	O
tumor	O
.	O

Unlike	B
its	O
histological	O
counterpart	O
,	O
Papillary	O
Craniopharyngioma	O
(	O
PCP	O
),	O
ACP	O
is	O
characterized	O
by	O
bimodal	O
incidence	O
,	O
with	O
spikes	O
during	O
childhood	O
and	O
adulthood	O
.	O

Also	O
unlike	B
PCP	O
,	O
for	O
which	O
promising	O
therapies	O
targeting	O
the	O
BRAFv600e	O
mutation	O
are	O
in	O
clinical	O
trials	O
,	O
ACP	O
is	O
known	O
to	O
harbor	O
only	O
a	O
mutation	O
in	O
the	O
CTNNB1	O
gene	O
,	O
leading	O
to	O
a	O
failure	O
of	O
normal	O
Î²	O
-	O
Catenin	O
degradation	O
,	O
with	O
resultant	O
cytoplasmic	O
and	O
nuclear	O
accumulation	O
in	O
a	O
subset	O
of	O
cells	O
,	O
where	O
it	O
can	O
act	O
as	O
a	O
transcription	O
factor	O
that	O
may	O
promote	O
ACP	O
pathogenesis	O
.	O

Unfortunately	O
,	O
this	O
understanding	O
has	O
not	O
yet	O
led	O
to	O
the	O
introduction	O
of	O
effective	O
targeted	O
therapies	O
against	O
ACP	O
.	O

As	O
such	O
,	O
current	O
therapies	O
consist	O
primarily	O
of	O
surgery	O
,	O
radiation	O
and	O
intracystic	O
treatments	O
.	O

While	B
downstream	O
effects	O
of	O
the	O
CTNNB1	O
mutation	O
appear	O
to	O
be	O
the	O
most	O
likely	O
driver	O
mutation	O
in	O
ACP	O
,	O
it	O
is	O
likely	O
that	O
tumorigenesis	O
is	O
multifactorial	O
.	O

Recent	O
studies	O
of	O
the	O
human	O
ACP	O
transcriptome	O
,	O
using	O
both	O
microarray	O
and	O
RNA	O
sequencing	O
,	O
have	O
identified	O
potential	O
novel	O
therapeutic	O
targets	O
.	O

However	B
,	O
this	O
work	O
has	O
focused	O
exclusively	O
on	O
pediatric	O
tumors	O
,	O
leaving	O
open	O
the	O
question	O
of	O
whether	B
these	O
potential	O
therapies	O
could	O
be	O
relevant	O
in	O
adult	O
patients	O
,	O
who	O
represent	O
approximately	O
69	O
%	O
of	O
all	O
patients	O
with	O
ACP	O
.	O

This	O
work	O
sought	O
to	O
investigate	O
,	O
using	O
bulk	O
RNA	O
sequencing	O
of	O
adult	O
and	O
pediatric	O
ACP	O
,	O
whether	B
there	O
is	O
evidence	O
that	O
patients	O
with	O
ACP	O
from	O
different	B
age	O
cohorts	O
could	O
be	O
expected	O
to	O
respond	O
to	O
the	O
same	O
targeted	O
therapeutic	O
strategies	O
.	O

In	O
order	O
to	O
identify	O
even	O
subtle	O
differences	O
in	O
the	O
transcriptome	O
profile	O
of	O
the	O
2	O
tissue	O
populations	O
,	O
we	O
conducted	O
a	O
highly	O
rigorous	O
mathematical	O
analysis	O
that	O
considered	O
the	O
potential	O
for	O
both	O
linear	O
and	O
non	O
-	O
linear	O
age	O
group	O
-	O
related	O
dependencies	O
within	O
the	O
data	O
.	O

Materials	O
and	O
methods	O
Tumor	O
samples	O
A	O
total	O
of	O
36	O
craniopharyngioma	O
tumor	O
samples	O
,	O
as	O
diagnosed	O
by	O
surgical	O
pathology	O
,	O
were	O
included	O
in	O
this	O
study	O
(	O
Table	O
S1	O
).	O

Twenty	O
-	O
seven	O
were	O
acquired	O
during	O
surgery	O
for	O
pediatric	O
patients	O
(	O
age	O
at	O
surgery	O
<	O
â	O
	O
18â	O
	O
years	O
;	O
meanâ	O
=	O
â	O
	O
8	O
.	O
4â	O
	O
years	O
,	O
medianâ	O
=	O
â	O
	O
8	O
.	O
0â	O
	O
years	O
),	O
and	O
9	O
from	O
adults	O
(	O
age	O
at	O
surgery	O
â	O
¥	O
18â	O
	O
years	O
;	O
meanâ	O
=	O
â	O
	O
47	O
.	O
9â	O
	O
years	O
,	O
medianâ	O
=	O
â	O
	O
44	O
.	O
0â	O
	O
years	O
).	O

The	O
pediatric	O
specimens	O
were	O
obtained	O
from	O
patients	O
who	O
underwent	O
surgery	O
at	O
member	O
institutions	O
of	O
the	O
Advancing	O
Treatment	O
for	O
Pediatric	O
Craniopharyngioma	O
(	O
ATPC	O
)	O
consortium	O
.	O

Adult	O
specimens	O
were	O
obtained	O
from	O
University	O
of	O
Colorado	O
Hospital	O
and	O
from	O
the	O
University	O
of	O
Alabama	O
,	O
Birmingham	O
.	O

Tumor	O
samples	O
were	O
snap	O
-	O
frozen	O
in	O
liquid	O
nitrogen	O
in	O
the	O
operating	O
room	O
and	O
subsequently	O
stored	O
in	O
freezers	O
at	O
â	O
	O
â	O
	O
80â	O
	O
Â	O
°	O
C	O
.	O

For	O
transport	O
between	O
institutions	O
,	O
samples	O
were	O
packaged	O
on	O
dry	O
ice	O
,	O
shipped	O
via	O
overnight	O
courier	O
,	O
and	O
immediately	O
placed	O
in	O
a	O
freezer	O
at	O
â	O
	O
â	O
	O
80â	O
	O
Â	O
°	O
C	O
.	O

RNA	O
extraction	O
and	O
sequencing	O
RNA	O
was	O
extracted	O
from	O
snap	O
-	O
frozen	O
samples	O
using	O
the	O
Allprep	O
DNA	O
/	O
RNA	O
Kit	O
(	O
QIAGENÂ	O
®,	O
Maryland	O
,	O
USA	O
).	O

The	O
quality	O
of	O
the	O
isolated	O
mRNA	O
was	O
determined	O
via	O
DNA	O
analysis	O
ScreenTape	O
(	O
Aligent	O
Technologies	O
).	O

Samples	O
that	O
passed	O
quality	O
control	O
were	O
used	O
to	O
generate	O
cDNA	O
libraries	O
using	O
the	O
Illumina	O
TruSeq	O
Stranded	O
mRNA	O
Sample	O
Prep	O
Kit	O
.	O

RNA	O
sequencing	O
was	O
carried	O
out	O
using	O
the	O
Illumina	O
HiSeq4000	O
platform	O
with	O
paired	O
-	O
end	O
reads	O
(	O
2â	O
	O
Ã	O
	O
â	O
	O
151	O
).	O

On	O
average	O
,	O
40	O
million	O
reads	O
were	O
collected	O
for	O
each	O
sample	O
and	O
outputted	O
to	O
FASTQ	O
files	O
.	O

Sequencing	O
reads	O
were	O
subjected	O
to	O
adapter	O
-	O
trimming	O
and	O
quality	O
control	O
using	O
the	O
Trimmomatic	O
package	O
.	O

Files	O
were	O
mapped	O
to	O
the	O
GRCh38	O
genome	O
(	O
v33	O
)	O
and	O
subsequently	O
sorted	O
to	O
yield	O
BAM	O
files	O
using	O
the	O
standard	O
STAR	O
pipeline	O
.	O

BAM	O
files	O
were	O
converted	O
to	O
feature	O
counts	O
using	O
the	O
R	O
Bioconductor	O
package	O
RSubread	O
.	O

Normal	O
pituitary	O
RNA	O
sequencing	O
data	O
was	O
obtained	O
from	O
the	O
GTEx	O
portal	O
(	O
www	O
.	O
gtexportal	O
.	O
org	O
).	O

Analysis	O
methodology	O
Due	O
to	O
the	O
possibility	O
that	O
adult	O
and	O
pediatric	O
transcription	O
patterns	O
would	O
be	O
distinguished	O
by	O
only	O
subtle	O
expression	O
differences	O
,	O
we	O
chose	O
a	O
multimodal	O
bioinformatic	O
approach	O
.	O

This	O
was	O
designed	O
to	O
assess	O
for	O
both	O
linear	O
and	O
non	O
-	O
linear	O
relationships	O
,	O
but	O
also	O
to	O
insulate	O
the	O
statistical	O
analysis	O
from	O
potentially	O
false	O
assumptions	O
.	O

Canonical	O
differential	O
expression	O
analysis	O
Feature	O
counts	O
for	O
transcriptomes	O
of	O
adult	O
and	O
pediatric	O
ACP	O
samples	O
were	O
analytically	O
processed	O
using	O
a	O
standard	O
DESeq2	O
protocol	O
.	O

As	O
the	O
experiment	O
intended	O
to	O
rule	O
out	O
differences	O
in	O
gene	O
expression	O
between	O
the	O
2	O
age	O
groups	O
,	O
an	O
Independent	O
Hypothesis	O
Weighted	O
(	O
IHW	O
)	O
p	O
-	O
value	O
threshold	O
of	O
0	O
.	O
1	O
was	O
utilized	O
to	O
filter	O
transcripts	O
identified	O
as	O
differentially	O
expressed	O
.	O

Results	O
were	O
visualized	O
using	O
a	O
Mass	O
Action	O
(	O
MA	O
)	O
plot	O
and	O
a	O
Euclidean	O
Distance	O
Matrix	O
was	O
employed	O
to	O
serve	O
as	O
a	O
qualitative	O
foundation	O
from	O
which	O
to	O
make	O
statistical	O
methodology	O
arguments	O
downstream	O
.	O

Caption	O
(	O
Fig	O
):	O
FIG	O
1	O
Global	O
Transcriptional	O
Profiling	O
of	O
Adult	O
and	O
Pediatric	O
ACP	O
Samples	O
.	O

a	O
MA	O
-	O
plot	O
visualizing	O
transcripts	O
indicating	O
significant	O
(	O
Independent	O
Hypothesis	O
Weighting	O
(	O
IHW	O
)	O
adjusted	O
p	O
-	O
value	O
<	O
â	O
	O
0	O
.	O
1	O
;	O
red	O
)	O
and	O
insignificant	O
genes	O
(	O
black	O
)	O
as	O
determined	O
in	O
differential	O
expression	O
analysis	O
;	O
transcripts	O
enriched	O
relative	O
to	O
pediatric	O
patients	O
are	O
log	O
fold	O
change	O
(	O
LFC	O
)	O
up	O
(>	O
â	O
	O
0	O
)	O
and	O
transcripts	O
enriched	O
relative	O
to	O
adult	O
patients	O
are	O
LFC	O
down	O
(<	O
â	O
	O
0	O
).	O

b	O
Euclidean	O
sample	O
distance	O
matrix	O
without	O
clustering	O
demonstrated	O
the	O
relative	O
heterogeneity	O
across	O
all	O
sample	O
groups	O
from	O
a	O
global	O
transcriptional	O
expression	O
perspective	O
.	O

c	O
-	O
e	O
Clustering	O
paradigms	O
utilized	O
in	O
dataset	O
exploration	O
.	O

c	O
Dendrogram	O
yielded	O
from	O
the	O
DIvisive	O
ANAlysis	O
(	O
DIANA	O
)	O
hierarchical	O
clustering	O
algorithm	O
.	O

d	O
Dendrogram	O
produced	O
by	O
the	O
AGlomerative	O
NESting	O
(	O
AGNES	O
)	O
hierarchical	O
clustering	O
algorithm	O
using	O
complete	O
linkage	O
.	O

e	O
Clustering	O
partitions	O
and	O
group	O
ellipsoids	O
generated	O
by	O
the	O
fuzzy	O
analysis	O
(	O
FANNY	O
)	O
probabilistic	O
k	O
-	O
centroid	O
technique	O
.	O

f	O
-	O
h	O
Silhouette	O
plots	O
depicting	O
mean	O
silhouette	O
width	O
across	O
a	O
range	O
of	O
numbers	O
of	O
clusters	O
.	O

Possible	O
silhouette	O
values	O
are	O
within	O
[	O
â	O
	O
â	O
	O
1	O
,	O
1	O
]	O
where	O
a	O
value	O
of	O
1	O
indicates	O
the	O
cluster	O
member	O
is	O
most	O
-	O
closely	O
related	O
to	O
the	O
members	O
within	O
that	O
cluster	O
and	O
dissimilar	O
to	O
those	O
outside	O
of	O
the	O
cluster	O
.	O

As	O
values	O
approach	O
â	O
	O
â	O
	O
1	O
,	O
the	O
opposite	O
is	O
true	O
which	O
indicates	O
the	O
cluster	O
member	O
is	O
an	O
outlier	O
within	O
the	O
cluster	O
.	O

f	O
Silhouette	O
plot	O
generated	O
from	O
the	O
DIANA	O
clustering	O
presented	O
in	O
1c	O
.	O

g	O
Silhouette	O
plot	O
produced	O
by	O
the	O
AGNES	O
algorithm	O
output	O
presented	O
in	O
1d	O
.	O

h	O
Silhouette	O
plot	O
yielded	O
by	O
the	O
FANNY	O
algorithm	O
results	O
visualized	O
in	O
1e	O
Divisive	O
,	O
agglomerative	O
,	O
and	O
probabilistic	O
clustering	O
was	O
performed	O
using	O
the	O
DIANA	O
,	O
AGNES	O
,	O
and	O
FANNY	O
functions	O
in	O
the	O
cluster	O
R	O
package	O
,	O
respectively	O
.	O

AGNES	O
was	O
implemented	O
with	O
the	O
complete	O
-	O
linkage	O
method	O
.	O

Complete	O
-	O
linkage	O
clustering	O
groups	O
variables	O
by	O
their	O
most	O
dissimilar	O
members	O
and	O
also	O
avoids	O
combining	O
clusters	O
with	O
highly	O
similar	O
elements	O
(	O
as	O
opposed	I
to	I
single	O
-	O
linkage	O
).	O

As	O
shown	O
below	O
in	O
Fig	O
.	O
Â	O
1b	O
,	O
we	O
expect	O
no	O
linear	O
dissimilarity	O
between	O
transcriptomes	O
relative	O
to	O
age	O
group	O
,	O
making	O
complete	O
-	O
linkage	O
an	O
appropriate	O
clustering	O
strategy	O
.	O

As	O
subtle	O
differences	O
in	O
the	O
gene	O
expression	O
patterns	O
could	O
be	O
expected	O
,	O
complete	O
-	O
linkage	O
was	O
employed	O
due	O
to	O
its	O
superiority	O
over	O
a	O
single	O
-	O
linkage	O
approach	O
in	O
handling	O
data	O
groups	O
that	O
closely	O
neighbor	O
one	O
another	O
.	O

DIANA	O
and	O
AGNES	O
calculate	O
metrics	O
for	O
cluster	O
organization	O
known	O
as	O
the	O
Divisive	O
Coefficient	O
(	O
DC	O
)	O
and	O
Agglomerative	O
Coefficient	O
(	O
AC	O
),	O
respectively	O
.	O

These	O
coefficients	O
range	O
between	O
0	O
and	O
1	O
,	O
and	O
indicate	O
the	O
precision	O
with	O
which	O
the	O
dendrogram	O
describes	O
the	O
data	O
,	O
with	O
1	O
being	O
the	O
most	O
ideal	O
structure	O
and	O
0	O
being	O
the	O
worst	O
.	O

As	O
FANNY	O
is	O
not	O
a	O
hierarchical	O
algorithm	O
,	O
and	O
is	O
visualized	O
in	O
principal	O
component	O
space	O
,	O
the	O
percent	O
of	O
variance	O
explained	O
serves	O
as	O
a	O
surrogate	O
value	O
for	O
AC	O
and	O
DC	O
(	O
i	O
.	O
e	O
.,	O
a	O
larger	O
percent	O
variance	O
explained	O
value	O
indicates	O
how	O
well	O
a	O
datasets	O
information	O
is	O
represented	O
in	O
the	O
decomposed	O
space	O
).	O

Although	O
cluster	O
analysis	O
is	O
a	O
primarily	O
descriptive	O
mathematical	O
technique	O
,	O
we	O
calculated	O
the	O
silhouette	O
width	O
as	O
a	O
means	O
to	O
make	O
a	O
quantitative	O
comparison	O
of	O
the	O
differential	O
expression	O
data	O
.	O

Silhouette	O
widths	O
range	O
between	O
â	O
	O
â	O
	O
1	O
and	O
1	O
.	O

A	O
value	O
of	O
1	O
indicates	O
that	O
the	O
cluster	O
members	O
are	O
closely	O
related	O
to	O
the	O
other	O
members	O
of	O
the	O
cluster	O
,	O
and	O
not	O
to	O
members	O
outside	O
the	O
cluster	O
.	O

A	O
value	O
of	O
â	O
	O
â	O
	O
1	O
suggests	O
the	O
cluster	O
member	O
is	O
an	O
outlier	O
within	O
the	O
cluster	O
and	O
is	O
actually	O
more	O
representative	O
of	O
other	O
clusters	O
.	O

The	O
mean	O
Silhouette	O
Value	O
was	O
calculated	O
for	O
a	O
range	O
of	O
cluster	O
numbers	O
for	O
the	O
DIANA	O
,	O
AGNES	O
,	O
and	O
FANNY	O
algorithms	O
(	O
Fig	O
.	O

1f	O
,	O
g	O
,	O
h	O
,	O
respectively	O
).	O

Information	O
theory	O
analysis	O
In	O
order	O
to	O
extend	O
the	O
analysis	O
beyond	O
the	O
linear	O
methodology	O
utilized	O
in	O
the	O
canonical	O
analysis	O
,	O
we	O
calculated	O
the	O
Kullback	O
-	O
Leibler	O
(	O
KL	O
)	O
divergence	O
(	O
DKL	O
)	O
and	O
Maximal	O
Information	O
Coefficient	O
(	O
MIC	O
).	O

This	O
was	O
necessary	O
because	O
non	O
-	O
linear	O
transcriptional	O
relationships	O
(	O
i	O
.	O
e	O
.,	O
dynamic	O
networks	O
of	O
transcripts	O
)	O
between	O
age	O
groups	O
could	O
exist	O
and	O
are	O
likely	O
abundant	O
,	O
as	O
seen	O
by	O
the	O
development	O
of	O
numerous	O
pathway	O
-	O
based	O
analytical	O
tools	O
(	O
e	O
.	O
g	O
.,	O
GSEA	O
,	O
GO	O
-	O
terms	O
,	O
Reactome	O
,	O
etc	O
.).	O

While	B
these	O
types	O
of	O
modules	O
are	O
interesting	O
they	O
often	O
require	O
predefined	O
lists	O
.	O

However	B
,	O
utilizing	O
information	O
theory	O
allows	O
us	O
to	O
inspect	O
potential	O
networks	O
in	O
the	O
absence	O
of	O
prior	O
known	O
networks	O
,	O
and	O
also	O
reduces	O
analytical	O
bias	O
.	O

DKL	O
is	O
a	O
mathematical	O
approach	O
to	O
identify	O
differences	O
between	O
data	O
distributions	O
through	O
non	O
-	O
linear	O
integration	O
.	O

While	B
this	O
is	O
most	O
commonly	O
used	O
to	O
compare	O
machine	O
learning	O
outputs	O
to	O
ground	O
truth	O
distributions	O
,	O
we	O
employed	O
it	O
by	O
treating	O
one	O
distribution	O
(	O
e	O
.	O
g	O
.,	O
pediatric	O
)	O
as	O
the	O
predicted	O
distribution	O
and	O
the	O
other	O
distribution	O
(	O
e	O
.	O
g	O
.,	O
adult	O
)	O
as	O
the	O
target	O
distribution	O
(	O
e	O
.	O
g	O
.	O

â	O
	O
ground	O
truthâ	O
).	O

This	O
scenario	O
effectively	O
asks	O
the	O
following	O
question	O
:	O
given	O
the	O
expression	O
distribution	O
of	O
the	O
adult	O
cohort	O
,	O
how	O
well	O
can	O
the	O
distribution	O
of	O
the	O
pediatric	O
cohort	O
be	O
predicted	O
.	O

To	O
calculate	O
DKL	O
,	O
raw	O
feature	O
counts	O
generated	O
by	O
RSubread	O
were	O
first	O
class	O
-	O
balanced	O
using	O
the	O
Synthetic	O
Minority	O
Oversampling	O
Technique	O
(	O
SMOTE	O
)	O
via	O
the	O
python	O
imblearn	O
package	O
.	O

DKL	O
values	O
were	O
then	O
calculated	O
for	O
the	O
synthetically	O
balanced	O
dataset	O
using	O
the	O
python	O
scipy	O
stats	O
module	O
.	O

MIC	O
is	O
used	O
to	O
measure	O
the	O
strength	O
of	O
any	O
linear	O
and	O
/	O
or	O
non	O
-	O
linear	O
relationship	O
between	O
two	O
variables	O
.	O

This	O
is	O
accomplished	O
by	O
binning	O
continuous	O
variables	O
and	O
iteratively	O
calculating	O
mutual	O
information	O
(	O
i	O
.	O
e	O
.,	O
the	O
dependence	O
between	O
variables	O
)	O
to	O
identify	O
the	O
maxima	O
.	O

By	O
plotting	O
MIC	O
against	O
Pearsonâ	O
	O
s	O
R	O
the	O
magnitude	O
of	O
the	O
relationship	O
between	O
the	O
variables	O
can	O
be	O
visualized	O
(	O
MICâ	O
=	O
â	O
	O
0	O
indicates	O
no	O
relationship	O
;	O
MICâ	O
=	O
â	O
	O
1	O
indicates	O
highly	O
related	O
),	O
as	O
can	O
the	O
nature	O
of	O
the	O
relationship	O
(	O
linear	O
vs	O
.	O
non	O
-	O
linear	O
).	O

MIC	O
was	O
calculated	O
using	O
the	O
python	O
minepy	O
module	O
.	O

HD	O
spot	O
analysis	O
Raw	O
feature	O
counts	O
derived	O
from	O
RSubread	O
were	O
submitted	O
to	O
the	O
HD	O
Spot	O
algorithm	O
.	O

Due	O
to	O
the	O
substantial	O
imbalance	O
of	O
data	O
classes	O
,	O
the	O
HD	O
Spot	O
algorithm	O
was	O
optimized	O
with	O
respect	O
to	O
maximizing	O
the	O
area	O
under	O
the	O
precision	O
-	O
recall	O
(	O
AUPR	O
)	O
curve	O
.	O

HD	O
Spot	O
developed	O
a	O
classifier	O
that	O
achieved	O
an	O
average	O
AUPR	O
value	O
of	O
1	O
.	O
00	O
over	O
5	O
-	O
fold	O
cross	O
-	O
validation	O
and	O
subsequently	O
determined	O
the	O
mean	O
absolute	O
Shapley	O
value	O
for	O
each	O
transcript	O
.	O

Shapley	O
values	O
can	O
conceptually	O
be	O
understood	O
as	O
importance	O
scores	O
.	O

In	O
this	O
context	O
,	O
a	O
higher	O
Shapley	O
value	O
means	O
a	O
transcript	O
is	O
more	O
important	O
in	O
determining	O
the	O
age	O
group	O
from	O
which	O
the	O
sample	O
was	O
taken	O
.	O

The	O
top	O
50	O
transcripts	O
ranked	O
by	O
Shapley	O
value	O
and	O
the	O
list	O
of	O
20	O
previously	O
identified	O
therapeutic	O
targets	O
were	O
then	O
submitted	O
for	O
Metascape	O
express	O
analysis	O
to	O
explore	O
potential	O
ontologic	O
connections	O
between	O
gene	O
sets	O
using	O
GO	O
terms	O
.	O

Results	O
Canonical	O
differential	O
expression	O
analysis	O
reveals	O
no	O
therapeutically	O
relevant	O
distinction	O
between	O
adult	O
and	O
pediatric	O
ACP	O
specimens	O
Overall	O
,	O
87	O
.	O
3	O
%	O
of	O
the	O
transcripts	O
interrogated	O
were	O
insignificant	O
(	O
IHW	O
p	O
-	O
value	O
>	O
â	O
	O
0	O
.	O
1	O
)	O
and	O
slightly	O
more	O
transcripts	O
enriched	O
within	O
the	O
pediatric	O
population	O
versus	O
the	O
adult	O
population	O
(	O
6	O
.	O
8	O
%	O
versus	O
5	O
.	O
9	O
%,	O
respectively	O
,	O
Fig	O
.	O

1a	O
).	O

Considerable	O
heterogeneity	O
between	O
all	O
samples	O
(	O
irrespective	O
of	O
age	O
group	O
)	O
was	O
identified	O
with	O
the	O
Euclidean	O
distance	O
matrix	O
(	O
Fig	O
.	O

1b	O
).	O

Both	O
the	O
agglomerative	O
and	O
divisive	O
clustering	O
algorithms	O
demonstrated	O
reliable	O
data	O
organization	O
(	O
Fig	O
.	O

1c	O
-	O
d	O
;	O
Divisive	O
Coefficient	O
[	O
DC	O
]	O
â	O
=	O
â	O
	O
0	O
.	O
66	O
,	O
Agglomerative	O
Coefficient	O
[	O
AC	O
]	O
â	O
=	O
â	O
	O
0	O
.	O
59	O
)	O
as	O
well	O
as	O
the	O
absence	O
of	O
distinct	O
clusters	O
between	O
the	O
adult	O
and	O
pediatric	O
ACP	O
samples	O
.	O

Congruently	O
,	O
probabilistic	O
analysis	O
in	O
2D	O
principal	O
component	O
space	O
,	O
using	O
FANNY	O
,	O
depicted	O
nearly	O
70	O
%	O
of	O
the	O
data	O
variance	O
(	O
69	O
.	O
93	O
%,	O
Fig	O
.	O

1e	O
)	O
and	O
failed	O
to	O
partition	O
the	O
data	O
into	O
groups	O
based	O
on	O
age	O
cohort	O
.	O

Further	O
analyses	O
of	O
these	O
clustering	O
approaches	O
,	O
using	O
silhouette	O
plots	O
to	O
quantify	O
clustering	O
integrity	O
,	O
demonstrated	O
that	O
kÂ	O
=	O
â	O
	O
2	O
yields	O
the	O
optimal	O
clustering	O
(	O
Fig	O
.	O

1f	O
-	O
h	O
).	O

However	O
,	O
all	O
silhouette	O
widths	O
are	O
close	O
to	O
0	O
(	O
maximum	O
â	O
	O
0	O
.	O
30	O
),	O
indicating	O
that	O
clusters	O
are	O
not	O
unique	O
from	O
one	O
another	O
and	O
cluster	O
memberships	O
could	O
easily	O
be	O
randomized	O
another	O
way	O
.	O

When	O
examined	O
as	O
a	O
whole	O
,	O
agglomerative	O
,	O
divisive	O
,	O
and	O
probabilistic	O
clustering	O
algorithms	O
yield	O
consistent	O
and	O
well	O
-	O
organized	O
results	O
,	O
indicating	O
that	O
the	O
transcriptomes	O
of	O
ACP	O
specimens	O
do	O
not	O
cluster	O
based	O
on	O
the	O
age	O
of	O
the	O
patient	O
from	O
which	O
they	O
were	O
obtained	O
.	O

Caption	O
(	O
Fig	O
):	O
FIG	O
2	O
Transcriptional	O
Profiling	O
of	O
Previously	O
Identified	O
Therapeutic	O
Targets	O
.	O

a	O
Previously	O
identified	O
therapeutic	O
targets	O
with	O
transcriptions	O
fold	O
-	O
change	O
metrics	O
for	O
adult	O
versus	O
pediatric	O
samples	O
.	O

A	O
positive	O
fold	O
-	O
change	O
indicates	O
enrichment	O
in	O
pediatric	O
patients	O
,	O
and	O
conversely	B
a	O
negative	O
value	O
indicates	O
enrichment	O
in	O
adult	O
patients	O
.	O

b	O
Volcano	O
plot	O
for	O
all	O
transcripts	O
with	O
previously	O
identified	O
targets	O
indicated	O
by	O
red	O
arrows	O
.	O

The	O
solid	O
black	O
horizontal	O
line	O
at	O
yâ	O
=	O
â	O
	O
1	O
indicates	O
the	O
threshold	O
for	O
p	O
-	O
value	O
significance	O
(	O
pÂ	O
<	O
â	O
	O
0	O
.	O
1	O
;	O
yâ	O
=	O
â	O
	O
â	O
	O
log	O
(	O
0	O
.	O
1	O
)	O
â	O
=	O
â	O
	O
1	O
).	O

c	O
-	O
e	O
Clustering	O
paradigms	O
utilized	O
in	O
dataset	O
exploration	O
.	O

c	O
Dendrogram	O
yielded	O
from	O
the	O
DIvisive	O
ANAlysis	O
(	O
DIANA	O
)	O
hierarchical	O
clustering	O
algorithm	O
with	O
respect	O
to	O
only	O
the	O
twenty	O
previously	O
identified	O
targets	O
.	O

d	O
Dendrogram	O
produced	O
by	O
the	O
AGlomerative	O
NESting	O
(	O
AGNES	O
)	O
hierarchical	O
clustering	O
algorithm	O
using	O
complete	O
linkage	O
with	O
respect	O
to	O
only	O
the	O
twenty	O
previously	O
identified	O
targets	O
.	O

e	O
Clustering	O
partitions	O
and	O
group	O
ellipsoids	O
generated	O
by	O
the	O
fuzzy	O
analysis	O
(	O
FANNY	O
)	O
probabilistic	O
k	O
-	O
centroid	O
technique	O
with	O
respect	O
to	O
only	O
the	O
twenty	O
previously	O
identified	O
targets	O
.	O

f	O
-	O
h	O
Silhouette	O
plots	O
depicting	O
mean	O
silhouette	O
width	O
across	O
a	O
range	O
of	O
numbers	O
of	O
clusters	O
.	O

f	O
Silhouette	O
plot	O
generated	O
from	O
the	O
DIANA	O
clustering	O
presented	O
in	O
2c	O
.	O

g	O
Silhouette	O
plot	O
produced	O
by	O
the	O
AGNES	O
algorithm	O
output	O
presented	O
in	O
2d	O
.	O

h	O
Silhouette	O
plot	O
yielded	O
by	O
the	O
FANNY	O
algorithm	O
results	O
visualized	O
in	O
2e	O
Our	O
group	O
previously	O
identified	O
a	O
group	O
of	O
twenty	O
potentially	O
targetable	O
transcripts	O
within	O
pediatric	O
ACP	O
.	O

The	O
primary	O
clinical	O
question	O
underlying	O
this	O
research	O
is	O
to	O
determine	O
whether	B
initial	O
treatment	O
strategies	O
against	O
ACP	O
should	O
be	O
differentiated	O
based	O
on	O
age	O
at	O
diagnosis	O
.	O

Accordingly	O
,	O
we	O
validated	O
these	O
targets	O
in	O
the	O
current	O
dataset	O
compared	O
to	O
normal	O
pituitary	O
(	O
Figure	O
S1	O
)	O
and	O
created	O
a	O
subset	O
of	O
the	O
transcriptome	O
data	O
focusing	O
on	O
these	O
twenty	O
targets	O
to	O
assess	O
differential	O
expression	O
status	O
(	O
Fig	O
.	O
Â	O
2a	O
and	O
b	O
).	O

Of	O
the	O
previously	O
identified	O
potential	O
targets	O
,	O
three	O
genes	O
were	O
significant	O
(	O
IHW	O
p	O
-	O
value	O
<	O
â	O
	O
0	O
.	O
1	O
):	O
SHH	O
,	O
MAPK14	O
,	O
and	O
AREG	O
.	O

Next	O
,	O
this	O
data	O
subset	O
was	O
subjected	O
to	O
the	O
same	O
divisive	O
,	O
agglomerative	O
,	O
and	O
probabilistic	O
clustering	O
protocols	O
(	O
Fig	O
.	O

2c	O
-	O
e	O
)	O
as	O
the	O
total	O
dataset	O
above	O
.	O

There	O
was	O
slight	O
improvement	O
in	O
data	O
organization	O
(	O
i	O
.	O
e	O
.,	O
an	O
increase	O
in	O
clustering	O
coefficients	O
;	O
DCâ	O
=	O
â	O
	O
0	O
.	O
78	O
,	O
and	O
ACâ	O
=	O
â	O
	O
0	O
.	O
77	O
,	O
relative	O
to	O
0	O
.	O
66	O
and	O
0	O
.	O
59	O
when	O
analyzing	O
the	O
full	O
transcriptome	O
).	O

Additionally	O
,	O
kÂ	O
=	O
â	O
	O
2	O
remained	O
the	O
superior	O
cluster	O
count	O
but	O
higher	O
k	O
values	O
improved	O
relative	O
to	O
the	O
clustering	O
performance	O
of	O
the	O
full	O
transcriptome	O
(	O
Fig	O
.	O

2f	O
-	O
h	O
).	O

Although	O
four	O
genes	O
were	O
significantly	O
differentially	O
expressed	O
,	O
the	O
data	O
subset	O
remained	O
linearly	O
undifferentiable	O
based	O
on	O
age	O
.	O

In	O
other	O
words	O
,	O
these	O
results	O
indicate	O
that	O
there	O
is	O
no	O
direct	O
linear	O
relationship	O
between	O
transcriptional	O
profiles	O
and	O
age	O
group	O
at	O
diagnosis	O
.	O

Information	O
theory	O
and	O
machine	O
learning	O
techniques	O
identify	O
a	O
cohort	O
of	O
transcripts	O
relevant	O
to	O
differentiating	O
adult	O
and	O
pediatric	O
patients	O
Caption	O
(	O
Fig	O
):	O
FIG	O
3	O
Information	O
Theory	O
-	O
Based	O
Analysis	O
Suggests	O
Majority	O
of	O
Genes	O
Have	O
Minimal	O
Linear	O
and	O
Non	O
-	O
linear	O
Relationships	O
with	O
Age	O
Groups	O
.	O

a	O
Kullback	O
-	O
Leibler	O
(	O
KL	O
)	O
divergence	O
representation	O
of	O
SHH	O
(	O
top	O
)	O
and	O
IL6R	O
(	O
bottom	O
)	O
distributions	O
for	O
adult	O
and	O
pediatric	O
samples	O
.	O

b	O
KL	O
-	O
divergence	O
versus	O
Log	O
Fold	O
Change	O
plot	O
,	O
with	O
previously	O
identified	O
therapeutic	O
targets	O
overlaid	O
and	O
all	O
points	O
colored	O
by	O
IHW	O
-	O
adjusted	O
p	O
-	O
value	O
,	O
demonstrating	O
relationship	O
between	O
calculated	O
LFC	O
and	O
informational	O
differences	O
.	O

Higher	O
KL	O
-	O
Divergence	O
values	O
indicate	O
that	O
a	O
gene	O
has	O
informational	O
difference	O
between	O
age	O
groups	O
.	O

As	O
KL	O
-	O
Divergence	O
is	O
an	O
asymmetric	O
method	O
,	O
the	O
scenario	O
of	O
having	O
a	O
pediatric	O
prior	O
(	O
left	O
)	O
and	O
an	O
adult	O
prior	O
(	O
right	O
)	O
are	O
both	O
shown	O
.	O

c	O
Pearson	O
Correlation	O
Coefficient	O
(	O
PCC	O
)	O
vs	O
Maximal	O
Information	O
Criterion	O
(	O
MIC	O
)	O
plot	O
with	O
previously	O
identified	O
targets	O
overlaid	O
.	O

MIC	O
scores	O
the	O
strength	O
of	O
a	O
relationship	O
from	O
0	O
(	O
no	O
relationship	O
)	O
to	O
1	O
(	O
noise	O
-	O
free	O
relationship	O
)	O
for	O
genes	O
between	O
the	O
age	O
groups	O
.	O

Points	O
A	O
and	O
B	O
on	O
the	O
graph	O
represent	O
where	O
genes	O
should	O
fall	O
if	O
they	O
have	O
a	O
strong	O
direct	O
or	O
inverse	O
linear	O
relationship	O
with	O
age	O
groups	O
.	O

Values	O
that	O
have	O
low	O
PCC	O
and	O
high	O
MIC	O
scores	O
indicate	O
genes	O
with	O
non	O
-	O
linear	O
(	O
i	O
.	O
e	O
.	O

dynamic	O
;	O
one	O
-	O
vs	O
-	O
many	O
)	O
relationships	O
.	O

d	O
Summary	O
statistics	O
of	O
where	O
genes	O
lie	O
on	O
the	O
PCC	O
vs	O
MIC	O
plot	O
along	O
with	O
their	O
respective	O
differential	O
expression	O
values	O
as	O
visualized	O
in	O
(	O
b	O
)	O
In	O
the	O
present	O
context	O
,	O
Kullback	O
-	O
Leibler	O
divergence	O
(	O
DKL	O
)	O
represents	O
the	O
difference	O
between	O
transcript	O
expression	O
profiles	O
of	O
the	O
two	O
age	O
groups	O
(	O
Fig	O
.	O
Â	O
3a	O
).	O

DKL	O
is	O
asymmetric	O
,	O
so	O
we	O
visualize	O
both	O
directions	O
of	O
the	O
relationship	O
(	O
i	O
.	O
e	O
.,	O
Pediatrics	O
to	O
Adults	O
,	O
and	O
Adults	O
to	O
Pediatrics	O
;	O
Fig	O
.	O

3b	O
).	O

These	O
results	O
demonstrate	O
that	O
qualitatively	O
the	O
global	O
transcriptomes	O
of	O
both	O
age	O
groups	O
are	O
informationally	O
similar	O
.	O

Of	O
the	O
four	O
differentially	O
expressed	O
therapeutic	O
targets	O
,	O
SHH	O
and	O
AREG	O
demonstrate	O
the	O
greatest	O
informational	O
difference	O
(	O
DKLâ	O
	O
â	O
	O
â	O
	O
3	O
)	O
although	O
still	O
less	O
than	O
50	O
%	O
of	O
maximum	O
(	O
DKLâ	O
	O
â	O
	O
â	O
	O
6	O
)	O
informational	O
differences	O
(	O
i	O
.	O
e	O
.,	O
they	O
are	O
not	O
among	O
the	O
top	O
contributors	O
for	O
informational	O
difference	O
between	O
age	O
groups	O
).	O

We	O
analytically	O
assed	O
both	O
linear	O
and	O
non	O
-	O
linear	O
relationships	O
by	O
comparing	O
the	O
MIC	O
versus	O
Pearsonâ	O
	O
s	O
R	O
(	O
Fig	O
.	O

3c	O
).	O

From	O
this	O
we	O
determined	O
that	O
of	O
the	O
41	O
,	O
914	O
transcripts	O
interrogated	O
only	O
0	O
.	O
03	O
%	O
(	O
NÂ	O
=	O
â	O
	O
13	O
)	O
genes	O
maintain	O
expression	O
levels	O
that	O
differ	O
based	O
on	O
age	O
group	O
(	O
Fig	O
.	O

3d	O
).	O

The	O
encoded	O
genes	O
include	O
a	O
long	O
intergenic	O
non	O
-	O
protein	O
coding	O
gene	O
,	O
innate	O
immune	O
system	O
related	O
genes	O
,	O
a	O
chromosomal	O
open	O
reading	O
frame	O
,	O
and	O
a	O
keratin	O
metabolism	O
related	O
gene	O
.	O

When	O
cross	O
-	O
checked	O
with	O
canonical	O
differential	O
analysis	O
methods	O
,	O
four	O
genes	O
(	O
FBXL16	O
,	O
COG8	O
,	O
CHST2	O
,	O
and	O
TMCC2	O
)	O
were	O
statistically	O
significant	O
as	O
determined	O
by	O
p	O
-	O
value	O
.	O

However	B
,	O
Log	O
Fold	O
Change	O
(	O
LFC	O
)	O
magnitudes	O
were	O
less	O
than	O
1	O
for	O
all	O
but	O
FBXL16	O
(	O
LFCâ	O
=	O
â	O
	O
1	O
.	O
38	O
).	O

Of	O
the	O
seven	O
genes	O
identified	O
,	O
none	O
are	O
currently	O
of	O
therapeutic	O
interest	O
.	O

Ontology	O
assessment	O
of	O
deep	O
learning	O
identified	O
age	O
group	O
-	O
differentiable	O
transcripts	O
Caption	O
(	O
Fig	O
):	O
FIG	O
4	O
Deep	O
Learning	O
Approach	O
HD	O
Spot	O
Identifies	O
Genes	O
Related	O
to	O
Adult	O
and	O
Pediatric	O
Cohort	O
Differences	O
From	O
Raw	O
Feature	O
Counts	O
.	O

a	O
Summary	O
plot	O
of	O
the	O
top	O
50	O
genes	O
identified	O
by	O
HD	O
Spot	O
as	O
being	O
the	O
most	O
important	O
in	O
separating	O
adult	O
and	O
pediatric	O
ACP	O
transcriptomes	O
.	O

b	O
Heatmap	O
of	O
GO	O
terms	O
found	O
to	O
be	O
enriched	O
in	O
Metascape	O
analysis	O
comparing	O
HD	O
Spot	O
-	O
identified	O
and	O
the	O
20	O
previously	O
identified	O
therapeutic	O
targets	O
.	O

Heatmap	O
color	O
represents	O
ontology	O
term	O
enrichment	O
Following	O
classification	O
using	O
the	O
HD	O
Spot	O
algorithm	O
,	O
the	O
50	O
(	O
0	O
.	O
20	O
%)	O
transcripts	O
with	O
the	O
highest	O
Shapley	O
values	O
(	O
Fig	O
.	O
Â	O
4a	O
)	O
and	O
the	O
20	O
previously	O
identified	O
potential	O
therapeutic	O
targets	O
were	O
examined	O
using	O
a	O
Metascape	O
analysis	O
(	O
Fig	O
.	O

4b	O
).	O

HD	O
Spot	O
identified	O
primarily	O
pseudogenes	O
,	O
novel	O
transcripts	O
,	O
and	O
non	O
-	O
coding	O
transcripts	O
as	O
most	O
differentiable	O
between	O
age	O
groups	O
.	O

Only	O
one	O
ontology	O
group	O
(	O
GO	O
:	O
0051222	O
)	O
is	O
enriched	O
in	O
HD	O
spot	O
analysis	O
and	O
it	O
is	O
also	O
enriched	O
(	O
though	O
more	O
significantly	O
)	O
with	O
respect	O
to	O
the	O
therapeutic	O
targets	O
.	O

The	O
lack	O
of	O
enrichment	O
returned	O
from	O
Metascape	O
analysis	O
reinforces	O
that	O
the	O
differential	O
genes	O
identified	O
are	O
not	O
well	O
studied	O
and	O
are	O
currently	O
not	O
of	O
therapeutic	O
interest	O
.	O

Importantly	O
,	O
HD	O
Spot	O
achieved	O
a	O
mean	O
5	O
-	O
fold	O
cross	O
-	O
validation	O
area	O
under	O
precision	O
-	O
recall	O
curve	O
value	O
of	O
0	O
.	O
97	O
,	O
indicating	O
that	O
the	O
derived	O
classifier	O
was	O
well	O
optimized	O
.	O

In	O
total	O
,	O
these	O
findings	O
indicate	O
that	O
while	B
there	O
may	O
be	O
underlying	O
transcriptional	O
difference	B
for	O
ACP	O
pathogensis	O
relative	O
to	O
pediatric	O
and	O
adult	O
patients	O
,	O
current	O
therapeutic	O
targets	O
do	O
not	O
maintain	O
age	O
-	O
dependent	O
linear	O
or	O
non	O
-	O
linear	O
expression	O
signatures	O
.	O

Discussion	O
Using	O
a	O
thorough	O
comparative	O
bioinformatic	O
analysis	O
following	O
bulk	O
tissue	O
RNA	O
sequencing	O
of	O
pediatric	O
and	O
adult	O
ACP	O
tissue	O
,	O
we	O
identified	O
no	O
gene	O
expression	O
differences	O
that	O
have	O
implications	O
regarding	O
potential	O
therapies	O
.	O

This	O
implies	O
that	O
potential	O
therapies	O
identified	O
or	O
initially	O
tested	O
in	O
either	O
the	O
adult	O
or	O
pediatric	O
population	O
will	O
have	O
relevance	O
in	O
the	O
other	B
age	O
group	O
.	O

To	O
our	O
knowledge	O
this	O
work	O
consists	O
of	O
the	O
largest	O
analysed	O
cohort	O
of	O
ACP	O
transcriptome	O
data	O
to	O
date	O
.	O

Canonical	O
differential	O
expression	O
techniques	O
demonstrated	O
no	O
clear	O
differences	O
between	O
age	O
groups	O
.	O

At	O
the	O
global	O
level	O
,	O
only	O
12	O
and	O
13	O
%	O
of	O
transcripts	O
yielded	O
a	O
Log	O
Fold	O
Change	O
(	O
LFC	O
)	O
with	O
an	O
IHW	O
-	O
adjusted	O
p	O
-	O
value	O
<	O
â	O
	O
0	O
.	O
1	O
.	O

Using	O
divisive	O
,	O
agglomerative	O
,	O
and	O
probabilistic	O
hierarchical	O
clustering	O
approaches	O
,	O
we	O
observed	O
that	O
while	O
clustering	O
was	O
at	O
a	O
relative	O
optimum	O
with	O
kÂ	O
=	O
â	O
	O
2	O
clusters	O
,	O
cluster	O
memberships	O
were	O
arbitrary	O
(	O
mean	O
silhouette	O
widths	O
<	O
â	O
	O
0	O
.	O
35	O
)	O
and	O
contained	O
a	O
mixture	O
of	O
age	O
groups	O
in	O
each	O
branch	O
.	O

In	O
the	O
context	O
of	O
the	O
twenty	O
previously	O
identified	O
potential	O
therapeutic	O
targets	O
,	O
we	O
found	O
that	O
only	O
SHH	O
,	O
AREG	O
,	O
and	O
MAPK14	O
were	O
differentially	O
expressed	O
with	O
adjusted	O
p	O
-	O
value	O
<	O
â	O
	O
0	O
.	O
1	O
.	O

Analysis	O
of	O
these	O
20	O
transcripts	O
demonstrated	O
the	O
same	O
clustering	O
performance	O
results	O
that	O
were	O
observed	O
with	O
analysis	O
of	O
the	O
entire	O
transcriptome	O
.	O

Specifically	O
,	O
adult	O
and	O
pediatric	O
patients	O
did	O
not	O
cluster	O
uniquely	O
and	O
inter	O
-	O
cluster	O
members	O
could	O
arbitrarily	O
be	O
replaced	O
by	O
intra	O
-	O
cluster	O
members	O
.	O

The	O
findings	O
from	O
the	O
canonical	O
techniques	O
were	O
confirmed	O
through	O
further	O
analysis	O
using	O
information	O
theory	O
principles	O
.	O

This	O
demonstrated	O
that	O
99	O
.	O
97	O
%	O
of	O
the	O
transcriptome	O
has	O
no	O
expression	O
level	O
relationship	O
with	O
the	O
age	O
group	O
of	O
the	O
patient	O
.	O

The	O
remaining	O
0	O
.	O
03	O
%	O
was	O
composed	O
of	O
a	O
mixed	O
collection	O
of	O
transcripts	O
that	O
have	O
not	O
been	O
implicated	O
in	O
tumor	O
pathogenesis	O
or	O
therapy	O
,	O
and	O
LFCs	O
were	O
modest	O
.	O

Next	O
,	O
we	O
sought	O
to	O
qualitatively	O
examine	O
non	O
-	O
linear	O
transcriptional	O
relationships	O
to	O
age	O
group	O
by	O
utilizing	O
KL	O
-	O
divergence	O
.	O

This	O
again	O
demonstrated	O
that	O
the	O
global	O
transcriptome	O
profile	O
for	O
pediatric	O
ACP	O
differs	O
very	O
little	O
from	O
that	O
of	O
adult	O
ACP	O
.	O

Quantitative	O
assessment	O
of	O
linear	O
and	O
non	O
-	O
linear	O
relationships	O
using	O
MIC	O
vs	O
.	O
Pearsonâ	O
	O
s	O
R	O
plots	O
revealed	O
that	O
over	O
99	O
%	O
of	O
transcripts	O
do	O
not	O
possess	O
strong	O
relationships	O
of	O
any	O
type	O
to	O
age	O
group	O
.	O

Importantly	O
,	O
the	O
required	O
synthetic	O
expansion	O
of	O
the	O
dataset	O
(	O
see	O
Methods	O
)	O
in	O
order	O
to	O
calculate	O
DKL	O
and	O
MIC	O
would	O
be	O
expected	O
to	O
artificially	O
magnify	O
any	O
data	O
relationships	O
.	O

Therefore	O
,	O
the	O
lack	O
of	O
any	O
clear	O
relationship	O
between	O
transcript	O
expression	O
and	O
age	O
group	O
in	O
this	O
context	O
further	O
supports	O
the	O
assertion	O
that	O
the	O
adult	O
and	O
pediatric	O
transcriptomes	O
lack	O
therapeutically	O
relevant	O
differeces	O
.	O

The	O
threshold	O
selected	O
to	O
distinguish	O
adult	O
from	O
pediatric	O
ACP	O
(	O
age	O
18â	O
	O
years	O
)	O
may	O
be	O
considered	O
arbitrary	O
.	O

However	B
,	O
the	O
bimodal	O
age	O
distribution	O
of	O
ACP	O
incidence	O
includes	O
a	O
nadir	O
between	O
age	O
20	O
and	O
age	O
39	O
.	O

This	O
implies	O
that	O
there	O
may	O
be	O
a	O
distinction	O
,	O
on	O
some	O
level	O
,	O
between	O
the	O
tumors	O
that	O
present	O
before	O
and	O
after	O
this	O
window	O
.	O

The	O
age	O
threshold	O
of	O
18â	O
	O
years	O
has	O
further	O
clinical	O
significance	O
because	O
it	O
relates	O
to	O
the	O
clinical	O
environment	O
(	O
pediatric	O
vs	O
.	O
adult	O
)	O
in	O
which	O
a	O
patient	O
may	O
receive	O
care	O
.	O

Furthermore	O
,	O
by	O
leveraging	O
the	O
deep	O
learning	O
technique	O
HD	O
Spot	O
,	O
we	O
identified	O
genes	O
,	O
in	O
a	O
manner	O
free	O
of	O
human	O
-	O
interpreter	O
bias	O
,	O
that	O
have	O
age	O
group	O
dependent	O
expression	O
profiles	O
.	O

HD	O
Spot	O
accurately	O
discriminated	O
between	O
pediatric	O
and	O
adult	O
transcriptomes	O
.	O

The	O
top	O
50	O
genes	O
contributing	O
to	O
this	O
classification	O
were	O
primarily	O
comprised	O
of	O
genomic	O
features	O
that	O
are	O
currently	O
poorly	O
understood	O
(	O
e	O
.	O
g	O
.,	O
pseudogenes	O
,	O
novel	O
transcripts	O
,	O
etc	O
.).	O

Through	O
utilizing	O
classical	O
genomic	O
analysis	O
protocols	O
,	O
information	O
theoretic	O
models	O
,	O
and	O
deep	O
learning	O
this	O
work	O
rigorously	O
interrogated	O
linear	O
and	O
non	O
-	O
linear	O
relationships	O
to	O
demonstrate	O
that	O
,	O
at	O
the	O
transcript	O
level	O
,	O
there	O
is	O
no	O
evidence	O
to	O
differentiate	O
therapy	O
between	O
adult	O
and	O
pediatric	O
ACP	O
patients	O
strictly	O
based	O
on	O
age	O
at	O
diagnosis	O
.	O

Limitations	O
Despite	O
the	O
rigorous	O
characterization	O
of	O
the	O
transcriptional	O
relationship	O
between	O
pediatric	O
and	O
adult	O
ACP	O
tumor	O
tissue	O
,	O
our	O
findings	O
are	O
limited	O
by	O
the	O
fact	O
that	O
only	O
RNA	O
expression	O
profiles	O
were	O
considered	O
.	O

This	O
provides	O
a	O
specific	O
window	O
into	O
the	O
genomic	O
landscape	O
.	O

It	O
does	O
not	O
provide	O
thorough	O
insight	O
into	O
potential	O
differences	B
in	O
the	O
epigenetic	O
environment	O
or	O
extracellular	O
milieu	O
between	O
pediatric	O
and	O
adult	O
ACP	O
.	O

Furthermore	O
,	O
the	O
transcriptome	O
data	O
analyzed	O
was	O
generated	O
through	O
bulk	O
RNA	O
sequencing	O
.	O

Given	O
heterogeneous	O
nature	O
of	O
ACP	O
tissue	O
,	O
bulk	O
sequencing	O
is	O
likely	O
to	O
lose	O
some	O
information	O
,	O
which	O
may	O
be	O
explored	O
in	O
more	O
detail	O
with	O
techniques	O
such	O
as	O
single	O
cell	O
RNAseq	O
,	O
RNA	O
mutation	O
analysis	O
or	O
protein	O
-	O
level	O
quantification	O
.	O

Lastly	O
,	O
there	O
is	O
also	O
still	O
potential	O
that	O
an	O
even	O
larger	O
dataset	O
contrasting	B
these	O
age	O
groups	O
(	O
which	O
to	O
our	O
knowledge	O
does	O
not	O
exist	O
)	O
may	O
still	O
reveal	O
more	O
therapeutically	O
important	O
differences	O
.	O

Such	O
studies	O
may	O
identify	O
biological	O
distinctions	O
that	O
could	O
guide	O
therapeutic	O
intervention	O
,	O
even	O
if	B
this	O
is	O
at	O
the	O
level	O
of	O
second	O
or	O
third	O
line	O
therapy	O
.	O

Conclusions	O
Analysis	O
using	O
multiple	O
bioinformatic	O
techniques	O
,	O
including	O
the	O
Deep	O
Learning	O
method	O
,	O
HD	O
Spot	O
,	O
indicates	O
that	O
there	O
is	O
no	O
therapeutically	O
relevant	O
distinction	O
between	O
ACP	O
tissuein	O
adult	O
and	O
pediatric	O
patient	O
.	O

This	O
implies	O
that	O
the	O
identification	O
of	O
biologically	O
-	O
guided	O
therapeutic	O
targets	O
,	O
and	O
the	O
potential	O
clinical	O
translation	O
of	O
such	O
targets	O
in	O
either	B
group	O
of	O
patients	O
may	O
also	O
be	O
relevant	O
in	O
the	O
other	O
.	O

As	O
such	O
,	O
recent	O
and	O
future	O
findings	O
regarding	O
ACP	O
may	O
be	O
applied	O
for	O
the	O
benefit	O
of	O
a	O
larger	O
group	O
of	O
patients	O
.	O

Future	O
work	O
including	O
more	O
in	O
depth	O
study	O
of	O
RNA	O
features	O
,	O
protein	O
expression	O
and	O
extracellular	O
characteristics	O
of	O
these	O
tumors	O
will	O
be	O
necessary	O
.	O

Supplementary	O
information	O
Publisherâ	O
	O
s	O
Note	O
Springer	O
Nature	O
remains	O
neutral	O
with	O
regard	O
to	O
jurisdictional	O
claims	O
in	O
published	O
maps	O
and	O
institutional	O
affiliations	O
.	O

Supplementary	O
information	O
Supplementary	O
information	O
accompanies	O
this	O
paper	O
at	O
10	O
.	O
1186	O
/	O
s40478	O
-	O
020	O
-	O
00939	O
-	O
0	O
.	O

Authorsâ	O
	O
contributions	O
Primary	O
Authors	O
:	O
EP	O
,	O
RW	O
.	O

Analysis	O
and	O
Interpretation	O
of	O
Data	O
:	O
EP	O
.	O

Experimental	O
Design	O
:	O
TCH	O
.	O

Experimental	O
Implementation	O
:	O
RW	O
,	O
AD	O
,	O
SS	O
,	O
AH	O
,	O
TV	O
,	O
CA	O
.	O

Internal	O
Reviewers	O
/	O
Editors	O
:	O
KL	O
,	O
NF	O
,	O
MH	O
,	O
TCH	O
.	O

Advancing	O
Treatment	O
for	O
Pediatric	O
Craniopharyngioma	O
(	O
ATPC	O
)	O
Consortium	O
Members	O
:	O
JJ	O
,	O
LM	O
,	O
RA	O
,	O
MS	O
,	O
RN	O
,	O
DL	O
,	O
GG	O
,	O
TN	O
,	O
RD	O
,	O
LK	O
,	O
EJ	O
,	O
GJ	O
,	O
KG	O
,	O
AS	O
,	O
JC	O
,	O
AL	O
,	O
AD	O
,	O
MK	O
,	O
TCH	O
.	O

The	O
author	O
(	O
s	O
)	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Funding	O
The	O
authors	O
wish	O
to	O
acknowledge	O
The	O
Brain	O
Tumor	O
Charity	O
for	O
funding	O
which	O
made	O
this	O
work	O
possible	O
(	O
GN	O
-	O
000522	O
(	O
181477	O
)).	O

Availability	O
of	O
data	O
and	O
materials	O
The	O
datasets	O
during	O
and	O
/	O
or	O
analyzed	O
during	O
the	O
current	O
study	O
is	O
available	O
from	O
the	O
corresponding	O
author	O
on	O
reasonable	O
request	O
.	O

Ethics	O
approval	O
and	O
consent	O
to	O
participate	O
All	O
patient	O
samples	O
were	O
acquired	O
after	O
consent	O
was	O
granted	O
according	O
to	O
the	O
Colorado	O
Multiple	O
Institutional	O
Review	O
Board	O
(	O
COMIRB	O
)	O
approved	O
study	O
guidelines	O
.	O

Consent	O
for	O
publication	O
Not	O
applicable	O
.	O

Competing	O
interests	O
The	O
authors	O
declare	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Robust	O
deep	O
learning	O
classification	O
of	O
adamantinomatous	O
craniopharyngioma	O
from	O
limited	O
preoperative	O
radiographic	O
images	O
Abstract	O
Deep	O
learning	O
(	O
DL	O
)	O
is	O
a	O
widely	O
applied	O
mathematical	O
modeling	O
technique	O
.	O

Classically	O
,	O
DL	O
models	O
utilize	O
large	O
volumes	O
of	O
training	O
data	O
,	O
which	O
are	O
not	O
available	O
in	O
many	O
healthcare	O
contexts	O
.	O

For	O
patients	O
with	O
brain	O
tumors	O
,	O
non	O
-	O
invasive	O
diagnosis	O
would	O
represent	O
a	O
substantial	O
clinical	O
advance	O
,	O
potentially	O
sparing	O
patients	O
from	O
the	O
risks	O
associated	O
with	O
surgical	O
intervention	O
on	O
the	O
brain	O
.	O

Such	O
an	O
approach	O
will	O
depend	O
upon	O
highly	O
accurate	O
models	O
built	O
using	O
the	O
limited	O
datasets	O
that	O
are	O
available	O
.	O

Herein	O
,	O
we	O
present	O
a	O
novel	O
genetic	O
algorithm	O
(	O
GA	O
)	O
that	O
identifies	O
optimal	O
architecture	O
parameters	O
using	O
feature	O
embeddings	O
from	O
state	O
-	O
of	O
-	O
the	O
-	O
art	O
image	O
classification	O
networks	O
to	O
identify	O
the	O
pediatric	O
brain	O
tumor	O
,	O
adamantinomatous	O
craniopharyngioma	O
(	O
ACP	O
).	O

We	O
optimized	O
classification	O
models	O
for	O
preoperative	O
Computed	O
Tomography	O
(	O
CT	O
),	O
Magnetic	O
Resonance	O
Imaging	O
(	O
MRI	O
),	O
and	O
combined	O
CT	O
and	O
MRI	O
datasets	O
with	O
demonstrated	O
test	O
accuracies	O
of	O
85	O
.	O
3	O
%,	O
83	O
.	O
3	O
%,	O
and	O
87	O
.	O
8	O
%,	O
respectively	O
.	O

Notably	O
,	O
our	O
GA	O
improved	O
baseline	O
model	O
performance	O
by	O
up	O
to	O
38	O
%.	O

This	O
work	O
advances	O
DL	O
and	O
its	O
applications	O
within	O
healthcare	O
by	O
identifying	O
optimized	O
networks	O
in	O
small	O
-	O
scale	O
data	O
contexts	O
.	O

The	O
proposed	O
system	O
is	O
easily	O
implementable	O
and	O
scalable	O
for	O
non	O
-	O
invasive	O
computer	O
-	O
aided	O
diagnosis	O
,	O
even	O
for	O
uncommon	O
diseases	O
.	O

Introduction	O
Deep	O
learning	O
is	O
a	O
subtype	O
of	O
artificial	O
intelligence	O
that	O
constructs	O
generalizable	O
models	O
for	O
data	O
representations	O
via	O
a	O
multilayer	O
abstraction	O
process	O
.	O

A	O
common	O
deep	O
learning	O
architecture	O
used	O
for	O
classification	O
of	O
visual	O
information	O
is	O
known	O
as	O
a	O
Convolutional	O
Neural	O
Network	O
(	O
CNN	O
).	O

CNNs	O
are	O
constructed	O
using	O
multiple	O
sequential	O
layers	O
containing	O
variants	O
of	O
the	O
multi	O
-	O
layer	O
perceptron	O
.	O

These	O
networks	O
have	O
demonstrated	O
generalization	O
capacity	O
for	O
identifying	O
both	O
linear	O
and	O
non	O
-	O
linear	O
latent	O
patterns	O
that	O
lead	O
to	O
differentiable	O
information	O
.	O

CNNs	O
and	O
other	O
variants	O
have	O
had	O
great	O
success	O
in	O
tasks	O
such	O
as	O
image	O
object	O
recognition	O
;	O
speech	O
recognition	O
,	O
translation	O
,	O
and	O
generation	O
;	O
and	O
medical	O
diagnostics	O
,	O
genetics	O
,	O
and	O
drug	O
discovery	O
.	O

These	O
applications	O
have	O
achieved	O
remarkable	O
success	O
,	O
to	O
some	O
extent	O
by	O
leveraging	O
very	O
large	O
amounts	O
of	O
labeled	O
training	O
data	O
.	O

An	O
example	O
is	O
the	O
ImageNet	O
Large	O
Scale	O
Visual	O
Recognition	O
Challenge	O
(	O
ILVSRC	O
).	O

This	O
leading	O
image	O
recognition	O
competition	O
challenges	O
competitors	O
to	O
advance	O
the	O
state	O
of	O
the	O
art	O
in	O
computer	O
-	O
guided	O
object	O
detection	O
and	O
classification	O
.	O

Using	O
the	O
ImageNet	O
dataset	O
,	O
comprising	O
over	O
1	O
.	O
4	O
million	O
images	O
across	O
more	O
than	O
1000	O
possible	O
categories	O
,	O
CNNs	O
are	O
achieving	O
error	O
rates	O
under	O
5	O
%.	O

Within	O
the	O
healthcare	O
space	O
,	O
reliable	O
CNN	O
inference	O
models	O
have	O
been	O
described	O
under	O
conditions	O
when	O
vast	O
amounts	O
of	O
training	O
data	O
are	O
available	O
.	O

Examples	O
include	O
dermatological	O
diseases	O
and	O
diabetic	O
retinopathy	O
.	O

However	B
,	O
when	O
such	O
models	O
are	O
trained	O
on	O
more	O
limited	O
datasets	O
,	O
the	O
results	O
are	O
often	O
unreliable	O
,	O
as	O
the	O
models	O
overfit	O
the	O
training	O
data	O
.	O

More	O
specifically	O
,	O
in	O
a	O
small	O
-	O
data	O
context	O
,	O
the	O
latent	O
features	O
that	O
a	O
network	O
models	O
are	O
likely	O
to	O
result	O
from	O
sampling	O
noise	O
that	O
exists	O
only	O
in	O
the	O
training	O
data	O
,	O
and	O
not	O
in	O
novel	O
test	O
data	O
.	O

Without	O
techniques	O
to	O
overcome	O
this	O
generalization	O
problem	O
,	O
CNNs	O
may	O
have	O
limited	O
applications	O
for	O
less	O
common	O
diseases	O
,	O
including	O
brain	O
tumors	O
.	O

One	O
technique	O
available	O
to	O
overcome	O
the	O
overfitting	O
complication	O
of	O
small	O
training	O
datasets	O
is	O
Transfer	O
Learning	O
(	O
TL	O
).	O

This	O
is	O
a	O
machine	O
learning	O
methodology	O
for	O
storing	O
knowledge	O
gained	O
from	O
solving	O
a	O
problem	O
within	O
one	O
domain	O
and	O
applying	O
that	O
knowledge	O
to	O
another	O
domain	O
.	O

The	O
success	O
of	O
TL	O
has	O
led	O
to	O
the	O
development	O
of	O
publicly	O
available	O
pre	O
-	O
trained	O
models	O
derived	O
from	O
top	O
ILSVRC	O
solutions	O
.	O

By	O
using	O
these	O
pre	O
-	O
trained	O
networks	O
to	O
generate	O
feature	O
embeddings	O
for	O
our	O
dataset	O
of	O
interest	O
,	O
we	O
enable	O
our	O
classifier	O
to	O
have	O
access	O
to	O
the	O
pattern	O
recognition	O
capabilities	O
of	O
these	O
state	O
-	O
of	O
-	O
the	O
-	O
art	O
architectures	O
.	O

Another	B
technique	O
commonly	O
applied	O
to	O
image	O
classification	O
problems	O
is	O
data	O
augmentation	O
.	O

This	O
process	O
synthetically	O
expands	O
a	O
dataset	O
by	O
applying	O
transformations	O
(	O
i	O
.	O
e	O
.	O

crop	O
,	O
rotate	O
,	O
blur	O
,	O
etc	O
.)	O

to	O
real	O
data	O
in	O
an	O
attempt	O
to	O
preserve	O
domain	O
-	O
specific	O
features	O
.	O

We	O
employed	O
two	O
separate	O
data	O
augmentation	O
approaches	O
.	O

The	O
first	O
was	O
a	O
stochastic	O
process	O
that	O
sampled	O
across	O
transformations	O
with	O
probability	O
thresholds	O
.	O

The	O
second	O
method	O
,	O
known	O
as	O
TANDA	O
(	O
Transformation	O
Adversarial	O
Networks	O
for	O
Data	O
Augmentation	O
),	O
is	O
a	O
ML	O
-	O
based	O
approach	O
that	O
uses	O
Generative	O
Adversarial	O
Networks	O
(	O
GANs	O
)	O
and	O
Recurrent	O
Neural	O
Network	O
(	O
RNNs	O
)	O
to	O
learn	O
the	O
optimal	O
combination	O
and	O
parameters	O
of	O
the	O
image	O
transformations	O
within	O
a	O
specific	O
dataset	O
.	O

TANDA	O
was	O
reported	O
to	O
yield	O
synthetic	O
data	O
in	O
which	O
feature	O
representations	O
are	O
distributed	O
and	O
invariant	O
,	O
thus	O
helping	O
disentangle	O
the	O
factors	O
of	O
variation	O
between	O
the	O
two	O
classes	O
.	O

An	O
additional	O
challenge	O
in	O
identifying	O
the	O
optimal	O
model	O
is	O
the	O
optimization	O
of	O
CNN	O
hyperparameters	O
.	O

This	O
remains	O
a	O
complicated	O
and	O
computationally	O
intensive	O
task	O
.	O

To	O
mitigate	O
the	O
computational	O
time	O
required	O
,	O
one	O
may	O
apply	O
a	O
meta	O
-	O
heuristic	O
parameter	O
optimization	O
in	O
the	O
form	O
of	O
an	O
asynchronously	O
parallelized	O
genetic	O
algorithm	O
.	O

This	O
optimization	O
procedure	O
allows	O
the	O
model	O
to	O
optimize	O
more	O
intelligently	O
over	O
the	O
solution	O
space	O
with	O
fewer	O
required	O
iterations	O
.	O

To	O
demonstrate	O
the	O
capacity	O
of	O
combining	O
deep	O
networks	O
,	O
transfer	O
learning	O
,	O
data	O
augmentation	O
,	O
and	O
genetic	O
algorithms	O
to	O
overcome	O
the	O
problem	O
of	O
overfitting	O
with	O
small	O
datasets	O
,	O
we	O
utilized	O
the	O
pediatric	O
brain	O
tumor	O
Adamantinomatous	O
Craniopharyngioma	O
(	O
ACP	O
).	O

ACP	O
is	O
a	O
neurologically	O
devastating	O
brain	O
tumor	O
that	O
is	O
notorious	O
for	O
causing	O
vision	O
loss	O
,	O
hypothalamic	O
injury	O
,	O
hormone	O
dysfunction	O
and	O
cerebrospinal	O
fluid	O
pathway	O
obstruction	O
,	O
among	O
other	O
injuries	O
.	O

This	O
damage	O
results	O
from	O
growth	O
of	O
the	O
tumor	O
in	O
the	O
sellar	O
/	O
suprasellar	O
region	O
of	O
the	O
brain	O
,	O
where	O
it	O
invariably	O
develops	O
.	O

Here	O
,	O
ACP	O
compresses	O
the	O
optic	O
apparatus	O
,	O
hypothalamic	O
-	O
pituitary	O
axis	O
,	O
and	O
cerebral	O
ventricular	O
system	O
.	O

While	B
ACP	O
is	O
a	O
histologically	O
benign	O
lesion	O
,	O
it	O
often	O
recurs	O
locally	O
,	O
which	O
makes	O
further	O
treatment	O
more	O
perilous	O
for	O
the	O
patient	O
.	O

As	O
such	O
,	O
ACP	O
has	O
been	O
associated	O
with	O
the	O
lowest	O
quality	O
of	O
life	O
scores	O
of	O
any	O
pediatric	O
brain	O
tumor	O
.	O

Current	O
therapeutic	O
management	O
of	O
ACP	O
is	O
limited	O
to	O
either	O
aggressive	O
surgical	O
resection	O
or	O
surgical	O
debulking	O
followed	O
by	O
external	O
beam	O
radiation	O
.	O

This	O
differs	B
considerably	O
from	O
the	O
therapy	O
for	O
other	B
tumors	O
that	O
present	O
in	O
the	O
sellar	O
/	O
suprasellar	O
region	O
.	O

For	O
example	O
,	O
Germinoma	O
,	O
one	O
of	O
the	O
most	O
common	O
tumors	O
in	O
the	O
radiographic	O
differential	O
diagnosis	O
of	O
ACP	O
,	O
is	O
effectively	O
treated	O
without	O
surgical	O
intervention	O
.	O

Other	O
masses	O
of	O
this	O
region	O
,	O
including	O
glioma	O
,	O
pituitary	O
adenoma	O
,	O
arachnoid	O
cysts	O
,	O
and	O
others	O
,	O
similarly	O
require	O
therapy	O
tailored	O
to	O
the	O
particular	O
entity	O
.	O

As	O
such	O
,	O
a	O
priori	O
knowledge	O
of	O
the	O
patients	O
diagnosis	O
would	O
considerably	O
improve	O
the	O
clinical	O
care	O
of	O
children	O
with	O
tumors	O
of	O
the	O
sellar	O
/	O
suprasellar	O
region	O
,	O
the	O
most	O
common	O
of	O
which	O
is	O
ACP	O
.	O

Radiographically	O
,	O
ACP	O
is	O
characterized	O
by	O
heterogeneous	O
solid	O
tissue	O
,	O
cystic	O
regions	O
,	O
and	O
calcification	O
.	O

Recent	O
data	O
indicate	O
that	O
ACP	O
and	O
other	O
tumors	O
of	O
the	O
sellar	O
/	O
suprasellar	O
region	O
may	O
be	O
accurately	O
diagnosed	O
using	O
current	O
radiographic	O
techniques	O
in	O
64â	O
	O
87	O
%	O
of	O
cases	O
.	O

This	O
sets	O
a	O
high	O
bar	O
for	O
machine	O
-	O
aided	O
diagnoses	O
,	O
but	O
also	O
leaves	O
room	O
for	O
clinically	O
relevant	O
improvement	O
.	O

While	B
ACP	O
is	O
the	O
most	O
common	O
sellar	O
/	O
suprasellar	O
pediatric	O
tumor	O
,	O
it	O
is	O
an	O
uncommon	O
entity	O
,	O
representing	O
2	O
to	O
5	O
%	O
of	O
all	O
pediatric	O
brain	O
tumors	O
,	O
with	O
an	O
incidence	O
of	O
approximately	O
1	O
.	O
9	O
per	O
million	O
patient	O
-	O
years	O
.	O

In	O
order	O
to	O
facilitate	O
research	O
into	O
this	O
tumor	O
,	O
Advancing	O
Treatment	O
for	O
Pediatric	O
Craniopharyngioma	O
was	O
formed	O
in	O
2015	O
.	O

This	O
consortium	O
includes	O
17	O
North	O
American	O
centers	O
,	O
which	O
share	O
tissue	O
and	O
clinical	O
data	O
regarding	O
children	O
with	O
ACP	O
,	O
thus	O
providing	O
source	O
data	O
for	O
this	O
research	O
.	O

In	O
addition	O
to	O
the	O
imaging	O
data	O
assembled	O
from	O
these	O
centers	O
,	O
we	O
added	O
data	O
from	O
St	O
.	O
Jude	O
Childrenâ	O
	O
s	O
Research	O
Hospital	O
,	O
thereby	O
assembling	O
a	O
generalizable	O
and	O
representative	O
dataset	O
of	O
both	O
ACP	O
and	O
other	O
sellar	O
/	O
suprasellar	O
entities	O
for	O
model	O
training	O
and	O
evaluation	O
.	O

In	O
summary	O
,	O
ACP	O
is	O
an	O
ideal	O
candidate	O
for	O
CNN	O
inference	O
due	O
to	O
its	O
consistent	O
anatomical	O
location	O
,	O
radiographically	O
recognizable	O
features	O
,	O
and	O
,	O
most	O
importantly	O
,	O
the	O
substantial	O
clinical	O
management	O
differences	B
between	O
ACP	O
and	O
the	O
other	O
brain	O
masses	O
that	O
lie	O
within	O
the	O
differential	O
diagnosis	O
.	O

However	O
,	O
given	O
its	O
incidence	O
,	O
ACP	O
lacks	O
the	O
volume	O
of	O
labeled	O
data	O
observed	O
in	O
more	O
common	O
disease	O
contexts	O
.	O

By	O
describing	O
a	O
mathematical	O
model	O
for	O
the	O
identification	O
of	O
ACP	O
,	O
we	O
present	O
a	O
computationally	O
economical	O
method	O
to	O
optimize	O
CNN	O
architectures	O
for	O
image	O
classification	O
in	O
contexts	O
that	O
do	O
not	O
afford	O
large	O
amounts	O
of	O
labeled	O
training	O
data	O
.	O

In	O
so	O
doing	O
,	O
we	O
create	O
a	O
non	O
-	O
invasive	O
diagnostic	O
tool	O
to	O
aid	O
in	O
the	O
reduction	O
of	O
mis	O
-	O
diagnoses	O
and	O
unnecessary	O
medical	O
intervention	O
.	O

Results	O
Baseline	O
predictive	O
results	O
Caption	O
(	O
Fig	O
):	O
FIG	O
1	O
Transfer	O
learning	O
networks	O
,	O
feature	O
embeddings	O
,	O
and	O
baseline	O
results	O
.	O

(	O
A	O
)	O
ILSVRC	O
network	O
models	O
utilized	O
,	O
with	O
their	O
top	O
1	O
%	O
and	O
top	O
5	O
%	O
accuracy	O
in	O
ILSVRC	O
competition	O
noted	O
.	O

(	O
B	O
)	O
Example	O
CT	O
and	O
MRI	O
images	O
for	O
both	O
ACP	O
and	O
NOTACP	O
.	O

(	O
C	O
)	O
ROC	O
(	O
left	O
)	O
and	O
AUC	O
(	O
right	O
)	O
values	O
for	O
all	O
twelve	O
networks	O
and	O
both	O
imaging	O
modalities	O
(	O
CT	O
top	O
,	O
MRI	O
bottom	O
).	O

The	O
diagonal	O
dashed	O
line	O
represents	O
performance	O
of	O
a	O
random	O
guess	O
.	O

Using	O
twelve	O
state	O
-	O
of	O
-	O
the	O
-	O
art	O
networks	O
that	O
have	O
publicly	O
available	O
deep	O
learning	O
models	O
from	O
the	O
TensorFlow	O
Hub	O
library	O
trained	O
on	O
the	O
ImageNet	O
ILSVRC	O
dataset	O
(	O
Fig	O
.	O
Â	O
1A	O
),	O
we	O
generated	O
feature	O
embedding	O
vectors	O
to	O
be	O
used	O
in	O
model	O
training	O
(	O
Fig	O
.	O
Â	O
1B	O
).	O

Baseline	O
experiments	O
were	O
conducted	O
by	O
training	O
a	O
single	O
fully	O
-	O
connected	O
layer	O
with	O
a	O
softmax	O
activation	O
function	O
and	O
stochastic	O
gradient	O
descent	O
(	O
SGD	O
)	O
optimization	O
algorithm	O
.	O

Using	O
whole	O
-	O
batch	O
training	O
,	O
a	O
learning	O
rate	O
of	O
0	O
.	O
01	O
,	O
and	O
a	O
training	O
duration	O
of	O
100	O
epochs	O
,	O
we	O
established	O
baseline	O
results	O
(	O
Fig	O
.	O
Â	O
1C	O
).	O

Across	O
all	O
twelve	O
feature	O
embeddings	O
,	O
on	O
average	O
the	O
classifier	O
accurately	O
labelled	O
individual	O
CT	O
scans	O
62	O
.	O
3	O
%	O
(	O
Top	O
-	O
5	O
Network	O
Average	O
;	O
maximum	O
performance	O
)	O
and	O
MRI	O
scans	O
45	O
.	O
7	O
%	O
(;	O
)	O
of	O
the	O
time	O
.	O

Model	O
selection	O
and	O
parameter	O
optimization	O
using	O
manual	O
selection	O
Caption	O
(	O
Fig	O
):	O
FIG	O
2	O
Genetic	O
algorithm	O
optimization	O
of	O
model	O
parameters	O
.	O

(	O
A	O
)	O
General	O
process	O
schematic	O
for	O
genetic	O
algorithm	O
parameter	O
optimization	O
.	O

Moving	O
from	O
left	O
to	O
right	O
,	O
a	O
feature	O
variant	O
is	O
selected	O
for	O
each	O
model	O
feature	O
to	O
create	O
individual	O
networks	O
(	O
Step	O
1	O
;	O
individuals	O
are	O
highlighted	O
in	O
unique	O
colors	O
).	O

Individuals	O
are	O
trained	O
and	O
evaluated	O
to	O
determine	O
fitness	O
and	O
ranked	O
accordingly	O
(	O
Step	O
2	O
).	O

Two	O
networks	O
are	O
chosen	O
from	O
the	O
fittest	O
population	O
and	O
a	O
new	O
network	O
is	O
derived	O
by	O
selecting	O
from	O
feature	O
variants	O
in	O
these	O
two	O
networks	O
,	O
and	O
variants	O
are	O
occasionally	O
mutated	O
(	O
i	O
.	O
e	O
.,	O
randomly	O
selected	O
from	O
the	O
population	O
pool	O
;	O
Step	O
3	O
).	O

(	O
B	O
)	O
Model	O
feature	O
and	O
respective	O
feature	O
variants	O
explored	O
in	O
first	O
phase	O
of	O
genetic	O
algorithm	O
optimization	O
.	O

Each	O
column	O
represents	O
a	O
model	O
feature	O
to	O
be	O
optimized	O
and	O
each	O
row	O
is	O
a	O
possible	O
feature	O
variant	O
for	O
the	O
GA	O
to	O
select	O
from	O
.	O

This	O
table	O
reflects	O
the	O
â	O
	O
Population	O
Poolâ	O
	O
(	O
A	O
).	O

(	O
C	O
)	O
Top	O
-	O
5	O
performing	O
networks	O
for	O
independent	O
CT	O
and	O
MRI	O
networks	O
after	O
10	O
generations	O
of	O
100	O
solution	O
populations	O
;	O
ranked	O
according	O
to	O
test	O
accuracy	O
.	O

(	O
D	O
)	O
Top	O
-	O
5	O
performing	O
networks	O
for	O
combined	O
CT	O
-	O
MRI	O
networks	O
after	O
10	O
generations	O
of	O
100	O
solution	O
populations	O
;	O
ranked	O
according	O
to	O
test	O
accuracy	O
.	O

To	O
address	O
the	O
computational	O
and	O
time	O
demands	O
associated	O
with	O
architecture	O
selection	O
and	O
hyperparameter	O
optimization	O
within	O
deep	O
learning	O
models	O
,	O
we	O
employed	O
a	O
parallelized	O
simple	O
genetic	O
algorithm	O
(	O
GA	O
)	O
to	O
more	O
rapidly	O
identify	O
optimal	O
combinations	O
of	O
feature	O
extractors	O
,	O
learning	O
parameters	O
,	O
and	O
hyperparameters	O
for	O
both	O
CT	O
and	O
MRI	O
(	O
see	O
Computational	O
Methods	O
;	O
Fig	O
.	O
Â	O
2A	O
).	O

We	O
employed	O
ten	O
different	O
model	O
features	O
to	O
optimize	O
the	O
parameters	O
of	O
the	O
(	O
1	O
)	O
fully	O
connected	O
classifier	O
network	O
;	O
(	O
2	O
)	O
the	O
pre	O
-	O
trained	O
deep	O
CNN	O
to	O
be	O
utilized	O
for	O
feature	O
embeddings	O
;	O
and	O
,	O
(	O
3	O
)	O
the	O
type	O
of	O
training	O
and	O
test	O
datasets	O
(	O
e	O
.	O
g	O
.	O

original	O
or	O
synthetically	O
expanded	O
by	O
augmentation	O
;	O
Fig	O
.	O
Â	O
2B	O
).	O

The	O
number	O
of	O
variants	O
for	O
each	O
model	O
feature	O
ranged	O
from	O
three	O
to	O
fifteen	O
,	O
making	O
the	O
total	O
number	O
of	O
possible	O
network	O
combinations	O
19	O
,	O
051	O
,	O
200	O
(	O
see	O
"	O
Methods	O
"	O
section	O
).	O

The	O
GA	O
allowed	O
for	O
more	O
intelligent	O
exploration	O
of	O
the	O
solution	O
space	O
and	O
reduced	O
the	O
overall	O
computational	O
time	O
required	O
.	O

By	O
performing	O
10	O
generations	O
of	O
100	O
solution	O
populations	O
with	O
a	O
generational	O
retention	O
rate	O
of	O
40	O
%,	O
a	O
negative	O
rejection	O
probability	O
of	O
10	O
%,	O
and	O
a	O
mutation	O
frequency	O
of	O
20	O
%,	O
we	O
explored	O
only	O
solutions	O
to	O
identify	O
the	O
top	O
5	O
performing	O
networks	O
of	O
the	O
final	O
generation	O
(	O
Fig	O
.	O
Â	O
2C	O
).	O

This	O
process	O
yielded	O
an	O
accuracy	O
increase	O
in	O
CT	O
of	O
only	O
3	O
.	O
75	O
%	O
(;	O
)	O
and	O
an	O
an	O
increase	O
of	O
16	O
.	O
8	O
%	O
(;	O
)	O
for	O
MRI	O
.	O

Model	O
selection	O
and	O
parameter	O
optimization	O
using	O
a	O
simple	O
genetic	O
algorithm	O
When	O
the	O
genetic	O
algorithm	O
was	O
employed	O
,	O
a	O
superior	O
network	O
became	O
apparent	O
for	O
both	O
CT	O
-	O
and	O
MRI	O
-	O
trained	O
classifiers	O
.	O

Interestingly	O
,	O
the	O
same	O
general	O
architectureâ	O
	O
ResNetâ	O
	O
was	O
selected	O
,	O
with	O
CT	O
data	O
favoring	O
the	O
V1	O
variant	O
and	O
MRI	O
favoring	O
the	O
V2	O
variant	O
.	O

The	O
primary	O
difference	B
between	O
these	O
architectures	O
is	O
the	O
use	O
of	O
batch	O
normalization	O
(	O
BN	O
)	O
between	O
every	O
layer	O
in	O
V2	O
as	B
opposed	I
to	I
V1	O
.	O

The	O
BN	O
transformation	O
is	O
particularly	O
resilient	O
toward	O
parameter	O
scale	O
because	O
backpropagation	O
through	O
a	O
layer	O
is	O
unaffected	O
by	O
the	O
scale	O
of	O
its	O
parameters	O
.	O

This	O
suggests	O
that	O
MRI	O
data	O
contained	O
more	O
erratic	O
feature	O
distributions	O
than	O
CT	O
and	O
therefore	O
benefited	O
from	O
the	O
more	O
regularized	O
representation	O
.	O

Further	O
,	O
the	O
superiority	O
of	O
each	O
respective	O
network	O
is	O
highlighted	O
by	O
their	O
selection	O
within	O
the	O
combined	O
CT	O
-	O
MRI	O
network	O
(;	O
Fig	O
.	O
Â	O
2D	O
).	O

Caption	O
(	O
Fig	O
):	O
FIG	O
3	O
Further	O
optimization	O
with	O
GA	O
.	O
(	O
A	O
).	O

Model	O
features	O
and	O
variants	O
available	O
for	O
solution	O
search	O
space	O
in	O
second	O
phase	O
of	O
GA	O
optimization	O
.	O

Each	O
column	O
represents	O
a	O
model	O
feature	O
to	O
be	O
optimized	O
and	O
each	O
row	O
is	O
a	O
possible	O
feature	O
variant	O
for	O
the	O
GA	O
to	O
select	O
from	O
.	O

(	O
B	O
)	O
Top	O
-	O
5	O
performing	O
networks	O
from	O
CT	O
and	O
MRI	O
trained	O
networks	O
as	O
optimized	O
by	O
the	O
GA	O
for	O
10	O
generations	O
of	O
100	O
solution	O
populations	O
.	O

(	O
C	O
)	O
Top	O
-	O
5	O
performing	O
networks	O
for	O
combined	O
CT	O
-	O
MRI	O
trained	O
networks	O
as	O
optimized	O
by	O
the	O
GA	O
for	O
10	O
generations	O
of	O
100	O
solution	O
populations	O
.	O

While	B
performance	O
improved	O
within	O
both	O
modalities	O
compared	O
to	I
the	O
pre	O
-	O
GA	O
results	O
,	O
this	O
method	O
searched	O
only	O
0	O
.	O
005	O
%	O
of	O
the	O
total	O
number	O
of	O
solutions	O
.	O

We	O
sought	O
to	O
verify	O
that	O
we	O
did	O
not	O
identify	O
a	O
local	O
minima	O
within	O
the	O
model	O
solution	O
space	O
by	O
exploring	O
0	O
.	O
1	O
%	O
of	O
all	O
solutions	O
.	O

In	O
every	O
GA	O
iteration	O
all	O
paramaters	O
were	O
equally	O
distributed	O
in	O
the	O
first	O
generation	O
,	O
but	O
by	O
the	O
last	O
generation	O
the	O
same	O
end	O
-	O
point	O
was	O
reached	O
with	O
similar	O
results	O
via	O
similar	O
â	O
	O
evolutionaryâ	O
	O
paths	O
to	O
those	O
presented	O
in	O
Fig	O
.	O
Â	O
2	O
(	O
data	O
not	O
shown	O
).	O

To	O
further	O
improve	O
model	O
generalization	O
,	O
we	O
performed	O
a	O
second	O
iteration	O
of	O
the	O
GA	O
with	O
fewer	O
parameters	O
(	O
Fig	O
.	O
Â	O
3A	O
).	O

In	O
this	O
iteration	O
,	O
we	O
allowed	O
the	O
GA	O
to	O
evolve	O
a	O
parameter	O
population	O
with	O
only	O
144	O
possible	O
combinations	O
for	O
CT	O
and	O
1944	O
possible	O
solutions	O
for	O
MRI	O
.	O

After	O
running	O
the	O
GA	O
on	O
the	O
new	O
refined	O
feature	O
lists	O
for	O
10	O
generations	O
with	O
100	O
solutions	O
per	O
generation	O
,	O
the	O
top	O
accuracy	O
for	O
CT	O
increased	O
by	O
a	O
further	O
1	O
.	O
54	O
%	O
(	O
T5NAÂ	O
=	O
Â	O
83	O
.	O
4	O
%;	O
MPÂ	O
=	O
Â	O
85	O
.	O
3	O
%;	O
Fig	O
.	O
Â	O
3B	O
).	O

Similarly	O
,	O
we	O
observed	O
an	O
increase	O
in	O
performance	O
for	O
CT	O
-	O
MRI	O
networks	O
(	O
T5NA	O
=	O
86	O
.	O
1	O
%;	O
MP	O
=	O
87	O
.	O
8	O
%;	O
Fig	O
.	O
Â	O
3C	O
).	O

Interestingly	O
,	O
however	B
,	O
the	O
solution	O
networks	O
for	O
MRI	O
classification	O
did	O
not	O
attain	O
the	O
same	O
level	O
of	O
accuracy	O
as	O
the	O
initial	O
GA	O
iteration	O
(	O
T5NA	O
=	O
78	O
.	O
5	O
%;	O
MP	O
=	O
80	O
.	O
8	O
%;	O
Fig	O
.	O
Â	O
3B	O
).	O

This	O
could	O
be	O
due	O
to	O
our	O
optimization	O
algorithm	O
erroneously	O
identifying	O
a	O
local	O
minimum	O
of	O
the	O
solution	O
space	O
,	O
as	B
opposed	I
to	I
the	O
desired	O
global	O
minimum	O
.	O

Stochastically	O
augmented	O
training	O
data	O
outperforms	O
TANDA	O
augmented	O
training	O
data	O
Caption	O
(	O
Fig	O
):	O
FIG	O
4	O
Test	O
performance	O
of	O
models	O
trained	O
on	O
stochastic	O
image	O
augmentation	O
and	O
GAN	O
-	O
LSTM	O
augmented	O
images	O
.	O

(	O
A	O
)	O
Exemplar	O
images	O
of	O
original	O
training	O
CT	O
(	O
top	O
)	O
and	O
MRI	O
(	O
bottom	O
),	O
with	O
randomly	O
augmented	O
variants	O
,	O
and	O
TANDA	O
-	O
augmented	O
variants	O
.	O

(	O
B	O
)	O
ROC	O
curves	O
for	O
CT	O
-	O
and	O
MRI	O
-	O
trained	O
networks	O
comparing	O
top	O
results	O
of	O
supervised	O
augmented	O
images	O
and	O
TANDA	O
-	O
generated	O
images	O
.	O

Dashed	O
lines	O
represent	O
ROC	O
curve	O
of	O
random	O
chance	O
classification	O
.	O

It	O
is	O
well	O
documented	O
that	O
data	O
augmentation	O
improves	O
performance	O
of	O
state	O
-	O
of	O
-	O
the	O
-	O
art	O
image	O
classification	O
models	O
.	O

Two	O
potential	O
data	O
augmentation	O
solutions	O
are	O
the	O
stochastic	O
-	O
based	O
and	O
ML	O
-	O
based	O
augmentation	O
pipelines	O
.	O

We	O
explored	O
both	O
solutions	O
,	O
using	O
the	O
publicly	O
available	O
python	O
modules	O
Augmentor	O
(	O
stochastic	O
-	O
based	O
)	O
and	O
TANDA	O
(	O
LSTM	O
-	O
GAN	O
-	O
based	O
)	O
to	O
oversample	O
our	O
training	O
data	O
to	O
1000	O
images	O
per	O
class	O
(	O
Fig	O
.	O
Â	O
4A	O
).	O

Interestingly	O
,	O
optimal	O
models	O
trained	O
on	O
stochastically	O
augmented	O
data	O
outperformed	O
those	O
same	O
architectures	O
trained	O
on	O
TANDA	O
augmented	O
data	O
(	O
Fig	O
.	O
Â	O
4B	O
).	O

This	O
finding	O
could	O
result	O
from	O
our	O
use	O
of	O
TANDA	O
with	O
parameters	O
given	O
for	O
the	O
MNIST	O
handwritten	O
-	O
image	O
dataset	O
context	O
,	O
rather	B
than	O
applying	O
TANDA	O
following	O
optimization	O
for	O
our	O
specific	O
context	O
.	O

While	B
this	O
represents	O
an	O
area	O
for	O
additional	O
investigation	O
,	O
current	O
literature	O
suggests	O
that	O
TANDA	O
can	O
be	O
expected	O
to	O
realize	O
improvements	O
of	O
2â	O
	O
4	O
%	O
in	O
CNNs	O
with	O
architectures	O
comparable	O
to	O
our	O
own	O
.	O

Given	O
this	O
fairly	O
small	O
improvement	O
,	O
there	O
exists	O
a	O
computational	O
efficiency	O
argument	O
that	O
favors	O
the	O
use	O
of	O
the	O
stochastic	O
process	O
,	O
especially	O
in	O
early	O
stage	O
investigations	O
,	O
or	O
in	O
contexts	O
where	O
computational	O
resources	O
are	O
limited	O
.	O

In	O
our	O
study	O
,	O
the	O
stochastic	O
approach	O
yielded	O
superior	O
results	O
without	O
the	O
requirement	O
to	O
train	O
and	O
evaluate	O
complex	O
machine	O
-	O
learning	O
systems	O
and	O
with	O
lesser	O
computational	O
demand	O
.	O

An	O
additional	O
aspect	O
of	O
our	O
data	O
that	O
could	O
favor	O
the	O
use	O
of	O
stochastic	O
data	O
augmentation	O
is	O
the	O
relative	O
conspicuity	O
of	O
the	O
critical	O
features	O
of	O
the	O
image	O
.	O

Both	O
due	O
to	O
the	O
nature	O
of	O
a	O
tumor	O
being	O
a	O
mass	O
lesion	O
,	O
and	O
the	O
quality	O
of	O
current	O
medical	O
imaging	O
technologies	O
,	O
the	O
primary	O
source	O
of	O
differentiable	O
information	O
in	O
the	O
images	O
that	O
compose	O
our	O
dataset	O
lies	O
within	O
the	O
sellar	O
/	O
suprasellar	O
region	O
(	O
discussed	O
in	O
the	O
following	O
section	O
),	O
with	O
a	O
gradient	O
of	O
decreasing	O
value	O
as	O
one	O
moves	O
radially	O
away	O
from	O
this	O
region	O
.	O

The	O
resultant	O
relative	O
simplicity	O
in	O
the	O
images	O
may	O
therefore	O
lead	O
to	O
only	O
a	O
marginal	O
difference	O
between	O
stochastic	O
augmentation	O
and	O
TANDA	O
.	O

Datasets	O
in	O
which	O
the	O
target	O
object	O
is	O
more	O
difficult	O
to	O
distinguish	O
from	O
the	O
background	O
(	O
for	O
example	O
,	O
identifying	O
a	O
person	O
wearing	O
black	O
and	O
white	O
stripes	O
among	O
a	O
group	O
of	O
zebras	O
)	O
may	O
,	O
however	B
,	O
better	O
demonstrate	O
the	O
advantage	O
of	O
the	O
more	O
complex	O
TANDA	O
methodology	O
.	O

Manual	O
objective	O
obfuscation	O
indicates	O
the	O
sellar	O
/	O
suprasellar	O
region	O
is	O
critical	O
to	O
class	O
identification	O
Caption	O
(	O
Fig	O
):	O
FIG	O
5	O
Pituitary	O
obfuscation	O
reveals	O
latent	O
features	O
exist	O
outside	O
canonical	O
ROI	O
for	O
CT	O
scans	O
.	O

(	O
A	O
)	O
Example	O
original	O
and	O
obfuscated	O
images	O
for	O
both	O
data	O
classes	O
and	O
both	O
imaging	O
modalities	O
.	O

(	O
B	O
)	O
ROC	O
curves	O
for	O
networks	O
trained	O
on	O
obfuscated	O
and	O
original	O
data	O
;	O
original	O
data	O
was	O
â	O
	O
Augmented	O
()	O
â	O
	O
variant	O
.	O

(	O
C	O
)	O
Baseline	O
ROC	O
curves	O
for	O
all	O
twelve	O
networks	O
trained	O
on	O
original	O
(	O
left	O
)	O
and	O
obfuscated	O
(	O
right	O
)	O
CT	O
images	O
.	O

(	O
D	O
)	O
Baseline	O
ROC	O
curves	O
for	O
all	O
twelve	O
networks	O
trained	O
on	O
original	O
(	O
left	O
)	O
and	O
obfuscated	O
(	O
right	O
)	O
MRI	O
images	O
.	O

To	O
understand	O
the	O
general	O
patterns	O
the	O
model	O
identified	O
as	O
class	O
indicators	O
,	O
we	O
performed	O
manual	O
objective	O
obfuscation	O
of	O
the	O
sellar	O
/	O
suprasellar	O
region	O
in	O
all	O
training	O
images	O
(	O
Fig	O
.	O
Â	O
5A	O
).	O

The	O
previously	O
identified	O
optimal	O
networks	O
were	O
trained	O
on	O
these	O
obfuscated	O
data	O
and	O
subsequently	O
used	O
to	O
infer	O
diagnosis	O
from	O
the	O
test	O
set	O
.	O

In	O
this	O
context	O
,	O
the	O
networks	O
failed	O
to	O
accurately	O
distinguish	O
ACP	O
from	O
NOTACP	O
images	O
(	O
Fig	O
.	O
Â	O
5B	O
).	O

Interestingly	O
,	O
however	B
,	O
when	O
the	O
baseline	O
networks	O
were	O
trained	O
using	O
obfuscated	O
data	O
,	O
some	O
networks	O
reliably	O
distinguished	O
data	O
classes	O
(	O
Fig	O
.	O
Â	O
5C	O
,	O
D	O
).	O

This	O
suggests	O
that	O
while	B
the	O
GA	O
-	O
identified	O
networks	O
utilize	O
image	O
patterns	O
within	O
the	O
sellar	O
/	O
suprasellar	O
region	O
,	O
other	B
non	O
-	O
optimized	O
networks	O
identify	O
latent	O
patterns	O
outside	O
of	O
the	O
sellar	O
/	O
suprasellar	O
region	O
,	O
which	O
is	O
the	O
anatomical	O
location	O
of	O
ACP	O
.	O

As	O
such	O
,	O
a	O
potential	O
improvement	O
to	O
our	O
model	O
could	O
be	O
to	O
integrate	O
feature	O
embeddings	O
from	O
all	O
networks	O
in	O
order	O
to	O
leverage	O
both	O
sellar	O
/	O
suprasellar	O
and	O
extra	O
-	O
sellar	O
patterns	O
within	O
the	O
data	O
.	O

Benchmarking	O
against	O
human	O
performance	O
and	O
assessment	O
of	O
hold	O
out	O
training	O
/	O
testing	O
approach	O
Caption	O
(	O
Fig	O
):	O
FIG	O
6	O
Optimized	O
network	O
classification	O
performance	O
versus	O
human	O
specialist	O
and	O
5	O
-	O
fold	O
cross	O
-	O
validation	O
evaluation	O
.	O

(	O
A	O
)	O
Radiologist	O
average	O
auROC	O
of	O
89	O
.	O
4	O
%,	O
83	O
.	O
3	O
%,	O
and	O
93	O
.	O
8	O
%	O
for	O
CT	O
,	O
MRI	O
,	O
and	O
CT	O
-	O
MRI	O
,	O
respectively	O
.	O

GA	O
-	O
optimzed	O
auROC	O
of	O
85	O
.	O
3	O
%,	O
83	O
.	O
3	O
%,	O
and	O
87	O
.	O
8	O
%	O
for	O
CT	O
,	O
MRI	O
,	O
and	O
CT	O
-	O
MRI	O
,	O
respectively	O
.	O

(	O
B	O
)	O
Schematics	O
of	O
5	O
-	O
fold	O
cross	O
-	O
validation	O
(	O
5F	O
-	O
CV	O
)	O
approaches	O
used	O
to	O
verify	O
the	O
perceived	O
improvement	O
yielded	O
by	O
augmented	O
training	O
data	O
(	O
scenario	O
3	O
vs	O
.	O
scenarios	O
1	O
and	O
2	O
).	O

Additionally	O
scenarios	O
1	O
and	O
2	O
investigate	O
the	O
effect	O
of	O
mixing	O
augmented	O
data	O
into	O
the	O
overall	O
data	O
pool	O
versus	O
only	O
augmenting	O
training	O
data	O
.	O

(	O
C	O
)	O
Performance	O
metrics	O
(	O
AUC	O
:	O
area	O
under	O
the	O
ROC	O
curve	O
;	O
Accuracy	O
:	O
standard	O
accuracy	O
metric	O
)	O
for	O
5F	O
-	O
CV	O
across	O
all	O
three	O
scenarios	O
.	O

Peak	O
performance	O
was	O
achieved	O
via	O
scenario	O
2	O
in	O
CT	O
(	O
AUCÂ	O
=	O
Â	O
88	O
.	O
0	O
%,	O
AccuracyÂ	O
=	O
Â	O
89	O
.	O
0	O
%)	O
and	O
MRI	O
(	O
AUCÂ	O
=	O
Â	O
97	O
.	O
5	O
%,	O
AccuracyÂ	O
=	O
Â	O
97	O
.	O
4	O
%).	O

In	O
the	O
context	O
of	O
CT	O
-	O
MRI	O
,	O
peak	O
performance	O
was	O
attained	O
in	O
scenario	O
3	O
(	O
AUCÂ	O
=	O
Â	O
97	O
.	O
8	O
%,	O
AccuracyÂ	O
=	O
Â	O
97	O
.	O
9	O
%).	O

Next	O
,	O
we	O
sought	O
to	O
compare	O
the	O
generalization	O
capacity	O
of	O
our	O
GA	O
-	O
optimized	O
models	O
against	O
the	O
performance	O
of	O
board	O
-	O
certified	O
pediatric	O
neuroradiologists	O
.	O

Using	O
the	O
same	O
test	O
dataset	O
(	O
1	O
JPEG	O
image	O
per	O
modality	O
per	O
unique	O
patient	O
)	O
used	O
to	O
determine	O
â	O
	O
fitnessâ	O
	O
within	O
the	O
GA	O
,	O
two	O
specialists	O
were	O
asked	O
to	O
classify	O
diagnosis	O
of	O
ACP	O
/	O
NOTACP	O
in	O
a	O
binary	O
context	O
(	O
Fig	O
.	O
Â	O
6	O
).	O

Our	O
optimal	O
models	O
performed	O
on	O
par	O
with	O
the	O
average	O
of	O
human	O
specialists	O
(),	O
although	O
â	O
	O
Radiologist	O
Aâ	O
	O
consistently	O
outperformed	O
our	O
models	O
across	O
the	O
board	O
.	O

As	O
mentioned	O
previously	O
,	O
recent	O
work	O
reported	O
an	O
accuracy	O
of	O
ACP	O
diagnosis	O
of	O
87	O
%	O
by	O
pediatric	O
neuroradiologists	O
using	O
a	O
complete	O
imaging	O
dataset	O
and	O
clinical	O
history	O
.	O

This	O
performance	O
corroborates	O
the	O
overall	O
generalization	O
capacity	O
of	O
the	O
models	O
presented	O
herein	O
.	O

Since	O
the	O
dataset	O
utilized	O
is	O
small	O
and	O
therefore	O
sensitive	O
to	O
selection	O
bias	O
,	O
there	O
is	O
concern	O
that	O
the	O
hold	O
-	O
out	O
approach	O
may	O
misrepresent	O
the	O
true	O
predictive	O
capacity	O
of	O
our	O
classifier	O
.	O

To	O
address	O
this	O
,	O
we	O
additionally	O
evaluated	O
our	O
classifier	O
using	O
five	O
-	O
fold	O
cross	O
-	O
validation	O
(	O
5F	O
-	O
CV	O
).	O

Our	O
GA	O
previously	O
identified	O
that	O
augmented	O
data	O
were	O
ideal	O
for	O
training	O
and	O
original	O
data	O
were	O
ideal	O
for	O
test	O
data	O
,	O
thus	O
we	O
chose	O
to	O
evaluate	O
5F	O
-	O
CV	O
in	O
three	O
different	O
scenarios	O
to	O
verify	O
that	O
augmenting	O
training	O
data	O
are	O
superior	O
(	O
Fig	O
.	O
Â	O
6	O
).	O

To	O
further	O
verify	O
the	O
power	O
of	O
our	O
classifier	O
,	O
we	O
chose	O
two	O
separate	O
approaches	O
as	O
to	O
when	O
data	O
is	O
augmented	O
.	O

Interestingly	O
,	O
the	O
5F	O
-	O
CV	O
data	O
suggests	O
model	O
performance	O
greater	O
than	O
results	O
yielded	O
in	O
the	O
hold	O
-	O
out	O
approach	O
(	O
Fig	O
.	O
Â	O
6C	O
).	O

We	O
see	O
that	O
for	O
CT	O
and	O
MRI	O
contexts	O
,	O
augmenting	O
only	O
training	O
data	O
yields	O
the	O
highest	O
results	O
(	O
88	O
.	O
9	O
%	O
and	O
97	O
.	O
3	O
%,	O
respectively	O
;	O
Fig	O
.	O
Â	O
6B	O
.	O

Scenario	O
2	O
)	O
and	O
classifiers	O
trained	O
on	O
original	O
data	O
perform	O
worse	O
,	O
as	O
expected	O
.	O

This	O
is	O
particularly	O
interesting	O
due	O
to	O
the	O
expectation	O
that	O
mixing	O
augmented	O
data	O
(	O
Fig	O
.	O
Â	O
6B	O
.	O

Scenario	O
1	O
)	O
should	O
increase	O
data	O
overlap	O
and	O
therefore	O
lead	O
to	O
overfitting	O
and	O
inflated	O
performance	O
metrics	O
.	O

Lastly	O
,	O
the	O
CT	O
-	O
MRI	O
context	O
demonstrated	O
that	O
peak	O
performance	O
was	O
attained	O
using	O
original	O
training	O
and	O
test	O
data	O
.	O

Since	O
the	O
CT	O
-	O
MRI	O
context	O
concatenates	O
feature	O
embeddings	O
along	O
a	O
1	O
-	O
dimensional	O
axis	O
,	O
perhaps	O
these	O
features	O
contain	O
sufficient	O
classification	O
information	O
without	O
the	O
need	O
for	O
augmentation	O
.	O

In	O
fact	O
,	O
information	O
needed	O
in	O
the	O
CT	O
-	O
MRI	O
context	O
may	O
be	O
obscured	O
or	O
dropped	O
by	O
concatenating	O
two	O
augmented	O
case	O
examples	O
.	O

In	O
summary	O
,	O
the	O
combination	O
of	O
hold	O
-	O
out	O
and	O
5F	O
-	O
CV	O
performance	O
metrics	O
firmly	O
verifies	O
the	O
robustness	O
of	O
our	O
GA	O
-	O
based	O
approach	O
and	O
our	O
resultant	O
classifiers	O
.	O

Discussion	O
Using	O
the	O
pediatric	O
brain	O
tumor	O
Adamantinomatous	O
Craniopharyngioma	O
as	O
an	O
example	O
of	O
a	O
clinical	O
entity	O
with	O
a	O
small	O
available	O
dataset	O
,	O
we	O
enhance	O
the	O
performance	O
of	O
a	O
baseline	O
Convolutional	O
Neural	O
Network	O
using	O
a	O
series	O
of	O
optimization	O
methodologies	O
,	O
including	O
Transfer	O
Learning	O
,	O
Data	O
Augmentation	O
(	O
supervised	O
and	O
unsupervised	O
),	O
and	O
Image	O
Obfuscation	O
.	O

The	O
application	O
of	O
a	O
Genetic	O
Algorithm	O
as	O
a	O
meta	O
-	O
heuristic	O
optimizer	O
realized	O
performance	O
improvements	O
of	O
approximately	O
23	O
%	O
for	O
CT	O
-	O
trained	O
networks	O
,	O
and	O
38	O
%	O
for	O
MRI	O
-	O
trained	O
networks	O
,	O
leading	O
to	O
test	O
accuracies	O
of	O
85	O
.	O
3	O
%,	O
83	O
.	O
3	O
%,	O
and	O
87	O
.	O
8	O
%	O
for	O
Computed	O
Tomography	O
(	O
CT	O
),	O
Magnetic	O
Resonance	O
Imaging	O
(	O
MRI	O
),	O
and	O
combined	O
CT	O
and	O
MRI	O
datasets	O
,	O
respectively	O
.	O

We	O
further	O
demonstrate	O
that	O
this	O
is	O
equivalent	O
to	O
the	O
diagnostic	O
accuracy	O
of	O
clinical	O
experts	O
().	O

Lastly	O
,	O
we	O
verified	O
the	O
results	O
of	O
the	O
hold	O
-	O
out	O
test	O
set	O
approach	O
we	O
utilized	O
by	O
demonstrating	O
increased	O
performance	O
under	O
the	O
auspices	O
of	O
5	O
-	O
fold	O
cross	O
-	O
validation	O
.	O

Notably	O
,	O
in	O
line	O
with	O
human	O
performance	O
,	O
combining	O
CT	O
and	O
MRI	O
together	O
resulted	O
in	O
higher	O
performance	O
across	O
the	O
board	O
.	O

This	O
is	O
likely	O
due	O
to	O
the	O
increase	O
in	O
relevant	O
information	O
put	O
forth	O
by	O
consideration	O
of	O
both	O
imaging	O
modalities	O
.	O

Furthermore	O
,	O
it	O
is	O
also	O
interesting	O
that	O
we	O
see	O
the	O
baseline	O
performance	O
of	O
CT	O
being	O
very	O
close	O
to	O
the	O
optimized	O
performance	O
in	B
contrast	I
to	I
the	O
larger	O
performance	O
improvement	O
seen	O
in	O
the	O
context	O
of	O
MRI	O
.	O

This	O
is	O
likely	O
due	O
to	O
the	O
intrinsic	O
differences	B
between	O
each	O
classification	O
problem	O
.	O

Meaning	O
,	O
that	O
the	O
pre	O
-	O
trained	O
network	O
feature	O
(	O
as	B
opposed	I
to	I
learning	O
rate	O
,	O
batch	O
size	O
,	O
regularization	O
,	O
etc	O
.)	O

in	O
the	O
CT	O
scenario	O
had	O
the	O
relative	O
greatest	O
impact	O
on	O
overall	O
model	O
performance	O
.	O

Through	O
this	O
kind	O
of	O
perspective	O
it	O
is	O
possible	O
to	O
utilize	O
the	O
GA	O
to	O
extract	O
feature	O
importance	O
information	O
from	O
the	O
GA	O
search	O
space	O
.	O

Additionally	O
,	O
the	O
asynchronous	O
parallelization	O
of	O
our	O
optimization	O
algorithm	O
increased	O
efficiency	O
both	O
in	O
terms	O
of	O
the	O
number	O
of	O
solutions	O
to	O
consider	O
as	O
well	O
as	O
the	O
computational	O
time	O
and	O
resources	O
required	O
to	O
complete	O
calculations	O
.	O

This	O
offers	O
evidence	O
that	O
these	O
techniques	O
may	O
be	O
broadly	O
applied	O
to	O
the	O
development	O
of	O
other	B
parameterized	O
machine	O
learning	O
models	O
in	O
the	O
context	O
of	O
limited	O
training	O
data	O
.	O

As	O
this	O
work	O
represents	O
an	O
initial	O
exploration	O
of	O
these	O
methodologies	O
,	O
the	O
presented	O
model	O
may	O
be	O
improved	O
.	O

For	O
example	O
,	O
it	O
is	O
possible	O
that	O
the	O
TANDA	O
algorithm	O
could	O
itself	O
be	O
optimized	O
by	O
a	O
GA	O
or	O
other	B
meta	O
-	O
heuristic	O
algorithm	O
,	O
such	O
as	O
particle	O
swarm	O
optimization	O
.	O

Another	B
possible	O
improvement	O
could	O
be	O
to	O
aggregate	O
feature	O
embeddings	O
from	O
all	O
networks	O
as	O
input	O
data	O
for	O
each	O
real	O
image	O
,	O
thus	O
synthetically	O
expanding	O
the	O
dataset	O
in	O
a	O
manner	O
that	O
leverages	O
pre	O
-	O
trained	O
feature	O
extraction	O
.	O

Lastly	O
,	O
we	O
explored	O
only	O
one	O
type	O
of	O
classifier	O
.	O

Other	B
classifiers	O
,	O
such	O
as	O
a	O
Random	O
Forest	O
-	O
based	O
method	O
or	O
a	O
deeper	O
classifier	O
,	O
while	B
possibly	O
more	O
prone	O
to	O
overfitting	O
,	O
may	O
also	O
improve	O
performance	O
.	O

Methods	O
Image	O
acquisition	O
Deidentified	O
preoperative	O
DICOM	O
image	O
sets	O
for	O
39	O
unique	O
patients	O
with	O
histologically	O
confirmed	O
ACP	O
were	O
obtained	O
through	O
the	O
Advancing	O
Treatment	O
for	O
Pediatric	O
Craniopharyngioma	O
consortium	O
()	O
and	O
the	O
St	O
.	O
Jude	O
Childrenâ	O
	O
s	O
Research	O
Hospital	O
().	O

Per	O
the	O
Colorado	O
Multiple	O
Institutional	O
Review	O
Board	O
and	O
United	O
States	O
Health	O
and	O
Human	O
Services	O
Regulation	O
45	O
CFR	O
46	O
,	O
this	O
study	O
was	O
exempt	O
from	O
requiring	O
Institutional	O
Review	O
Board	O
approval	O
.	O

Where	O
otherwise	O
concerned	O
,	O
appropriate	O
informed	O
consent	O
was	O
obtained	O
in	O
accordance	O
with	O
the	O
Declaration	O
of	O
Helsinki	O
(	O
v	O
.	O
2013	O
).	O

Sagittal	O
T1	O
-	O
weighted	O
MRI	O
and	O
axial	O
non	O
-	O
contrast	O
CT	O
image	O
series	O
were	O
selected	O
,	O
based	O
on	O
the	O
fact	O
that	O
the	O
2	O
modalities	O
are	O
used	O
in	O
a	O
complementary	O
manner	O
in	O
the	O
clinical	O
setting	O
.	O

A	O
board	O
-	O
certified	O
pediatric	O
neurosurgeon	O
selected	O
individual	O
images	O
from	O
each	O
series	O
,	O
based	O
on	O
their	O
demonstration	O
of	O
the	O
disease	O
process	O
.	O

These	O
were	O
exported	O
as	O
pixel	O
JPEG	O
images	O
.	O

This	O
procedure	O
was	O
also	O
performed	O
on	O
analogous	O
imaging	O
studies	O
from	O
47	O
unique	O
patients	O
with	O
histologically	O
confirmed	O
non	O
-	O
ACP	O
sellar	O
/	O
suprasellar	O
lesions	O
(	O
NOTACP	O
),	O
which	O
were	O
in	O
the	O
radiological	O
differential	O
diagnosis	O
of	O
ACP	O
.	O

These	O
included	O
pilocytic	O
astrocytoma	O
(),	O
germinoma	O
(),	O
pilomixoid	O
astrocytoma	O
(),	O
optic	O
glioma	O
(),	O
pituitary	O
adenoma	O
(),	O
arachnoid	O
cyst	O
(),	O
prolactinoma	O
(),	O
mature	O
teratoma	O
(),	O
low	O
grade	O
glioma	O
(),	O
renal	O
cell	O
carcinoma	O
(),	O
Rathkeâ	O
	O
s	O
cyst	O
(),	O
lipoma	O
(),	O
and	O
Langerhans	O
cell	O
histiocytosis	O
().	O

NOTACP	O
image	O
datasets	O
were	O
obtained	O
from	O
the	O
radiology	O
department	O
at	O
Childrenâ	O
	O
s	O
Hospital	O
Colorado	O
()	O
and	O
St	O
.	O
Jude	O
Childrenâ	O
	O
s	O
Research	O
Hospital	O
().	O

For	O
training	O
,	O
we	O
utilized	O
23	O
ACP	O
and	O
30	O
NOTACP	O
patient	O
datasets	O
.	O

We	O
extracted	O
three	O
representative	O
images	O
per	O
patient	O
and	O
imaging	O
modality	O
(	O
6	O
images	O
per	O
patient	O
,	O
318	O
images	O
total	O
).	O

The	O
test	O
dataset	O
was	O
comprised	O
of	O
16	O
ACP	O
and	O
17	O
NOTACP	O
patients	O
,	O
with	O
one	O
representative	O
image	O
selected	O
per	O
patient	O
and	O
imaging	O
modality	O
(	O
66	O
images	O
total	O
;	O
33	O
MRI	O
and	O
33	O
CT	O
).	O

Transfer	O
learning	O
and	O
model	O
architecture	O
Caption	O
(	O
TABLE	O
-	O
WRAP	O
):	O
TABLE	O
1	O
Pre	O
-	O
trained	O
networks	O
utilized	O
.	O

Network	O
Source	O
Feature	O
vector	O
size	O
Inception	O
V1	O
https	O
://	O
tfhub	O
.	O
dev	O
/	O
google	O
/	O
imagenet	O
/	O
inception_v1	O
/	O
feature_vector	O
/	O
1	O
1024	O
Inception	O
V2	O
https	O
://	O
tfhub	O
.	O
dev	O
/	O
google	O
/	O
imagenet	O
/	O
inception_v2	O
/	O
feature_vector	O
/	O
1	O
1024	O
Inception	O
V3	O
https	O
://	O
tfhub	O
.	O
dev	O
/	O
google	O
/	O
imagenet	O
/	O
inception_v3	O
/	O
feature_vector	O
/	O
1	O
2048	O
Inception	O
ResNet	O
V2	O
https	O
://	O
tfhub	O
.	O
dev	O
/	O
google	O
/	O
imagenet	O
/	O
inception_resnet_v2	O
/	O
classification	O
/	O
1	O
1536	O
ResNet	O
V1	O
50	O
https	O
://	O
tfhub	O
.	O
dev	O
/	O
google	O
/	O
imagenet	O
/	O
resnet_v1_50	O
/	O
feature_vector	O
/	O
1	O
2048	O
ResNet	O
V1	O
101	O
https	O
://	O
tfhub	O
.	O
dev	O
/	O
google	O
/	O
imagenet	O
/	O
resnet_v1_101	O
/	O
feature_vector	O
/	O
1	O
2048	O
ResNet	O
V1	O
152	O
https	O
://	O
tfhub	O
.	O
dev	O
/	O
google	O
/	O
imagenet	O
/	O
resnet_v1_152	O
/	O
feature_vector	O
/	O
1	O
2048	O
ResNet	O
V2	O
50	O
https	O
://	O
tfhub	O
.	O
dev	O
/	O
google	O
/	O
imagenet	O
/	O
resnet_v2_50	O
/	O
feature_vector	O
/	O
1	O
2048	O
ResNet	O
V2	O
101	O
https	O
://	O
tfhub	O
.	O
dev	O
/	O
google	O
/	O
imagenet	O
/	O
resnet_v2_101	O
/	O
feature_vector	O
/	O
1	O
2048	O
ResNet	O
V2	O
152	O
https	O
://	O
tfhub	O
.	O
dev	O
/	O
google	O
/	O
imagenet	O
/	O
resnet_v2_152	O
/	O
feature_vector	O
/	O
1	O
2048	O
NASNet	O
-	O
A	O
Large	O
https	O
://	O
tfhub	O
.	O
dev	O
/	O
google	O
/	O
imagenet	O
/	O
nasnet_large	O
/	O
feature_vector	O
/	O
1	O
4032	O
PNASNet	O
-	O
5	O
Large	O
https	O
://	O
tfhub	O
.	O
dev	O
/	O
google	O
/	O
imagenet	O
/	O
pnasnet_large	O
/	O
feature_vector	O
/	O
2	O
4320	O
Modules	O
were	O
accessed	O
using	O
the	O
respective	O
URL	O
and	O
standard	O
TensorFlow	O
Hub	O
methods	O
.	O

Transfer	O
learning	O
was	O
completed	O
by	O
extracting	O
dense	O
one	O
-	O
dimensional	O
feature	O
vectors	O
(	O
image	O
signatures	O
)	O
using	O
models	O
fully	O
trained	O
on	O
the	O
ILSVRC	O
-	O
2012	O
-	O
CLS	O
dataset	O
.	O

These	O
models	O
are	O
publicly	O
available	O
on	O
TensorFlow	O
Hub	O
(	O
TableÂ	O
1	O
).	O

Resultant	O
image	O
signatures	O
were	O
given	O
as	O
inputs	O
to	O
a	O
single	O
fully	O
-	O
connected	O
layer	O
of	O
the	O
standard	O
formwhere	O
is	O
the	O
activation	O
function	O
.	O

Prior	O
to	O
activation	O
,	O
input	O
image	O
signatures	O
were	O
transformed	O
via	O
a	O
dropout	O
layer	O
with	O
feature	O
keep	O
probabilities	O
being	O
one	O
of	O
25	O
%,	O
50	O
%,	O
75	O
%,	O
or	O
100	O
%	O
(	O
i	O
.	O
e	O
.	O

no	O
dropout	O
).	O

We	O
explored	O
the	O
application	O
of	O
several	O
activation	O
functions	O
(	O
softmax	O
,	O
softplus	O
,	O
softsign	O
,	O
ReLU	O
,	O
leaky	O
ReLU	O
,	O
and	O
log	O
softmax	O
)	O
readily	O
available	O
within	O
the	O
TensorFlow	O
library	O
.	O

Model	O
loss	O
was	O
calculated	O
using	O
the	O
canonical	O
categorical	O
cross	O
-	O
entropy	O
function	O
.	O
where	O
applied	O
,	O
model	O
regularization	O
was	O
implemented	O
using	O
or	O
(	O
Tikhonov	O
)	O
regularization	O
using	O
native	O
TensorFlow	O
commands	O
against	O
either	O
model	O
weights	O
,	O
biases	O
,	O
or	O
both	O
.	O

Each	O
model	O
architecture	O
was	O
then	O
exposed	O
to	O
one	O
of	O
the	O
following	O
optimizers	O
:	O
Gradient	O
Descent	O
,	O
Adam	O
,	O
Adagrad	O
,	O
Adadelta	O
,	O
RMSProp	O
,	O
Momentum	O
,	O
FTRL	O
,	O
Proximal	O
Adagrad	O
,	O
and	O
Proximal	O
Adadelta	O
.	O

Training	O
batch	O
sizes	O
were	O
one	O
of	O
2	O
,	O
5	O
,	O
10	O
,	O
20	O
,	O
or	O
120	O
images	O
.	O

Training	O
duration	O
ranged	O
from	O
10	O
to	O
125	O
epochs	O
.	O

Lastly	O
,	O
the	O
learning	O
rate	O
utilized	O
for	O
training	O
was	O
one	O
of	O
0	O
.	O
00001	O
,	O
0	O
.	O
0001	O
,	O
0	O
.	O
001	O
,	O
0	O
.	O
005	O
,	O
0	O
.	O
01	O
,	O
0	O
.	O
05	O
,	O
and	O
0	O
.	O
1	O
.	O

We	O
acknowledge	O
the	O
F1	O
score	O
as	O
being	O
a	O
widely	O
utilized	O
accuracy	O
metric	O
for	O
models	O
that	O
are	O
trained	O
on	O
imbalanced	O
datasets	O
,	O
especially	O
in	O
the	O
computer	O
science	O
field	O
.	O

While	B
our	O
original	O
training	O
dataset	O
is	O
indeed	O
slightly	O
imbalanced	O
towards	O
the	O
NOTACP	O
class	O
,	O
we	O
use	O
a	O
balanced	O
test	O
dataset	O
ubiquitously	O
.	O

In	O
addition	O
,	O
our	O
augmented	O
training	O
datasets	O
are	O
numerically	O
balanced	O
.	O

We	O
chose	O
to	O
evaluate	O
network	O
performance	O
using	O
the	O
clinically	O
commonplace	O
metrics	O
of	O
Receiver	O
Operating	O
Characteristic	O
(	O
ROC	O
)	O
curve	O
and	O
area	O
under	O
the	O
ROC	O
curve	O
(	O
AUC	O
)	O
as	O
they	O
more	O
readily	O
translate	O
meaning	O
to	O
clinical	O
practioners	O
.	O

Genetic	O
algorithm	O
The	O
genetic	O
algorithm	O
(	O
Algorithm	O
1	O
)	O
was	O
adapted	O
from	O
a	O
set	O
of	O
publicly	O
available	O
repositories	O
,	O
and	O
it	O
is	O
specifically	O
utilized	O
herein	O
as	O
a	O
meta	O
-	O
parameter	O
optimization	O
solution	O
.	O

Briefly	O
,	O
we	O
randomly	O
select	O
one	O
model	O
feature	O
(	O
e	O
.	O
g	O
.,	O
loss	O
function	O
,	O
learning	O
rate	O
,	O
batch	O
size	O
,	O
etc	O
.)	O

for	O
each	O
of	O
the	O
features	O
listed	O
in	O
Fig	O
.	O
Â	O
2b	O
,	O
this	O
set	O
of	O
features	O
comprises	O
a	O
singular	O
â	O
	O
individualâ	O
.	O

For	O
a	O
given	O
generation	O
,	O
we	O
generated	O
100	O
of	O
these	O
â	O
	O
individualsâ	O
.	O

Each	O
individual	O
is	O
asynchronously	O
processed	O
and	O
the	O
â	O
	O
fitnessâ	O
	O
of	O
an	O
individual	O
is	O
the	O
AUC	O
value	O
described	O
above	O
.	O

After	O
the	O
full	O
generation	O
has	O
been	O
evaluated	O
,	O
a	O
top	O
fraction	O
is	O
carried	O
over	O
to	O
the	O
next	O
generation	O
.	O

The	O
following	O
generation	O
is	O
created	O
by	O
randomly	O
selecting	O
model	O
features	O
found	O
in	O
the	O
individuals	O
that	O
comprise	O
the	O
top	O
fraction	O
of	O
the	O
the	O
previous	O
generationâ	O
	O
akin	O
to	O
â	O
	O
offspringâ	O
	O
from	O
a	O
â	O
	O
motherâ	O
	O
and	O
â	O
	O
fatherâ	O
	O
set	O
.	O

It	O
is	O
worth	O
noting	O
that	O
genetic	O
algorithms	O
are	O
prone	O
to	O
identifying	O
local	O
minima	O
which	O
can	O
lead	O
to	O
biased	O
optimization	O
results	O
,	O
though	O
we	O
have	O
attempted	O
to	O
mitigate	O
this	O
by	O
using	O
random	O
mutation	O
.	O

A	O
visual	O
schematic	O
for	O
this	O
process	O
can	O
be	O
seen	O
in	O
Fig	O
.	O
Â	O
2a	O
.	O

The	O
search	O
space	O
of	O
the	O
genetic	O
algorithm	O
included	O
19	O
,	O
051	O
,	O
200	O
possible	O
solutions	O
(	O
12	O
pre	O
-	O
trained	O
networks	O
learning	O
rates	O
batch	O
sizes	O
training	O
epochs	O
optimizers	O
activation	O
functions	O
dropout	O
rates	O
regularization	O
methods	O
training	O
datasets	O
test	O
datasets	O
).	O

Note	O
,	O
that	O
although	O
there	O
are	O
only	O
9	O
optimizers	O
explicitly	O
listed	O
in	O
Fig	O
.	O
Â	O
2B	O
that	O
the	O
proximal	O
optimizers	O
have	O
4	O
unique	O
variants	O
(	O
no	O
regularization	O
,	O
l1	O
-	O
regularization	O
,	O
l2	O
-	O
regularization	O
,	O
and	O
l1	O
/	O
l2	O
-	O
regularization	O
;	O
as	O
demarcated	O
by	O
the	O
asterisk	O
in	O
the	O
figure	O
),	O
yielding	O
15	O
possible	O
optimizers	O
.	O

The	O
AUC	O
â	O
	O
fitnessâ	O
	O
value	O
is	O
determined	O
for	O
each	O
network	O
by	O
evaluating	O
on	O
the	O
test	O
mentioned	O
above	O
().	O

On	O
our	O
system	O
we	O
were	O
capable	O
of	O
running	O
10	O
networks	O
simultaneously	O
at	O
any	O
given	O
time	O
,	O
and	O
runtime	O
for	O
10	O
generations	O
with	O
(	O
i	O
.	O
e	O
.,	O
1000	O
networks	O
)	O
was	O
approximately	O
1â	O
	O
1	O
.	O
5Â	O
days	O
.	O

Image	O
augmentation	O
and	O
synthetic	O
data	O
expansion	O
by	O
TANDA	O
Standard	O
image	O
augmentation	O
was	O
performed	O
using	O
the	O
Augmentor	O
python	O
library	O
.	O

Training	O
data	O
was	O
augmented	O
using	O
a	O
pipeline	O
implementing	O
a	O
random	O
distortion	O
(,	O
,	O
,	O
),	O
followed	O
by	O
a	O
random	O
rotation	O
(),	O
then	O
a	O
random	O
zoom	O
(,	O
),	O
and	O
finally	O
a	O
random	O
left	O
-	O
right	O
flip	O
().	O

CT	O
and	O
MRI	O
data	O
were	O
each	O
sampled	O
using	O
this	O
pipeline	O
for	O
either	O
100	O
or	O
1000	O
iterations	O
.	O

Test	O
images	O
were	O
sampled	O
using	O
this	O
pipeline	O
,	O
with	O
all	O
probabilities	O
being	O
set	O
to	O
1	O
.	O
0	O
.	O

Test	O
images	O
were	O
sampled	O
using	O
this	O
pipeline	O
either	O
10	O
or	O
100	O
times	O
.	O

Unsupervised	O
GAN	O
-	O
based	O
image	O
generation	O
was	O
performed	O
via	O
minor	O
adaptation	O
to	O
the	O
TANDA	O
python	O
library8	O
initialized	O
with	O
the	O
following	O
parameters	O
:	O
LSTM	O
-	O
class	O
generator	O
;	O
generator	O
learning	O
rate	O
of	O
;	O
discriminator	O
learning	O
rate	O
of	O
;	O
gamma	O
equal	O
to	O
0	O
.	O
5	O
;	O
one	O
mean	O
-	O
squared	O
-	O
error	O
(	O
MSE	O
)	O
layer	O
;	O
MSE	O
-	O
term	O
coefficient	O
of	O
;	O
transformation	O
sequence	O
length	O
of	O
10	O
;	O
no	O
per	O
-	O
image	O
standardization	O
;	O
trained	O
using	O
a	O
batch	O
size	O
of	O
5	O
and	O
for	O
a	O
duration	O
of	O
5	O
epochs	O
.	O

We	O
sought	O
to	O
extract	O
the	O
generated	O
images	O
as	O
JPEG	O
files	O
for	O
visualization	O
,	O
as	B
opposed	I
to	I
direct	O
import	O
into	O
an	O
end	O
-	O
classifier	O
.	O

1000	O
ACP	O
and	O
1000	O
NOTACP	O
synthetic	O
images	O
were	O
generated	O
for	O
both	O
CT	O
and	O
MRI	O
modalities	O
.	O

Computational	O
hardware	O
and	O
software	O
All	O
computational	O
programs	O
were	O
performed	O
on	O
a	O
64	O
-	O
bit	O
RedHat	O
Enterprise	O
Linux	O
HPC	O
running	O
CentOS	O
7	O
.	O
4	O
.	O
1708	O
.	O

Python	O
based	O
programs	O
were	O
executed	O
in	O
a	O
virtual	O
environment	O
containing	O
Python	O
3	O
.	O
6	O
with	O
the	O
following	O
modules	O
:	O
Augmentor	O
(	O
v	O
0	O
.	O
2	O
.	O
2	O
),	O
Matplotlib	O
(	O
v	O
2	O
.	O
2	O
.	O
2	O
),	O
Numpy	O
(	O
v	O
1	O
.	O
14	O
.	O
15	O
),	O
Pandas	O
(	O
v	O
0	O
.	O
23	O
.	O
3	O
),	O
Ray	O
(	O
v	O
0	O
.	O
6	O
.	O
4	O
),	O
Sci	O
-	O
kit	O
Image	O
(	O
v	O
0	O
.	O
14	O
.	O
0	O
),	O
TensorFlow	O
(	O
v	O
1	O
.	O
12	O
.	O
0	O
),	O
and	O
TensorFlow	O
Hub	O
(	O
v	O
0	O
.	O
2	O
.	O
0	O
).	O

Publisher	O
'	O
s	O
note	O
Springer	O
Nature	O
remains	O
neutral	O
with	O
regard	O
to	O
jurisdictional	O
claims	O
in	O
published	O
maps	O
and	O
institutional	O
affiliations	O
.	O

Author	O
contributions	O
Project	O
Conception	O
:	O
EP	O
,	O
TCH	O
;	O
Project	O
Design	O
:	O
EP	O
,	O
TCH	O
;	O
Software	O
Generation	O
:	O
EP	O
;	O
Data	O
Acquisition	O
:	O
RW	O
,	O
NS	O
,	O
DM	O
,	O
SS	O
,	O
PK	O
,	O
RCEA	O
,	O
TNN	O
,	O
GG	O
,	O
MS	O
,	O
JMJ	O
,	O
EMJ	O
,	O
DDL	O
,	O
AS	O
,	O
AMD	O
,	O
JC	O
,	O
LK	O
,	O
KG	O
,	O
RN	O
,	O
RD	O
,	O
ETK	O
,	O
GJ	O
,	O
MHH	O
;	O
Data	O
Analysis	O
:	O
EP	O
,	O
KJ	O
;	O
Data	O
Interpretation	O
:	O
EP	O
,	O
KJ	O
,	O
AMD	O
,	O
NF	O
,	O
TCH	O
;	O
Manuscript	O
Composition	O
:	O
EP	O
,	O
RW	O
,	O
TCH	O
;	O
Manuscript	O
Revisions	O
:	O
KJ	O
,	O
AMD	O
,	O
NF	O
,	O
TCH	O
;	O
Data	O
availability	O
The	O
dataset	O
analyzed	O
during	O
the	O
current	O
study	O
is	O
available	O
from	O
the	O
corresponding	O
author	O
on	O
reasonable	O
request	O
.	O

Competing	O
interests	O
The	O
authors	O
declare	O
no	O
competing	O
interests	O
.	O

